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2Abstract
Brn-Sc (Brn3.1,  POU4F3) encoding a POU domain transcription factor is a candidate 
gene for late onset  sensorineural  hearing loss, which is exhibited by a large proportion 
of the  ageing  population.  To  identify  common  sequence  variants  at  the Brn-3c  locus 
mutation scanning of the Brn-3c cDNA, intron and 5’-flanking region was performed by 
PCR-SSCP  analysis in 45  members of the general population.  Seven polymorphic sites 
were  identified  of which five within the Brn-3c  5’-flanking region  appear  common.  A 
functional  screening  approach  utilising  in-vitro  assays  suggests  that  at  least  three 
common  sequence  variants  in  the  Brn-3c  5’-flanking  region  could  have  a  functional 
affect:  -566(GT)i7-23,  -1391A>C  and a complex multi-allelic poly-G polymorphism at - 
3432  that  exhibits  multiple variations  in  length together with  single base  substitutions 
within the guanine repeat.  The -3432poly-G polymorphism modifies the binding affinity 
of an  OC-2  derived  nuclear  protein  and  there  is  convincing  evidence  that  this  is  the 
transcription  factor  SP1.  Use  of  purified  human  recombinant  SP1  protein,  in-vitro 
translated  SP1  and in-vitro translated  SP3  confirms that the -3432polyG polymorphism 
modulates  a  high  affinity  SP  family binding  site  and  evidence  suggests that this alters 
the regulation of the Brn-3c promoter when SP1  levels are limiting, p<0.05. Moreover, 
the  data  suggest  a  functional  interaction between the  -3432poly-G  polymorphism  and 
the -566(GT)i7.23 repeat which associate to determine the response of the Brn-3c gene to 
SP1.  Similarly,  evidence  suggests that the variant allele,  -1391C  has a reduced affinity 
for an OC-2 derived nuclear protein and this is consistent with a significant decrease in 
basal  activity of the Brn-3c promoter,  p<0.05.  Both -3432poly-G polymorphism and - 
1391A>C were genotyped for a pilot association study but allelic frequencies were not 
found to  significantly  differ between the patient  and control populations examined  (by 
% 2  analysis).  Further  large-scale  population  studies  are  required  to  establish  whether 
these common sequence variants are associated with late onset hearing loss.
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USH Usher syndrome1.0 Introduction.
1.1 An introduction to hearing loss.
Hearing loss is one of the most common, costly and least understood disabilities of man. 
The most recent figures scored in 2002 estimate that worldwide 250 million people have 
a disabling hearing impairment (http://www.who.org). In the U.K. alone, approximately 
9 million people suffer with hearing loss and of these around 75 % have developed the 
hearing loss with increasing age (http://www.mid.org).  Hearing loss is often described 
as a ‘hidden’ or ‘invisible’ disability. Indeed, it is not always immediately apparent that 
a person is deaf or hearing impaired. Yet, this seemingly innocuous, invisible disability 
has  severe  consequences.  Hearing  loss  deprives  sufferers  of  their  main  means  of 
communication and can lead to social isolation, loneliness and depression.
Hearing loss  can manifest  at  any age;  congenital  deafness  (present  at birth)  is 
known  to  affect  approximately  1   in  1000  children  and  a  further  1   in  1000  develop 
permanent hearing loss before adulthood (Morten,  1991;  Mason and Herrmann,  1998; 
Parving,  1999).  In addition, many adults go on to develop progressive hearing loss  as 
they age;  16% of adults (17-80 years) have a hearing impairment of at least 25 decibels 
and  for  the  60-plus  population  this  figure  is  more  than  30%,  increasing  to  60%  for 
people aged over 70 years of age (Davis  1989  and  1995).  Moreover,  the scale of this 
problem  is  set  to  increase  as  life  expectancy  increases.  This  presents  a  major public 
health  problem  and  is  a  significant  economic  burden.  According  to  the  world  health
tVi
organisation adult onset hearing loss ranks  15  under the leading causes of the ‘global 
burden  of disease’  and  2nd  in  the  leading  causes  of  ‘years  lived  with  a  disability’ 
(http://www.who.org).
The causes of hearing loss are diverse. Approximately 50% of congenital cases 
of hearing loss are due to genetic defects (Morton,  1991). Around 25% of cases are due 
to environmental factors such as bacterial and viral infections, prematurity and exposure 
to ototoxic agents.  Of the remaining 25% of cases the etiology is obscure but a genetic 
basis is suspected (Morton,  1991; for review see Schrijver 2004). In contrast, late onset 
hearing  loss  of sensorineural  origin,  which  is  exhibited  by  a  large  proportion  of the 
ageing population is thought to be due to a complex genetic -  environmental interplay 
within  which  acoustic  trauma is  a major  factor  (for reviews  see  Jennings  and  Jones, 
2001; Fransen et al, 2003; Ohlemiller, 2004; Gates and Mills, 2005).
16Congenital  hearing loss  attributed to  genetic origins  can present  as an isolated 
condition termed non-syndromic deafness or it can present in conjunction with another 
phenotype(s)  elsewhere  in  the  body  in  which  case  it  is  termed  syndromic  deafness. 
Currently,  greater than 400  syndromes have been reported  in  which hearing loss  is  a 
characteristic  feature  and  within  which  the pathology varies  enormously (for reviews 
see Keats and Berlin,  1999; Friedman et al, 2003). Non-syndromic deafness is the more 
common of the two, accounting for about 70% of cases (Morten,  1991) and generally is 
mostly  sensorineural  in  origin  (for  review  see  Schrijver,  2004).  It  is  a  highly 
heterogeneous trait, at present nearly 100 loci have been reported from which 39 genes 
have  been  identified  (Van  Camp  and  Smith,  Hereditary  Hearing  Loss  Home  Page, 
http://webhost.ua.ac.be/hhh/) and it can be further categorized according to the mode of 
inheritance.  The  majority  of  genes  that  cause  non-syndromic  deafness  present  as 
autosomal recessives accounting for around 11% of cases; these loci are denoted DNFB. 
Autosomal  dominant genes  account for around 22% of the remaining cases  and these 
loci  are  denoted  DFNA.  Only  1%  is  X-chromosome  linked  (DFN)  and  less  than  1% 
show  mitochrondrial  modes  of  inheritance  (Morton,  1991).  Generally,  autosomal 
dominant  non-syndromic  hearing  loss  is  post-lingual  (develops  after  acquisition  of 
speech)  and  progressive  whereas,  autosomal  recessive  non-syndromic  hearing  loss  is 
prelingual  (develops  before  acquisition  of  speech)  and  is  severe  to  profound  (for 
reviews see Bitner-Glindzicz, 2002; Petersen, 2002; Schrijver, 2004).
The  basis  of this  project  is  to  investigate  genetic  susceptibility  to  late  onset 
hearing  loss  of sensorineural  origin,  which  is  exhibited  by  a  large  proportion  of the 
ageing population.  For the purpose of this thesis the term late onset hearing loss was 
adopted as the nomenclature of choice rather than the terms presbycusis or age-related 
hearing  loss  (ARHL)  which  have  frequently  been  used  to  describe  the  common, 
symmetric,  sensorineural  high  frequency loss  of hearing typical  with  advancing years 
(Zheng et al,  1998;  Alam et al, 2001;  Unal  et al, 2005;  for reviews  see Fransen et al, 
2003;  Gates  and  Mills,  2005).  There are conflicting reports  in the literature regarding 
definition of the term presbyacusis (Zheng et al,  1998; Alam et al, 2001; Seidman et al, 
2000; Jennings and Jones, 2001). Whereas, the term ARHL is somewhat misleading it 
indicates hearing loss  solely due to the intrinsic process of auditory ageing.  When,  in 
reality  ARHL  is  an  extremely  complicated  trait  and  many  factors  are  thought  to 
contribute to the pathology.  A complex genetic environmental interaction is suspected 
to underlie the aetiology (for reviews see Jennings and Jones, 2001; Fransen et al, 2003; 
Ohlemiller,  2004;  Gates  and  Mills,  2005)  and  delineating  the  effect  of  individual
17exogenous factors such as noise trauma and exposure to ototoxic agents from the ageing 
process  itself  is  problematic  if  not  impossible.  Furthermore,  to  compound  matters 
accumulating  evidence  suggests  that  ARHL  and  noise-induced  hearing  loss,  NIHL 
(hearing loss  caused by prolonged exposure to moderate level  sound)  are not separate 
pathologies but overlapping phenomena (for reviews  see Ohlemiller,  2004;  Gates  and 
Mills,  2005).  Therefore,  I  have  adopted  the  term  7ate  onset  hearing  loss’  as  it 
encompasses the multi-factorial nature of this disease.  Defining late onset hearing loss 
is discussed further in section 1.5.1.
Delineating the  genetic basis  of late onset hearing loss  is  extremely important 
not  least  because  of its  significant  social  and  economic  burden  but  also  because  at 
present of all common and complex traits the fundamental pathophysiology of late onset 
hearing loss  is probably the least well understood.  Unravelling the molecular basis of 
the hearing process itself has been a slow process especially when compared alongside 
progress made in other sensory systems such as the visual system; this coupled with the 
complexity of late onset hearing loss has hindered our understanding of this disease at 
the molecular level.  Significant  limiting factors have been the difficulties  imposed by 
the  inaccessibility  of  the  inner  ear  and  in  obtaining  sufficient  amounts  of  cochlea 
material to study. In addition, the highly heterogenous nature of congenital hearing loss 
has further compounded the difficulty and hence, slowed progress.
At the onset of this project no common genetic variants had been identified as a 
risk  factor  for  susceptibility  to  late  onset  hearing  loss.  Understanding  the  common 
genetic variants that contribute to late onset hearing loss is extremely important; it will 
help clarify the underlying disease mechanism and molecular pathways involved.  This 
will  help  pave  way  for  therapeutic  intervention  to  slow  or  ultimately prevent  loss  of 
hearing  with  advancing  age.  It will  also  complement  the  knowledge  gained  from  the 
study  of rare  monogenic  forms  of  syndromic  and  non-syndromic  hearing  loss  and 
extend our understanding of the basic hearing process.
During this introduction the structure and function of the ear will be discussed 
with  emphasis  on  the  cochlea  and  the  sensory  hair  cells  within  -  highly  specialised 
auditory cells  crucial  for mechanoelectrical  transduction  and  loss  of which is  a major 
cause of late onset hearing loss (for reviews see Jennings and Jones, 2001; Fransen et al, 
2003; Gratton and Vazquez, 2003; Ohlemiller, 2004; Gates and Mills et al, 2005). The 
complex  transcription  factor  interactions  and  Notch  signalling  events  that  underlie 
auditory hair  cell  development  will  be  summarised  followed  by a  discussion  of how 
elucidation  of genes  involved  in  syndromic  and  non-syndromic  forms  of hereditary
18hearing  loss  have  driven  forward  tremendous  progress  in  our  understanding  of the 
hearing process at the molecular level and how theoretically any of these genes could be 
involved  in  susceptibility to  late  onset  hearing loss.  The pathophysiology of late onset 
hearing  loss  and  the  cellular  and  molecular  mechanisms  that  underlie  development  of 
this  disease will  be  explored together with methods  available to  study the genetics  of 
this  complex  disease.  Finally,  candidate  genes  for  susceptibility  to  late  onset  hearing 
loss at the onset of this project and that have emerged during the course of this project 
will be  discussed  with  emphasis  on Brn-Sc  (also  known as Brn3.1  and POU4F3),  the 
candidate  gene  for  susceptibility  to  late  onset  hearing  loss  that  is  the  focus  of this 
project.
191.2  The  structure  and  function  of  the  mammalian  ear:  the
auditory pathway.
The  adult  mammalian  ear  is  a highly complex,  specialized  organ  and  can  be  simply 
divided into three main components: the external, middle and inner ear (see Fig.  1.1). A 
prominent funnel shaped auricle and the external acoustic meatus form the external ear; 
sound  waves  are  collected  by the  former  and  the  latter  acts  as  the  auditory  canal  to 
conduct  sound  waves  inwards  to  the  tympanic  membrane  which  in response vibrates 
(Lee,  1999;  Moore  and  Dailey,  1999).  Hence,  its  common  name,  the  eardrum.  The 
tympanic membrane is  a thin,  almost circular covering that partitions the external  and 
middle  ear.  Hearing  loss  manifesting  from  a  defect  of the  external  or  middle  ear  is 
termed  conductive  (Lee,  1999).  The middle  ear resides  within the petrous part of the 
temporal  bone  and  is  an  air  filled  chamber termed,  the tympanic cavity across  which 
extend three auditory ossicles: the malleus, incus and stapes to form the ossicular chain, 
see  Fig.  1.1  (Lee,  1999;  Moore  and  Dailey,  1999).  The  lower portion  of the malleus 
embeds  into  the  tympanic  membrane  and  at  the  far  end  of the  chain  the base  of the 
stapes, known as the footplate, occupies the oval window of the inner ear.  Fixation of 
the  stapes  footplate  to  the  oval  window  results  in  otosclerosis,  a  common  form  of 
conductive,  adult  onset  hearing  loss  treatable  by  corrective  surgery  (for  review  see, 
Menger  and  Tange,  2003).  The  incus  resides  between  the  malleus  and  stapes  and 
articulates with them.  The middle ear functions to transform  acoustic energy from the 
medium of air to the medium of fluid. This is achieved by the tympanic membrane and 
ossicular chain acting in concert;  the vibrating movements of the tympanic membrane 
are transmitted along the ossicular chain to the oval window of the inner ear (Lee,  1999; 
Moore and Dailey,  1999). Displacement of the ossicular chain is directly related to the 
frequency  and  intensity  of  the  sound  input  and  transmission  is  most  efficient  at 
frequencies crucial for understanding speech (500 to 3000 Hz) (Lee,  1999; Moore and 
Dailey,  1999).  The  ageing  process  has  minimal  affect  on  the  middle  ear;  the 
components of the middle ear are subject to age-related changes but this seems to have 
negligible effect on their function (Wiley et al, 1999).
The inner ear is highly intricate; it has evolved to process sounds across six and 
nine octaves (for review see Nobili et al,  1998). Continuous with the middle ear in the 
petrous  part  of the  temporal  bone,  the  inner  ear is  composed  of a very  sophisticated 
closed system of membranous ducts and chambers known as the membranous labyrinth 
(for review see Forge and Wright, 2002). This endolymph-filled membranous labyrinth
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Figure  1.1  A  schematic  drawing  of  the  mammalian  ear.  The  three  main  sections  of  the 
mammalian  ear  are  shown:  the  external  ear  (auricle  and  external  auditory  canal),  the  middle  ear 
(auditory ossicles) and the inner ear (vestibular apparatus and cochlea).
(Reproduced from Kalatzis et al, 1998).
is surrounded by a fluid, perilymph, and lies suspended within the cavities of the bony 
labyrinth  - the walls of which consist of dense bone  known as the otic capsule (Lee, 
1999; Moore and Dailey,  1999). The membranous labyrinth can be subdivided into two 
chief  sections  defined  by  function:  the  vestibular  complex  and  the  cochlea,  which 
constitute the  highly  specialized  sensory organs of the  inner ear essential  for balance 
and  hearing,  respectively (see  Fig.  1.1).  Hearing  loss manifesting  from defects  in the 
cochlea  or  auditory  nerve,  the  VIII  nerve,  is  termed  sensorineural  (Lee,  1999).  The 
vestibular  complex  is  composed  of  the  vestibule  and  (at  the  posterior  end)  three 
semicircular canals lined by semicircular ducts and arranged such that they form three 
planes  in  space  giving  an  overall  three dimensional  structure  (Lee,  1999;  Moore  and 
Dailey,  1999).  The  vestibule  chamber  contains  the  saccule  and  utricle  and  the  oval 
window of the inner ear on its lateral wall. Specialized sensory neuroepithelia within the 
saccule  and  utricle  (the  maculae)  detects  linear  acceleration,  and  specialized  sensory 
neuroepithelia  within  the  semicircular  ducts  (the  cristae  ampullae)  detects  angular 
acceleration;  this  collectively  maintains  the  equilibrium  essential  for  normal  balance 
(Lee,  1999;  Moore and Dailey,  1999;  for review see Forge and Wright, 2002).  A key
21component of this specialised sensory neuroepithelia is the hair cell, which will not be 
discussed  further  for  the  vestibular  complex  but  will  be  described  in  detail  for  the 
cochlea where sound processing is performed (see section 1.2.1).
The cochlea located within the cochlear duct contains the auditory machinery to 
process the sound signals received from the middle ear. It is a remarkable organ “able to 
respond  to  sound-driven  vibrations  of only  +/-  0.3nm  -   the  diameter  of  an  atom” 
(Hudspeth,  1997).  It is  a highly active  structure  and  compared to the middle ear it is 
severely  affected  by the  ageing process  (for  review  see  Gates  and  Mills,  2005).  The 
distinctive coil of the cochlea is due to the spiral canal that originates at the vestibule 
and winds 2.5  times around a bony core, the modiolus (Lee,  1999; Moore and Dailey,
1999). The cochlea duct, the scala media (filled with endolymph) is securely suspended 
across  the  perilymph-filled  spiral  canal  by the  spiral  ligament  and  the  osseous  spiral 
lamina of the modiolus.  This  in  effect,  creates two perilymph-filled  channels running 
horizontally  along  each  side  of the  cochlea  duct:  the  scala  vestibuli  and  the  scala 
tympani.  The  endolymph has  a high potassium  ion but low  sodium  ion  concentration 
whereas  the  perilymph has  a high  sodium  ion  concentration  and  is  low  in  potassium 
ions  (for review see Forge and Wright,  2002).  Maintenance of these differing cochlea 
fluids is crucial  for the hearing process; this is achieved in part by ionic pumps in the 
stria vascularis located on the lateral wall of the cochlea duct that pump potassium ions 
into the endolymph (Takeuchi et al, 2000). Hence, ensuring that a high positive resting 
potential,  the  endocochlea  potential  is  maintained  to  drive  mechanoelectrical 
transduction for hearing.
Two  membranes,  the  vestibular  and  basilar  membranes  form  the  upper  and 
lower  surfaces  of  the  cochlea  duct,  respectively.  Along  the  length  of  the  basilar 
membrane  lies  the  organ  of  Corti  and  it  is  here  that  the  specialized  sensory 
neuroepithelia of the cochlea is located and mechanoelectrical transduction mediated by 
auditory  hair  cells  is  performed  (see  Fig. 1.2).  The  organ  of  Corti  is  a  highly 
differentiated  and ordered  structure  consisting of two morphologically distinct sets  of 
hair cells: inner hair cells (IHCs) and outer hair cells (OHCs) in addition to an array of 
supporting cells: Deiter’s cells, Hensen’s cells and pillar cells (for review see Forge and 
Wright,  2002).  Typically,  three  rows  of  OHCs  are  precisely  arranged  along  the 
longitudinal axis of the organ of Corti clearly distinguishable from a single row of IHCs 
(for review see Forge and Wright, 2002). A gelatinous membrane termed, the tectorial 
membrane  overlies  the hair  cells.  The  sensory hair cells  do  not  directly contact  each 
other, but instead are surrounded by supporting cells (see Fig. 1.2). This alternating hair
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Figure 1.2 A cross section of the cochlea to show the sensory neuroepithelia for hearing.  Inner 
and outer hair cells of the organ of Corti are shown surrounded by supporting cells (Deiter’s cells and 
Henscn’s cells). The organ of Corti lies on the basilar membrane that extends along the coil of the 
cochlea duct. The tectorial membrane overlies the hair cells.
(Reproduced from Gates and Mills, 2005).
cell:  supporting cell  arrangement  forms the  predominant  cell  network  in  the  organ  of 
Corti.
In  the  cochlea,  the  sound  input  is  processed  from  mechanical  energy  into 
hydraulic energy into its final form, electrical energy. This is achieved by the vibrations 
(the  mechanical  energy)  of the footplate of the stapes in and out of the oval  window 
creating  waves  of hydraulic  pressure  (the  hydraulic  energy)  in  the  perilymph  of the 
vestibule (Lee,  1999;  Moore and  Dailey,  1999).  The hydraulic waves ascend  towards 
the apex of the cochlea via the  scala vestibuli.  In doing so  the force of the hydraulic 
wave  displaces  the  basilar  membrane  this  in  turn  triggers  mechanoelectrical 
transduction  mediated  by  the  sensory  hair  cells  (see  section  1.2.1  below)  and 
transmission  of a  complex  array  of frequencies  that  constitutes  the  sound  input  as  a
23pattern of afferent electrical nerve impulses (the electrical energy) to the higher auditory 
centres in the brain (Lee, 1999; Moore and Dailey, 1999).
Sound input in the form of hydraulic waves peak at different positions along the 
length of the basilar membrane; peak position being dependent on the sound frequency. 
Tonotopic  organization  of the  cochlea  ensures  that  for  every  frequency  there  is  an 
optimum locus on the basilar membrane where the hair cells are maximally sensitive to 
that frequency. The cochlea base is tuned for high frequencies (up to 20kHz in humans) 
and the apex for lower (as low as 20Hz in humans); this is facilitated, at least in part, by 
the innate properties of the hair cells along the coil of the cochlea duct. For example, the 
calcium and calcium-activated potassium channels found in hair cells are expressed in a 
gradient along the longitudinal axis of the cochlea duct; the cells at the base containing 
a  greater  clustering  of ion  channels  compared  to  those  at  the  apex  which,  in  effect 
results  in  hair  cell-to-cell  variation  (for  review  see  Ashmore  and  Mammano,  2001; 
Hudspeth, 2005;  LeMasurier and Gillespie, 2005).  It is loss of these auditory hair cells 
along  a  basal  to  apical  gradient,  which  is  a  major  cause  of late  onset  hearing  loss 
exhibited by a large proportion of the ageing population (for reviews see Jennings and 
Jones, 2001;  Fransen et al, 2003; Gratton and Vazquez, 2003; Ohlemiller, 2004; Gates 
and Mills et al, 2005).
1.2.1  Hair cells: the mechanoelectrical transducers of the cochlea.
Hair  cells  are  crucial  for hearing;  they  are  the  mechano-electricial  transducers  of the 
cochlea. Loss of these cells from the cochlea is a major cause of late onset hearing loss 
(for reviews see Jennings and Jones, 2001;  Fransen et al, 2003;  Gratton and Vazquez, 
2003; Ohlemiller, 2004; Gates and Mills et al, 2005) and abnormalities in these cells are 
responsible  for  various  forms  of hereditary  non-syndromic  congenital  deafness  (see 
section  1.4  and  Van  Camp  and  Smith,  Hereditary  Hearing  Loss  Home  Page, 
http://webhost.ua.ac.be/hhh/).  Paramount to their function is their apical  specialization 
for the detection of movement, the mechanosensory hair bundle.  Composed of around 
20-300 specialized microvilli, termed stereocilia the hair bundle protrudes towards the 
overlying tectorial membrane within the cochlea duct. The stereocilia are composed of a 
rigid core of parallel actin filaments that gradually narrows as it anchors the stereocilia 
securely into the cuticular plate, a solid support composed of actin located on the apical 
surface of hair cells  (for review  see  Steel  and  Kros,  2001;  Forge  and Wright,  2002). 
Three-dimensionally the stereociliary hair bundle resembles a pyramid-shaped array
24(a)  (b)
stereocilium
Figure  1.3  Hair  cell  stereocilia  and  their  tip-links.  (a)  Scanning  electron  microscopy  of  the 
stereociliary  hair  bundle  of an  outer  hair  cell;  three-dimensionally  this  resembles  a  pyramid-shaped 
array,  (b)  Fine  detail  of the  tip-link;  crucial  stereocilium  -   stereocilium  connections  that  link  each 
stereocilium to the side of their immediate taller neighbour.
(Reproduced from Petit et al, 2001).
(see Fig.  1.3).  Along the  length of the stereocilia extend  extracellular lateral  links that 
formstereocilium - stereocilium connections within the array; lateral links are thought to 
be important in hair bundle stability (for review see Forge and Wright, 2002). At the tip 
of each stereocilium extend stereocilium - stereocilium connections termed tip-links that 
connect each  stereocilium  to  the  side of their  immediate  taller neighbour,  see  Fig.  1.3 
(Pickles  et  al,  1984,  Kachar  et  al,  2000);  tip-links  are  thought  to  be  crucial  for 
mechanoelectrical  transduction.  It  has  been  proposed  that  Cadherin-23  (Cdh23)  is  a 
major component of the tip-link (Siemens et al, 2004; Sollner et al, 2004; Tsuprun et al,
2004);  Cdh23  is  thought  to  link  stereociliary  tips  through  a  homophilic  binding 
mechanism  (Siemens  et  al,  2004).  However,  this  evidence  is  based  on  expression 
studies  in  mice  at  early  embryonic  stages  and  has  been  contradicted  by  others  who 
report  that  Cdh23  is  absent  from  the  apex  of stereocilia  in  adult  mice  (Lagziel  et  al, 
2005;  Michel et al, 2005). It has been proposed that the mechanoelectrical transduction 
channels are attached to the ends of the tip links (for review see Hudspeth, 2005).
Displacement  of the  basilar  membrane  deflects  the  hair  bundle  resulting  in  a 
‘shearing’  motion  of  the  stereocilia  against  the  mass  of  the  overlying  tectorial
25membrane.  This  causes  the  stereocilia to  pivot  towards  their  nearest  taller neighbour 
creating a wave of movement within the pyramid-shaped stereociliary hair bundle (for 
review see Hudspeth, 2005).  It has been proposed that the deflection of the stereocilia 
causes  the  tip-links  to  act  as  ‘gating  springs’;  an  increase  in  tension  opens  the 
mechanoelectrical  transduction  channels  causing  an  influx  of  cations  -   probably 
predominantly potassium  and to  less  extent,  calcium  into  the hair cell  depolarizing it 
(Corey  and  Hudspeth,  1983;  Howard  and  Hudspeth,  1988;  Holt  and  Corey,  2000). 
However, other evidence is not in agreement with this proposal; structural examination 
of the tip link at high resolution suggests that the tip link itself, is not the gating spring 
(Kachar  et  al,  2000).  At  present,  the  molecular  identity  of  the  mechanoelectrical 
transduction channel  is unknown.  A member of the transient receptor potential  (TRP) 
superfamily of ion channel proteins, TRPA1, has been suggested as a strong candidate 
based on a repertoire of data by Corey et al, 2004.  However, recent evidence disputes 
this;  mice  knockout  for the TRPA1  gene  are  not  deaf and  exhibit  a normal  auditory 
brainstem response (Kwan et al, 2006).
Depolarization  of  OHCs  and  IHCs  in  this  manner  leads  to  defined  cellular 
responses  reflective  of  their  distinct  morphological  nature.  The  cylindrical  shaped 
OHCs receive the majority (about 80%) of the efferent innervation of the cochlea and 
are responsible  for  ‘cochlea amplification’  a process  that  augments  the motion  of the 
basilar membrane so that the sound input is sensitised 100-fold (for reviews see, Nobili 
et al,  1998; Ashmore and Mammano, 2001; Hudspeth, 2005; LeMasurier and Gillespie, 
2005). Structurally, the arrangement of the OHCs facilitates this; their stereociliary hair 
bundle  contacts  the  overlying tectorial  membrane  and  they ride on  the motion  of the 
basilar  membrane  in  such  a  way  that  minute  forces  are  channelled  back  into  the 
dynamics  of  this  membrane  (for  reviews  see  Nobili  et  al,  1998;  Ashmore  and 
Mammano,  2001;  Hudspeth,  2005;  LeMasurier  and  Gillespie,  2005).  How  this 
mechanism of amplification occurs has yet to be clarified, but one likely proposal is the 
mechanism of ‘somatic electromotility’. This features a cellular motor that is known to 
pack densely in the lateral plasma membrane of the OHCs. In this model a change in the 
endocochlea  potential  resulting  from  the  shearing  motion  of the  stereocilia  drives  a 
conformational change in the motor molecule that causes the OHCs to characteristically 
lengthen  and  shorten  thus  forming  an  active  feedback  mechanism  whereby  the 
mechanics  of the  basilar  membrane  is  enhanced  (for  review  see  Nobili  et  al,  1998; 
Ashmore  and  Mammano,  2001;  Hudspeth,  2005;  LeMasurier  and  Gillespie,  2005). 
Prestin,  a member of the solute carrier family 26 (SLC26A)  of anion transporters has
26been  confirmed  as  the  motor molecule  (Zheng  et  al,  2000a,  Belyantseva  et  al,  2000, 
Liberman et al, 2002; for review see Dallos and Fakler, 2002).
In  comparison,  the  flask-shaped  IHCs  receive  the  majority  of  afferent 
innervation of the cochlea (around 90-95%) and rapidly transmit the sound signal (fine- 
tuned and maximally amplified by the OHCs) to the higher auditory centres in the brain. 
IHCs lack axons and dendrites;  at their base they make afferent synaptic contacts with 
the axonal terminals of the cochlea branch of the VUIth nerve (for review see Hudspeth, 
2005). Thus, it is IHCs that are the primary sensory receptors of the cochlea. This role is 
facilitated by unique L-type calcium channels at their basolateral surface; voltage-gated 
calcium channels that activate extremely rapidly but inactive very slowly (Platzer et al,
2000).  Depolarisation of IHCs drives the opening of the voltage-gated L-type calcium 
channels  leading to  a rise in  intracellular calcium  in the  IHC  cytoplasm.  This  in turn 
stimulates  neurotransmitter release  at  glutamatergic  synapses  on  the  auditory  afferent 
nerves  for  signal  propagation  and  hence,  timely  couples  IHC  depolarisation  to 
neurotransmitter release for hearing (for reviews  see Hudspeth,  2005;  LeMasurier and 
Gillespie, 2005).
1.2.2  The vulnerability of auditory hair cells.
Clearly,  hair  cells  of  the  cochlea  are  highly  specialised  sensory  cells;  they  play  a 
paramount role in the hearing process.  Loss of IHCs causes severe deafness. Whereas, 
loss of functional OHCs but not IHCs causes a shift in hearing thresholds (around 60-80 
decibels) this abolishes the fine-tuning of the sound input, which is crucial for frequency 
discrimination (for review see Forge and Wright, 2002; Hudspeth, 2005). Thus, perhaps 
not surprising it is loss of auditory hair cells that is a major cause of late onset hearing 
loss  (for  reviews  see  Jennings  and  Jones,  2001;  Fransen  et  al,  2003;  Gratton  and 
Vazquez, 2003; Ohlemiller, 2004; Gates and Mills et al, 2005).
Loss  of auditory hair cells concomitant with  loss  of hearing is  exacerbated by 
the fact that in mammal’s hair cell loss cannot be replaced by mitosis; auditory hair cells 
are terminally differentiated.  Furthermore, mammals do not posses the inherent ability 
to regenerate cochlea hair cells from surrounding supporting cells although this has been 
documented  in  other  species  including fishes,  amphibians,  and birds  (for reviews  see 
Feghali  et  al,  1998;  Staecker and Van De Water,  1998;  Bermingham-McDonogh  and 
Rubel,  2003;  Matsui  et  al,  2005).  At  birth  we  have  a  limited  number  of hair  cells, 
around  16,000 are present per cochlea (for review see Hudspeth, 2005) and these must
27be  maintained  in  our  lifespan  if we  are  to  retain  our  ability  to  hear  into  old  age. 
However, the intrinsic propensity of auditory hair cells to be maintained is exacerbated 
by  the  inherent  nature  of these  cells;  they  are  extremely  delicate  and  tremendously 
susceptible to damage by exogenous stress. Many environmental factors are thought to 
accelerate development of late onset hearing loss via their effects on hair cells. Acoustic 
trauma  is  probably  the  most  widely recognised  environmental  stress  to  auditory hair 
cells  (Emmerich  et  al,  2000;  Chen  and Fechter,  2003;  for review  see Lynch  and  Kil, 
2005). This is perhaps not surprising given that the delicate stereociliary hair bundles on 
the apical  surface of the hair cells intercept sound-induced vibrations from the middle 
ear.  Acoustic  trauma  can  manifest  from  exposure  to  an  isolated  incident  of intense 
sound or in comparison,  and perhaps rather simply,  the cumulative hub  of daily noise 
exposure -  a factor that has the potential to vary widely across different individuals over 
their lifespan. Viral infections and ototoxic therapeutic agents such as cisplatin used in 
chemotherapy,  and  gentamicin  an aminoglycoside antibiotic that is  widely used  as  an 
antimicrobial  agent  are  additional  sources  of  exogenous  stress  that  are  extremely 
deleterious  to  hair  cells  (for  review  see  Rybak  and  Whitworth,  2005).  Certainly,  for 
some  people  development  of  hearing  loss  induced  by  exposure  to  aminoglycoside 
antibiotics  is  due  to  presence  of a predisposing mutation  in  a  mitocochondrial  gene. 
Three mutations: A1555G, C1494T and delT961Cn in the mitochondrial  12S ribosomal 
RNA  gene  all  seem  to  confer  increased  susceptibility  to  the  ototoxic  effects  of 
aminoglycoside antibiotics  (for review see Fischel-Ghodsian,  2003;  Fischel-Ghodsian 
et al, 2004).
Studies with animals show that many acquired environmental stresses including 
acoustic trauma and ototoxic agents cause hair cell death via apoptosis (for reviews see 
Lefebvre  et  al,  2002;  Holley  et  al,  2005;  Cheng,  et  al,  2005;  Rybak  and  Whitworth,
2005). In addition, whether exogenous stress is inflicted through use of aminoglycoside 
antibiotics, cisplatin or through exposure to acoustic trauma, the outer hair cells appear 
the  most  susceptible  to  damage,  particularly  in  the  basal  region  of the  cochlea  (for 
reviews see Lynch and Kil, 2005; Rybak and Whitworth, 2005). This is evident in late 
onset hearing loss, which is characterised by hearing loss that predominates in the high 
frequencies  (for reviews  Jennings  and  Jones,  2001;  Fransen  et  al,  2003;  Gratton  and 
Vazquez, 2003; Ohlemiller, 2004; Gates and Mills et al, 2005).
Maintenance of hearing into  old  age is thought to be  strongly dependent upon 
the  continued  function  and  expression  of genes  that  are  involved  in  the  repair  and 
maintenance of auditory hair cells in response to exogenous stress and that are needed
28for long-term survival. Hence, common sequence variants in the general population that 
impair  the  functioning  or  expression  of  such  genes  could  be  a  risk  factor  for 
susceptibility to late onset hearing loss. Bm-3c is the candidate gene for susceptibility to 
late onset hearing loss that is the focus of this project and appears to function as a long­
term pro-survival  factor for auditory hair cells (Erkman et al,  1996, Xiang et al,  1997, 
Xiang et al,  1998 and Vahava et al,  1998); this will be discussed further in sections  1.8 
and 1.9.
291.3  Development of sensory hair cells.
The mammalian inner ear originates from the otic placode, a thickening of the ectoderm 
adjacent to the dorsal hindbrain that also gives rise to the VIII  ganglion neurons that 
will innervate the sensory hair cells of the inner ear (for reviews see Fritzsch and Beisel, 
2001; Fekete and Wu, 2002; Barald and Kelley, 2004). During embyrogenesis the octic 
placode invaginates to  form the otocyst,  a simple epithelial  sac.  The otocyst develops 
via  a  complex  pattern  of  morphogenetic  events  involving  proliferation,  apoptosis, 
migration  and  differentiation  to  form  the membraneous  labyrinth  of the inner ear;  an 
elaborate  fluid  filled  structure that  contains  the  specialised  sensory neuroepithelia  for 
hearing, motion and gravity (for reviews see Fritzsch and Beisel, 2001; Fekete and Wu, 
2002;  Barald  and  Kelley,  2004).  During  this  process  various  transcription  factor 
interactions  underlie  the  complex  cell  fate  decisions  that  are  made  to  ensure 
specification of various cell types that shape the intercalated sensory compartments that 
form the inner ear (for reviews see Fekete and Wu, 2002, Barald and Kelley, 2004).
The  sensory  neuroepithelia  for  hearing  resides  within  the  organ  of Corti  that 
extends along the coil of the cochlea duct.  As discussed, the organ of Corti is a highly 
differentiated  and  ordered  structure  consisting  of an  alternating  arrangement  of hair 
cells surrounded by supporting cells. In most mammals, a single row of inner hair cells 
is orderly arranged along the coil of the cochlea duct flanked by three rows of outer hair 
cells  on  the  outer  side  of the  spiral  (for  review  see  Forge  and  Wright,  2002).  The 
sequence  of developmental  events  that  dictates  this  specific  cellular  organization  is 
known to  act  along a basal  to  apical  developmental  gradient  and  appears to be based 
around a developmental model known as lateral inhibition (for reviews see Bryant et al, 
2002;  Fekete  and  Wu,  2002;  Hawkins  and  Lovett,  2004).  Understanding  the 
developmental  pathway  that  underlies  auditory  hair  cell  development  is  extremely 
important;  auditory hair cells have not been  shown to regenerate in mammals  and by 
understanding  how  these  hair  cells  are  specified  future  therapeutic  approaches  to 
hearing loss involving gene and stem cell therapies will be facilitated. Some of the main 
aspects of auditory hair cell development will be discussed.
1.3.1. Notch signalling in hair cell development in the auditory system.
Lateral  inhibition is  a mechanism by which cells  of a common origin go on to  adopt 
different  fates.  Simplistically,  the  basis  of  this  model  is  that  from  an  equivalent
30population of precursor cells  once a cell is committed to its primary fate this inhibits 
surrounding cells from committing to the same fate. Consequently, the surrounding cells 
follow  an  alternative developmental pathway.  In the developing organ of Corti  lateral 
inhibition  appears  to  be  mediated  by Notch  signalling  (for  reviews  see  Bryant  et  al, 
2002;  Fekete  and  Wu,  2002;  Hawkins  and  Lovett,  2004).  Notch  proteins  are  trans­
membrane  receptors  that  are  activated  by  direct  cell-cell  interactions  with  a  ligand- 
expressing  cell;  they  are  important  components  of  intracellular  signal  transduction 
cascades  that  regulate  specification  of cell  fate  (for  review  see  Weinmaster,  1998). 
Upon ligand binding it is proposed that proteolytic cleavage results in the dissociation 
of the intracellular domain of notch, which then translocates to the nucleus to activate 
target genes (for review see Weinmaster, 1998).
Zine  et  al,  2000 provided  clear evidence  that Notch  signalling is  important  in 
determining whether cells differentiate as hair cells or supporting cells. An investigation 
into the spatiotemporal expression pattern of Notchl  receptor and its ligands (Jagl  and 
Jag2)  in  the  developing  auditory  sensory  neuroepithelia  of  the  rat  revealed  an 
overlapping  but  distinct  expression  pattern.  During  early  hair  cell  differentiation 
(between El 8 and birth) Notch  1   and Jag 1   expression predominate in supporting cells 
whereas  Jag  2  predominates  in  newly  formed  hair  cells.  Shortly  after  birth  the 
expression dynamics change, hair cells as well as supporting cells express Notch  1   and 
Jag  2  expression  is  down-regulated  in  hair  cells.  The  significance  of this  expression 
pattern  on  development  of the orderly hair cell-supporting cell  network is  evident by 
treatment  of  developing  organ  of  Corti  explants  in  the  rat  with  antisense 
oligonucleotides directed against either Notchl  or Jagl. Interference of Notch signalling 
in this manner results in disruption of the normal cellular organization in the organ of 
Corti;  extra rows of hair cells are generated that are often not separated by supporting 
cells. In agreement with this, targeted deletion of the Jag2 gene in mice leads to an extra 
row of inner and outer hair cells presumably through disruption of Notch signalling to 
limit hair cell formation (Lanford et al, 1999). Similarly, Deltal  is another Notch ligand 
that is expressed by hair cells of the inner ear (Morrison et al,  1999) and in zebrafish, 
the deltaAdx2 allele, a dominant negative mutant of the zebrafish deltaA gene leads to an 
increase  in  the  number  of hair  cells  in  the  zebrafish  inner  ear  concomitant  with  a 
decrease in the size of the supporting cell population (Riley et al,  1999).  In support of 
this data, recently it has been shown that targeted deletion of the deltal  gene in mice 
leads to excess production of auditory hair cells (Brooker et al, 2006). Collectively this 
evidence  is  consistent  with  the  concept  whereby  hair  cells  use  Notch  signalling  to
31ensure  that  adjacent  cells  adopt  different  cell  fates  and  hence,  the  differentiation  of 
neighbouring  cells  into  supporting  cells.  More  recent  evidence  indicates  that  lateral 
inhibition  of hair  cell  differentiation  may not be  the  only role  of Notch  in  inner  ear 
development.  Over-expression  of  activated  Notch  in  the  chick  otocyst  reveals  that 
Notch also appears to function in specification of the prosensory patch from which hair 
cells and supporting cells will subsequently arise (Daudet and Lewis, 2005).
1.3.2  Transcription  factors  involved  in  hair  cell  development  in  the 
auditory system.
Development of the orderly hair cell-supporting cell network in the organ of Corti is not 
just dependent on Notch signalling. Many transcription factors are also involved in this 
process  and  have  been  established  to  play  crucial  roles  in  hair  cell  specification, 
differentiation  and  maintenance.  In  addition,  it  appears  that  at  least  some  of these 
transcription  factors  exhibit  interplay  with  components  of  the  Notch  pathway  (for 
reviews see Bryant et al, 2002; Fekete and Wu, 2002; Hawkins and Lovett, 2004).
Mathl  encodes  a  basic  helix-loop-helix  transcription  factor.  It  is  a  mouse 
homologue of the Drosophila melanogaster proneural gene atonal and is crucial for the 
generation  of sensory  hair  cells  in  mice  (Bermingham  et  al,  1999;  Zheng  and  Gao, 
2000). Bermingham et al,  1999 created Mathl-null mice by replacing the coding region 
of Mathl  with P-galactosidase (P-gal).  Examination of P-gal expression in Mathl-null 
(p-gal/p-gal) and heterozygous (p-gal/-) mice revealed that P-gal staining recapitulated 
the endogenous Mathl  expression pattern.  Mathl  expression (p-gal) is detected in the 
prospective  sensory epithelia of the otic vesicle at  E l2.5  before the hair cells  start to 
differentiate.  Expression  continues  throughout  the  epithelia  from  which  the  sensory 
organs will arise and in (P-gal/-) mice is restricted to the hair cells by E l8.5.  Scanning 
electron  and  transmission  electron microscope  analysis  showed  that  these  Mathl-null 
(p-gal/p-gal)  mice  failed  to  form  hair  cells  but  not  supporting  cells.  Progenitor  cells 
within  the  sensory  epithelia  appear  unable  to  differentiate  into  hair  cells;  hair  cell 
specific  markers  fail  to  stain  in  Mathl-null  mice at  a time by which  the markers  are 
expressed in wild type mice.  This knockout approach indicates that Mathl  is required 
for the specification of hair cells. A Mathl  transgenic approach in postnatal rat cochlear 
explant cultures is in agreement with this (Zheng and Gao, 2000).  The overexpression 
of Mathl  in the non-sensory cells of the greater epithelial ridge (adjacent to the organ of 
Corti)  where it is not normally expressed is sufficient to drive them into hair cells.  In
32addition,  overexpression  of  Mathl  in  supporting  cells  of  the  utricle,  part  of  the 
vestibular  complex  induces  their trans-differentiation  into  hair  cells  (Zheng  and  Gao,
2000).  Clearly  Mathl  is  an  important  developmental  gene  involved  in  hair  cell  fate 
determination.
Recent  evidence  suggests  that  although  Mathl  expression  is  crucial  for  the 
selection  and/or  differentiation  of hair  cells,  it  does  not  underlie  specification  of the 
initial  cell  lineage  that  forms  the  common  origin  from  which  sensory hair  cells  and 
supporting cells will  arise.  Instead,  Mathl  appears to  act downstream of this  cell  fate 
decision by selecting cells  from this already specified domain,  a patch of cells named 
the sensory primordium. This is an area of cells that have undergone their final mitosis, 
from which the complete population of sensory hair cells and supporting cells that form 
the mature organ of Corti will originate. Evidence suggests expression of Mathl in these 
cells once they have exited the cell cycle is the trigger to become hair cells rather than 
supporting cells.  It is proposed that lateral inhibition restricts Mathl  expression in the 
surrounding cells, which go on to develop as supporting cells (Chen et al, 2002).
More recently, a transgenic approach using an adenoviral vector has shown that 
Mathl  transfected  into  the  cochlea  of  adult  guinea  pigs  profoundly  deafened  by 
systemic  administration  of kanamycin  induces  generation  of hair  cells  and  improves 
hearing  thresholds  suggesting  regeneration  of functional  hair  cells  (Izumikawa  et  al, 
2005). Direct transdifferentiation of existing supporting cells into hair cells is thought to 
be the mechanism behind the hair cell regeneration. This data holds promise;  it shows 
that manipulating expression of an important developmental gene is a potential strategy 
for gene therapy in the mature cochlea. However, the data presented by Izumikawa et al 
is in its infancy. Although regenerated IHCs seem normal morphologically regenerated 
OHCs do not appear fully differentiated and acquisition of their normal functional role 
to fine-tune and amplify the sound input seems unlikely.
Mathl  is clearly a major positive regulator of hair cell specification.  Hes-1  and 
Hes-5  are  two  basic  helix-loop-helix  transcription  factors  that  participate  in 
development  of the orderly hair cell-supporting cell  network  in the organ of Corti by 
functioning  as  negative  regulators  of  inner  and  outer  hair  cell  differentiation, 
respectively (Zheng et al, 2000b; Zine et al, 2001). Hes-1 knockout and Hes-5 knockout 
mice  exhibit  a  significant  increase  in  the  number  of IHCs  and  OHCs,  respectively 
(Zheng et al, 2000b; Zine et al, 2001). The expression of Mathl  in these supernumerary 
hair cells (Zine et al, 2001) coupled with the fact Hes-1  overexpression in postnatal rat 
cochlea explant cultures can prevent production of supernumerary hair cells induced by
33ectopic Mathl  expression (Zheng et al, 2000b) has lead to the suggestion that Hes-1  and 
Hes-5  may  regulate  hair  cell  differentiation  by  antagonising  the  actions  of  Mathl. 
Although,  whether  Hes-1  and  Hes-5  directly regulate  Mathl  expression  to  limit  the 
number of hair cells that form is not completely clear at present.  In neuronal  systems 
there is evidence to  implicate that Hes-1  and Hes-5  are regulated by Notch signalling 
(Ohtsuka  et  al,  1999).  It  is  possible  that  this  also  occurs  in  the  developing  sensory 
epithelia  of the  cochlea;  expression  of components  of the  Notch  signalling  pathway 
including Jag2 and Notchl  are modified in the developing organ of Corti of Hes-1  and 
Hes-5 knockout mice (Zine and Ribaupierre, 2002).
In summary, the current evidence suggests that the decision as to whether a cell 
that has exited the cell cycle and formed part of the sensory primordium becomes a hair 
cell or supporting cell depends on a complex interplay between notch signaling, and the 
opposing  actions  of positive  and  negative basic helix-loop-helix  transcription  factors. 
Zine  and  Ribaupierre,  2002  present  a  good  overview  of  this  pathway  and  this  is 
summarized in Fig. 1.4.  After specification of the hair cell fate expression of Bm-3c, a 
POU  domain transcription factor is crucial  for the mature differentiation of hair cells; 
targeted deletion of the Bm-3c gene in mice leads to generation of immature hair cells 
that cannot develop stereociliary bundles (Erkman et al,  1996, Xiang et al, 1997,  1998). 
Therefore,  Bm-3c  appears  to  act  downstream  of Mathl  in  hair  cell  development.  In 
agreement  with  this,  the  ectopic  overexpression  of Bm-3c  in  postnatal  rat  cochlear 
explant cultures does not lead to the generation of supernumerary hair cells (Zheng and 
Gao, 2000). Bm-3c is the candidate gene for susceptibility to late onset hearing loss that 
is the focus of this project and will be discussed further in section 1.8 and 1.9.
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Figure 1.4 A schematic representation of a putative model to summarise the hair cell : supporting 
cell developmental pathway.  The decision as to whether a cell becomes a hair cell or supporting cell 
depends on a complex interplay between basic helix-loop-helix transcription factors (Hesl  and Hes5) 
and components of the Notch signalling cascade: the Notch 1  receptor (Nl) and the Notch ligands Jagl, 
Jag2, and Deltal (Dill in diagram). RBP-Jk: recombination sequence specific binding protein at the site 
Jk (also known as CBF1, core binding factor-1).  RBP-Jk is a DNA binding protein that is reported to 
form a complex with the cleaved intracellular domain of the Notch 1 receptor which then translocates to 
the nucleus to activate expression of target genes: shown as Hes 1 and Hes 5 in the diagram.
Reproduced from Zine and Ribaupierre, 2002.
351.4  The genetics of deafness.
The auditory process that enables us to hear is extremely complex and this is paralleled 
by  the  complexity  of  the  cochlea  in  the  inner  ear  where  the  sound  processing  is 
performed.  Genetically deafness  is  extremely heterogenous;  currently around  100  loci 
have  been  identified  for  non-syndromic  deafness  and  of the  39  genes  identified  the 
majority are expressed within the cochlear of the inner ear (see Van Camp and Smith, 
Hereditary  Hearing  Loss  Home  Page,  http://webhost.ua.ac.be/hhh/  and  Table  1.1). 
Cochleafhair  cells  play  a prime  role  in  the  auditory pathway they  are paramount  for 
mechanoelectrical  transduction  and  an  intricate  range  of molecular  components  are 
involved in hair cell function. Consequently, it is perhaps not surprising that defects in 
hair  cells  are  responsible  for  many  congenital  forms  of hereditary  hearing  loss  (for 
review see Petit et al, 2001; Petit 2006; Table 1.1). In addition, it is loss of cochlear hair 
cells  that  appears  to  be  a major cause  of late onset hearing  loss  exhibited by a large 
proportion of the ageing population (for reviews see Jennings and Jones, 2001; Fransen 
et al, 2003; Gratton and Vazquez, 2003; Ohlemiller, 2004; Gates and Mills et al, 2005). 
However,  in  comparison  to  many  congenital  forms  of  hereditary  hearing  loss  the 
genetics of late onset hearing loss is poorly understood at present.
The mutations responsible for monogenic forms of hereditary hearing loss often 
have  a  profound  effect  on  protein  function  and  within  the  last  decade  have  driven 
forward  great  progress  in  our  understanding  of  the  basic  hearing  mechanism  by 
identification  of many key players  in  the  hearing  process  (for  reviews  see  Steel  and 
Kros,  2001;  Bitner-Glindzicz,  2002;  Petit  2006).  The  discovery  of novel  congenital 
deafness genes in humans has been facilitated, in part, due to the closeness in homology 
between the human and mouse genomes. The identification of many spontaneous mouse 
mutants that underlie deafness in mice and subsequent mapping of the genes responsible 
has  aided  identification of human deafness  genes  (for review  see Probst and Camper, 
1999, Kieman and Steel, 2000; Ahituv and Avraham, 2002; Avraham, 2003). Similarly, 
the  large-scale  mouse  mutagenesis  screens  using  the  chemical  mutagen  N-ethyl-N- 
nitrosourea (ENU) to induce random point mutations into the DNA sequence has aided 
identification of novel genes involved in the hearing process in recent years and many 
more  are  still  anticipated  (for  review  see  Parkinson  and  Brown,  2002).  A  thorough 
discussion of the role of all 39 genes
36Table 1.1: Genes underlying hereditary non-syndromic deafness and 
corresponding mouse mutants (reproduced from Petit, 2005).
Primary defect Gene Gene product Forms  of human  deafness Mouso mutants
Hair celt* MY  07A Myosin VILA (motor protein) DFNB2F retinopathy* 
(Usher 1B) DFNA11
Shaker-1  (S?it)
MY015 Myosin  XV (motor protein) DFNB3 Shaker 2 (S/iZ)
MY06 Myosin VI  (motor protein) DFNA22 i cardiomyopathy* 
DFNB37
Snell's waltzer  iSv)
MY03A Myosin IIIA (motor protein) DFNB30
MYOIA Myosin  IA (motor protein) DFNA48
ACTG1 y-Actin (cytoskeietal  protein) DFNA20 (DFNA26)
USH1C Harmonin (PDZ domain-containing protein) DFNB18 ± retinopathy* 
(Usher 1C)
Deaf drcier (Dk-r)
Doaf drcier 2 Jackson
(Dfcr-ZJ)
WHRN Whirtin (PDZ domain-containing protein) DFNB31 Whirier (WJ)
CDH23 Cadher in-23 (cell-adhesion protein) DF NB12 t  retinopathy* 
(Usher ID)
W alter (V)
PC  DM 5 Protocadherin-15 (cell-adhesion  protein) DFNB23  t retinopathy* 
(Usher IF)
Ames waltzor lA v)
TMIE TMIE  (transmembrane domain-containing 
protein)
DFNB6 Spinner (S'r)
STRC Store odl in DFNB16
SLC26A5 Prestin (anion transporter) OFNB61 Slc26a5  f  c
ESPN Espin  (actin-bundling protein) DFNB36.  DFNA" Jorkcr1  Jo)
KCNQ4 KCNQ4 (K.*  channel  subunit) DFNA2
TMC1 TMC1  Itranemembrano channel liko protein) DFNB7  (DFNB11),  DFNA36 Doafnass (On) 
Beethoven iSrft)
OTOF Otoferlin (putative vesicle traffic protein) DFNB9
POU4F3 POU4F3 (transcription factor) DFNA16 Brn3c  '  ‘  Dreidl (Ddl)
Non-sentory cok* GJB2 Connexin-26 (gap junction protein) DFNB1,  DFNA3 i  keratodermia* 
(Vohwinkol,  palmoplantar kere 
toderma.  KID, Bart-Pumphrey)
Cx2&J,m >  Cmn
GJB6 Connexin-30 (gap junction protein) DFNB1,  DFNA31 keratodermia* 
(KID)
Cx30"~°
Cx26"  ICx30'’  '
GJB3 Connexin-31  (gap junction protein) DFNAi‘>
SLC26A4 Pendrin (1   Cl  transporter) DFNB41 thyroid goiter* 
(Pendred)
Pas  '  *
CRYM M-Cristallin lthyroid hormone binding protein?) OFNA,B
OTOA Otoancorin  (cell surface protein) DFNB 22
CLDN14 Claudin-14 (tight junction protein) DFNB 29 Clan 14  ,  r
COCH Cochlin (extracellular  matrix component) DFNA9
TMPRSS3 TMPRSS3 (transmembrane serine proteaso) DFNB8 (DFNB10)
MYH9 Myosin  IIA Imotor protein) DFNA17 j: giant platelets* 
(Fechtner)
MYH14 Myosin  IIC (motor protein) DFNA4
EYA4 EYA4 (transcriptional coactivator) DFNA10
POU3F4 POU3F4 (transcription factor) DFN3 Sex  linked fidget (sJf) 
Brn4  '  f
Tectorial membrane COL11A2 Collagen XI («2-chain) (extracellular 
matrix component)
DFNA13 1 osteochondro 
dysplasia* (Stickler  2)
C o l1 1 a 2 '°
TECTA 3-Tectorin (extracellular matrix component) DFNA8 (DFNA12). DFNB21 Tacts  ' "•
Unknown HDIA1 Diaphanous-1 Icytoekeleton regulatory protein) DFNA1
DFNA5 Unidentified DFNA6 DtnaS  '  *
WFS1 Wolframin  lendoplasmic-reticulum 
membrane protein)
DFNA6(DFNA14,
DFNA38) tdiabetas and optic 
atrophy* (Wolfram)
Tilted? (r/r)
TFCP2L3 TFCP2L3 (transcription factor) DFNA28
MTRNR1 Mitochondrial  12S rRNA ND*
MTTS1 Mitochondrial tRNA“ '1UCN' ND*
*Syndromic deafness.
"Subscript I < 3Mwtai undefined locus number.
‘Mutant obtained by gene knockout.
‘‘Mutant obtained  by targeted gene Inactivation in the cochlear and vestfcular aenaory epithelia. 
‘Abbreviation: ND. not defined nomenclature.
involved  in  non-syndromic  deafness  in  humans  that  have  been  identified  to  date  is 
beyond the scope of this discussion. However, some of the genes underlying hereditary 
hearing loss that have been identified in recent years will be discussed to demonstrate 
the  heterogeneity involved  and  the  complexity of the hearing process.  Genes  will  be 
discussed  according  to  the  nature  of the  defect  they  impose  including:  defects  that 
impair  the  functioning  of  the  delicate  cochlear  hair  cells,  that  upset  the  ionic 
homeostasis of the inner ear and that impair the functioning of the tectorial membrane.
371.4.1  Hair cell defects.
Many  abnormalities  in hair cells  that  cause deafness^ result  from  cytoskeietal  defects. 
For  example,  mutations  in  the  genes  encoding  the  unconventional  (non-muscle) 
myosins  (myosin  VI,  VIIA,  and  XV)  all  impair  hair  cell  structure  in  some  manner 
mainly by disrupting the organisation of the stereociliary hair bundle (for reviews  see 
Petit et al, 2001; Redowicz, 2002; Ahmed et al, 2003). Unconventional myosin proteins 
are  actin-based  motor molecules  that  channel  the  energy of ATP  hydrolysis  to  drive 
their motor along actin filaments. The structural integrity of the stereociliary hair bundle 
is  paramount  for  mechanoelectrical  transduction.  Hence,  mutations  in  the 
unconventional  myosins  underlie  many  forms  of hereditary  deafness.  For  example, 
mutations  in  myosin  VI  and  XV underlie  non-syndromic  deafness  loci  DFNA22  and 
DFNB3,  respectively.  Whereas,  mutations  in  myosin  VIIA  underlie  both  dominant 
(DFNA11)  and  recessive  (DFNB2)  forms  of non-syndromic  deafness.  Mutations  in 
myosin VIIA are also responsible for a syndromic form of hearing loss, Usher syndrome 
type  IB (for reviews see Petit et al, 2001; Redowicz, 2002; Ahmed et al, 2003). Usher 
syndrome  (USH)  is  the  most  common  cause  of  deafness  that  is  associated  with 
blindness.  The  shaker-1   mutant  is  a mouse  model  for  Usher  syndrome  type  IB;  the 
stereocilia are extremely disorganised and this leads to their eventual degeneration (for 
review  see  Ahmed  et  al,  2003).  Similar to  the  unconventional  myosins,  harmonin  is 
another important cytoskeietal component of hair cells and is located within the hair cell 
body and  stereociliary hair bundle.  Mutations  in the gene encoding harmonin,  a PDZ 
(Postsynaptic  density  protein,  Disc-large,  ZO-1)  domain  containing  protein  underlie 
Usher syndrome type 1C (Bitner-Glindzicz et al, 2000; Verpy et al, 2000) and DFNB 18 
(Jain et al,  1998). Recently, a number of investigations have reported that myosin VIIA 
together  with  several  other  USH  type  1   proteins  that  have  been  identified  to  date 
including  Cdh23  (USHID),  protocadherin  15  (USHIF)  and  SANS  (USH1G)  bind  to 
PDZ domains within harmonin to  form a dynamic functional  ‘protein network’  in the 
stereocilia  hair  bundle  that  is  essential  for  structural  integrity  (Boeda  et  al,  2002; 
Siemens et al, 2002; for reviews see El Amraoui and Petit, 2005; Reiners et al, 2006). 
This functional protein network is thought to be crucial for maturation of the hair cell 
stereocilia  during  development  and  may  also  be  involved  in  the  mechanoelectrical 
transduction process (for reviews see El Amraoui and Petit, 2005; Reiners et al, 2006.
381.4.2  Defects that impair the ionic homeostasis of the inner ear.
The ionic homeostasis of the inner ear is crucial for hair cell function.  The endolymph 
surrounding the hair cell stereocilia is enriched in potassium ions and this is crucial to 
maintain  the  endocochlea  potential  essential  for  mechanoelectrical  transduction  (for 
review  see  Forge  and  Wright,  2002).  Consequently,  defects  in  molecules  that  play 
important  roles  in  maintaining  the  ionic  balance  of the  inner  ear  lead  to  deafness. 
Mutations  in  the  voltage-gated  potassium  channel  KCNQ4  underlie  DFNA2  and  are 
thought to impair the potassium recycling in the inner ear (Coucke et al,  1999; Kubisch 
et al,  1999; Van Hauwe et al, 2000).  Similarly, mutations in the PDS gene that encodes 
the  protein pendrin are  responsible for Pendred  syndrome (the most  common form of 
hereditary  syndromic  deafness)  and DFNB4  (for review  see Petit  et  al,  2001;  Bitner- 
Glindzicz,  2002;  Schrijver,  2004).  Pendrin  is  an  anion transporter  and  is  proposed to 
function in endolymph homeostasis within the cochlear duct.  It appears that mutations 
in  PDS  that  abolish  the  transport  of ions  result  in  the  syndromic  form  of deafness, 
whereas mild mutations that simply impair the transmission of ions manifest in the non- 
syndromic form (Scott et al, 2000).
Mutations in the genes encoding gap junction proteins that are expressed in the 
inner  ear  are  also  thought  to  impair  the  potassium  recycling  of the  inner  ear.  Gap 
junction  proteins  are  a  major  means  of direct  cell-cell  communication  and  within  the 
inner  ear  are  found  in  abundance  in  the  supporting  cells  population  but  are  not 
associated with hair cells (for review see Forge and Wright. 2002). It is thought that the 
gap junctions  enable  the  supporting  cell  population  in  the  organ  of Corti  to  channel 
potassium  ions  away  from the  endolymph  surrounding  the  hair  cell  stereocilia.  Three 
genes  implicated  in  gap  junction  formation  in  the  inner  ear  have  been  identified  in 
hereditary  deafness;  these  are  the  connexins  genes:  GJB2  (DFNB1,  DFNA3),  GJB6 
(DFNB1, DFNA3) and GJB3 (DFNAi) (for reviews see Rabionet et al, 2000; Petit et al, 
2001; Gerido and White, 2004). Mutations in GJB2 underlie around 50% of all cases of 
autosomal  recessive,  non-syndromic,  congenital  deafness  in  Caucasian  populations. 
Mutations  in  two  other  connexin  genes  GJB6  and  GJB3  do  not  show  such  a  high 
prevalence  in  causing  hearing  loss  (for  reviews  see Rabionet  et  al,  2000;  Petit  et  al, 
2001;  Gerido and White,  2004).  More than 50 different mutations have been identified 
in  GJB2,  the  majority  are  recessive  mutations  that  underlie DFNB1.  However,  some 
mutations  present  as  dominant  and  underlie  DFNA3.  Certain  mutations  show  a  high 
prevalence depending on the ethnic background.  The recessive mutation 35delG is very 
common  in  Caucasian  populations  particularly  those  of  European-Mediterranean
39descent, but has yet to be identified in Japanese,  or African-American populations,  and 
it appears rare in Asian populations.  In contrast, the  167delT and 235delC mutations in 
GJB2 are prevalent amongst Jewish and Japanese populations, respectively (for reviews 
see Rabionet et al, 2000; Petit et al, 2001; Gerido and White, 2004).
1.4.3 Tectorial membrane defects.
The tectorial membrane that overlies the sensory neuroepithelia of the organ of Corti is 
a gelatinous membrane composed of an extracellular matrix; it provides a support that 
facilitates  deflection  of  the  underlying  hair  cell  stereocilia  for  mechanoelectrical 
transduction (for reviews see Forge and Wright, 2002; Hudspeth, 2005). Consequently, 
mutations  in  genes  encoding  components  of this  extracellular  matrix  are  causative  of 
hereditary hearing impairment.  TECTA  that encodes the a-tectorin protein is one such 
gene;  it  is  responsible  for  both  DFNA8/12  and  DFNB21  (for  reviews  see  Bitner- 
Glindzicz,  2002;  Petit,  2005).  Similarly  mutations  in  COL11A2  that  encodes  the  a2 
chain of the structural protein collagen XI, an important extracellular matrix component 
of the tectorial membrane are responsible for DFNA13  in addition to  some syndromic 
forms of deafness (for reviews see Bitner-Glindzicz, 2002; Petit, 2005).
In  summary,  it  is clear that  many of the genes underlying  syndromic and non- 
syndromic  forms  of hereditary  hearing  loss  encode crucial  components of the cochlea 
that  are  essential  for  maintaining  structural  integrity.  Identification  of the  causative 
mutations  responsible  for  monogenic  forms  of  hereditary  hearing  loss  have  reaped 
tremendous  advances  in  our  understanding  of  the  molecular  basis  of  the  hearing 
mechanism  and  indeed,  hearing  loss  attributable  to  monogenic  defects.  However,  in 
contrast to these monogenic congenital forms of syndromic and non-syndromic hearing 
loss  very  little  is  known  about  the  genetic  basis  of late  onset  hearing  loss,  which  is 
exhibited by a large proportion of the ageing population. Theoretically, any of the genes 
involved  in  congenital  forms  of hearing  loss  are  candidates  for  susceptibility  to  late 
onset  hearing  loss;  milder  mutations  may  exist  with  phenotype  of  late  onset. 
Understanding  the  pathophysiology  and  the  genetics  of  late  onset  hearing  loss  is 
explored in detail in the next section (1.5).
401.5  Understanding  the  pathophysiology  of  late  onset  hearing
loss.
1.5.1  Defining late onset hearing loss.
Historically,  age-related  hearing  loss  (ARHL)  has  been  classified  into  four  distinct 
categories based on audiometry and histological data: sensory, strial (metabolic), neural 
and  conductive  (Schuknecht,  1955;  1964;  Schuknecht  and  Gacek,  1993).  Under  this 
framework  laid  down  by  Schuknecht,  sensory ARHL  is  categorised  physically by an 
elevation of hearing thresholds in the high frequencies and at the cellular level by a loss 
of hair  cells  in  the  basal  turn  of the  cochlea.  Strial  ARHL  is  characterised  by  an 
elevation of hearing thresholds across all frequencies producing a flat audiogram and by
c-
degeneration  of the  stria  vasularis.  Neural  ARHL  is  defined  by  a  sloping  audiogram 
with  all  frequencies  reduced  and  a  loss  in  the  number  of  spiral  ganglion  neurons. 
Existence of conductive ARHL is hypothetical and is predicted to contain a descending 
sloping audiogram without any specific pathological  associations.  Hence,  its existence 
remains  controversial.  In  reality,  there  appears  an  overlap  between  these  pathologies 
and convincing evidence for discrete forms of ARHL is lacking (Scholtz et al, 2001; for 
reviews see Fransen et al, 2003;  Gratton and Vazquez, 2003;  Ohlemiller, 2004;  Gates 
and  Mills,  2005).  Indeed,  the most  common  form  of ARHL  appears  to be bilaterally 
symmetrical,  most  pronounced  in  the  high  frequencies  and  sensorineural  in  origin. 
Histopathologic investigations reveal that a progressive loss of hair cells initiating in the 
basal  turn  of  the  cochlea  and  proceeding  along  a  basal  to  apical  gradient  is  the 
predominant abnormality and this is usually coupled with a reduction in the number of 
spiral  ganglion  neurons.  OHCs  are  more  severely  affected  than  IHCs;  the  OHC  loss 
preceding IHC loss. Loss of spiral ganglion neurons where present appears secondary to 
hair cell  loss  (for reviews  see Jennings and Jones,  2001;  Fransen  et al, 2003;  Gratton 
and  Vazquez,  2003;  Ohlemiller et  al,  2004,  Gates  and  Mills,  2005).  It is this  type of 
sensorineural  hearing  loss  concomitant  with  ageing  that  is  the  focus  of this  project, 
which for clarity will be referred to as  ‘late onset hearing loss’  and the general aim of 
this  project  is  to  investigate  the  genetic  factors  that  underlie  susceptibility  with  the 
intention to help elucidate why only some people retain good hearing into old age.
Late onset hearing loss is an extremely common and complex disease becoming 
increasingly common with advancing age. Similar to many other common diseases such 
as  cardiovascular  disease,  diabetes,  cancer  and  asthma,  late  onset  hearing  loss  is 
regarded as a polygenic, multi-factorial disease, the aetiology of which is suspected to
41involve a complex genetic-environmental interplay (for reviews see Jennings and Jones, 
2001,  Fransen  et  al,  2003;  Gratton  and  Vazquez,  2003;  Ohlemiller,  2004;  Gates  and 
Mills, 2005). Delineating the pathophysiology of late onset hearing loss is complex due 
to  the  multi-factorial  nature  of the  disease.  Genetic  susceptibility  is  confounded  by 
environmental  factors  including  noise  trauma  and  ototoxic  drugs,  and  possibly 
nutritional  health.  Breaking  all  these  factors  down  into  discrete  categories  and 
understanding their individual contribution to development of late onset hearing loss is 
extremely difficult if not impossible.  Drawing a clear distinction between hearing loss 
due to  the  ‘ageing’  process  and chronic noise exposure is particularly problematic,  as 
there  appears much overlap between these two  factors.  Indeed,  it is likely that ARHL 
and noise-induced  hearing loss,  NIHL (hearing loss  caused by prolonged  exposure to 
moderate  level  sound)  are  not  separate  pathologies  but  overlapping  phenomena  (for 
reviews  see Ohlemiller et al,  2004;  Gates  and Mills,  2005).  In agreement with this,  it 
has  been  proposed  that  sensory  ARHL  as  characterised  by  Schuknecht,  1955;  1964; 
Schuknecht and Gacek,  1993, in some cases at least, has more to do with the cumulative 
effect  of acquired  acoustic trauma than the intrinsic process  of auditory ageing  alone 
(for reviews see Ohlemiller et al, 2004;  Gates and Mills, 2005).  Consequently,  for the 
purpose  of this  thesis  the  common,  symmetric,  sensorineural  high  frequency  loss  of 
hearing concomitant with advancing years was not defined by either of the commonly 
used  terms:  ARHL  or  presbyacusis.  It  is  clear  that  ARHL  is  not  just  due  to  the 
inevitable process  of ageing in the auditory system.  Indeed,  there is  a large degree of 
inter-individual variability in onset of hearing loss and some people retain good hearing 
into old age (for reviews see Gates and Mills, 2005).  In addition, there are conflicting 
reports in the literature regarding use of the term presbyacusis, which translated literally 
means  ‘elder  hearing’.  Presbyacusis  has  been  described  as  ‘the  progressive 
sensorineural hearing loss associated with ageing’ (Zheng et al,  1998; Alam et al, 2001) 
and  in  contrast,  much more broadly,  as  ‘the natural  failure of hearing with  advancing 
years  caused by degenerative changes in the internal  ear’  (Jennings  and Jones,  2001). 
Hence, for the purpose of this thesis and for clarity the term late onset hearing loss was 
adopted  to  describe  the  common,  symmetric,  sensorineural  high  frequency  loss  of 
hearing  with  advancing  years  to  encompass  the  multifactorial  nature  of this  disease. 
Late  onset  hearing  loss  was  viewed  as  hearing  loss  manifesting  from  acquired 
environmental insults (for example, acoustic trauma and ototoxic agents) to the auditory 
system  combined  with  the  intrinsic  process  of auditory  ageing.  This  concept  of late
42onset  sensorineural  hearing  loss  is  in  agreement  with  the  current  consensus  as 
documented in the following recent reviews: Ohlemiller, 2004; Gates and Mills, 2005.
1.5.2  The genetic basis of late onset hearing loss.
At  present  genetic  susceptibility  to  late  onset  hearing  loss  is  poorly  understood  in 
humans.  Monogenic traits including syndromic and nonsyndromic forms of congenital 
hearing loss often result from deleterious mutations within the coding regions of single 
genes  that  have  a profound  effect  on  protein  function.  In  contrast,  it  is  thought  that 
moderate  variations  in  gene  expression  or  function  at  multiple  loci  underlie 
susceptibility to complex traits such as late onset hearing loss (for review see Fransen et 
al,  2003).  A genetic basis underlying susceptibility to late onset hearing loss has long 
been  suspected.  This  is  illustrated  from  studies  involving  industrial  workers  who  are 
exposed to the same noise over the duration of their career.  For example, jute weavers 
are exposed to constant high-level noise (99-102 decibels) as an occupational hazard yet 
not all go on to develop late onset hearing loss induced by noise trauma; differences as 
great as 70dB have been reported between the least and most effected workers (Taylor 
et  al,  1965).  Hence,  suggesting  that  genetic  factors  may  be  conferring  increased 
susceptibility to chronic noise in the most affected workers. In addition, for some people 
at  least,  it  is  clear  that  susceptibility  to  late  onset  hearing  loss  is  inherited.  The 
heritability of late onset hearing loss is estimated to be in the region of 35 to 55% based 
on data scored from two studies: a Swedish population based study designed to examine 
the contributions of genetic and environmental factors on the development of ARHL in 
male twins (Karlsson et al,  1997), and an auditory study undertaken on members of the 
Framingham  Heart  Study  to  compare  hearing  threshold  levels  between  genetically 
unrelated  people  (spouse  pairs)  and  genetically  related  people  (sibling  pairs,  parent- 
child pairs) (Gates et al, 1999).
In mice, steady progress is beginning to be made in unravelling the genetics of 
late onset hearing loss.  Certain inbred strains of mice are prone to development of late 
onset sensorineural hearing loss (or ARHL as it is commonly referred to in mice) and 
considerable variation in onset and severity of the hearing loss is exhibited (Erway et al, 
1993, Willott et al,  1998, Johnson et al, 2000). Three loci have been identified in mice 
that underlie  susceptibility to  ARHL:  Ahll  on mouse chromosome  10  (Johnson et al, 
1997)  and  in more recent years,  Ahl2  on mouse chromosome  5  (Johnson and Zheng, 
2002) and Ahl3 on mouse chromosome  17 (Nemoto et al, 2004). The gene responsible
43for Ahll  has been identified as cadherin-23, Cdh23, (Bryda et al, 2001; Di Palma et al, 
2001a; Noben-Trauth et al, 2003) and evidence, albeit controversial, suggests that this is 
an  important  structural  component  of the  stereocilia  tip  link  (Siemens  et  al,  2004; 
Sollner  et  al,  2004;  Tsuprun  et  al,  2004;  Lagziel  et  al,  2005;  Michel  et  al,  2005). 
Currently,  the  genes  underlying  loci  Ahl2  and  Ahl3  have  yet  to  be  identified  at  the 
molecular level.  However,  once identified the genes responsible for Ahl2  and Ahl3  in 
mice would join Cdh23 (Ahll) as good candidates for genetic susceptibility to late onset 
hearing loss in humans (Cdh23 as a candidate gene for late onset hearing loss in humans 
is discussed further in section 1.7.1).
At the onset of this project no common genetic variant had been identified as a 
risk  factor  for  susceptibility  to  late  onset  hearing  loss  in  humans.  Although,  a  rare 
genetic variant in the Bm-3c gene had been found to be responsible for a monogenic 
form of adult onset hearing loss, DFNA15, in a large Israeli-Jewish family (Vahava et 
al,  1998).  As  such the  Bm-3c  gene represented  an  excellent  candidate gene in which 
common sequence variants with a subtle effect on expression or function could underlie 
susceptibility to late onset hearing loss in the general population. The Bm-3c gene is the 
candidate gene chosen for the focus of this project and evidence that this gene is a good 
candidate gene for susceptibility to late onset hearing loss is reviewed in section 1.8.
1.5.3  The  interaction  between  noise  trauma  and  ageing  in  the  auditory 
system.
It has  been  suggested  that  the  effects  of ‘ageing’  and  ‘chronic  noise’  on  the  cochlea 
contribute  to  the  same  pathology.  That  is,  ARHL  and  NIHL  (hearing  loss  caused  by 
prolonged  exposure  to  moderate  level  sound)  are  not  separate  pathologies  but 
phenomena that overlap.  In agreement with this proposal the impact of acoustic trauma 
and ageing can both be localised to the high frequency region of the cochlea and at the 
cellular level  both NIHL  and  sensory ARHL  are  characterised by similar histological 
defects; a main feature of which is a loss of auditory OHCs (for reviews see Fransen et 
al, 2003; Ohlemiller et al, 2004). Furthermore, after a lifetime of chronic noise exposure 
ARHL  and NIHL  are reported  to be practically indistinguishable  audiometrically (for 
review  see  Fransen  et  al,  2003).  However,  the  relationship  between  chronic  noise 
exposure  and  ageing  in  the  cochlea  is  equivocal  and  the  mechanism  by which  these 
factors  may  induce  the  same  pathology is  far  from  clear.  Several  models  have  been 
proposed  to  explain  the  interaction  between  NIHL  and  ARHL  (for  review  see
44Rosenhall,  2003).  The  traditional,  and perhaps  simplest  concept  is  that  the  effects  of 
chronic noise exposure and ageing are ‘additive’; each adds to the pathology (for review 
see  Rosenhall,  2003).  Indeed,  it  is  thought  that  sensory  ARHL  as  characterised  by 
Schuknecht,  1955;  1964;  Schuknecht  and  Gacek,  1993,  has  more  to  do  with  the 
cumulative  effect  of acquired  acoustic  trauma  than  the  intrinsic  process  of auditory 
ageing  alone  (for  reviews  see  Ohlemiller  et  al,  2004;  Gates  and  Mills,  2005).  An 
alternative  concept  is  that  chronic  noise  exposure  and  ageing  interact  to  cause  the 
pathology;  that  is,  gene-environmental  interactions  underlie the pathology rather than 
just a purely additive effect between a gene(s) and the environment. Indeed, in mice an 
interaction between NIHL and ARHL is well  documented and there is good evidence 
that noise exposure can accelerate onset of ARHL in genetically susceptible mice.  For 
example, mice homozygous for the ARHL gene, Ahll  (Cdh23 753A  / Cdh23753A ) develop 
ARHL  but  these  mice  exhibit  an  accelerated  ARHL  if they  are  exposed  to  acoustic 
trauma (Erway et al, 1996, Davis et al, 2001; Davis et al, 2003).
In practice,  it is likely that both additive and non-additive effects as illustrated 
by Ahl 1   homozygous mice are important in explaining the relationship between chronic 
noise exposure and ageing in the cochlea. Furthermore, the recent finding that Cdh23 is 
also  implicated  in susceptibility to NIHL in mice (Holme and  Steel,  2004)  suggests a 
common  molecular  pathway(s)  may  be  involved  in  the  pathogenesis  of NIHL  and 
ARHL lending further support to the suggestion that ARHL and NIHL are not distinct 
pathologies.
1.5.4  Cellular and molecular mechanisms of late onset hearing loss.
It  is  clear that  a complex  genetic -  environmental  interplay underlies  susceptibility to 
late onset hearing loss and that a major cause of this disease is loss of auditory hair cells 
(for reviews see Jennings and Jones, 2001, Fransen et al, 2003;  Gratton and Vazquez, 
2003; Ohlemiller, 2004; Gates and Mills, 2005). However, the aetiology of the disease 
that leads to the loss of these hair cells is as yet uncertain.  Hair cell loss could be the 
result  of  pathological  changes  intrinsic  to  hair  cells  or  it  could  be  secondary  to 
pathological changes extrinsic to hair cells; some of the possible molecular mechanisms 
intrinsic to hair cells will be discussed.
Many  lines  of  evidence  from  studies  with  rodents  suggest  that  apoptosis 
underlies  the  aetiology of hair cell  loss  concomitant with ageing  and  development of 
late onset hearing loss (Usami et al,  1997, Zheng et al,  1998, Alma et al, 2001). Zheng
45et al,  1998 measured the distortion product of otoacoustic emission (DPOAE) in aged 
gerbils  compared  to  young  for  an  indication  of  outer  hair  cell  function  and  in 
accordance  with  this  analysis  examined  the  incidence  of apoptosis  in  the  cochlea  of 
these gerbils by the TUNEL (Terminal  dUTP  nick end labelling)  assay.  This analysis 
revealed  TUNEL  positive  cells  predominantly  in  OHCs  compared  to  IHCs  and  the 
TUNEL  positive  cells  correlated  strongly  with  the  aged  gerbils  that  showed 
deterioration in cochlearfunction compared to the young control group and aged gerbils 
that  showed  no  signs  of  deterioration  in  cochlea  function  (Zheng  et  al,  1998). 
Furthermore, immunohistochemical analysis on the cochlea in aged gerbils for specific 
members  of the  apoptosis  cascade  suggests  that  apoptotic  cell  death  observed  in  the 
aged cochlea is due to suppression of bcl-2 protein expression and caspase-3  activation 
(Alam  et  al,  2001).  Within  the  organ  of Corti  of aged  gerbils,  the  number of bcl-2- 
immunostained  cells  was  found to be  significantly decreased  along the basal,  second, 
and apical turns and this was in accordance with a significant increase in the number of 
Caspase-3p20  immunostained  cells.  These  results  were  not  observed  in  the  young 
gerbils,  and  were  more  marked  in  the  aged  gerbils  that  had  severely  deteriorated 
DPOAE responses suggestive of dysfunction at the OHC level (Alam et al, 2001). It is 
possible that  the  apoptotic  loss  of auditory hair  cells  is  the  end point  of a molecular 
pathway(s) that underlies the pathophysiology of late onset hearing loss.  Accordingly, 
genes involved in initiating or regulating apoptosis in hair cells are potential candidates 
for susceptibility to  late onset hearing loss;  common sequence variants  in  such  genes 
could confer increased risk to this disease.
Ageing can be regarded an inherent process of cellular deterioration due to the 
progressive accumulation of metabolic and physiological changes (Partridge and Gems,
2002).  Several  theories  have  been  proposed  to  explain  the  ageing  process  at  the 
molecular level including: the dysdifferentiation theory of ageing, the telomerase theory 
of ageing and the ‘mitochondrial clock theory’ of ageing (also known as the membrane 
hypothesis of ageing). It is suggested that aspects of all these theories are applicable to 
the  ageing  process  and  indeed  hearing  loss  associated  with  ageing  (Seidman  et  al,
2002).  Consequently,  genetic  susceptibility  to  late  onset  hearing  loss  could  be 
precipitated by common sequence variants in genes involved in any of these molecular 
pathways.  One  theory to  have received  particular  attention  in  recent years  to  explain 
hearing  loss  associated  with  ageing  is  the  ‘mitochondrial  clock  theory’  of  ageing 
(Seidman et al, 1997, 2000, 2002, 2004, Fischel-Ghodsian et al, 2004, Ohlemiller, 2004, 
Pickles,  2004).  The  ‘mitochondrial  clock  theory’  is  based  upon  the  generation  of
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are  the  extremely  reactive  by-products  of  oxidative  metabolism  produced  by  the 
mitochondria.  One  physiological  feature  of ageing  is  a  reduced  blood  flow  to  many 
tissues including the cochlea and this results in increased ROS generation (Seidman et 
al, 1996). The ROS have the potential to damage mitochondrial DNA leading to specific 
deletions and ROS can lead to a reduction in the mitochondrial membrane potential with 
impaired mitochondrial function leading to yet more ROS production. Hence, the main 
tenet of this theory is the more damage that is accumulated the more the mitochondrial 
clock is accelerated to the point where the mitochondrion is rendered bioenergetically 
deficient.  Therefore,  long-term  survival  of  auditory  hair  cells  and  maintenance  of 
hearing may depend at least in part on the energy status of the mitochondria.
There  is  much  evidence  to  support the  involvement  of ROS  in  the molecular 
pathogenesis of late onset hearing loss (McFadden et al,  1999a; McFadden et al  1999b; 
Ohlemiller  et  al,  1999;  Staecker  et  al,  2001).  One  such  line  of evidence  stems  from 
superoxide  dismutase-1,  SOD1  (also  known  as  copper/zinc  superoxide  dismutase, 
Cu/Zn SOD) knockout mice (McFadden et al,  1999a; McFadden et al  1999b).  SOD1  is 
a cellular antioxidant enzyme that catalyzses the dismutation of the superoxide radical 
thus  averting  direct  cellular  damage  via  this  radical  (McCord  and  Fridovich,  1969). 
Mice knockout for the SOD1 gene exhibit increased susceptibility to ARHL; age-related 
changes in cochlea pathology including loss of auditory hair cells are more marked in 
SOD1  knockout mice  compared to  equivalent  aged  wild-type  mice  (McFadden  et  al, 
1999a; McFadden et al  1999b) and this correlates with a significantly greater elevation 
in ABR thresholds at 8, 16 and 32kHz for SOD1 knockout mice compared to equivalent 
aged wild-type mice (McFadden et al  1999a). Interestingly, mice with targeted deletion 
of the SOD1  gene are also more susceptible to NIHL (Ohlemiller et al, 1999) suggesting 
that at least one molecular mechanism whereby ageing and acoustic trauma contribute 
to  late  onset  hearing  loss  is  mediated  via  superoxide  radical  generation.  This  is  in 
agreement  with  the  notion  that  ARHL  and  NIHL  are  not  separate  pathologies  but 
phenomena united by a common molecular pathway(s).
A  role  for  ROS  in  the  molecular  pathogenesis  of NIHL  is  well  documented 
(Ohinata  et  al,  2003;  Yamashita  et  al,  2004;  for  review  see  Lynch  and  Kil,  2005). 
Interestingly, acoustic trauma to the cochlea is not the only exogenous stress that results 
in ROS generation; generation of ROS are also implicated in hair cell damage following 
use  of  ototoxic  agents  for  example,  cisplatin  and  aminoglycoside  antibiotics  (for 
reviews see Kopke et al,  1999; Campbell et al, 2003; Rybak and Whitworth, 2005). It is
47suggested  that  oxidative  stress  inflicted  on  auditory  hair  cells  via  any  of  these 
environmental insults may underlie the apoptotic hair cell death that is observed in the 
cochlea when these exogenous factors are tested in animal models of hearing loss (for 
reviews  see  Duan  et  al,  2002;  Lefebvre  et  al,  2002;  Le  Prell  et  al,  2003;  Fischel- 
Ghodsian et al, 2004). It is tempting to speculate that these environmental insults on the 
cochlea act at least in part, by accelerating the demise of the mitochondrial clock. More 
recent evidence to illustrate the importance of functional mitochondria for maintenance 
of hearing into old age stems from transgenic mice that carry a proof reading-deficient 
version  of  the  mitochondrial  DNA  polymerase  y  (POLG);  these  mice  accumulate 
mitochondrial mutations and exhibit an accelerated ageing including ARHL (Kujoth et 
al, 2005).
In  summary,  late  onset  hearing  loss  is  an  extremely  common  and  complex 
disease  attributable  to  a  complex  genetic-environmental  interplay.  The  predominant 
type of late onset hearing loss in adults and exhibited by a large proportion of the ageing 
population  is  sensorineural  in origin and  a loss  of cochlear hair cells,  specifically the 
outer  hair  cells  is  one  of the  main  histological  defects.  It  is  likely  that  apoptosis 
underlies  cochlea hair cell  loss  and  that  survival  is  to  some  extent  interrelated to  the 
energy  status  of  the  mitochondria.  In  any  case  it  seems  clear  that  increased  ROS 
generation whether through acquired auditory stress such as noise trauma and ototoxic 
agents or the inherent process of auditory ageing plays a crucial pathogenic role.
481.6  Methods  for  studying  late  onset  hearing  loss:  a  complex
disease.
Similar to many other common diseases such as cardiovascular disease, diabetes, cancer 
and  asthma,  late  onset  hearing  loss  is  an  extremely  common  and  complex  trait.  A 
complex trait can be defined as a ‘disease where susceptibility is controlled by multiple 
genetic and environmental risk factors and where each of these risk factors has only a 
modest effect on susceptibility’  (Cardon and Abecasis, 2003).  Identifying the common 
genetic variants that predispose to complex disease such as late onset hearing loss is of 
immense importance; it will facilitate our understanding of the disease at the molecular 
level  and provide  a basis  upon which therapeutic intervention to  slow or halt disease 
progression  can  be  developed.  One  model  that  has  been  proposed  to  explain  genetic 
susceptibility  to  complex  traits  is  the  common  disease:  common  variant  (CD:CV) 
hypothesis (for reviews see Smith and Lusis, 2002; Wright et al, 2003). The principle of 
this model is that common genetic variants in the general population (with a rare allele 
frequency of or greater than  1%) underlie  susceptibility to  common  complex  disease. 
Hence,  common alleles that predispose to the disease will be more prevalent amongst 
affected  individuals  than  those  who  remain  unaffected  and  these  alleles  have  the 
potential to be identified in large-scale population based case-control association studies 
(Risch  and  Merikangas,  1996).  However,  delineating  the  genetic  basis  of late  onset 
hearing loss as with all traits of a complex nature is difficult.  Genetic susceptibility is 
confounded by environmental interplay and this is exacerbated by the polygenic nature 
of the  disease;  a  plethora  of  factors  are  thought  to  interact  to  determine  the  final 
phenotype.
1.6.1  The nature of DNA sequence variation that underlies susceptibility to 
complex disease.
Genetic predisposition to complex disease such as late onset hearing loss is thought to 
result  from  subtle  inter-individual  variations  in  gene  function  and  /  or  expression  at 
multiple loci (for reviews see Smith and Lusis, 2002; Fransen et al, 2003; Wright et al,
2003).  Consequently,  the  nature  of DNA  sequence  variants  that  predispose  to  such 
complex traits are thought to have a mild effect on phenotype and these could manifest 
within any of the  following regions  of a candidate  gene:  the  coding region,  intron or 
regulatory  region(s).  For  example,  common  sequence  variants  that  occur  within  the
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substitutions that although may not change an amino acid in the protein product could 
affect  alternative  splicing  of  the  gene.  Indeed,  synonymous  single  nucleotide 
substitutions  have  the  potential  to  impair  existing  or  create  novel  exonic  splicing 
enhancer or silencer sites  leading to  an accumulation of both  aberrantly and  correctly 
spliced  transcripts  that  have  a mild  affect  on  phenotype.  In  a  similar manner,  single 
nucleotide substitutions within intronic splicing enhancer or silencer sites can lead to a 
similar  effect  (for  review  see  Nissim-Rafinia  and  Kerem,  2002).  Alternatively,  non- 
synonymous single nucleotide substitutions that result in amino acid substitutions could 
have  a  mild  affect  on  phenotype  if  they  occur  outside  of  well-conserved  protein 
domains that are crucial for functioning of the encoded protein.
Traditionally searches for sequence variants in disease genes have focussed on 
the  coding  region  of candidate  genes  as  opposed  to  the  regulatory  regions  with  the 
effect(s)  of  sequence  variants  in  the  promoter  of  a  candidate  gene  often  going 
uncharacterised  and  being  excluded  from  analysis.  However,  sequence  variants  that 
manifest within the regulatory region of a candidate gene have the potential to result in 
subtle inter-individual varations in gene expression. For example, promoter variants can 
disrupt  existing or create novel  cis-acting elements  and hence,  modify the binding of 
transcription  factors  needed  for  gene  regulation.  Indeed,  there  is  increasing  evidence 
that  sequence  variants  within  gene  regulatory  regions  underlie  susceptibility  to 
common, complex disease (Dawson et al,  1993; Zhang et al,  1999; Jormsjo et al, 2000; 
Niimi  et  al,  2002).  In  addition,  the  importance  of promoter variants  as  a  source  of 
common inter-individual sequence variation is clearly evident from a recent large-scale 
systematic  study  into  the  extent  of functional  sequence  variation  that  occurs  within 
proximal promoter sequences (Hoogendoom et al, 2003). Hoogendoom et al examined 
the  first  500bp of 5’-flanking promoter sequence  in  170 human promoters  and  found 
that around 35% of the distal promoters screened contained common sequence variants, 
typically in the form of single nucleotide substitutions and of the promoter haplotypes 
examined  approximately  one  third  significantly  altered  transcriptional  activity  when 
tested in reporter gene assays (Hoogendoom et al, 2003).
Furthermore, sequence variants that affect gene regulation are not just limited to 
the promoter of a gene they can manifest in the 3’- or 5’-untranslated region (UTR) of a 
gene.  UTR  sequence  is  transcribed  to  mRNA  but  is  not  translated  to  protein  and  is 
involved in the control of gene expression at the post-transcriptional level by affecting 
mRNA  stability  and  translation  (for  reviews  see  Conne  et  al,  2000;  Misquitta  et  al,
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cis-acting elements within the UTR of candidate genes have the potential to modifying 
the  binding  of  proteins  needed  for  gene  regulation  thus,  leading  to  subtle  inter­
individual differences in gene expression that may be important in the pathophysiology 
of complex disease (Lambert et al, 2003; Hu et al, 2005; Wang et al, 2006). Therefore, 
when  attempting  to  study  complex  disease  and  attempts  are  made  to  elucidate  the 
genetic determinants responsible,it is important to consider the nature of DNA sequence 
variation that is likely to underlie susceptibility.
1.6.2  Genetic approaches to dissect the genetic factors that contribute to 
late  onset  hearing  loss  susceptibility:  linkage  and  candidate  gene  case- 
control association analysis.
Two methods that have been widely used in an attempt to delineate the genetic basis of 
complex  disease  are:  linkage analysis  and the candidate gene case-control  association 
approach (Lander and Schork,  1994, Douglas et al, 2001, Shifman et al, 2002, Botstein 
and  Risch,  2003).  Classically,  linkage  analysis  examines  the  segregation  of specific 
genetic  markers  with  the  disease  phenotype  in  affected  family  pedigrees  to  map  the 
disease  locus  in  the  genome;  it  makes  no  assumptions  about  the  gene  involved  in 
disease susceptibility. If the map position can be narrowed down sufficiently then genes 
within the candidate region can be examined for the presence of mutations in affected 
subjects. Linkage analysis has been used very successfully in the identification of genes 
that have a major effect on disease phenotype and follow classic Mendelian inheritance 
patterns  for  example,  in  the  identification  of  the  many  genes  found  to  underlie 
monogenic forms of hereditary deafness (see Van Camp and Smith, Hereditary Hearing 
Loss  Home  Page,  http://webhost.ua.ac.be/hhh/).  A  mutation  that  co-segregates  only 
with affected individuals and is clearly deleterious to protein function is typically taken 
as  evidence  for  involvement  of  the  gene  in  the  disease  phenotype.  However,  in 
comparison  linkage  analysis  has  not  been  so  successful  in  the  detection  of  genes 
responsible for complex  disease (for reviews  see Risch,  2000;  Altmuller et al,  2001). 
Complex  diseases  do  not  confo<-cn  to  classic  Mendelian inheritance  and  consequently, 
linkage  analysis  is  confounded  by  many  factors  including:  genetic  heterogeneity, 
incomplete  penetrance,  phenocopies,  polygenic  inheritance,  and  gene-environmental 
interactions  (Lander  and  Schork,  1994).  Furthermore,  when  the  disease  phenotype 
manifests later in life such as is the case with late onset hearing loss, the availability of
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members  of the  elder generations is problematic and  severely limits the progress  that 
can be made using linkage analysis. However, using subjects originally recruited as part 
of the Framingham heart  study and their offspring a large-scale genome wide linkage 
study to identify chromosomal loci that underlie susceptibility to hearing loss associated 
with ageing has been performed (DeStefano et al, 2003).  Using DNA and audiometric 
data from 328 families spanning 2 or 3 generations six chromosomal loci were mapped, 
but linkage was not found at statistically significant levels. Interestingly, four of the loci 
mapped in this study overlapped with genes known to cause congenital deafness and of 
these three  are involved  in the Usher syndromes:  Mysoin Vila (Usher  IB),  harmonin 
(Usher 1C) and the yet to be identified gene responsible for Usher 1A. It is possible that 
subtle mutations in these genes induce a moderate effect on development of late onset 
hearing  loss.  However,  one  anomaly  with  the  study  by  DeStefano  et  al,  is  that  it 
focussed on low and medium frequency hearing loss and not the high frequency hearing 
loss typical of sensorineural hearing loss commonly associated with ageing.
Currently, no loci that underlie susceptibility to the common sensorineural high 
frequency  loss  of hearing  associated  with  ageing  have  been  successfully  mapped  by 
linkage  analysis.  Indeed,  evidence  gained  from  other  diseases  suggests  that  using 
linkage analysis to identify the genetic determinants of complex traits of adult onset is 
only  successful  where  a  severe  and  clear definition  of phenotype  can be targeted  for 
studies  (for reviews  see  Lander  and  Schork,  1994;  Risch,  2000;  Botstein  and  Risch,
2003). This approach focuses on cases of the disease where there is the strongest genetic 
effect,  which  is  therefore  easier  to  detect.  For  example,  identification  by  linkage 
analysis  of the  BRCA1  gene  in  breast  cancer  susceptibility  was  facilitated  by  only 
including subjects with an early age of onset in the study (Hall et al,  1990; Miki et al, 
1994).  In  other  more  heterogeneous  disorders  where  many  factors  both  genetic  and 
environmental  may interact  to  produce  the  phenotype  such  as  cardiovascular disease 
and  schizophrenia, linkage  analysis  has  proved much  less  successful  (for reviews  see 
Risch, 2000; Botstein and Risch, 2003).
Traditionally, case-control association studies are based on the pre-selection of a 
candidate  gene using available pathophysiological  knowledge about the disease under 
study  and  examining whether  sequence  variants  in  the  candidate  gene  are  associated 
with the complex trait. One advantage of using case-control  association analysis rather 
than  linkage  analysis  for  the  study of complex  disease  is  that  sample  recruitment  is 
often more practically achievable. Case-control association studies do not depend on the
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searching for genetic associations between a group of genetically unrelated people that 
have the disease compared to a control population of genetically unrelated people who 
do not have the disease. Hence, recruitment of for example, a large group of unrelated 
subjects  with  late onset hearing loss is more practically achievable than  finding large 
families  with  multi  generational  affected  elder  surviving  members.  In  this  regard 
association analysis is not limited by late onset of disease phenotype to the same extent 
as linkage analysis. However, the main advantage of the case-control association study 
approach to detect genetic determinants of complex disease is that it provides far greater 
power than linkage analysis to detect genes of moderate effect (Risch and Merikangas, 
1996). This is important given that the genetic determinants that contribute to late onset 
hearing loss are likely to be of moderate effect.
Although,  a powerful  approach to  study complex  disease the association study 
approach is not without its pitfalls. One confounding factor in association based analysis 
is that a sequence variant found to be at a significantly higher frequency in the  ‘case’ 
population  compared  to  the  ‘control’  population  in  a  single  association  study  is  not 
conclusive evidence for involvement of the sequence variant in the disease phenotype; 
false-positive  associations  can  occur (type  I  error)  (for reviews  see  Cardon  and  Bell, 
2001; Hirschhom et al, 2002; Donahue and Allen, 2005).  Population stratification (the 
presence  of multiple  subgroups  with  different  allele  frequencies  within  a population) 
resulting  from  ethnic  admixture (the presence of two  or more different  ethnic groups 
within  a  population)  can  lead  to  false-positive  associations  if the  case  and  control 
populations  are  not  ethnically  matched  (for  reviews  see  Cardon  and  Bell,  2001; 
Hirschhom et al, 2002; Donahue and Allen, 2005). Allele frequencies are known to vary 
amongst different ethnic groups; over-representation of a high-risk ethnic sub-group in 
the  case population  could  lead to  a significant difference in  allele  frequency between 
case  and  control  populations being misinterpreted  as  evidence for involvement of the 
sequence variant in disease susceptibility.  However, there are many ways to minimise 
this  problem;  most  importantly  measures  should  always  be  taken  to  obtain  well- 
characterised  case  and  control  cohorts  that  are  ethnically  matched  and  population 
stratification, if present, can be corrected (Reich and Goldstein, 2001).
It  must  also  be  considered  that  a  statistically  significant  difference  in  allele 
frequencies between  case  and  control  populations  can  arise not because the  sequence 
variant is the casual allele but because it is a neutral variant in linkage disequilibrium 
with the casual allele at the same or another locus due to the tendency of closely linked
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have been established to have an affect on function or expression of the candidate gene 
under  study  one  increases  the  likelihood  that  a  positive  association  is  due  to 
identification of the causal sequence variant.
Historically,  one  of  the  main  pitfalls  of  the  candidate  gene  case-control 
association  study  approach  to  identify  the  genetic  determinants  that  contribute  to 
complex  disease has been  a lack of replication;  many case-control  association studies 
that have reported a positive association have failed to be independently replicated (for 
reviews see Cardon and Bell, 2001; Hirschhom et al, 2002). Lack of replication can be 
due  to many factors  including but not  limited  to:  type  I  error in  initial  study,  type  II 
error (false-negative association) in subsequent follow up study; often due to a lack of 
power,  and  problems  in  defining  the  phenotype  of  the  disease  under  investigation 
between  studies  (for  reviews  see  Cardon  and  Bell,  2001;  Hirschhom  et  al,  2002; 
Donahue  and  Allen,  2005).  However, many of these anomalies  can be reduced  if not 
overcome.
Lack  of  replication  in  many  small-scale  case-control  association  studies  to 
identify genetic determinants of complex disease which by nature are likely to have a 
weak  effect  on  disease  susceptibility  suffer  from  the  ‘winner’s  curse’  phenomenon
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(Lohmueller et al, 2003).  This phenomena arises because the first positive publication 
tends to over-estimate the extent of the genetic effect and subsequent follow up studies 
use  too  few  samples  (a  hundred  to  a  few  hundred  cases  and  controls  or  less) 
consequently  they  suffer  from  a  lack  of power  and  the  association  is  not  replicated. 
However,  large  sample  sizes  and/or  a  meta-analysis  (pooling  multiple  independent 
studies  together)  can  rectify  this  shortcoming  (Altshuler  et  al,  2000;  Keavney  et  al, 
2000; Lohmueller et al, 2003). Indeed, as reviewed by Hirschhom et al, 2002 the effect 
of the Pro 12All  variant in the peroxisome proliferator-activated receptor-gamma gene 
(PPARy) on type II diabetes risk was initially reported to be 3-fold. Subsequent studies 
failed to  replicate this but  follow-up  studies using large populations revealed that the 
risk was much smaller,  1.25-fold. Similarly, the need for association studies to use large 
sample  sizes  to  achieve  consistency  with  replication  has  been  shown  by  analysis  of 
sequence  variants  in  the  angiotension-converting  enzyme  (ACE)  gene  and  risk  to 
cardiovascular disease (Keavney et al, 2000). Furthermore, as emphasised by Rebbeck 
et al, 2004 the lack of replication in many association studies may be because many of 
these  use  sequence  variants  that  are  uncharacterised.  A  variant  that  is  linked  to  a 
functional variant in one population may not be linked in another and will therefore not
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known to have an effect on function or expression of the candidate gene under study}  the 
likelihood of identifying the causal variant is increased and therefore so is the likelihood 
of replication in different samples.
Importantly,  despite  earlier  problems  the  case-control  association  study 
approach focussing on the pre-selection of a candidate gene has already been used very 
successfully  to  identify  genetic  risk  factors  in  complex  traits  including  Alzheimer’s 
disease  [apolipoprotein  E,  APOE]  (Corder  et  al,  1993),  type  II  diabetes  [peroxisome 
proliferator-activated receptor-gamma, PPARy] (Deeb et al,  1998; Altshuler et al, 2000) 
and deep vein thrombosis [factor V] (Bertina et al,  1994; Dahlback,  1997). Undeniably, 
it has been widely applied in delineation of the genetic risk factors for cardiovascular 
disease  (for  reviews  see  Daley and  Cargill,  2001;  Green,  2001;  Herrmann  and  Paul, 
2002;  Humphries  et  al,  2004).  For  example,  a  4G/5G  insertion  /  deletion  sequence 
variant at -675  in the plasminogen activator inhibitor type  1   (PAI-1) promoter appears 
to  modify  binding  of  a  transcriptional  repressor  and  is  thought  to  be  important  in 
regulation  of  the  PAI-1  gene  (Dawson  et  al,  1993);  this  sequence  variant  has 
consistently been  associated with  susceptibility to thrombotic disease (for reviews see 
Nordt et al, 2001; Dellas and Loskutoff, 2005).
At present the  candidate  gene  case-control  association  study approach appears 
one of the most suitable methods with which to delineate the genetic basis of late onset 
hearing loss. This is especially so given that it provides far greater power than linkage 
analysis to detect genes of modest effect (Risch and Merikangas, 1996). For example, as 
highlighted by Hirschhom and Daly, 2005 the common Pro 12Ala variant in PPARy was 
found to affect the risk of type II diabetes by case-control  association analysis but this 
would never have been achieved by linkage analysis;  at least one million affected sib- 
pairs would be needed to  achieve statistical  significance using linkage.  However,  this 
does not mean that linkage analysis should not be considered for analysis of complex 
traits.  It is probably more appropriate to view linkage and candidate gene case-control 
association  analysis  as  somewhat  complementary  approaches  to  study  genetic 
susceptibility  to  complex  disease.  Large-scale  genome  wide  linkage  analysis  using 
affected  sib-pairs  has  provided  candidate  chromosomal  loci  from  which  case-control 
association analysis performed within the candidate region has been used to identify the 
genetic variant associated with the complex trait; using this approach genetic variants in 
the ADAM33 gene have been associated with susceptibility to asthma (Van Eerdewegh 
et al, 2002).
551.6.2.1  The International Haplotvpe Map (HapMap) project.
Recently, the International Haplotype Map (HapMap) project has been formed with the 
aim  to  characterise  the  common  patterns  of DNA  sequence  variation  in  the  human 
genome  (International  HapMap  Consortium,  2003).  This  will  in  effect  catalogue  the 
extent of linkage disequilibrium throughout the entire genome as a series of haplotype 
blocks.  A  haplotype  block  is  fundamentally  a  chromosomal  region  of high  linkage 
disequilibrum and limited haplotype diversity. A limited number of common haplotypes 
account  for  all  common  haplotypes  within  the  block  and  these  can  potentially  be 
identified by genotyping a selected number of SNPs, so named ‘tag-SNPs’  (for reviews 
see  Johnson  et  al,  2001;  Cardon  and  Abecasis,  2003).  Large-scale  genome  wide 
association studies using tag-SNPs are anticipated upon completion of the HapMap and 
this approach is predicted to be of immense importance in facilitating our understanding 
of the  genetic  factors  that  contribute  to  complex  disease  (for  review  see  Farrall  and 
Morris,  2005;  Hirschhom  and  Daly,  2005).  Indeed,  it  will  certainly  be  useful  in 
identifying novel  genetic risk  factors  in  genes  that have  yet  to  be  identified  or well- 
characterised  and  hence,  are  not  currently  implicated  in  late  onset  hearing  loss 
susceptibility.  However,  the  outcome  of  such  large-scale  genome  wide  association 
studies  is  some  time  away and many important decisions  regarding the design of the 
study,  the  analysis  and  the  interpretation  of the  large  sets  of data that  will  no  doubt 
accumulate still need to be made. For example, the exact number of tag-SNPs that will 
need  to  be  genotyped  in order to  provide  information  about the majority of common 
variants in the human genome is unclear at present; the most recent estimates suggest a 
few  hundred  thousand  for  subjects  of European  descent  with  much  larger  numbers 
likely  for  subjects  of African  descent  (for  review  see  Hirschhom  and  Daly,  2005). 
Ultimately, the number will be subject to many variables; the efficiency of tag-SNPs in 
regions  of low  linkage  disequilibrium  is just  one  such  consideration  (for review  see 
Hirschhom and Daly, 2005; Wang et al, 2005).  Furthermore,  genotyping all these tag- 
SNPs in each case and control individual is a most challenging and costly undertaking. 
Especially given that sample sizes need to be large (several thousand cases and controls) 
to  achieve  high  statistical  power  not  only  because  the  genetic  determinants  that 
contribute to complex traits are likely to induce moderate effects but because one must 
account  for  the  multiple-hypothesis  testing  when  using  a  genome-wide  association 
approach  (for  reviews  see  Farrall  and  Morris,  2005;  Hirschhom  and  Daly,  2005; 
Lawrence et al, 2005; Wang et al, 2005). Indeed, Hirschhom and Daly propose that pilot 
experiments  are  needed  to  test  the  merits  of  the  genome-wide  association  study
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associations  to  for  example,  haplotype  blocks  are  found  using  this  genome-wide 
association  study approach  the  causal  variant  implicated  in  disease  susceptibility will 
still need to be identified with in-vitro and/or in-vivo functional  analysis.  It is only by 
gaining knowledge  of the  functional  effect(s)  of a genetic  variant that their causative 
role in  disease pathogenesis  can be  fully assessed  and  a  greater understanding  of the 
cellular  and  molecular  mechanisms  that  underlie  disease  susceptibility  can  be 
established.  Consequently,  the  genome  wide  association  study  approach  should  be 
considered  a  complementary  method  to  the  traditional  candidate  gene  case-control 
association  study  approach.  The  genome  wide  association  study approach  provides  a 
long-term,  future method to  identify novel  late onset hearing loss  susceptibility genes 
whereas the current candidate gene approach provides a quicker route to determine the 
effect of known candidate genes on susceptibility to late onset hearing loss.
1.6.3  Quantitative  trait  analysis  to  dissect  the  genetic  factors  that 
contribute to late onset hearing loss susceptibility.
The  traditional  case-control  association  study  approach  to  identify  the  genetic 
determinants that contribute to complex disease involves stringent classification of the 
phenotype under study into discrete forms. One is either classified as having the disease 
under  study  or  not.  A  drawback  of this  approach  to  detect  the  genetic  variants  that 
underlie late onset hearing loss susceptibility is that it dichotomises what can be viewed 
as a quantitative trait; deterioration of hearing with advancing age is extremely common 
and it is whether this deterioration reaches levels which affect the individual’s daily life 
that  determines  whether  they  become  classified  as  a  patient.  Dichotomising  a 
quantitative trait results in a reduction of statistical power (Page and Amos, 1999).
Fransen  et  al,  2003  have  proposed  that  it  would  be  more  useful  to  define  a 
continuous parameter for ARHL that represents the degree of hearing ability in a given 
subject  compared  to  a median  value  and  to  use  this  continuous  parameter  to  enable 
analysis of ARHL as a quantitative trait.  Hence, rather than dichotomising subjects as 
either having late onset hearing loss or not and trying to find significant differences in 
allele or genotype frequencies between these two discrete populations one would seek to 
find  associations  between  sequence  variants  in  a  candidate  gene  and  severity of late 
onset hearing loss. Recently, in order to analyse ARHL as a quantitative trait Fransen et
57al, 2004 have devised a novel method based upon defining a quantitative trait value for 
ARHL.
In  defining a quantitative trait value  for ARHL Fransen  et  al,  2004 used  a Z- 
score  approach  to  describe  the  extent  by  which  an  individual  is  affected  by  ARHL. 
Fransen et al, used a Z-score to represent how frequency specific hearing thresholds for 
a given individual differ from median values for a particular age and gender (Fransen et 
al, 2004).  This approach is appealing,  as it will  enable genetic analysis of ARHL as a 
quantitative  trait  with  greater  statistical  power  to  detect  genes  of modest  effect  as 
opposed to a binary trait concurrent with a loss of statistical power due to discrete ‘case’ 
versus  ‘control’  classification  of  what  is  effectively  a  more  continuous  than 
discontinuous parameter. To illustrate this approach Fransen et al, genotyped a random 
sample of 101  subjects for a common sequence variant in the cochlin (COCH) gene, the 
gene, which underlies DFNA9 (Robertson et al,  1998) and converted audiometric data 
obtained for these subjects into a series of Z-scores. No association between extent of 
hearing loss (Z-score) and COCH genotype was found in this pilot study, but the pilot 
study  represented  a  random  sample  of subjects  and  was  based  on  a  relatively  small 
sample size.  Indeed,  it is  clear from the study by Fransen et al,  2004 that with larger 
sample sizes (Fransen et al, 2004 propose 500-1000 samples) the Z-score approach to 
analyse late onset hearing loss as a quantitative trait could be a promising method with 
which to delineate the genetic factors that underlie susceptibility.
In  summary,  the  case-control  association  study  approach  offers  some  clear 
advantages to delineate the genetic basis of late onset hearing loss compared to linkage 
analysis;  a main advantage of which is that it provides far greater power than linkage 
analysis to detect genes of modest effect (Risch and Merikangas, 1996). The large-scale 
genome wide association studies that will emerge in the future upon completion of the 
HapMap  will  certainly facilitate identification of the genetic determinants responsible 
for late onset hearing loss susceptibility. However, these results are some time away and 
at present  carefully designed  case-control  association  studies  using well-characterised 
patient  cohorts  and  focussing  on  functional  sequence  variants  in  the  genes  that  are 
already known to be good candidates for late onset hearing loss susceptibility offer an 
instant  and  promising  approach.  Furthermore,  recent  developments  by  Fransen  et  al 
providing  a means  by which  to  analyse  late  onset hearing loss  as  a quantitative  trait 
suggest  that this novel method to  analyse  candidate genes  for late  onset hearing  loss 
susceptibility will be a future, powerful approach.
581.6.4  The mouse as a model organism for late onset hearing loss.
There is strong similarity between the structure and functioning of the auditory system 
in humans  and mice and the mouse,  as a model  organism, has proved very useful  for 
studies  of hearing  and  hearing  loss  in  humans.  Specifically,  ‘comparative  genomics’ 
between human and mouse genomes has lead to the elucidation of many genes involved 
in congenital  forms of non-syndromic deafness in humans (for reviews see Probst and 
Camper,  1999; Kieman and Steel, 2000; Ahituv and Avraham, 2002; Avraham, 2003). 
Consequently, use of mice as a model organism to facilitate our understanding of late 
onset  hearing  loss  pathogenesis  in  humans  is  an  appealing  approach,  although  not 
without its limitations.
The problem  with  dissecting the pathophysiology of late onset hearing loss  in 
humans  is  that  the  aetiology  of  this  disease  is  extremely  complex;  a  genetic- 
environmental  interaction  is  thought  to  underlie  susceptibility  and  deciphering  the 
effects  of ageing on  the  auditory system  in humans  from  confounding  environmental 
factors such as noise trauma is difficult. This is further compounded given that it seems 
ARHL and NIHL are not separate pathologies but over lapping phenomena (for reviews 
see Ohlemiller et al, 2004;  Gates and Mills, 2005).  Hence, one advantage of using the 
mouse as a model organism for late onset hearing loss is that the effects of ageing and 
noise  exposure  on  the  auditory  system  can  be  studied  separately.  Mice  are  easy  to 
manipulate  and  experiments  can  be  performed  in  a  quiet  or  noise-controlled 
environments  as  appropriate.  Furthermore, mice have a short life-span (approximately 
three years at most) and the effect of the ageing process on the auditory system can be 
observed  within  a  small  time  frame.  In  addition,  use  of inbred  strains  reduces  inter­
laboratory experimental variation when experimental data is compared across different 
laboratories.  It  also  minimises  intra-experimental  variation  when  experiments  are 
repeated as the complication of a variable genetic background is removed (for review 
see Avraham, 2003). On the other hand the limited life-span of the mouse coupled with 
the  nature  of  the  environment  in  which  they  tend  to  be  raised  (quiet,  free  from 
exogenous stress) can also be regarded a clear disadvantage.  Late onset hearing loss in 
humans can take many years to manifest (for example,  with onset at 50, 60,  70 years 
and above)  and the extent of exogenous stress encountered,  especially noise trauma is 
an important factor in the pathogenesis.  Furthermore, the genetic determinants of late 
onset  hearing  loss  disease  susceptibility  are  likely to  have  subtle  effects;  such  subtle 
effects  are  extremely unlikely to be identified in 2 to  3  year old mice that have been 
raised in a quiet, controlled environment.
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of the genes responsible for and / or that promote ARHL and NIHL in mice can provide 
clues  as  to  which  genes  may be  involved  in  late  onset  hearing  loss  susceptibility  in 
humans.  It has been known  for some time that depending on the  genetic background 
inbred strains of mice are prone to development of late onset sensorineural hearing loss, 
often termed  ‘Ahl’  (Erway et al,  1993; Willott et al,  1998;  Johnson et al,  2000).  One 
such  inbred  strain  that  is  extremely  well  characterised  is  C57BL/6J;  late  onset 
sensorineural  hearing loss  is  inherited  in these mice  as  a recessive trait (Erway et  al, 
1993; Johnson et al,  1997; Parham,  1997; Spongr et al,  1997). C57BL/6J mice develop 
high-frequency sensorineural hearing loss that manifests around 3-6 months of age and 
progresses to a severe hearing loss by 1   year of age. Pathologically, histological analysis 
shows  that  OHCs  of the  cochlea  are  more  susceptible  than  IHCs  and  degeneration 
progresses along a basal to  apical gradient.  At 6 months of age degeneration of spiral 
ganglion neurons is also evident (Spongr et al,  1997). This phenotype is very similar to 
that  of late  onset  sensorineural  hearing  loss  that  has  been  described  in  humans  (for 
reviews see Jennings and Jones, 2001; Fransen et al, 2003; Gratton and Vazquez, 2003; 
Ohlemiller et al,  2004,  Gates  and Mills, 2005).  Furthermore,  C57BL/6J mice are also 
susceptible to NIHL (Erway et al,  1996; Davis et al, 2001);  all these features make the 
C57BL/6J mouse strain a promising model for at least some of the genetic factors that 
may  contribute  to  late  onset  hearing  loss  susceptibility  in  humans.  Indeed,  genetic 
mapping  in  C57BL/6J  mice  has  identified  the  locus  responsible  for  late  onset 
sensorineural hearing loss, Ahll  (Johnson et al,  1997) and this gene has recently been 
identified  as  Cadherin-23,  Cdh23  (Bryda et  al,  2001;  Di  Palma  et  al,  2001a;  Noben- 
Trauth et al, 2003). Cdh23 appears to be an important component of stereocilia tip-links 
(Siemens  et  al,  2004;  Sollner  et  al,  2004;  Tsuprun  et  al,  2004;  Lagziel  et  al,  2005; 
Michel  et  al,  2005)  raising  the  possibility  that  this  gene  or  other  genes  involved  in 
stereocilia  integrity  could  underlie  late  onset  hearing  loss  susceptibility  in  humans. 
Cdh23  as a candidate gene for late onset hearing loss in humans and additional loci for 
late  onset  sensorineural  hearing  loss  that  have  been  mapped  in  mice  are  discussed 
further in section 1.7.1.
Importantly, understanding how genes involved in ARHL and NIHL function in 
mice  and  the mechanism by which they cause or promote ARHL and NIHL in these 
animals  (for example, by additive effects or by epistatic interactions that may or may 
not be dependent on the environment) can give insight into the underlying mechanisms
9 I that are responsible for late onset hearing loss in humans. For example, in CBy-dfw  /+
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calcium pump localised to stereocilia hair bundles) (Yamoah et al,  1998; Dumont et al, 
2001) can accelerate onset of the ARHL phenotype in these mice (for review see Davis 
et  al,  2003;  see  also  section  1.7.2  for more detail).  Therefore,  it  is possible  a similar 
interaction  between  Cdh23  and  PMCA2  or  at  least,  genes  involved  in  stereocilia 
integrity  and  maintenance  of ionic  homeostatsis  in  the  cochlea  may be  applicable  to 
development of late onset hearing loss in humans (this is discussed in section 1.7.2).
The ease with which mice can be manipulated genetically is a powerful tool for 
aiding our understanding of the cellular and molecular pathways that underlie late onset 
hearing loss susceptibility.  Targeted gene deletion to create  ‘knockout’  mice with null 
copies of the gene of interest means the function of any gene and hence,  its potential 
role in late onset hearing loss susceptibility can effectively be examined. This technique 
does  however,  have  its  limitations.  Functional  redundancy  within  gene  families  can 
mask the effect of the knockout gene under study and knockout of some genes is limited 
by embryonic  lethality.  Nevertheless,  it is  clear that by loss  of function  studies  some 
genes  either increase  susceptibility to NIHL or ARHL in mice.  For example,  targeted 
deletion  of  the  PMCA2  gene  increases  susceptibility  to  NIHL  in  PMCA2  +/- 
heterozygotes  (Kozel  et  al,  2002)  whereas,  targeted  deletion  of the  Barhll  gene  (a 
homeobox  transcription  factor)  in  Barhl-/-  mice  leads  to  profound  deafness  due  to 
degeneration of inner and outer hair cells in the organ of Corti that is progressive with 
age (Li et al, 2002).  Moreover, it is clear that in mice loss of function of some genes 
increases susceptibility to both NIHL and ARHL for example,  the cellular antioxidant 
enzyme SOD1  (McFadden et al,  1999a; McFadden et al,  1999b; Ohlemiller et al,  1999; 
McFadden  et  al,  2001)  raising the notion that ARHL  and  NIHL may not be  separate 
pathologies but overlapping phenomena (all these genes are explored further in section 
1.7 as candidates for late onset hearing loss in humans).
In summary, it is clear that the mouse is a valuable model organism for study of 
late  onset  hearing  loss  in  humans  not  least  because  of some  practical  benefits  but 
because the nature of genes involved in ARHL or NIHL in mice provide candidates for 
the  study  of  late  onset  hearing  loss  in  humans.  In  addition,  by  elucidating  the 
mechanisms by which genes involved in ARHL and NIHL in mice function clues can 
be  gained  into  the underlying mechanisms  that  are  responsible  for late  onset hearing 
loss in humans. However, it is important to remember that mice and humans are entirely 
different species and at present none of the genes involved in ARHL or NIHL in mice 
have been convincingly identified in late onset hearing loss susceptibility in humans.
611.7  Candidate genes for late onset hearing loss.
Late onset hearing loss  is  an  extremely complex pathology and becomes increasingly 
common  with  advancing  age.  Susceptibility to  late  onset hearing  loss,  as  with  many 
traits of a complex nature is thought to be due to subtle variations in gene expression or 
function at multiple loci coupled with environmental interplay (for reviews see Jennings 
and  Jones,  2001,  Fransen  et  al,  2003;  Gratton  and Vazquez,  2003;  Ohlemiller,  2004; 
Gates and Mills, 2005).  In principle, genetic variation in a candidate gene could act to 
amplify or to reduce risk of developing late onset hearing loss and the degree of risk in 
any  one  individual  is  likely  to  be  subject  to  the  nature  of epistatic  interactions  and 
exogenous  stress  encountered.  This  forms  the  basis  for  late  onset  hearing  loss  as  a 
multifactorial  disease.  In theory,  any of the  genes  expressed  within the inner ear  and 
crucial to auditory function  <5  a candidate for susceptibility to late onset hearing loss; 
milder phenotypes may exist for some of the many genes involved in congenital forms 
of non-syndromic sensorineural hearing loss. However, the predominant cellular defect 
associated  with  late  onset  hearing  loss  is  a  progressive  loss  of hair  cells  from  the 
cochlea  (for  reviews  see Jennings  and  Jones,  2001;  Fransen  et  al,  2003;  Gratton  and 
Vazquez, 2003; Ohlemiller et al, 2004, Gates and Mills, 2005). Accordingly, any of the 
various genes involved in maintaining hair cell  structure and function (for reviews see 
Steel  and  Kros,  2001,  Petit  et  al,  2001)  are  particularly  good  candidates  for 
susceptibility to this disease.
At the onset of this project very few genes were implicated as strong candidate 
genes for susceptibility to late onset hearing loss in humans. One of the most promising 
candidates was the POU domain transcription factor Bm-3c.  Several lines of evidence 
had  accumulated  to  suggest  that  Bm-3c  functions  in  maturation  and  maintenance  of 
auditory hair cells during development and ultimately as a life-long pro-survival factor 
for these sensory hair cells (Erkman et al, 1996, Xiang et al, 1997, Xiang et al, 1998 and 
Vahava et al,  1998). Given that loss of auditory hair cells appears to be the main cause 
of late onset hearing loss, these features make Bm-3c a very strong candidate gene for 
susceptibility to this disease (evidence to implicate Bm-3c as a good candidate gene for 
late  onset  hearing  loss  is  reviewed  in  section  1.8).  During  the  course  of this  project 
several  additional promising candidate genes for late onset hearing loss have emerged 
and case-control association analysis has been performed on a few of these (Fortunato et 
al,  2004;  Unal  et  al,  2005).  It  is  not  possible  to  discuss  exhaustively  all  possible 
candidate genes  for late onset hearing loss but some of the more promising candidate
62genes that have emerged in recent years and join Bm-3c as a good candidate gene for 
susceptibility to this disease will be discussed below.
1.7.1  Candidate genes for late onset hearing loss that have emerged from 
mapping experiments in mice: with emphasis on Cadherin-23.
Probably some of the strongest candidate genes for susceptibility to late onset hearing 
loss in humans have emerged from mapping experiments in mice. Certain inbred strains 
of mice  are particularly susceptible to  late onset  sensorineural  hearing  loss  (which  is 
often  termed  Ahl)  (Erway  et  al,  1993;  Willott  et  al,  1998;  Johnson  et  al,  2000)  and 
currently  three  loci  have  been  mapped  termed:  Ahll,  Ahl2  and  Ahl3  on  mouse 
chromosome 10 (Johnson et al, 1997), 5 (Johnson and Zheng, 2002) and 17 (Nemoto et 
al,  2004),  respectively.  The  gene  responsible  for  Ahll  is  the  first  gene  causing  non- 
syndromic hearing loss of late-onset that has been identified and mapped in the mouse 
(Johnson et al,  1997) and has long been known to be inherited as a recessive trait in the 
C57BL/6J  inbred mouse strain (Erway et al,  1993).  In  addition,  Ahll  is implicated in 
late onset hearing loss exhibited by at least  10 different strains of mice (Johnson et al,
2000). The human orthologoue of Ahll  and the recently identified loci, Ahl2 and Ahl3, 
are all good candidates for susceptibility to late onset hearing loss in humans. Although 
at  present,  the  genes  responsible  for Ahl2  and  Ahl3  have  yet  to  be  identified  at  the 
molecular  level.  However,  several  candidate  genes  have  been  proposed  for  Ahll 
(Johnson  et  al,  1997,  2000)  and  recent  evidence  indicates  that  Cadherin  23  (Cdh23) 
underlies  Ahll  (Bryda et  al,  2001,  Di  Palma et  al,  2001a; Noben-Trauth et al,  2003). 
Cadherins are transmembrane proteins important in cell-cell interactions and within the 
cochlea  Cdh23  is  crucial  for  organization  of the  stereocilia  array  (Di  Palma  et  al, 
2001a).  Recent  evidence  suggests  that  Cdh23  is  a  main  component  of the  tip-link 
joining  adjacent  stereocilia  (Siemens  et  al,  2004;  Sollner  et  al,  2004;  Tsuprun  et  al,
2004). Although, this evidence is somewhat controversial and has been contradicted by 
others (Lagziel et al, 2005; Michel et al, 2005) who report that Cdh23 is absent from the 
apex of stereocilia in adult mice.
Evidence that Cdh23  underlies Ahll  stems from the identification of mutations 
in  Cdh23  as  underlying  the  waltzer mutation  in  the mouse  (Di  Palma  et  al,  2001a); 
waltzer (Cdh23v) maps to the same region of mouse chromosome 10 as Ahll  (Bryda et 
al,  1997,  Bryda  et  al,  2001)  suggesting  they  are  allelic.  In  an  attempt  to  elucidate 
mutations  in  Cdh23  that  underlie  Ahll  82  single  nucleotide  substitutions  have been
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untranslated regions in C57BL/6J and CAST/Ei  strains of mice (CAST/Ei retain good 
hearing  into  old  age)  (Di  Palma  et  al,  2001b).  Theoretically,  any  of these  could  be 
responsible  for  Ahll  in  C57BL/6J  mice.  Di  Palma  et  al,  2001b  ruled  out  10  single 
nucleotide  substitutions  that  led  to  amino  acid  substitutions  in  the  coding  region  of 
Cdh23  as  the  cause  of Ahl  as  these  also  appeared  in the mouse  strain  CBA/CaJ  that 
retain hearing throughout their life.  Similarly, single nucleotide substitutions within the 
5’- and 3’-untranslated regions of Cdh23  and an isoform of Cdh23 with a spliced exon 
68 that is predominantly expressed in the organ of Corti^have been excluded as the basis 
of the Ahll phenotype in C57BL/6J mice (Di Palma et al, 2001b). Di Palma et al, 2001b 
suggested that it may be one of the 61  apparently “silent” single nucleotide substitutions 
that do not alter the amino acid sequence that predispose to Ahll  in C57BL/6J mice. It 
was  predicted  that  these  single nucleotide substitutions  could  affect  exon  splicing by 
disrupting exonic splicing enhancer or silencer motifs.  This  is  certainly possible,  it is 
known  that  10-15%  of disease  causing mutations  in human  genes  affect^ pre-mRNA 
splicing  (Nissim-Rafinia  et  al,  2002).  Recent  evidence  is  in  agreement  with  this 
suggestion; a synonymous single nucleotide substitution in exon 7 of Cdh23, Cdh23753A , 
that causes in-frame skipping of exon 7 has been found to exhibit significant association 
with Ahll  (Noben-Trauth et al, 2003). Twenty-seven of thirty-one inbred mouse strains 
characterised with ARHL were found to carry the variant allele, Cdh23 753A ,  and of 25 
inbred  mouse  strains  that  do  not  develop  ARHL,  22  carried  the  wild-type  allele, 
Cdh23 7530 (Noben-Trauth et al, 2003).
In  humans  different  allelic  forms  of  Cdh23  underlie  both  the  recessive 
syndromic-hearing  loss  trait  Usher  syndrome  type  ID  (Bolz  et  al,  2001)  and  non- 
syndromic  autosomal  recessive  deafness  DFNB12  (Bork  et  al,  2001).  Hence,  it  is 
certainly feasible that mild allelic variants of Cdh23 may contribute to late onset hearing 
loss in the general population.  Recent evidence certainly suggests that this may be so 
(Yang et al, 2006).  A small-scale case-control association study on  194 noise-exposed 
Chinese  workers  comprising  93  workers  with  NIHL  and  101  workers  with  normal 
hearing  as  determined  by audiometric  analysis  revealed  an  association between  three 
sequence  variants  in  the  Cdh23  gene  and  NIHL  (Yang  et  al,  2006).  It  would  be 
interesting to  see if these associations are also detectable in noise-exposed Caucasians 
or  indeed  Caucasian  subjects  classified  with  late  onset  hearing  loss  of sensorineural 
origin.  In  any case  it is  clear that the  study by Yang et  al  requires  confirmation  in a 
larger cohort for validation.
641.7.2  The genetic interaction between Cdh23 and PMCA2: relevance to late
onset hearing loss pathology.
In 1998, Street et al showed that mutations in PMCA2 are responsible for the congenital 
dealhess that underlies the deaf waddler (dfw) phenotype in the mouse; these mice are 
deaf, exhibit a wobbly gait when walking and display head bobbing (Street et al, 1998). 
In the cochlea  PMCA2  is localised to the stereocilliary hair bundle in particular, the 
stereocilia of OHCs (Dumont et al, 2001).  PMCA2 functions to exclude calcium from 
the stereocilia (Yamoah et al,  1998) and appears crucial in maintaining the calcium rich 
endolymph surrounding the stereocilia necessary for proper functioning of the hair cells 
(Wood et al, 2004). Two mutant alleles of dfw exist; both arose spontaneously in mice 
of different strains. An amino acid substitution in a conserved residue underlies the dfw 
allele  (that  originated  in  mice  of  the  C3H/HeJ  strain),  whereas  a  2bp  deletion  is
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predicted to cause a truncated protein in the second allelic form, dfw  (that originated in 
a substrain of BALB/cByJ mice termed, CBy-dfw2J) (Street et al,  1995, Noben-Trauth 
et al,  1997, Street et al,  1998). Both of these mutations present as recessive. However, 
depending on the genetic background of the mice, a modifier gene termed  modifier of
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deaf waddler (mdfw) can precipitate hearing loss in dfw  heterozygotes via an epistatic 
intereaction  (Noben-Trauth  et  al,  1997).  The  auditory  brainstem  response  (ABR)  of
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CBy dfw  /+ mice are abnormal, elevated thresholds manifest that show a progressive 
dependence on age; hearing loss initiates four weeks after birth progressing to complete 
deafness  by  12  weeks  of age  (one  would  expect  CBy  dfw2J/+  mice  to  have  normal 
hearing consistent with the recessive nature of the mutation).
An  elegant  series  of experiments  have  shown that the  early onset progressive
9 I
hearing loss  in CBy dfw  /+ mice is due to homozygosity with respect to Ahll;  Ahll 
(Cdh23)  is  mdfw.  Indeed,  evidence  indicates  that  mdfw  is  allelic  to  both  Ahll  and 
Cdh23v that underlies the waltzer mutation in the mouse (Byrda et al, 2001; Zheng and 
Johnson, 2001).  Hence,  suggesting that the Ahll, mdfw, and waltzer loci all represent 
the  same  gene,  Cdh23.  In  agreement  with  this,  the  synonymous  single  nucleotide 
substsitution  identified  in  exon  7  of  Cdh23,  753A,  that  correlates  with  Ahll  also
9 I
segregates with mdfw in CBy-dfw  /+ mice in addition to  all mouse strains that show 
allelism  between  the  Ahll  and  mdfw  loci  (Noben-Trauth  et  al,  2003).  Hence,  mice 
homozygous  for the  Ahll  gene  (Cdh23 753A /  Cdh23 753A )  exhibit  ARHL but  an  earlier 
ARHL is exhibited in these mice if they also possess a mutant copy of PMCA2 termed,
91 dfw  .  Calcium  binding  is  known  to  be  essential  for  cadherin  function.  Thus,  it  is
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could accelerate onset of the Cdh23753A / Cdh23753A  phenotype.
It  is  possible  that  an  epistatic  relationship  between  Cdh23  and  PMCA2  as 
observed  in  the  mouse  is  applicable  to  development  of  late  onset  hearing  loss  in 
humans.  Schultz  et  al,  2005  have  recently  reported  a  genetic  interaction  between 
CDH23 and PMCA2 underlies the hearing loss in a Caucasian family that presents with 
autosomal  recessive,  non-syndromic  sensorineural  hearing  loss  manifesting  in the  first 
decade  of life.  In  this  family  all  affected  members  exhibit  severe  to  profound  high- 
frequency hearing loss that has been  attributed to  a homozygous mutation in CDH23 
(F1888S)  but  for  some  members  the  hearing  loss  phenotype  is  much  more  severe 
affecting all frequencies and this is proposed to be due to a mutation in PMC  A 2 termed, 
V586M.  Hence,  it is certainly likely that mild variants in CDH23 may exist that confer 
susceptibility  to  late  onset  hearing  loss  in  the  general  population  and  it  is  possible 
individuals homozygous  for a mutant  allele  of CDH23  may be particularly  susceptible 
to late onset hearing loss if they also possess a mutant copy of PMCA2.
In addition, both Cdh23 and PMCA2 are known to confer susceptibility to NIHL 
in mice (Erway et al,  1996, Davis et al, 2001; Kozel et al, 2002; Holme and Steel, 2004. 
It has been known for some time that mice that have a genetic predisposition to ARHL 
due to  homozygosity at  Ahll  are  also  more  susceptible to NIHL  (Erway et  al,  1996, 
Davis  et  al,  2001).  Similarly,  both mice heterozygous for a presumed null mutation in 
Cdh23  (Holme  and  Steel,  2004)  and  a null  allele  of PMCA2  (Kozel  et  al,  2002)  are 
susceptible  to  NIHL.  This  raises  the  possibility  that  individuals  carrying  mild  allelic 
variants in CDH23 or PMCA2 may be more vulnerable to the effects of acoustic trauma. 
Indeed,  following  acoustic  over-stimulation  the  intracellular  calcium  concentration  of 
OHC  is  known to  be  elevated  (Fridberger  et  al,  1998)  and  it  is  proposed  that NIHL 
exhibited  by  PMCA2+/-  mice  is  due  to  a  reduced  ability  to  counteract  any  rises  in 
cytoplasmic calcium which in turn is deleterious to the functioning of the OHCs (Kozel 
et  al,  2002).  Furthermore,  it is known that  stereocilia can be flattened by exposure to 
excessive  noise  (Wang  et  al,  2002).  Cdh23  is  paramount  for  organisation  of  the 
stereocilia array (Di Palma et al, 2001a) and is thought, albeit somewhat controversially, 
to  be  an  important  structural  component  of stereocilia tip-links  (Siemens  et  al,  2004; 
Sollner et al, 2004; Tsuprun et al, 2004; Lagziel et al, 2005; Michel et al, 2005). Hence, 
it  is  certainly  conceivable  how  subtle  variant(s)  in  PMC  A 2  and  /  or  CDH23  in  the 
general  population  that  impair  the  functioning  or  expression  of these  genes  could 
predispose to late onset hearing loss precipitated by acoustic trauma.
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CDH23 and PMC  A 2 represent excellent candidate genes for susceptibility to late onset 
hearing  loss  in  humans.  Furthermore,  the  evidence  gained  from  mice  suggests  that  if 
allelic  variants  in  CDH23  and  PMC  A 2  are  present  in  combination  and  an  epistatic 
interaction between these two genes predisposes to late onset hearing loss in humans, 
onset of the hearing loss phenotype could be greatly accelerated by exposure to acoustic 
trauma.
1.7.3  BarhH  a hair cell  survival factor is a good  candidate gene for late 
onset hearing loss.
Loss of inner ear sensory hair cells appears to be the main cause of late onset hearing 
loss  (for  reviews  see  Jennings  and  Jones,  2001;  Fransen  et  al,  2003;  Gratton  and 
Vazquez,  2003; Ohlemiller et al,  2004, Gates and Mills, 2005).  Accordingly, any genes 
involved  in  hair  cell  survival  are  very good  candidates  for  susceptibility to  late  onset 
hearing loss. It has become apparent that Barhll, which encodes a transcription factor, is 
required for long-term survival of sensory hair cells (Li et al, 2002).  Barhll  belongs to 
the Bar subset of homeobox genes and is closely related to the Drosophila BarHl  and 
BarH2 genes that are important in development of the eye and external sensory organs 
(Bulfone et al, 2000).
Li  et  al,  2002  created  Barhll  null  mice by  swapping the Barhll-coding region 
for  the  lacZ  reporter  gene.  In  the  developing  mouse  inner  ear  the  Barhll  mRNA 
transcript can first be detected at El4.5 in the sensory hair cells (a time by which many 
hair cells  are  already  formed)  and  expression continues into  postnatal  stages.  In adult 
mice  heterozygous  and  homozygous  for  the  Barhll  null  allele,  expression  of  lacZ 
(which  represents  endogenous  Barhll  expression)  suggests  that  Barhll  expression 
continues  into  adulthood,  particularly  in  the  OHCs  where  strong  p-galactosidase 
staining is observed. The consequence of the Barhll  deletion in the Barhll-null mice  (- 
/-) is a profound deafness by  10 months of age that initially starts as a preferential loss 
of low-frequency sounds.  At the cellular level, this is due to a progressive degeneration 
of inner and outer hair cells in the organ of Corti that is exacerbated with advancing age. 
In-line  with  the  initial  low-frequency loss,  OHCs  degenerate  along  an  apical  to basal 
gradient that is clearly underway by PI9.  IHCs,  in contrast do  not  start to  degenerate 
until  sometime  after  6  months  of age  and  when  they  do  so  it  is  along  the  reverse 
gradient compared to OHCs.  IHC degeneration is clearly evident at  10 months of age. 
Barhll  does  not  appear  to  be  involved  in  the  initial  generation,  or  differentiation  of
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postnatal life and label for Bm-3c along with several other markers specific to hair cells. 
In  addition,  the  stereociliary bundle  can be  observed  on  the  hair  cells  of Barhll-null 
mice  (Li  et  al,  2002).  Barhll  therefore  joins  Bm-3c  as  another  gene  that  appears 
paramount  for the  survival  of cochlear hair cells.  In  fact,  Barhll  may be the  stronger 
candidate for long-term maintenance of cochlea hair cells; hair cell defects in Barhll- 
null mice exhibit a much later onset compared to Bm-3c-null mice (Erkman et al, 1996, 
Xiang et al,  1997,  Li et al, 2002).  Additionally, the presence of Bm-3c protein cannot 
prevent the  eventual  degeneration  of cochlea hair cells  in  Barhll-null  mice  (Li  et  al, 
2002 report that Bm-3c is expressed in hair cells of Barhll-null mice at P0-P6). Given 
their  respective  expression  profiles,  it  is  tempting  to  speculate  that  Bm-3c  may  be 
involved in regulating expression of Barhll  in inner ear sensory hair cells. (Xiang et al, 
1998, Li et al, 2002).
Li  et  al,  proposed  that  Barhll  does  not  directly  underlie  the  hair  cell 
degeneration exhibited in the Barhll  (-/-) mice. Instead, it is suggested that Barhll  is the 
key to maintenance of a component/s that is expressed in hair cells of the organ of Corti 
along a longitudinal gradient and crucial for their long-term survival. The voltage-gated 
potassium  channel,  KCNQ4,  is  suggested  as  a  good  candidate  having  an  expression 
pattern in IHCs and OHCs along a gradient that reflects their degeneration in Barhll  (-/- 
)  mice.  This hypothesis  is  appealing as mutations  in the KCNQ4  channel  are already 
known to be responsible for a form of autosomal dominant nonsyndromic progressive 
deafness, DFNA2 (Kubisch et al,  1999, Coucke et al,  1999). In DFNA2, it appears that 
mutations in the pore region may impair the ion selectivity of the channel upsetting the 
K+ homeostasis  in  the inner ear (Kubisch  et  al,  1999,  Van  Hauwe  et  al,  2000).  One 
disparity  with  these  observations,  is  that  defects  in  KCNQ4  tend  to  manifest  in  a 
preferential  high-frequency  hearing  loss,  and  although  this  is  in  agreement  with  the 
nature  of  late  onset  hearing  loss  exhibited  by  a  large  proportion  of  the  ageing 
population, it is not in agreement with the nature of the hearing loss initially exhibited 
in the Barhll  (-/-) mice. However, this may be due to the species difference; mice do not 
have the same potential as humans to accumulate exogenous damage to hair cells owing 
to their short lifespan. Barhll  has yet to be identified as the defective gene in any form 
of human deafness, but this may just be a matter of time. In any case, Barhll  represents 
a very good candidate gene for late onset hearing loss and it is possible that common 
sequence  variants  in  this  gene  may  prevail  in  the  human  population  and  underlie 
susceptibility to this disease.
681.7.4  Evidence that genes involved in ROS regulation are good candidates
for late onset hearing loss.
In  recent  years  much  evidence  has  accumulated  to  implicate  ROS  generation  in  the 
molecular pathogenesis of late onset hearing loss (McFadden et al, 1999a; McFadden et 
al  1999b; Ohlemiller et al,  1999;  Staecker et al, 2001).  It is proposed that with ageing 
increased  ROS  generation  compromises  the  energy status  of the  mitochondria  in  the 
sensory hair cells, which eventually contributes to the loss of these cells with age (for 
reviews see Fischel-Ghodsian et al, 2004, Ohlemiller, 2004, Pickles, 2004). In addition, 
there  is  increasing  evidence  that  ROS  generation  is  involved  in  hair  cell  damage 
following  acquired  environmental  insults  to  the  auditory  system  including  acoustic 
trauma (Ohinata et al, 2003; Yamashita et al, 2004; for review see Lynch and Kil, 2005) 
and use of ototoxic agents (for reviews see Kopke et al,  1999; Campbell, 2003; Rybak 
and Whitworth, 2005). Accordingly, it can be reasoned that common sequence variants 
that lead to dysfunction or a reduction in expression levels of genes involved in ROS 
homeostasis have the potential to influence ones vulnerability to late onset hearing loss.
The  key  intrinsic  antioxidant  enzymes  in  the  cochlea  and  other  tissues  that 
protect  cells  from  oxidative  stress  include  the  superoxide  dismutases  (SODs),  the 
glutathione  peroxidases  (Gpxs),  catalase  and  the  enzymes  involved  in  glutathione 
regulation (for reviews see Forsberg et al, 2001; Zelko et al, 2002). Of these some of the 
most promising candidates for susceptibility to late onset hearing loss are SOD1  (also 
known  as  copper/zinc  SOD,  Cu/ZnSOD)  and  glutathione  peroxidase-1   (Gpxl).  As 
discussed  previously  (section  1.5.4)  SOD1  knockout  mice  exhibit  increased 
susceptibility to  ARHL  (McFadden  et  al,  1999a;  McFadden  et  al,  1999b)  and  NIHL 
(Ohlemiller et al,  1999; McFadden et al, 2001). These findings clearly implicate SOD1 
as a candidate gene for late onset hearing loss susceptibility in humans. Moreover, they 
have  implications  for the  effects of ageing and acoustic trauma on  late onset hearing 
loss  pathology  by  suggesting  a  common  mechanism  concerning  superoxide  radical 
generation  is  involved.  Similarly,  Gpxl  like  SOD1  is  expressed  in  the  cytosol  and 
functions  alongside  SOD1  to  regulate  levels  of ROS  (for review  see  Forsberg  et  al,
2001). Mice with targeted deletion of the Gpxl  gene exhibit increased susceptibility to 
NIHL (Ohlemiller et al, 2000;  McFadden et al, 2001)  and exhibit histological  defects 
characteristic of ARHL (Ohlemiller et al, 2000). Accordingly, both these factors make 
Gpxl a good candidate gene for susceptibility to late onset hearing loss in humans.
Recently,  a  case-control  association  study  on  noise-exposed  workers  from  an 
aircraft factory has revealed an association between NIHL and sequence variants in two
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PON2  (paraoxonase  2)  suggesting  that  these  sequence  variants  predispose  to  NIHL 
(Fortunato  et  al,  2004).  Although  these  associations  were  based  on  a  very  limited 
number of samples (94 noise-exposed workers of which 63  subjects were characterised 
with NIHL and 31  with normal hearing) and this study clearly requires replication in a 
larger  cohort  for  validation;  it  can  certainly  be  envisaged  how  polymorphisms  in  the 
SOD2  gene  may  predispose  to  late  onset  hearing  loss.  SOD2  is  localised  to  the 
mitochondria and is the sole enzyme in the mitochondria that catalyses the dismutation 
of the  superoxide radical to hydrogen peroxide and water (for review see Zelko et al,
2002).  Given that the energy status of the mitochondria is thought to be imperative for 
maintenance  of hearing  into  old  age  (the  cochlea  is  a  highly  active  structure;  OHCs 
amplify the sound input and this is a process, which requires great energy expenditure) 
it  can  certainly be  perceived  how any  sequence variants that  impaired the function or 
expression of SOD2 could predispose to late onset hearing loss.
More recently, a significant association has been reported between ARHL and a 
sequence  variant  in  the  N-acetyltransferase  2  {NAT2)  gene;  a  phase  II  detoxification 
enzyme  involved  in  the  metabolism  of ROS  (Unal  et  al,  2005).  However,  similar  to 
many  of the  current  association  studies  into  late  onset  hearing  loss  susceptibility  that 
have been reported in recent years (Fortunato et al, 2004; Yang et al,  2006), the study 
by Unal et al was based on a small number of samples (68 subjects with ARHL and 98 
controls) and its validity to late onset hearing loss susceptibility awaits replication in a 
larger cohort.
In  summary,  it is clear that  many genes have emerged in recent years as good 
candidates  for  susceptibility  to  late  onset  hearing  loss  in  humans  and  no  doubt  many 
more  will  surely  continue to  emerge.  Amongst those  identified  as  good  candidates  in 
recent  years  are  genes  involved  in  stereocilia  integrity  (CDH23),  hair  cell  survival 
(BARHL1), maintenance of calcium homeostasis in the cochlea (PMCA2) and regulation 
of ROS  homeostasis in the cochlea (SODJ,  SOD2,  GPXJ).  Positive associations have 
been reported for CDH23 (Yang et al, 2006), SOD2 and PON2 (Fortunato et al, 2004) 
and susceptibility to NIHL and between NAT2 and  susceptibility to ARHL (Unal et al,
2005).  However,  each  of these  studies  requires  confirmation  in  a  larger  cohort  for 
validation.  In addition,  in the absence of functional analysis it is not clear whether the 
sequence variants reported by Fortunato et al,  and Yang et al are the causal mutations 
that are be responsible for the hearing loss pathophysiology.
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genes for susceptibility to late onset hearing and at present, still remains so. Brn-3c as a 
candidate gene for late onset hearing loss is explored in detail in the next section,  1.8.
711.8  The candidate gene approach: Brn-3c.
At the onset of this project there was a scarcity of candidate genes for susceptibility to 
late onset hearing loss; Brn-3c, a POU domain transcription factor was one of the most 
promising  candidates.  Bm-3c  is  one  of three  highly  homologous  genes  collectively 
known  as  the  Bm-3  family  categorised  under  division  IV  of the widely  characterised 
POU protein family (for review  see Latchman,  1999).  Bm-3a (also known as Brn3.0, 
POU4F1) and Brn-3b (also known as Brn-3.2, POU4F2) the additional members of the 
Bm-3  family  are  important  developmental  regulators  involved  in the  maintenance  and 
survival  of  specific  neuronal  cell  sub-types  in  the  nervous  system  and  retina, 
respectively  (Erkman  et  al,  1996;  Gan  et  al,  1996;  McEvilly et  al,  1996;  Xiang et  al, 
1996;  Eng  et  al,  2001  and  discussed  further  in  section  1.9.2).  In  recent  years  much 
evidence  has  accumulated  to  suggest  that  Bm-3c  functions  in  maturation  and 
maintenance of sensory hair cells during development and ultimately as a life-long pro­
survival factor for these hair cells (Erkman et al,  1996,  Xiang et al,  1997,  Xiang et al, 
1998 and Vahava et al,  1998). This is important as loss of auditory hair cells appears to 
be the main cause of late onset hearing loss (for reviews see Jennings and Jones, 2001; 
Fransen  et  al,  2003;  Gratton  and  Vazquez,  2003;  Ohlemiller  et  al,  2004;  Gates  and 
Mills, 2005).  Evidence in support of the proposal that Brn-3c is a good candidate gene 
for late onset hearing loss will now be discussed.
1.8.1  Evidence  to  implicate  Bm-3c  as  a  candidate  gene  for  late  onset 
hearing loss.
In the nervous system and certain regions of the brain Bm-3c is expressed in a specific 
but overlapping expression pattern with other members of the Bm-3  family (for review 
see  Ryan  and  Rosenfeld,  1997).  However,  in  the  inner  ear Bm-3c  is  the  only  Bm-3 
factor expressed in hair cells and expression is confined to the sensory hair cells of both 
the  auditory  and  vestibular  systems  (Erkman  et  al,  1996,  Xiang  et  al,  1997,  1998). 
Immunolabeling  studies  in  mice  with  a  specific  anti-Bm-3c  antibody  show that  in the 
otocyst  Bm-3c  expression initiates  early  during  development  at  E l2.5  in presumptive 
hair cells  of the developing  sensory epithelia (Xiang et al,  1998).  Strong and  selective 
expression of Bm-3c  can then be clearly detected  in auditory and vestibular hair cells 
from  embryonic  day  14.5,  a  time  by  which  time  all  inner  ear  sensory  epithelia  are 
formed (Xiang et al,  1997,  1998). Expression appears restricted to postmitotic hair cells
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adulthood (Erkman et al, 1996, Xiang et al, 1997, 1998).
The  functional  significance  of specific Bm-3c  expression  in inner ear sensory 
hair cells is evident in Bm-3c ‘knockout mice’ (-/-) which were generated independently 
by two laboratories through targeted deletion of the Bm-3c gene (Erkman et al,  1996, 
Xiang et  al,  1997).  Bm-3c (-/-) mice exhibit complete loss  of cochlear and vestibular 
hair cells by early postnatal life followed by severe degeneration of spiral and vestibular 
ganglia neurons (Erkman et al,  1996, Xiang et al,  1997). This is because although hair 
cells  initially  generate  in  Bm-3c  (-/-)  mice  and  undergo  the  initial  stages  of 
differentiation they fail to undergo full maturation. Cells morphologically similar to hair 
cells  can  be  observed  in  the  organ  of  Corti  of  Bm-3c  (-/-)  mice  at  E l6.5  which 
immunostain positively for hair cell specific markers myosin VI and Vila (Xiang et al, 
1998).  However,  the  ability  to  acquire  complete  specialization  is  abolished;  the 
molecular cues needed  for formation of the highly organized  stereociliary hair bundle 
appear  lost.  Indeed,  the  apical  surface  of the  organ  of Corti  is  completely  clear  of 
stereociliary  hair  bundles  by  PO  (Erkman  et  al,  1996,  Xiang  et  al,  1997,  1998). 
Furthermore,  in the vestibular system partially differentiated hair cells  fail to undergo 
correct  migration  (Xiang  et  al,  1998).  The  consequence  of absence  of Bm-3c  on  the 
morphology of the inner ear is specific; in adult Bm-3c (-/-) mice the exterior portion, 
middle  ear,  and  overall  infrastructure  of the  cochlear  and  vestibular  system  remain 
intact (Xiang et al,  1997). In the cochlea aberrations are only seen in the neighbouring 
areas  alongside  the  loss  of the  inner  and  outer  hair  cells;  the  columnar  Pillar  cells 
characteristic  of the  tunnel  of Corti  are  generally  absent  and  Deiter’s  cells  cannot be 
clearly  defined  (Xiang  et  al,  1997).  Terminal  dUTP  nick  end  labelling  (TUNEL)  on 
serial sections of sensory epithelia from Bm-3c (-/-) mice shows that the incompletely 
differentiated hair cells progressively degenerate by apoptosis during development such 
that  the  total  loss  of these  cells  is  evident  in  the  sensory epithelia  shortly after birth 
(Xiang et al, 1998). The loss of the spiral and vestibular ganglia neurons in the Bm-3c (- 
/-)  mice  also  proceeds  by apoptosis  (Xiang  et  al,  1998),  but  is  regarded  a  secondary 
effect of hair cell  loss because Bm-3c  is restricted to hair  cells  in the inner ear.  It is 
proposed that the sensory ganglia neurons depend on the hair cells for trophic support. 
Indeed, hair cells are known to express brain-derived neurotrophic factor (BDNF) and 
neurotrophin-3  (NT-3)  and  sensory  neurons  express  the  appropriate  neurotrophic 
receptors  (for  reviews  see  Fritzsch  and  Beisel,  2001,  Marzella  and  Gillespie,  2002).
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NT-3 expression in hair cells (Clough et al, 2004).
Taken together, the evidence from Bm-3c (-/-) mice shows that presence of Bm- 
3c  protein  is  needed  for hair cell  maturation  and  maintenance.  It  is  feasible that  as  a 
POU domain transcription factor Bm-3c regulates expression of genes needed by hair 
cells for complete maturation and  survival.  Certainly,  expression of the Bm-3c protein 
is needed for formation of the highly organized stereociliary hair bundle (Erkman et al, 
1996, Xiang et al,  1997,  1998).  In addition, it is clear that the complete loss of Bm-3c, 
at least in mice,  will ultimately end in hair cell death;  directly or indirectly presence of 
Bm-3c protein can prevent the progressive apoptotic degeneration of inner ear sensory 
hair  cells  (Xiang  et  al,  1998).  Hair  cells  are  paramount  to  auditory  and  vestibular 
function.  Consequently  the  morphological  defects  in  the  Bm-3c  (-/-)  mice  manifest 
physically  as  complete  deafness  coupled  with  balance  and  co-ordination  defects  and 
marked  hyperactivity  (Erkman  et  al,  1996,  Xiang  et  al,  1997).  Interestingly,  this 
phenotype  appears  limited  to  mice  homozygous  for targeted  deletion of Bm-3c,  mice 
that  are  heterozygous  and  express  one  functional  copy  of  the  Bm-3c  gene  are 
indistinguishable  from the wild  type;  they  appear normal in all  aspects (Erkman et  al, 
1996, Xiang et al,  1997).
Significant  evidence  in  agreement  with  the  notion  that  Bm-3c  is  a  good 
candidate gene for late onset hearing loss in humans is obtained from a study of hearing 
loss within  a large  Israeli-Jewish  family (Vahava et  al,  1998).  In this  family,  an eight 
base-pair deletion in the POU homeodomain of Brn-3c causes adult onset hearing loss 
DFNA15  with  an  autosomal  dominant  mode  of progressive  late  onset  hearing  loss 
(Vahava et al,  1998).  In affected family members the hearing loss phenotype manifests 
between the ages  18 to 30 years and progresses to a moderate to severe deafness by 50 
years  of age.  All  affected  family  members  tested  heterozygous  for  the  8bp  deletion 
(Vahava et al,  1998). Hence, in this family at least, possession of one wild type allele of 
Brn-3c is not  sufficient to maintain normal  hearing past early adulthood.  The fact that 
the hearing loss is not  congenital  and exhibits a delayed onset  suggests that Bm-3c is 
needed to maintain hair cell function in the long-term. Taken together with the evidence 
from Bm-3c (-/-) mice  (Erkman et al,  1996, Xiang et al,  1997 and  1998) this implies 
that  Bm-3c  may  function  as  a pro-survival  factor for inner ear  sensory  hair  cells not 
only during  development but  also throughout  life.  Indeed,  Bm-3c  is  ideally placed  to 
function  as  a  life-long  pro-survival  factor  for  hair  cells.  Bm-3c  expression within the 
inner ear is restricted to hair cells and is maintained into adulthood (Erkman et al,  1996,
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a cytoskeletal component of the hair cells, Bm-3c has the ability to modulate expression 
of many  genes  needed  for  hair  cell  function  and  survival.  These  features  are  very 
appealing  when  considering  Brn-3c  as  a  candidate  gene  for  late  onset  hearing  loss 
because loss of auditory hair cells appears to be the main cause of this disease.
1.8.2  Understanding the molecular mechanism bv which an 8bp deletion 
in  the  POU  homeodomain  of  Bm-3c  causes  adult  onset  hearing  loss. 
PFNA15.
In the Israeli-Jewish family with DFNA15 the presence of one wild-type allele of Brn- 
3c is not sufficient to maintain hearing past early adulthood (Vahava et al,  1998). Two 
proposals  that  have  been  suggested  to  explain  the  mechanism  of the  hearing  loss  in 
family  members  affected  by  DFNA15  are  haploinsufficiency  or  a  dominant  negative 
effect  of the  mutant  Bm-3c  protein  on  the  function  of the  wild-type  Bm-3c  protein 
(Vahava et al,  1998).  In DFNA15 the 8bp deletion is in exon 2 of the Brn-3c gene and 
this  is  predicted  to  result  in  a  frame  shift  commencing  at  codon  295  and  inducing 
premature termination of translation at codon 299.  It is thought that in members of the 
Israeli  family  with  DFNA15,  a  truncated  protein  of 298  amino  acids  is  produced  in 
addition to the 338 amino acid wild-type protein.  This concept is supported by in-vitro 
analysis; the mutated transcript is translated in cell culture producing a truncated protein 
of the predicted size relative to the wild-type protein (Weiss et al, 2003).
Given that the mutated transcript is probably translated in members of the Israeli 
family with DFNA15  if haploinsufficiency of Bm-3c (half the normal levels of Bm-3c) 
underlies  the  hearing  loss  phenotype  then  this  is  probably  through  functional 
redundancy of the mutant copy of Bm-3c.  Haploinsufficiency resulting from functional 
redundancy  of the  mutant  Bm-3c  protein,  a  truncated  protein  of 298  amino  acids  is 
certainly feasible. The DNA binding affinity of the mutant protein is predicted to be low 
or  completely  abolished  because  the  deletion  removes  the  majority  of the  carboxyl 
terminus  of the  POU  homeodomain  including  the  recognition  helix  that  makes  base 
contacts  with  the  DNA  (Vahava  et  al,  1998).  Recent  in-vitro  experiments  aimed  to 
delineate  the  effect  of the  8bp  deletion  on  the  function  of the  Bm-3c  protein  are  in 
agreement with this notion;  in-vitro translated mutant Bm-3c exhibits minimal binding 
to  a  consensus  Bm-3  binding  site  (Weiss  et  al,  2003).  If mutant  Bm-3c  protein  has 
reduced  affinity  for  its  DNA  recognition  motifs  in-vivo  then  expression  of  genes
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DNA  binding  ability  may  not  be  the  only  factor  leading  to  functional  redundancy  of 
mutant Bm-3c protein.  Two nuclear localisation signals have been identified in the Bm- 
3c  protein:  a  monopartite  element  spanning  amino-acids  274  to  278  and  a  bipartite 
element spanning amino-acids 314 to 331  (Weiss et al, 2003). In members of the Israeli 
family that  carry the  8bp  deletion  it  is  predicted  that the bipartite nuclear localisation 
signal is lost.  The consequence of loss of the bipartite nuclear localisation signal on the 
function  of  the  Bm-3c  protein  is  impaired  nuclear  targeting;  immunolocalisation 
analysis  shows  that  around  50%  of the  mutant  protein  is  retained  in  the  cytoplasm 
(Weiss  et  al,  2003).  Hence,  Bm-3c-dependent  expression  of hair  cell  survival  genes 
could  be  further compromised by the  cytoplasmic  compartmentalisation  of a normally 
nuclear transcription factor.  In addition,  the first amino  acid lost in the 8bp deletion is 
isoleucine at position 22 of the POU homeodomain (Vahava et al,  1998).  This position 
has been established as an area of functional  significance in the Bm-3  family (Dawson 
et  al,  1996b,  Dawson  et  al,  1998,  Budhram-Mahadeo  et  al,  1998)  and  its  loss  in the 
mutant Bm-3c protein is likely to have a profound effect on the function of the protein. 
Indeed,  data  obtained  from  transient  transfection  assays  are  in  agreement  with  the 
concept that expression of downstream targets of Bm-3 c are compromised by the nature 
of the 8bp deletion; the mutant Bm-3c protein, truncated at 298 amino-acids loses most 
of its transactivating ability (Weiss et al, 2003, Clough et al, 2004).
Interestingly, mice that lack one functional copy of Bm-3c do not develop adult 
onset hearing loss; Bm-3c (+/-) mice at the end of their life-span do not show a greater 
hearing loss or exhibit a greater extent of cochlear degeneration compared to equivalent 
aged-wild-type  animals  (Keithley  et  al,  1999).  This  is  at  odds  with  the  notion  that 
haploinsufficiency  of Bm-3c underlies adult  onset  hearing loss in DFNA15.  However, 
using  the  mouse  as  a  model  organism  for  late  onset  hearing  loss  in  humans  has  its 
limitations.  The  data  reported  by  Keithley  et  al,  1999  could  be  limited by the  mouse 
strain used in the study, but more importantly mice have a short lifespan living to three 
years  at  most  and  the  mice used  by  Keithley  et  al,  1999  were  raised  in  a  controlled 
environment.  This  contrasts  widely with  the  situation for humans.  Humans  live  much 
longer,  are  exposed  to  environmental  insults  and  accordingly  have  the  potential  to 
accumulate exogenous damage to hair cells over a very long period of time.  In patients 
with  DFNA15  if hair  cells  are  already  ‘vulnerable’  at the  molecular level  due to  less 
Bm-3c  protein product they may only be  able to  sustain a certain level  of exogenous 
distress before the onset of hearing loss.  The late onset of hearing loss phenotype seen
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deletion do not exhibit hearing loss until  18-30 years of age. Furthermore, it should be 
considered that Bm-3c expression could be subject to  autoregulation in mice and that 
this  compensates  for  the  loss  of  one  allele  in  Bm-3c  (+/-)  mice  by  up-regulating 
transcription from the single copy allele so levels of Bm-3c protein are not dissimilar to 
wild-type.  This  is  certainly possible.  Autoregulation  of gene expression is  a common 
control  mechanism  amongst eukaryotic transcription  factors  (for review  see Bateman, 
1998),  many  members  of  the  POU  transcription  factor  family  appear  subject  to 
autoregulation (Delhase et al,  1996; Malik et al,  1996; Trieu et al, 2003) and in Bm-3a 
(+/-) mice autoregulation of Bm-3 a has been shown to compensate for the loss of one 
allele of Bm-3a (Trieu et al, 2003). Nevertheless to explain the different phenotype in 
humans and mice with one functional copy of Bm-3 c Vahava et al originally proposed 
that  mutant  Bm-3c  in  DFNA15  may  impair  the  functioning  of the  wild-type  Bm-3c 
protein  by  a  dominant  negative  effect  (Vahava  et  al,  1998).  However,  when  tested 
experimentally  mutant  Bm-3c  protein  shows  little  ability  to  bind  to  a  consensus 
sequence for the Bm-3 family and does not interfere with the binding of wild-type Bm- 
3c (or Bm-3b) to this sequence (Weiss et al, 2003). In agreement with this observation, 
mutant Bm-3c loses most of its transactivating ability and co-transfections of wild-type 
and  mutant  Bm-3c  expression  constructs  show  that  mutant  Bm-3c  protein  does  not 
affect  the  ability of wild-type  Bm-3c protein  to  transactivate  luciferase reporter gene 
constructs  containing downstream  targets  of Bm-3c  (Weiss  et  al,  2003,  Clough  et  al,
2004). These experiments suggest that a dominant negative effect of the mutant Bm-3c 
protein is unlikely to be responsible for the hearing loss phenotype in members of the 
Israeli  family  with  DFNA15.  However,  it  must  be  considered  there  are  many 
mechanisms by which a mutant protein can exert a dominant negative effect over the 
function of the wild-type protein. Accordingly it cannot be ruled out that in-vivo mutant 
Bm-3c hinders contact with a co-factor of wild-type Bm-3c. The N-terminal region of 
mutant Bm-3c protein is probably intact in-vivo; this could compete with wild-type Bm- 
3 c for binding to an as yet unidentified protein target of Bm-3 c required for some Bm- 
3 c regulation.
Finally it should also be considered that the hearing loss phenotype in members 
of the  Israeli  family that  carry the  8bp  deletion  in  Bm-3c may be  due  to  a  ‘gain  of 
function’  mechanism acquired by the mutant Bm-3c protein; mutant Bm-3c may have 
novel  functional properties.  This is  certainly possible,  in-vitro  analysis  shows that the 
298  amino  acid mutant Bm-3c protein loses a bipartite nuclear localisation signal  and
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al, 2003).  In addition, pulse-chase analysis has shown that the mutant Bm-3c protein is 
more  stable  than  the  wild-type  protein  (Weiss  et  al,  2003).  These  novel  features 
acquired by the mutant Bm-3c protein maybe deleterious to hair cell function over time.
In summary, it is clear that an 8bp deletion in the POU homeodomain of Brrt-3c 
causes adult onset hearing loss, DFNA15.  In-vitro analysis with mutant Bm-3c protein 
shows that  its DNA binding ability and transcriptional activity are all but  lost,  nuclear 
targeting is impaired and proteiiv stability of the mutant protein is enhanced compared to 
wild  type  (Weiss  et  al,  2003,  Clough et  al,  2004).  Weiss  et  al,  propose that  it is this 
repertoire of functional defects that ultimately ends in cochlear hair cell loss and adult 
onset hearing loss, DFNA15. The exact mechanism by which the 8bp deletion in Brn-3c 
results in adult onset hearing loss is speculative, but there is strong evidence to suggest 
functional  redundancy  of mutant  Bm-3c.  Consequently,  haploinsufficiency  of Brn-3c 
may  compromise  expression  of genes  involved  in hair cell  survival.  This  is important, 
as  if haploinsufficiency  of Brn-3c underlies DFNA15  and  is  sufficient  to  induce  adult 
onset  hearing  loss manifesting between ages  18-30  years  it can  certainly be envisaged 
how mild sequence variants in Brn-3c might contribute to late onset hearing loss in the 
ageing population.  For example, a common sequence variant in the promoter of Brn-3c 
could have a subtle effect on Bm-3c expression that is not phenotypically evident until 
the fifth or sixth decade of life.  Certainly, a dominant negative effect of the mutant Bm- 
3c protein on the function of the wild-type Bm-3c protein appears unlikely.  A gain of 
function mechanism is possible but currently there is no evidence to suggest the mutant 
Bm-3c protein has novel functional properties that are deleterious to hair cells. Finally, 
it  should  also  be  considered  that  the mechanism by which the  8bp  deletion in Brn-3c 
causes adult  onset hearing loss DFNA15  may not be attributed to a single mechanism 
but  rather  a  mixture  of molecular  mechanisms  that  manifest  in the  late  onset  hearing 
loss  phenotype.  The  8bp  deletion  in  the  POU  homeodomain  of Brn-3c  identified  by 
Vahava  et  al,  has  only  been  identified  in  one  family,  the  Israeli-Jewish  family.  It 
appears to be a rare mutation; it has not been shown to underlie hearing loss in any other 
families.  Evidence  as  discussed  here  suggests  that  Bm-3c  is  paramount  for  hair  cell 
maturation  and  long-term  survival.  Hence,  it  is  conceivable  how  common  sequence 
variants in the Brn-3c gene that have a moderate effect on function or expression of this 
gene  may  be  a  risk  factor  for  late  onset  hearing  loss  that  is  exhibited  by  a  large 
proportion of the ageing population.
781.9  The Brn-3 family: the wider picture.
The POU domain transcription factor Bm-3c is, as has been discussed,  clearly a good 
candidate gene for susceptibility to late onset hearing loss in humans.  Bm-3c together 
with  Bm-3 a and  Bm-3b,  two  highly homologous  genes,  constitutes  the  Bm-3  family 
(for review see Latchman,  1999) the founder member of which, Bm-3a, was originally 
identified in 1989 by He et al. The background to the Bm-3 family will now be explored 
followed  by  molecular  and  functional  characterization  of  this  family  with  special 
emphasis placed on Bm-3c and how these findings relate to the role of Bm-3c in inner 
ear sensory hair cells.
The sequence homology shared between the Bm-3 POU factors extends to the I- 
POU  factor  from  Drosophila  and  the  Unc-86  factor  from  the  nematode  C.  elegans. 
Collectively these POU proteins form a subset division IV, of a much larger and widely 
characterized family of POU proteins. Currently on the basis of sequence homology up 
to  six  subsets  of POU  factors  exist (for details of the other  subsets  see the  following 
reviews:  Verrijzer and Van der Vliet,  1993; Andersen and Rosenfeld, 2001). The term 
“POU”  refers  to  the  DNA-binding  domain  shared  by  members  of the  POU  protein 
family and derives from the original four family members shown to share this region of 
homology:  Pit-l/GHF-1,  Oct-1,  Oct-2,  and  Unc-86.  Pit-1  belongs  to  subset  I  of the 
POU protein family;  expression is restricted to the anterior pituitary gland where it is 
essential  in  development  and  maintenance  of  specific  cell  types  (for  review  see 
Andersen  and  Rosenfeld,  2001).  The octamer binding transcription  factors  Oct-1  and 
Oct-2 are categorized under subset II. Oct-1  is ubiquitously expressed and is important 
in regulation of housekeeping genes. In contrast, Oct-2 has a more restricted expression 
pattern confined to B-lymphocytes of the immune system and specific neuronal cells of 
the nervous system where it has been shown to play an important role in regulation of 
gene expression (for review see Latchman et al, 1999). Unc-86, the first C.elegans POU 
domain protein to be identified (Finney et al, 1998) belongs to subset IV and is a critical 
regulator of neuronal cell lineage and terminal differentiation of neurons (for review see 
Ryan  and  Rosenfeld,  1997).  It  is  well  known  that  POU  proteins  function  as 
developmental regulators. They are important in development of the nervous, endocrine 
and immune  system where they play important roles in determination of cell  lineage, 
cell proliferation, migration, terminal differentiation and survival in these systems (for 
reviews  see  Wegner et  al,  1993,  Latchman  et  al,  1999  and  Andersen  and  Rosenfeld, 
2001).
791.9.1  The POU domain.
The  POU  domain  is  the  evolutionary  conserved  DNA  binding  domain  shared  by 
members of the POU protein family. It is a bipartite structural entity typically stretching 
150-160 amino acids and consisting of an amino-terminal POU specific domain (POUs) 
and  a carboxyl-terminal POU  homeodomain (POUh).  The POUs is a highly conserved 
moiety  that  is  unique  to  the  POU  protein  family  and  is  composed  of four a-helices 
spanning 74-82  amino-acids.  A conserved cluster of basic amino acids defines the first 
and fourth helices and the boundaries of the POUs are enriched in acidic residues.  The 
POUh is the  second  most  highly  conserved  region  and  is  related  to  that  found in the 
classic homeobox proteins.  The POUh comprises three a-helices over a 60 amino acid 
stretch with clusters of basic amino-acids characterising the boundaries of the POUh. In 
each  sub-domain the  second  and  third helix form the distinctive helix-tum-helix motif, 
and  the  third  helix,  the  recognition  helix,  is  able  to  make  base  contacts  in the  major 
groove  of DNA  (for  reviews  see  Verrijzer  and  Van  der  Vliet,  1993;  Andersen  and 
Rosenfeld, 2001).
A variable  linker region of 15-27  amino  acids  separates each  sub-domain.  The 
linker plays  an  important  role  in  conferring flexibility upon DNA binding  (For review 
see  Phillips  and  Luisi,  2000).  A  linker  length  between  10-14  amino  acids  facilitates 
binding  of the  class  II  POU  factor  Oct-1  to  an  octamer  site  whereas  shorter  linker 
lengths  place  constraints  on  the  DNA  binding  ability  of Oct-1  (Van  Leeuwen  et  al,
1997).  Both the POUs and POUh are important for DNA binding; cooperative binding 
of  the  sub-domains  allows  efficient  sequence-specific  recognition  of  asymmetrical 
DNA-binding motifs that are typical for POU domain proteins (Aurora et al,  1992).
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Figure 1.5 A schematic diagram to illustrate the bipartite POU domain. Diagram is not to sacle.The 
POU  domain  is  characterised by  an  amino-terminal  POU  specific  domain  (POUs)  and a  carboxyl- 
terminal POU homeodomain (POUh).  The POUs domain consists of four a-helicies (shown as yellow 
shaded boxes HI  -  H4)  the first and  fourth of which are defined by a  region of basic amino acids 
(shown as +++ in diagram).  The POUH  contains three a-helicies (shown as blue shaded boxes HI  -  
H3);  a region of basic amino acids precedes helix  1  and defines the carboxyl boundary of helix 3.  A 
variable linker region (indicated by the solid black line with two hatches) separates each sub-domain. 
The function of each sub-domain and the linker is discussed within the text.
Reproduced and modified from Wegner et al, 1993.
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capable  of binding  as  homo-  and  hetero-dimers  (for  reviews  see  Phillips  and  Luisi, 
2000;  Andersen  and  Rosenfeld,  2001).  It is  not  clear how  Bm-3  factors bind to their 
cognate sites in-vivo’ , although dimer formation has been observed on an experimentally 
derived consensus sequence for the Bm-3  family (Gruber et al,  1997). The function of 
the POU domain is not limited to DNA binding; it is also capable of mediating specific 
protein-protein  contacts  that  are  important  for  functional  activity  of  POU  domain 
proteins (for review see Andersen and Rosenfeld, 2001).
Strong sequence homology in the POU domain exists between the Bm-3 family 
members; in humans they share approximately 95% sequence identity at the amino acid 
level  (Xiang et al,  1995).  Of the  11  amino-acid residues  in the POU  domain that  are 
exchanged between Bm-3  family members,  6 reside in the linker region (Xiang et al, 
1995).  Upstream of the POU domain, similarity between the Bm-3  factors is less well 
conserved. The exception is a N-terminal region termed the upstream homology domain 
(UHD) that is also found in the other class IV POU domain factors (Xiang et al, 1995).
1.9.2  Molecular and  functional  characterisation  of the  Brn-3 family:  with 
emphasis on Brn-3c.
The Bm-3  factors  share distinct but overlapping patterns of expression in the nervous 
system and are all  involved in the terminal differentiation and survival of specific cell 
types. Bm-3 a is the most widely expressed factor of the Bm-3 family, expression ranges 
from peripheral sensory neurons to specific nuclei of the central nervous system where 
it is plays an important role in the differentiation and survival of neuronal cell subtypes. 
Mice with targeted deletion of the Bm-3 a gene exemplify this,  they exhibit defects in 
sensory neurite outgrowth (Eng et al,  2001)  and undergo an extensive loss of sensory 
and motor neurons in the nervous system which leads to their death shortly after birth 
(McEvilly et al,  1996, Xiang et al, 1996). Within the nervous system Bm-3b expression 
exhibits  a  strong  spatial  overlap  with  that  of Bm-3 a,  but  differs  temporally  and  in 
relative protein abundance. This is particularly evident within the ganglion cell layer of 
the retina where the onset of Bm-3b  expression commences  several  days  earlier than 
that  of Bm-3a  (for  review  see  Ryan  and  Rosenfeld,  1997).  Accordingly,  mice  with 
targeted  deletion  of the  Bm-3b  gene  exhibit  a  specific  loss  of retinal  ganglion  cells 
leading to blindness  and do not die after birth (Erkman et al,  1996,  Gan et al,  1996). 
Subsequent  analysis  has  established  that  Bm-3b  is  not  involved  in  initial  fate
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axonal outgrowth and survival of these cells (Gan et al, 1999, Wang et al, 2000). Bm-3c 
expression is the most restricted of the Bm-3  family; expression in the nervous system 
is limited (for review see Ryan and Rosenfeld,  1997), it is expressed in the retina but is 
the last Bm-3  factor to be expressed (Xiang et al,  1995) and Bm-3c is the only Bm-3 
factor expressed in hair cells of the inner ear (Erkman et  al,  1996,  Xiang et al,  1997, 
1998). The significance of this expression pattern is reflected in the Bm-3c (-/-) mice as 
discussed previously (see  section  1.8.1);  these mice  are viable,  but deaf with balance 
defects due to loss of sensory hair cells from the vestibulo-cochlea system of the inner 
ear (Erkman et al, 1996, Xiang et al, 1997).
The  Bm-3  family is  encoded by separate  genes  on  separate  chromosomes but 
exhibits  closeness  in  sequence  homology.  In  humans,  Bm-3c  has  been  mapped  to 
chromosome  5q31  (Xiang et al,  1995),  Bm-3a to chromosome  13q21.1-q22  (Xiang et 
al,  1995)  and  Bm-3b  to  chromosome  4q31.2  (Xiang  et  al,  1993).  The  human  Bm-3 
factors  are  closely  related  to  their  murine  counterparts  exhibiting  98%  amino-acid 
identity (Xiang et al, 1995). Mouse orthologues of Bm-3a, 3b and 3c have been mapped 
to mouse chromosomes 14E1-E3, 8F1-F5 and 18B3-E1, respectively (Theil et al, 1994). 
Structurally,  the  human  Bm-3  gene  family  are  very  similar  composed  of two  small 
exons intervened by a small  intron at the same relative position in the protein coding 
region  (Xiang  et  al,  1995)  and  this  structural  similarity  extends  to  their  mouse 
homologues  (Theil  et  al,  1993,  1994).  Bm-3a  is  well  characterised  at  the  molecular 
level;  short  [Bm-3a(S)]  and long [Bm-3a(L)]  isoforms have been identified in human 
(Xiang et al,  1995) and mice (Thiel et al,  1993) which appear to be under the control of 
two distinct promoters for the Bm-3 a gene (Frass et al, 2002, Thomas et al, 2004). Both 
isoforms contain the C-terminal POU domain but the short form lacks an 84 amino-acid 
motif termed  the  N-terminal  activation  domain  (Thiel  et  al,  1993).  To  date  no  short 
isoform of Bm-3c has been identified only a long form of 388 amino-acids (Xiang et al, 
1995)  which, similar  to  Bm-3a/ is  characterised  by  an  N-terminal  activation  domain 
(Smith et al,  1998b; Sud et al, 2005) in addition to the POU domain at the C-terminus.
Currently,  the  mechanism  by  which  Bm-3c  functions  as  a  POU  domain 
transcription factor and regulates gene expression in sensory hair cells of the inner ear is 
not well understood. This contrasts with the situation for Bm-3 a in neuronal cells where 
much  more  progress  has  been  made.  The  distinct  domains  of  Bm-3 a  are  well 
characterised  and  allow  Bm-3 a to  function  in  a bi-functional  manner (for review  see 
Latchman et al,  1999,  see also Faulkes et al, 2004).  In neuronal cells Bm-3a(L) has a
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in part via the activation of Bcl-2 (Smith et al, 1998a) and Bcl-x (Smith et al, 2001) and 
these  effects  are  dependent  upon  the  N-terminal  activation  domain  of  Bm-3 a. 
Consequently, the Bm-3a(S) which lacks the N-terminal activation domain is limited in 
function;  it  cannot  enhance  neuronal  survival.  However,  both  forms  of Bm-3 a  (Bm- 
3a(L)  and  Bm-3a(S))  can  activate  expression  of genes  involved  in neurite  outgrowth 
because  in  contrast  to  Bm-3a(L)  activation  of  Bcl-2  and  Bcl-x  these  effects  are 
dependent upon  the  POU  domain  of Bm-3 a  functioning  as both  a DNA  binding and 
transactivation domain; the valine residue at position 22 of the POUh being paramount 
for this effect (for review see Latchman et al, 1999).
In neuronal cell  lines it has been shown that Bm-3c is able to transactivate the 
same genes as Bm-3 a, although generally, to a weaker extent (Budhram-Mahadeo et al, 
1995,  Smith  et  al,  1998b).  Co-transfections  in ND-7  cells  of CAT  reporter construct 
carrying  either the  SNAP-25,  a-intemexin,  or one  of the  three  neurofilament  subunit 
promoters with a Bm-3c expression vector showed Bm-3c could activate each of these 
promoter constructs previously shown to be activated by Bm-3a (Smith et al,  1998b). 
This  is  conceivable  as  the  Bm-3c  factors  are capable of binding to  the  same binding 
sites although subtle differences in affinity for binding site sequence may exist (Gruber 
et  al,  1997).  However,  in the absence of in-vivo  data it is  questionable whether these 
neuronally expressed genes are genuine targets of Bm-3c.
Smith et al,  1998b, reported that the transactivating effect of Bm-3c was limited 
to  neuronal  cell  lines  and  in  contrast  to  Bm-3a-dependent  activation  of the  same 
promoter constructs could not be achieved by the POU domain in isolation. Indeed, by 
deleting discrete regions of Bm-3c and creating Bm-3c fusion proteins with the GAL-4 
DNA  binding  domain  the  trans-activating  ability  of Bm-3c  was  localised  to  a  177 
amino-acid  region  in  the  N-terminal  of Bm-3c.  Since,  the  transactivating  ability  of 
intact  Bm-3c  and the Bm-3c N-terminal  activation domain as  a GAL4 fusion protein 
was only observed in neuronal cell lines, it was concluded by Smith et al. that the Bm-3c 
N-terminal  activation domain is neuronal  cell specific and a neuronal cell  specific co­
activator  was  suggested  to  be  responsible  for  this  effect.  However,  recent  evidence 
disputes  the  notion  that  the N-terminal  activation  domain  of Bm-3c  is  neuronal  cell 
specific (Clough et al, 2004,  Sud et al, 2005).  It has recently emerged that Bm-3c can 
transactivate  specific  BDNF  and  NT-3  promoter  constructs  in  inner  ear  sensory 
epithelial derived cell lines, OC-1  and OC-2, and this is dependent on functional Bm-3c 
with an intact N-terminal domain (Clough et al, 2004).  Hence,  suggesting that at least
83one  mechanism  whereby  Bm-3c  may  function  in  inner  ear  sensory  hair  cells  is  by 
transactivating  the  expression  of  downstream  targets  via  its  N-terminal  activation 
domain.  Recent molecular analysis on Bm-3c by Sud et al, 2005  is in agreement with 
this suggestion. In an attempt to delineate the mechanism by which Bm-3c functions in 
hair cells Sud et al, 2005 linked discrete regions of Bm-3c to the DNA binding domain 
of the heterologous transcription factor GAL4 (similar to Smith et al, 1998b in neuronal 
cells) and assayed the ability of these constructs to regulate the activity of a promoter 
containing GAL4 DNA binding sites in OC-1  and OC-2  cell lines.  The results of this 
analysis showed that only the intact N-terminal domain of Bm-3c, expressed  as a GAL4 
fusion protein, is able to strongly activate luciferase reporter constructs containing Gal-4 
binding  sites.  Sub-fragments  of  the  Bm-3c  N-terminal  expressed  as  Gal-4  fusion 
proteins,  or a construct expressing the isolated POU domain were not able to  achieve 
this effect.  Furthermore, overexpression of the Bm-3c N-terminal activation domain as 
a  discrete  moiety  did  not  interfere  with  the  activation  of  the  GAL4  heterologous 
promoter by the Bm-3c:GAL4 fusion protein containing the intact N-terminal activation 
domain of Bm-3c.  Hence, suggesting that the ability of the Bm-3c N-terminal domain 
to function as an activation domain in inner ear sensory hair cells is due to an intrinsic 
property of this domain and not the recruitment of a co-factor.
The  failure  of  the  isolated  POU  domain  of  Bm-3c  to  function  as  a  dual 
activating and DNA binding domain on promoter constructs shown to be activated by 
Bm-3c  in  neuronal  cell  lines  (Smith  et  al,  1998b)  and  inner  ear  sensory  epithelial 
derived cell  lines (Clough et al, 2004,  Sud et al, 2005) may be due to the fact that the 
POUh domain of Bm-3c contains the amino acid isoleucine at position 22. This position 
is  a critical  determinant  of functional  activity  amongst members  of the  Bm-3  family 
(Dawson et al,  1996b,  1998).  It is responsible for Bm-3a and Bm-3b functioning as an 
antagonistic pair of transcription factors (for review see Latchman et al,  1999). Indeed, 
Bm-3 a  generally  functions  to  transactivate  target  promoters  for  example,  the  genes 
involved in neurite outgrowth (SNAP-25 and the three neurofilament subunits) whereas, 
Bm-3b represses expression of these genes and also prevents their activation by Bm-3 a 
(for review see Latchman et al, 1999). These opposing behaviours of Bm-3a and Bm-3b 
relate  to  the  valine  present  at position  22  of the  POUh in  Bm-3 a  and  the isoleucine 
found at this position in Bm-3b, and are suggested to be mediated by specific protein- 
protein interactions at this position (Dawson et al,  1998).  The POU domain of Bm-3c 
containing the  same  amino-acid  as Bm-3b  at position 22  of the POUh,  isoleucine,  is
84hence  unlikely to  function  as  a  discrete  activating-DNA binding domain  in  inner  ear 
sensory hair cells.
Despite a clear difference at position 22 of the POUh, the POU domain is almost 
identical  between  members  of the  Bm-3  family  (Xiang  et  al,  1995)  and  the  Bm-3 
factors exhibit highly similar DNA binding properties on consensus sequences derived 
by random oligonucleotide selection (Xiang et al,  1995,  Gruber et al,  1997).  This has 
lead  to  the  suggestion  that  the  Bm-3  factors  may  mediate  downstream  events  via  a 
shared  molecular  mechanism  and  hence,  be  functionally  equivalent.  Recently,  some 
evidence has been gathered in agreement with this suggestion (Wang et al, 2002, Pan et 
al,  2005).  Studies  from Bm-3b/Bm-3c double knockout mice suggest that Bm-3c can 
partially compensate  for loss of Bm-3b in the retina;  Bm-3b/Bm-3c double knockout 
mice exhibit a greater loss of retinal ganglion cell axons compared to Bm-3b knockout 
mice  alone  (Wang  et  al,  2002).  Similarly,  but  using  a knock-in  approach  Bm-3 a has 
been shown to compensate functionally for Bm-3b in retinal ganglion cells (Pan et al,
2005).  However,  this  finding  is  at  odds  with  the  antagonist  mechanism  of  action 
observed for Bm-3a and Bm-3b in neuronal cells (for review see Latchman et al, 1999). 
As Bm-3c is the only Bm-3 factor expressed in inner ear sensory hair cells, it is possible 
that targeted replacement of the Bm-3c gene with that of Bm-3 a, or Bm-3b may help 
clarify if the mechanism by which Bm-3c functions in these cells involves a common 
pathway to that of Bm-3 a or Bm-3b in neuronal or retinal ganglion cells, respectively.
In  summary,  evidence  suggests  that  Bm-3c  functions  as  a  transcriptional 
activator in sensory hair cells of the inner ear; the N-terminal activation domain of Bm- 
3c being crucial  for this  effect.  It is also possible that due to  containing isoleucine at 
position 22 of the POUh Bm-3c may function as a repressor of gene transcription and 
hence,  contain  dual  activating  /  repressing  properties  although,  this  remains  to  be 
confirmed. In any case, it is clear that given the selective expression pattern of Bm-3c in 
hair cells, the evidence gained from Bm-3c (-/-) mice and the evidence for the role of 
other members  of the Bm-3  family in controlling gene expression in other cell types, 
Bm-3c is likely to be a critical determinant of coordinating gene expression in hair cells. 
Furthermore, these genes are likely to be involved in hair cell maintenance and survival 
-  attributes that make Bm-3c an excellent candidate gene for susceptibility to late onset 
hearing loss.
851.9.3  How does Brn-3c act as a pro-survival factor for hair cells?
It is clear, from in-vitro molecular analysis that Bm-3c may function as a transcriptional 
activator  in  inner  ear  sensory  hair  cells.  In  addition,  the  presence  of isoleucine  at 
position  22  of the  POUh  raises  the  possibility  that  Bm-3c  may  also  function  as  a 
transcriptional  repressor.  Taken  together,  this  suggests  that  Bm-3c  may  be  a  bi- 
functional transcription factor in inner ear sensory hair cells. However, currently little is 
known about bona fide target genes of Bm-3c in hair cells or in other tissues within the 
nervous  system  where  Bm-3c  is  expressed  and  how  they  are regulated.  Progress  has 
been hindered by the  extremely limited number of hair cells  per cochlea  (only about 
16,000 in mammals) and the difficulties in accessing these cells and maintaining them 
in culture. However, it is evident from patients with DFNA15 and studies with Bm-3c (- 
/-)  mice  that  downstream  targets  of  Bm-3c  are  likely  to  be  involved  in  hair  cell 
maturation  and  maintenance.  Indeed  there  is  evidence  that  Bm-3c  may  be  directly 
involved  in  regulating  neurotrophin  gene  expression  in  the  inner  ear,  expression  of 
which is crucial for innervation of the mature hair cell (Clough et al, 2004).
From studies with Bm-3c (-/-) mice it is clear that loss of Bm-3c leads to hair 
cell death; directly or indirectly presence of Bm-3c protein can prevent the progressive 
apoptotic  degeneration  of hair cells  (Xiang et  al,  1998).  There  is  increasing evidence 
from studies with rodents to suggest apoptosis underlies the aetiology of hair cell loss 
associated with ageing and development of late onset hearing loss (Usami et al,  1997, 
Zheng  et  al,  1998,  Alma  et  al,  2001;  and  discussed  in  section  1.5.4).  Therefore,  it  is 
possible  that  at  least  one  mechanism  whereby  Bm-3c  functions  as  a  long-term  pro­
survival factor for hair cells is via continued involvement in apoptosis. The Bcl-2 family 
is a well-characterised family of proteins involved in apoptosis in many cell types (for 
review Chan and Yu, 2004).  Interestingly,  as discussed, Bm-3a, a close homologue of 
Bm-3c that functions as a survival factor for neuronal cells can induce the expression of 
anti-apoptotic members of this  family in particular,  Bcl-2  (for review of the evidence 
see  Latchman,  1998)  and  Bcl-x(L)  (Smith  et  al,  2001).  Hence,  it  is  very tempting to 
speculate that Bm-3c functions in hair cells in a manner not dissimilar to that of Bm-3a 
in neuronal cells, namely as an anti-apoptotic factor by directly regulating expression of 
genes that are members of the apoptosis cascade. The molecular mechanisms by which 
Bcl-2  functions  as  an  anti-apoptotic  factor  are  complex  and  have  yet  to  be  fully 
elucidated  but  one  such  mechanism  appears  to  be  via  inhibiting  the  generation  of 
reactive oxygen species from the mitochondria (for review see Jang and Surh, 2003).
86Recently a spontaneous mouse mutant, dreidel (ddl), has been identified in Bm- 
3c  (see  http://jaxmice.jax.org/strain/003484.html).  The  ddl  mutation  removes  a  TG 
dinucleotide  at  338bp  in  the  Bm-3c  coding  region  and  is  predicted  to  result  in  a 
truncated protein lacking the POU domain. The (ddl/ddl) mice are deaf and the hearing 
loss  phenotype  is  reported  to  be  similar  to  that  of the  Bm-3c  (-/-)  mice  leading  the 
suggestion that the (ddl/ddl) mice hold promise as a second mouse model  for loss of 
function of Bm-3c.  By comparing mRNA expression profiles from E l6.5 inner ears of 
(ddl/ddl)  and  wild-type  mice,  the  transcription  factor  growth  factor  independence  1  
(Gfi-1) has been reported as a downstream target gene of Bm-3c in hair cells (Hertzano 
et al, 2004). Hertzano et al, reported similarities between outer hair cell morphology and 
degeneration in Bm-3c (-/-), (ddl/ddl) and Gfi-1  (-/-) mice and suggested that the loss of 
outer hair cells  in the Bm-3c (-/-)  and  (ddl/ddl) mice is due to  a failure of Bm-3c to 
maintain Gfi-1  expression. However, more evidence is needed to clarify this issue. The 
evidence provided by Hertzano et al, 2004 does not establish whether Bm-3c regulates 
Gfi-1  directly and morphological comparisons were only made at certain developmental 
time points. Hence, although it is possible that Gfi could underlie some of the outer hair 
cell loss seen in the Bm-3c (-/-) and (ddl/ddl) mice it is presumptive to conclude that it 
underlies  ‘all’  the outer hair cell  loss observed.  Furthermore,  in Gfi-1  (-/-) mice inner 
hair cells are present along the entire length of the cochlea duct, at least at El 8.5, and 
this contrasts widely with the situation for Bm-3c mutant mice. Nevertheless the work 
of Hertzano et al, does raise the possibility that Bm-3c may have an indirect effect on 
members  of  the  apoptosis  cascade,  as  at  least  one  role  of  Gfi-1  that  has  been 
characterised in other cell types, is to prevent apoptosis. Gfi-1  can inhibit cell death by 
directly repressing the pro-apoptotic gene Bax  (Grimes  et  al,  1996b).  Additionally,  as 
highlighted by Hertzano et al, 2004 Gfi-1  can promote STAT3 signals by a virtue of its 
ability  to  sequester  the  STAT3  inhibitor  PIAS3  (Rodel  et  al,  2000),  and  STAT3 
signalling has been reported to transactivate members of the anti-apoptotic Bcl-2 family 
(Fukada et al, 1996; Catlett-Falcone et al, 1999). The identification of STAT3 protein in 
the outer hair cells of the cochlea by Hertzano et al, is in agreement with this concept.
One well-known stimulus whereby a cell’s fate can be pushed towards apoptosis 
is withdrawal of growth factors or when survival signals become limiting. With this in 
mind it is of interest that growth factors have been shown to maintain mammalian hair 
cells in-vitro\ OHC losses in adult quinea pig organ of Corti explants can be prevented 
by  treatment  with  many  growth  factors  including  acidic  fibroblast  growth  factor, 
insulin-like growth factor-1   and epidermal growth factor amongst others (Maigrange et
87al,  2002).  It  is  tempting  to  speculate  that  Bm-3c  may  function  as  a  long-term  pro­
survival factor for hair cells by regulating expression of growth factors needed for their 
maintenance.  Interestingly,  patients  with  Turner  syndrome  that  is  characterized  by  a 
lack of the growth factor estrogen, commonly undergo an early presbyacusis (Hultcrantz 
et al,  1994) suggesting that the growth factor estrogen may be important in maintenance 
of hearing.  There  appear  to  be  very  few  studies  reported  in  the  literature  regarding 
estrogen  and  hearing  although  it  has  been  suggested  that  estrogens  may  confer  a 
protective effect on hearing (Jonsson et al,  1998). Estrogen receptors are reported to be 
expressed  in  auditory  hair  cells  of mice  and  rats  (Stenberg  et  al,  1999),  and  in  the 
‘Turner  mouse’  an  animal  model  of  Turner  syndrome,  premature  presbyacusis  is 
observed concomitant with deterioration of outer hair cells in the cochlea (Hultcrantz et 
al, 2000). Interestingly, there is evidence that members of the Bm-3 family, Bm-3a and 
Bm-3b  can  functionally interact  with the  estrogen receptor (Budhram-Mahadeo  et  al,
1998), but whether this applies to Bm-3c and has significance to the pro-survival role of 
Bm-3c in hair cells can only be speculated upon at present.
In  summary,  the  downstream  target  genes  of Bm-3c  in  inner ear  sensory hair 
cells are largely unidentified at present. However, it is clear from evidence gained with 
Bm-3c  (-/-)  mice  and  patients  with  DFNA15  that  downstream  targets  of Bm-3c  are 
likely to function in hair cell maturation and long-term survival. Currently, experiments 
are  underway  using  both  in-vitro  (our  laboratory)  and  in-vivo  (Avraham  et  al) 
approaches  to  identify  Bm-3c  target  genes.  It  is  hoped  that  by  utilising  both  these 
approaches  and  identifying  downstream  targets  of Bm-3c  in  hair  cells  elucidation  of 
hair cell survival pathways will be facilitated. By gaining a greater understanding of the 
molecular players  in hair cell  survival  therapeutic intervention to  slow  and ultimately 
prevent loss of hearing with advancing years will be aided.1.10  The aim of the project.
The aim of this project is to investigate genetic susceptibility to late onset sensorineural 
hearing loss (as defined in section 1.5.1) using a candidate gene case-control association 
study approach.  The candidate gene to be investigated is Bm-3c (also known as Brn3.1 
and  POU4F3),  a  POU  domain  transcription  factor  that  within  the  inner  ear  is 
specifically expressed in hair cells (Erkman et al,  1996; Xiang et al,  1997,  1998). At the 
onset  of  this  project  Brn-3c  was  one  of  the  most  promising  candidate  genes  for 
susceptibility  to  late  onset  hearing  loss.  In  recent  years,  many  additional  promising 
candidate genes for susceptibility to late onset hearing loss have emerged (reviewed in 
section  1.7).  However,  Bm-3c  still  remains  one  of  the  strongest  candidates. 
Collectively,  evidence  suggests  that  Bm-3c  functions  in  hair  cell  maturation  and 
maintenance  during  development  and  ultimately  as  a  life-long  pro-survival  factor  for 
hair cells (Erkman et al,  1996,  Xiang et  al,  1997,  Xiang et al,  1998 and Vahava et al, 
1998).  Given that loss of auditory hair cells appears to be the main cause of late onset 
hearing loss (for reviews see Jennings and Jones, 2001, Fransen et al, 2003; Gratton and 
Vazquez, 2003; Ohlemiller, 2004; Gates and Mills, 2005) these features make Brn-3c an 
excellent  candidate  gene  for  susceptibility to  this  disease  (a  detailed  discussion of the 
evidence  to  implicate Bm-3c  as  a  good  candidate  gene  for  late  onset  hearing loss is 
reviewed in section 1.8).
Late  onset  hearing  loss  is  an  extremely  common  and  complex  disease.  Genetic 
predisposition to late onset hearing loss, as with all traits of a complex nature, is thought 
to  be  due to  moderate  variations in gene  expression  or function  at multiple  loci.  The 
CD:CV  hypothesis  states  that  genetic  susceptibility  to  common  disease  is  due  to 
common genetic variants present with a rare allele frequency of or greater than  1% in 
the  general  population  (for  reviews  see  Smith  and  Lusis,  2002;  Wright  et  al,  2003). 
Therefore,  in  line  with  the  CD:CV  model  it  was  hypothesized  that  common  inter­
individual  sequence variants in the Brn-3c gene or within the regulatory regions of this 
gene that have a subtle affect on function or expression of Bm-3 c, respectively could be 
a risk factor for  susceptibility to this disease.  To investigate this hypothesis four main 
aims were devised for this project that are summarised and discussed below:
891)  To identify common sequence variants in the Brn-3c gene.
2)  To  use  in-vitro  assays  where  available  and  assess  whether  common  sequence 
variants in the Brn-3c gene are functional.
3)  To initiate collection of a well-characterised patient cohort for late onset hearing 
loss.
4)  To assess whether common and functional sequence variants in the Bm-3c gene 
are  a  risk  factor  for  late  onset  hearing  loss  by  means  of a  pilot  case-control 
association study.
1.10.1 Identification of common sequence variants in the B rn -3 c gene.
Common  sequence variants  are proposed to underlie  susceptibility to  common disease 
and are reported to exist with a rare allele frequency of or greater than 1% in the general 
population; this is the basis of the CD:CV hypothesis (for reviews see Smith and Lusis, 
2002; Wright et al, 2003).  At the time of commencing this project minimal information 
was reported in the public SNP databases for the Brn-3c gene. Therefore, in an attempt 
to  identify  common  sequence variants in the Bm-3c gene that  may predispose to  late 
onset hearing loss it was decided to perform mutation scanning of the Brn-3c gene in a 
small  sample  consisting  of members of the general population.  This line  of analysis  is 
explored in Chapter 4.
1.10.2 Establishing whether common sequence variants in the B rn -3 c 
gene are functional.
If common sequence variants are identified in the Bm-3c gene these could be  ‘causal’ 
and pathogenic for late onset hearing loss or they could be neutral variants that have no 
affect on susceptibility to this disease. As discussed previously (section 1.6.2 and  1.6.3) 
use  of functional  sequence  variants  in  case-control  association  analysis  is  extremely 
important.  Use of well-characterised functional sequence variants increases the chances 
of finding a positive association as the likelihood of a false-positive association due to 
identification  of what  is  in  effect  a  neutral  sequence variant  in  linkage  disequilibrium 
with the casual variant  at the  same  or another locus is reduced.  In addition,  it is only
90when  the  function  and  the  effect(s)  of  the  causal  sequence  variant  have  been 
functionally  characterised that  its  role  in  disease  pathogenesis  can be well  understood 
and its effect on disease risk can be evaluated with confidence. Hence, making for more 
robust  interpretation  of case-control  association  data  and  increasing  the  likelihood  of 
replication in subsequent independent studies.  Therefore, for the purpose of this project 
it was decided that any common sequence variants identified in the Brn-3c gene would 
be assayed for functional impact with respect to Bm-3c by appropriate in-vitro analysis. 
For example,  common sequence variants within the promoter of Brn-3c could result in 
subtle  inter-individual  differences  in  Brn-3c  expression  by  modifying  cis-acting 
elements and hence,  the binding affinity of transcription factors.  Therefore,  if common 
sequence variants within the promoter of Bm-3c are identified in this project these will 
be  tested  in-vitro  to  see  if they  modify  transcription  factor  binding  by  using  nuclear 
protein extracts from a suitable cell line. Common promoter variants that have an affect 
on  protein  binding  will  then  be  assessed  further  by  utilising  suitable  cell  lines  for 
reporter gene assays to determine if differences in sequence and hence binding affinity 
manifest  in  functional  differences  in  regulation  of  the  Brn-3c  gene.  Similarly,  if 
common  sequence variants are identified  in the coding region  of Bm-3c  or the intron 
(the Brn-3c gene is characterised by a single non-coding intron) these too will be tested 
in-vitro for functional impact using suitable techniques as appropriate depending on the 
location  of the  sequence  variant.  The  rationale  behind  techniques  used  for  functional 
analysis is  discussed further in Chapter 5  and functional analysis of common sequence 
variants in the Bm-3c gene is discussed throughout Chapters 5-7.
1.10.3  Collection  of  a  well-characterised  patient  cohort  for  late  onset 
hearing loss.
The long-term aim of this project is to assess whether common and functional sequence 
variants in the Brn-3c gene are a risk factor for late onset hearing loss by means of a 
case-control association study (see next section,  1.10.4). In order for this part of the aim 
to  stand  a  chance  of success  large  and  well-characterised  patient  cohorts  are  needed. 
However,  at the  onset  of this project well-characterised patient  cohorts for late onset 
hearing  loss  were  scarce.  Consequently,  it  was  an  important  aim  of this  project  to 
initiate collection of a large, well-characterised patient cohort for late onset hearing loss 
that could be used in subsequent association analysis. Therefore, in accord with this aim 
sample  collection  from  subjects  characterised  by  a  consultant  audiologist  as  having  a
91late onset hearing loss was initiated from the adult hearing aid clinic at the Royal Free 
Nose,  Ear  and  Throat  Hospital,  London,  U.K.  at  the  onset  of this  project.  Ethical 
approval for this part  of the project was granted from the Royal Free Local Research 
Ethics  Committee  (6202).  More  information  concerning  this  aspect  of the  project  is 
described in Method section 3.2.1 and discussed in Chapter 8 section 8.2.
1.10.4  Establishing whether common and functional sequence variants in 
the B rn -3 c gene are a risk factor for late onset hearing loss by means of a 
case-control association study.
The ultimate aim of this project is to use a case-control association study approach to 
assess whether common and functional sequence variants in the Bm-3c gene are a risk 
factor for late  onset  hearing  loss.  As  has been  discussed  previously  (section  1.5)  late 
onset hearing loss is a complex disease and consequently,  the relative risk contributed 
by any one sequence variant is thought to be small. Hence, in order for the power of the 
association  study  to  be  sufficient  to  detect  a  positive  association  large  and  well- 
characterised patient cohorts are needed.  Collection of a late onset hearing loss patient 
cohort  was  initiated  (see  section  1.10.3)  in  order  to  perform  association  analysis  in 
accord with this part  of the  aim.  However,  it was acknowledged  at  the  outset  of this 
project that the number of patients with late onset hearing loss that it would be possible 
to recruit into this study within the time frame of this PhD project may limit the power 
of the association analysis that could be performed.  Therefore, the association analysis 
performed for this PhD project was considered a preliminary study.  This line of analysis 
is discussed further in Chapter 8.
In summary, by fulfilling these aims genetic variation in the Brn-3c gene would 
be characterised and through functional analysis insight may be gained into how Bm-3c 
an important hair cell pro-survival factor functions and / or how this gene is regulated. 
Indeed,  currently  the  molecular  mechanism  by  which  Bm-3c  functions  as  a  POU 
domain transcription  factor  in  inner  ear  sensory  hair  cells  is  not well understood  and 
very little is known as to how the Bm-3c gene is regulated; the downstream targets of 
Bm-3c  are  largely  unidentified  and  no  transcription  factors  involved  in  regulation  of 
Bm-3c  have  been  elucidated.  By  collection  of a well-characterised  patient  cohort  for 
late onset hearing loss one would be able to evaluate with confidence the affect of Bm- 
3 c as a risk factor for late onset hearing loss by using sequence variants only for which 
there  is  evidence  that  they  are  functional  in  subsequent  association  analysis.  It  was
92accepted at the outset of this project that this line of analysis would be limited by the 
power of the preliminary association study that it would be possible to perform within 
the  time  constraints  of this  PhD  project.  However,  a  preliminary  association  study 
would  provide  information  on  allele  frequency  and  pave  way  for  a  large-scale 
population based case-control association study, which is beyond the time frame of this 
PhD project. It is through performing this type of analysis that a greater understanding 
of the  genetic  factors  that underlie  susceptibility to  late  onset  hearing loss  should  be 
achieved.
931.11  Publications before submission of this thesis.
Before submission of this thesis two important publications have come to light:
Johnson et al, 2006. Strain background effects and genetic modifiers of hearing in mice. 
Brain Res. 1091:  79-88.
Report five additional Ahl loci (Ahl4 -  Ahl8) that have been mapped in mice.
Van Laer et al,  2006.  The contribution of genes involved in potassium-recycling in the 
inner ear to noise-induced hearing loss. Hum Mutat. 27:  786-795.
Report an association between sequence variants in three genes (KCNE1, KCNQ1  and 
KCNQ4)  involved  in potassium recycling in  the inner  ear and  susceptibility to noise 
induced hearing loss. The authors report the sequence variant p.D85N in KCNE1  as a 
possible  causative  sequence  variant  based  on  subsequent  functional  analysis  (this  is 
discussed further in section 9.0: General Discussion and Conclusion).
942.0  The Aim Of The Project.
The aim of this project is to investigate Bm-Sc as a candidate gene for susceptibility to 
late onset hearing loss.  To investigate this hypothesis four main aims were devised for 
this  project  that  are  summarised  below  and  discussed  in  detail  in  Chapter  1,  section 
1.10:
1)  To identify common sequence variants in the Brn-3c gene.
2)  To  use  in-vitro  assays  where  available  and  assess  whether  common  sequence 
variants in the Brn-3c gene are functional.
3)  To initiate collection of a well-characterised patient cohort for late onset hearing 
loss.
4)  To assess whether common and functional sequence variants in the Brn-3c gene 
are  a  risk  factor  for  late  onset  hearing  loss  by  means  of a  pilot  case-control 
association study.
953.0  Materials And Methods
3.1  Materials.
3.1.1 Chemicals and equipment.
Chemicals  were  purchased  from  Amersham  Biosciences,  BDH,  Invitrogen,  Promega 
and Sigma unless otherwise stated.
Restriction endonucleases were purchased from Promega.
[y-32 P]-ATP and [a-32P]-dCTP were purchased from Amersham Biosciences.
Nunclon™ plasticware for tissue culture was purchased from Fisher Scientific.
Experimental  manipulations  were performed using  autoclaved  MilliQ double distilled 
water (ddFhO).
3.1.2 Plasmids.
pGEM®-T easy vector, pGL3-Basic vector, pGL3-Promoter vector, pRL-SV40 vector, 
phRL-null  vector,  pSi  mammalian  expression  vector  and  pCi  mammalian  expression 
vector were purchased from Promega.
The  mammalian  expression  vector  pEVR2-Spl  was  kindly  provided  by  Professor 
Guntram  Suske,  University of Marburg,  Germany  and  has been  described previously 
(Hagen et al, 1992).
The  Drosophilia  expression  vector  pPac-USp3  was  kindly  provided  by  Professor 
G.Suske as before and has been described previously (Dennig et al, 1996).
The  mammalian  dominant  negative  SP1  expression  vector  pEBGN-SPl  was  kindly 
provided  by  Professor  Gerald  Thiel,  University  of  the  Saarland  Medical  Centre, 
Germany  and  has  been  described  previously  (Petersohn  and  Thiel,  1996;  Lietz  et  al, 
2003).
96The  mammalian  expression  vector  CMV5-Gfi-1  was  kindly  provided  by  Professor 
Horwitz,  University of Washington  and  has been described previously (Grimes  et  al, 
1996b).
3.1.3 Abbreviations.
ATP Adenosine 5’-triphosphate
dATP deoxyadenosine triphosphate
dCTP deoxycytidine triphosphate
dGTP deoxyguanosine triphosphate
DMSO Dimethyl sulphoxide
dNTPs Dideoxynucleotide triphosphates
dTTP deoxythymidine triphosphate
DTT Dithiothreitol
EDTA Ethylenediamine tetra-acetic acid
EGTA Ethylene glycol-bis (P-aminoethyl ether)-N,N,N’N’-tetraacetic acid.
IPTG Isopropyl-P-D-thiogalactopyranoside
LB Luria-Bertani medium
NP40 Nonidet-P-40
OC-2 organ of Corti-2
PBS Phosphate buffered saline
rpm revolutions per minute
SDS Sodium dodecyl sulphate
SSC Sodium chloride/sodium citrate buffer
TAE Tris-actate-EDTA electrophoresis buffer
TBE Tris-borate-EDTA electrophoresis buffer
TEMED N,N,N ’N ’ -tetramethylethylenediamine
X-gal 5-bromo-4chloro-3-indolyl-p -D-glactropyranoside
973.1.4  Stock solutions.
Stock solutions were made up using autoclaved MilliQ deionised water unless otherwise 
stated.
6x DNA loading buffer: 15%  Ficoll,  0.25%  bromophenol  blue,  0.25% 
xylene cyanol.
Denaturing solution: 
Hybridisation solution:
1.2M NaCl, 0.4M NaOH.
6x SSC, 0.5% SDS, 2.5x Denhardts solution.
lOOx Denhardts solution: 2% Ficoll, 2% Polyvinyl Pyrrolidone, 2% BSA.
SDS-polyacrylamide gel
5% Stacking gel: 5% acrylamide, 0.125M Tris (pH 6.8), 0.1% SDS, 
0.1% ammonium persulfate, 0.1% TEMED.
8% Resolving gel: 8% acrylamide, 0.375M Tris (pH 8.8), 0.1% SDS, 
0.1% ammonium persulfate, 0.06% TEMED.
lx SDS gel-loading buffer: 50mM  Tris-Cl  (pH  6.8),  2%  SDS,  10%  glycerol, 
0.1 % bromophenol blue, 1  OOmM DTT.
lOx Western running buffer:  0.25M Tris, 1.92M glycine, 1% SDS.
Blotting buffer: 25mM Tris, 192mM glycine, 30% methanol.
Tris Buffered Saline-Tween:  20mM Tris (pH 7.6), 150mM NaCl, 0.1% Tween-
(TBS-T)  20.
TBS-T
(10% non fat milk powder):  10% (w/v) non-fat milk powder (Marvel), TBS-T.
TBS-T
(5% non fat milk powder):  5% (w/v) non-fat milk powder (Marvel), TBS-T.
98Formamide gel-loading buffer:  98%  formamide,  0.1%  xylene  cyanol,  0.1%
bromophenol blue, 9.8mM EDTA (pH 8.0).
4% non-denaturing 
polyacrylamide gel 
(for EMSA analysis):
lOx TBE:
50x TAE:
Parker buffer lOpM Zinc: 
Parker buffer lOOpM Zinc: 
L-Broth:
LB-Agar:
20x SSC:
4% acrylamide, 0.25x TBE, 0.037% TEMED, 
0.07% ammonium persulphate.
0.89M Tris-borate, 20mM EDTA (pH 8.0).
2.0M Tris,  1M  Glacial  acetic acid,  50mM  EDTA 
(pH 8.0).
20mM Hepes (pH 7.9), 50mM KC1, 0.5mM DTT, 
8% ficoll, 1  OpM zinc sulphate.
20mM Hepes (pH 7.9), 50mM KC1, 0.5mM DTT, 
8% ficoll, 1  OOpM zinc sulphate.
1%  tryptone  (DUCHEFA),  0.5%  yeast  extract 
(DUCHEFA), 0.17M NaCl.
L-broth  containing  1.5%  Micro  Agar 
(DUCHEFA).
3M NaCl, 0.3M trisodium citrate.
993.2  Methods.
3.2.1  Patient samples
For initial mutation scanning of the Bm-3c gene genomic DNA samples were obtained 
from  45  random  individuals  and  kindly  provided  by  Dr  Maria  Bitner-Glindzicz, 
Institute  of Child  Health,  University  College  London,  U.K.  Genomic  DNA  samples 
were obtained from individuals predominantly of Caucasian ethnicity.
For  the  association  study  patients  were  characterised  by  Dr  Barbara  Cadge, 
Audiological  Physician,  Institute  of  Laryngology  and  Otology,  University  College 
London, U.K as having a late onset sensorineural hearing loss (for definition see section
1.5.1)  and were recruited from the adult hearing aid clinic at the Royal Free Nose, Ear 
and Throat Hospital,  London, U.K.  Ethical  approval was granted from the Royal Free 
Local Research Ethics Committee (6202). Patients were identified in advance from the 
forthcoming  clinic  appointments  lists  and  sent  the  Patient  Information  Sheet,  Patient 
Questionnaire:  Adult Onset Hearing Loss and Consent form (see Appendix A). Where 
available identification of suitable patients was based on diagnostic audiogram. Patients 
were excluded from recruitment if: less than 30 years of age, history of known dementia 
and / or learning disability or patient identified  as requiring an  interpreter (which  are 
likely to cause problems with the consent procedure). On day of attendance at clinic all 
patients in receipt of the Patient Information Sheet were asked if they wished to accept 
or  decline  the  invitation  to  participate  in  the  study.  If accepted,  signed  consent  was 
obtained,  patients  were  asked  to  donate  a  blood  sample  (5mls)  and  data  sets  were 
collected on patients according to the Patient Questionnaire (see Appendix A). Data sets 
collected  on  patients  included  gender,  age,  ethnicity,  diagnostic  audiogram,  age  of 
onset,  family history of hearing  loss,  history  of noise  exposure  including both  acute 
(sudden) and chronic exposure (for example, occupational noise exposure) in addition to 
details of significant medical problems. Upon review of patient data sets, patients were 
further  excluded  from  the  study  if:  they  were  non-Caucasians,  upon  diagnostic 
audiogram hearing loss was identified as conductive, a specific known aetiology of the 
sensorineural  hearing  loss  was  identified  for  example:  acoustic  neuroma  (a  non- 
cancerous  growth  near  auditory nerves),  Meniere’s  disease,  evidence  of head  trauma 
leading to sudden sensorineural hearing loss or evidence of acute noise exposure leading 
to sudden sensorineural hearing loss. Patients were not excluded from the study if there 
was an asymmetric hearing loss as long as the better hearing ear was consistent with the 
criteria for late onset sensorineural hearing loss. In these cases onset of hearing loss was
100dated from the better hearing ear characteristic of late onset sensorineural hearing loss 
and the worst hearing ear (due to hearing loss manifesting from childhood infections, 
mastoid surgery or Meniere’s disease) was ignored.
For  the  control  sample  group  genomic  DNA  samples  were  obtained  from 
random, healthy members of the general population and kindly provided by Professor 
Patricia  Woo,  Centre  for  Paediatric  Adolescent  Rheumatology,  Windeyer  Institute, 
University College London, U.K.  and have been described previously (see Crawley et 
al,  1999).  Data sets  available on  subjects included  gender,  age  and ethnicity.  For the 
association study subjects of Caucasian ethnicity were selected.
3.2.2  The polymerase chain reaction (PCR).
All PCR reactions were performed with an Eppendorf Mastercycler Gradient.
3.2.2.1  PCR for SSCP analysis.
Primers  were  designed  using  Primer3  software  (http://frodo.wi.mit.edu/cgi- 
bin/primer3/primer3  www.cgi)  to  generate  overlapping  PCR  amplicons  covering  the 
complete  coding  region  of  Bm-3c  (NCBI  GenBank  Accessions:  U 10060.1  and 
U10061.1), the intron (NCBI GenBank Accession:  AF043452.1), and  1.5Kb of the 5’- 
flanking  region  (Reference  sequence:  Ensembl  transcript  ID  ENST00000230732;  see 
Appendix B). An additional set of primers were designed to span a dinucleotide (GT)n 
repeat at -3495bp within the 5’-flanking region.  Primers were purchased from Qiagen 
(http://oligos.qiagen.com) and re-suspended at 1  OOpM in ddFUO; sequence of primers is 
summarised in Table 3.1,  section  3.2.18.  Each PCR reaction was optimised to ensure 
specific amplification of the required band by varying the magnesium concentration and 
annealing temperature of the reaction and visualisation of a single band of the correct 
size by agarose gel electrophoresis. Reactions were performed on lOOng genomic DNA, 
with  0.2pM  of each  primer,  200pM  dNTPs,  lOmM  Tris-HCL  (pH9.0),  50mM  KC1, 
0.1% Triton X-100, 2.0mM MgCb, and 0.5U of Taq DNA polymerase (Promega) in a 
total volume of 50pl.  Reactions were supplemented with DMSO 5% (v/v) as required 
(see  Table  3.1,  section  3.2.18).  Thermal  cycling  was  performed  under  the  following 
conditions:  denaturation  at  94°C  for 30  seconds,  annealing at optimal pre-determined 
temperature for 30 seconds,  extension at 72  °C  for 30 seconds,  for 30 cycles, with an 
initial  denaturation  step  of 94°C  for  5  minutes  and  a  final  extension  of 72°C  for  7 
minutes.
1013.2.2.2 PCR for site-directed mutagenesis at -1391A>C.
PCR was performed on  10ng double-stranded plasmid DNA (p-Luc-1391C) using the 
QuikChange®  Site-Directed  Mutagenesis  Kit  (Stratagene)  with  125ng  each primer:  - 
1391aSDM-S  (5’  GCAGCGTAGTCGAGGTCCAGGATTC  3’)  and  -139USDM-AS 
(5’ GAATCCTGGACCTCGACTACGCTGC 3’),  lpl of dNTP mix,  lx reaction buffer 
and 2.5U of PfuTurbo DNA polymerase mix in a total volume of 50pl. Thermal cycling 
was performed at 95°C for 30 seconds followed by  12 cycles of: 95°C for 30 seconds, 
55°C for 1   minute and 68°C for 8 minutes. Post-PCR 40pl of the PCR mix was used in 
a Dpnl digest to digest the template plasmid DNA (non-mutated) and  1  pi of the Dpnl- 
treated  DNA  was  used  in  a  transformation  reaction  according  to  the  manufacturer’s 
instructions (the target nucleotide at -1391  for site-directed mutagenesis is highlighted 
in black bold within the primer sequence shown).
3.2.2.3 PCR for generation of a 710bp fragment spanning  - 5 6 6 ( G T ) n   in the Brn- 
3c 5’-flankinq region.
To generate a 710bp fragment spanning -566(GT)n in the Bm-3c 5’-flanking region for 
use  in  sub-cloning  PCR  was  performed  on  lOOng  genomic  DNA  of pre-determined 
genotype at -566(GT)n based on the initial SSCP screen. Primers 3cP4-S and 3cP10-AS 
(for sequence  see Table  3.1,  section 3.2.18) were used in a standard PCR reaction as 
described in section 3.2.2.1  but with an annealing temperature of 60.3°C, an annealing 
and an extension stage of 45  seconds and PCR reactions were supplemented with 5% 
DMSO.
3.2.2.4  PCR  for  generation  of  a  398bp  fragment  spanning  - 3 4 9 5 ( G T ) n .   - 
3 4 5 7 ( G A ) n  and -3432polv-G polymorphism in the Brn-3c 5'-flankinq region.
To  generate  a  398bp  fragment  spanning  -3495(GT)n,  -3457(GA)n  and  -3432poly-G 
polymorphism in the Bm-3c 5’-flanking region PCR was performed on  lOOng genomic 
DNA with primers 3cP12-S: 5’ GAGCTCCTGAAGCAGTGTCT 3’ and 
3cP12-AS:  5’  GCAATTTGTAACAGCCTCTATGC  3’  in a standard PCR reaction as 
described in section 3.2.2.1  but with an annealing temperature of 59°C.  Post-PCR the 
resulting  amplicon  was  sub-cloned  into  pGEM®-T  easy  vector  (Promega)  for 
sequencing.
1023.2.2.5 PCR for construction of expression vector pSi-DBD-SP1.
PCR was performed on  lOOng double-stranded plasmid DNA (pEBGN-SPl) using the 
BD Advantage ™ 2 PCR Kit (BD Biosciences) for high fidelity PCR with 0.2jliM   each 
primer:  SplDomNeg-S  (5'  ATGCTGGTTCCGCGTGGATCAC  3')  and  SplDomNeg- 
AS (5' CCCTCACTCTAGAGTCGC 3'), 200pM dNTPs,  lx Advantage 2 PCR buffer, 
lx Advantage 2 DNA polymerase mix in a total volume of 50pl. Thermal cycling was 
performed  at  95°C  for  1   minute  followed by 30  cycles  of:  95°C  for  30  seconds  and
68°C for 1  minute, with a  final extension of 70°C for 7 minutes.
3.2.3 Single strand conformational polymorphism (SSCP) analysis.
All  amplicons  generated by PCR for SSCP  analysis were within the size range  130 - 
302bp (see Table 3.1,  section  3.2.18).  For SSCP,  a 2pl  aliquot of each  amplicon was 
mixed with 6pl  of Formamide reagent (52%  Formamide,  lOmM  EDTA,  0.05%  SDS, 
0.02 % Bromophenol blue and 0.02 % Xylene cyanol). Samples were heated at 90°C for 
3  minutes,  snap-cooled  on  ice  and  loaded  onto  a  non-denaturing  polyacrylamide  gel 
with pre-formed sample wells (CleanGel 48S, DNA Analysis  Kit,  Pharmacia Biotech. 
Dimensions  after rehydration  250  x  110  x  0.5mm,  stacking  gel  T  =  5  %,  C  =  3  %,
separating  gel  T  =  10  %,  C  =  2  %).  SSCP  was  performed  on a  Multiphor  II
electrophoresis  unit with  a Multitemp thermostatic circulator unit  at 4,  10  and 20  °C 
using the  CleanGel  DNA  analysis kit (Pharmacia Biotech).  Bands were visualised by 
silver  staining  according  to  the  DNA  Silver  Staining  Kit  (Pharmacia  Biotech). 
Amplicons that displayed abnormal  SSCP migration patterns indicative of a sequence 
variant were directly cloned into the pGEM®-T easy vector (Promega) for sequencing. 
Both strands were sequenced on an ABI Prism 3100 Genetic Analyser (see section 3.2.7 
and Table 3.3,  section 3.2.18) and compared to the reference sequence (see Appendix 
B).  Variants identified are described with respect to the first A of the ATG translation 
start as +1.
3.2.4 Cell culture.
3.2.4.1  Culture of OC-2 cells.
The mouse inner ear sensory epithelial cell line, Organ of Corti-2 (OC-2) was obtained 
from  Professor  Matthew  Holley,  University  of  Bristol,  U.K..  OC-2  cells  were
103maintained  at  33°C,  5  %  carbon  dioxide  in  Eagle’s  minimal  essential  medium 
(Biowhittaker) supplemented with glutamax (2mM),  10% foetal calf serum and 50U/ml 
y-interferon.  Cells were seeded at a density of approximately  1-2 xlO5  cells per 75cm2 
flask (Nunclon™) and passaged when cells reached approximately 80% confluency.
3.2.4.2 Preparation of OC-2 nuclear extracts.
Nuclear extracts were prepared  from OC-2  cells using an adaptation of Alkalay et al, 
1995.  Briefly,  OC-2  cells were grown in large  175cm2  flasks (Nunclon™) until  80 % 
confluent, washed once in cold PBS (calcium and magnesium free) and covered in 3mls 
of cold  cytoplasmic lysis buffer (lOmM  Hepes pH  7.6,  ImM  EDTA,  O.lmM  EGTA, 
lOmM KC1,  ImM DTT,  ImM sodium pyrophosphate,  ImM sodium orthovanadate and 
lx Complete, Mini protease inhibitor cocktail, Roche). Incubated on ice for 10 minutes, 
harvested with a rubber policeman and transferred to a series of eppendorf tubes. NP40 
was added to the top side of each eppendorf at a final concentration of 0.6%, tubes were 
vortexed for a few seconds (left no longer than 5 minutes) and extracts were spun down 
at  13,000 rpm for 30 seconds at 4 °C. The supernatant was removed and all traces of 
cytoplamsic lysis buffer removed  from the pellet.  50pl of nuclear lysis buffer (20mM 
Hepes pH 7.6, 0.2mM EDTA, O.lmM EGTA, 25% glycerol, 0.42M NaCl,  ImM DTT, 
ImM  sodium  pyrophosphate,  ImM  sodium  orthovanadate  and  lx  Complete,  Mini 
protease inhibitor cocktail, Roche) was added to each pellet and nuclear proteins were 
extracting by freeze-thawing by transferring eppendorfs from an ethanol/dry ice bath to 
a 37°C water bath and repeating three times. Extracts were spun down at 13,000 rpm for 
10 minutes at 4 °C and the supernatant containing nuclear proteins, pooled. The protein 
concentration was  determined by spectroscopy using the  formula below*  and  extracts 
were aliquoted, snap frozen and stored at -80°C.
’Concentration ng/pl = (1.55 x A280) -  (0.76 x A260).
3.2.4.3  Preparation  of  OC-2  nuclear  extracts  transfected  with  an  expression 
vector for Gfi-1.
The day before transfection OC-2 cells were plated into 90mm dishes (Nunclon™) at 5 
x  105  cells per dish.  OC-2  cells  were transfected with  1.2pg of either pCi  expression 
vector (Promega) or CMV5-Gfi-1  expression vector according to the calcium phosphate 
precipitation method (Gorman, 1985); three dishes of transfected cells were prepared for 
each expression vector. Twenty-four hours after transfection the medium was removed
104and  a  standard  glycerol  shock  was  performed  (15%  glycerol).  Forty-eight  hours  after 
glycerol  shock cells were harvested for nuclear extract as described in section 3.2.4.2 
using 1ml of cold cytoplasmic lysis buffer per dish.
3.2.5 In-Vitro Transcription and Translation.
Generation of in-vitro translated (IVT) SP1  and SP3 protein was performed using pSi- 
SP1  and pSi-SP3  expression plasmids as templates (expression plasmids are described 
in section 3.2.8.2). Reactions were performed on  lpg of each expression plasmid using 
the TnT® T7 Quick Coupled Transcription / Translation System (Promega) according 
to the manufacturer’s instructions.
3.2.6 The electrophoretic mobility shift assay (EMSAT
3.2.6.1  Design and annealing of oligonucleotides.
Complementary oligonucleotides were designed to span the sequence variation on wild 
type and variant alleles and to include any putative transcription factor binding sites as 
identified from using Matlnspector software
(www.genomatix.de/products/MatInspector/index.htmiy  Sequence  of  consensus 
binding  sites  and  mutated  binding  sites  were  obtained  from  the  Santa  Cruz 
Biotechnology, Inc. website (www.scbt.com) unless stated otherwise.  Oligonucleotides 
are  summarised  in  Table  3.2  (section  3.2.18);  5'-  overhangs  were  added  to  each 
oligonucleotide  as  specified  in  Table  3.2  to  facilitate  subsequent  sub-cloning.  All 
oligonucleotides  were  purchased  from  Qiagen  (http://oligos.qiagen.com)  and 
resuspended at 1  pg/pl in ddF^O.
Complementary  oligonucleotides  were  annealed  by  combining  lOpg  of each 
oligonucleotide with Maniatis medium salt buffer (50mM NaCl,  lOmM Tris-Cl pH 7.5, 
lOmM MgCl2 and  ImM DTT), heating at 95°C  for  10 minutes and slowly cooling to 
room temperature. Annealed oligonucleotides were visualised as retarded bands on 3 % 
agarose  gels  stained  with  ethidium  bromide  (0.25pg/ml);  annealed  oligonucleotides 
migrate significantly slower than their single stranded counterparts.
3.2.6.2 5'end-labellinq of annealed oligonucleotides.
Annealed oligonucleotides were 5' end-labelled in a standard T4 polynucleotide kinase 
reaction with [y-  P] ATP (Sambrook et al, 1989) to generate radioactive probes for use
105in  EMSA  analysis;  T4 polynucleotide kinase catalyses the transfer of the y-phosphate 
from ATP to the 5'-terminal, hydroxyl end of polynucleotides. Briefly, 50ng of annealed 
oligonucleotide was combined with 3 pi of [y-  P] ATP, 5U of T4 polynucleotide kinase 
and  lx  standard  kinase  buffer  (Promega)  in  a  total  volume  of 20pl.  The  labelling 
reaction  was  allowed  to  proceed  for  30  minutes  to  1   hour at  37°C.  After which,  the 
reaction  volume  was  diluted  to  lOOpl  with  ddPhO  and  the  labelled,  double  stranded 
oligonucleotides  purified  by  passage  through  a  G25  Sephadex  column  with 
centrifugation (1500rpm for 3  minutes).  The success of the labelling reaction for each 
probe was  determined by measuring the counts per second  (cps) with a mini-monitor 
Geiger counter (Mini 900 Ratemeter, Thermo Electron Corporation). Probes producing 
readings > 2Kcps/100pl at a distance of 1cm were used in EMSA analysis.
3.2.6.3  The binding reaction.
Binding  reactions  and  subsequent  analysis  was  performed  according  to  the  protocol 
described below unless  otherwise  stated.  Binding reactions  were performed in  Parker 
buffer (20mM Hepes pH  7.9,  50mM KC1,  ImM EDTA,  0.5mM  DTT and  8  % ficoll) 
with 3pg of poly (dl/dC) and where appropriate either 8-10 pg of OC-2 nuclear protein 
extract,  129-258ng recombinant human SP1  protein (Promega) or appropriate quantity 
of in-vitro translated  SP1  or SP3 protein in a total volume of 20pl.  Binding reactions 
were pre-incubated on ice for 10 minutes before the addition of the y-32 P labelled probe 
(lng) and then for a further 30 minutes on ice. For competition experiments unlabelled 
competitor  DNA  was  added  after  the  10  minute  pre-incubation  at  25-  to  1000-fold 
molar excess and allowed to incubate for a further 20 minutes on ice prior to addition of 
labelled probe.  For supershift analysis  l-3pl  of:  mouse monoclonal  anti-SPl  antibody 
[SP1  (1C6)  X;  Santa  Cruz  Biotechnology,  Inc.],  goat  polyclonal  anti-Gfi-1  antibody 
[Gfi-1  (N-20)  X;  Santa  Cruz  Biotechnology,  Inc.],  rabbit  polyclonal  anti-OCT-2 
antibody [OCT-2 (C-20) X; Santa Cruz Biotechnology, Inc] or mouse monoclonal anti- 
ATF-1  antibody  [ATF-1  (C41-5.1) X;  Santa Cruz Biotechnology,  Inc.]  were added to 
the binding reaction subsequent to  addition of labelled probe and allowed to incubate 
for 30 minutes on ice.  Samples were loaded onto a pre-run (30 minutes at 200V) 4 % 
non-denaturing polyacrylamide gel (dimensions: 200 x 200 x 3mm) and electrophoresed 
in 0.25x TBE for 2  Vz hours at 200V, at 4 °C using standard Bio-RAD electrophoretic 
equipment. The gel was placed on Whatman 3 MM paper, covered with Saran wrap and 
dried with a Gel Master™  gel dryer vacuum system (Jencons-PLS, model  1426) for 2
106hours at 80°C.  Shifted protein-DNA complexes were visualised by autoradiography of 
the  dried  gel  on  BioMax  MS  (Kodak),  BioMax  MR  (Kodak)  or  Hyperfilm™  MP 
(Amersham Biosciences) film as appropriate, at -80°C.
3.2.7 DNA Sequencing.
DNA sequencing was performed by Mr Ian Gerrard or Mr John Cheshire at Windeyer 
Sequencing,  Windeyer  Institute,  University  College  London,  U.K.  Approximately 
1  OOng purified PCR product or 200-500ng purified plasmid DNA was sequenced on an 
ABI  Prism  3100  Genetic  Analyser  (PE  Biosystems).  The  fluorescent  dye  deoxy 
terminator  methodology that  utilises  the  BigDye  chemistries  (BigDye  terminator,  PE 
Biosystems)  was  employed  by  cycle  sequencing  with  AmpliTaq™  DNA  Polymerase 
FS; this way, labelled ddNTP terminators are incorporated during the asymmetric PCR. 
Alternatively, DNA sequencing was performed by Mr Colin Herd at MRC geneservice, 
Babraham  Bioincubator,  Cambridge,  U.K.  on  an  ABI  3730  DNA  Analyser  using 
BigDye  terminator  chemistries  version  3.1  (BigDye  terminator,  PE  Biosystems). 
Primers  used  in  sequencing  are  summarised  in  Table  3.3  (section  3.2.18).  DNA 
sequencing chromatograms were visualised using BioEdit  Sequence Alignment Editor 
software (http://www.mbio.ncsu.edu/BioEdit/bioedit.htmlV
3.2.8 Plasmid construction.
3.2.8.1  Human Brn-3c promoter constructs.
The luciferase reporter vector pGL3-Basic (Promega) carrying 3.6Kb (bases -80bp to - 
3670bp)  of the human Bm-3c promoter (pgl3b-Bm3c-3.6) had already been cloned in 
our laboratory from the human PAC library RPCI1  (HGMP, MRC, U.K.) by Mr Sanjay 
Jagutpal;  this  construct  was  used  as  template  to  form  a  series  of Bm-3c  promoter- 
luciferase reporter gene constructs that each carried a distinct 5’ haplotype of the Bm-3c 
promoter. The genetic background of the Bm-3c promoter insert in pgl3b-Bm3c-3.6 at 
regions  established  from  the  initial  PCR-SSCP  screen  to  be  polymorphic  was 
determined by direct sequencing to be -3495(GT)i5, -3457(GA)2, -3432(G)gCG (poly-G 
allele SNPG1), -1391C,  -566(GT)2o and -386C (see Table 3.4,  section 3.2.18). Hence, 
pgl3b-Bm3c-3.6 carries the variant allele, C, at -1391  and was also known as construct 
p-Luc-1391C. In the first instance, construct p-Luc-1391C (pgl3b-Bm-3c-3.6) was used 
as a template in a site-directed mutagensis (SDM) reaction (QuikChange®, Stratagene)
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GCAGCGTAGTCGAGGTCCAGGATTC  3’  and  -139USDM-AS:  5’
GAATCCTGGACCTCGACTACGCTGC 3’ to modify the variant allele C at position - 
1391  to the wild type allele, A, to form construct p-Luc-1391A. Thus, generating two 
different Bm-3c luciferase-reporter gene constructs that differed in the nature of the - 
1391  allele (see Table 3.4, section 3.2.18). For convenience construct p-Luc-1391A was 
also referred to as p-Luc-SNPG1.566GT20 in some experiments.
Construct p-Luc-SNPG1.566GT20 (p-Luc-1391A) was used as a template to form 
constructs  p-Luc-SNPGl-566GTi6  and  p-Luc-SNPGl_566G T 23  that  both  carried  allele 
SNPG1  at  position  -3432  together  with  the  native  5’  haplotype  at  -3457  and  -3495 
[(GA)2 and  (GT)^ respectively]  but differed in the number of dinucleotide repeats  at 
position  -566.  Briefly,  primers  3cP4-S  and  3cP10-AS  (for  sequence  see  Table  3.1, 
section 3.2.18) were used in a PCR reaction to generate a 710bp fragment spanning the - 
566(GT)n repeat  using  genomic  DNA  samples  of genotype  that  had been  determined 
from the initial SSCP screen (see section 3.2.2.3 for details of the PCR reaction). Post- 
PCR the resultant amplicons were sub-cloned into pGEM®-T easy vector, sequenced to 
confirm genotype:  [-566(GT)i6 : -386C]  and [-566(GT)23  :  -386C],  cleaved with SacII, 
and the resulting 380bp restriction fragments ligated into Sac// digested p-Luc-SNPGl. 
566G T 20.  A  PCR  screen  with  primers  3cP5-S  and  3cP6-AS  confirmed  the  correct 
(forward)  orientation  of the  SacII inserts  in  these  constructs  (see  Table  3.4,  section 
3.2.18).
An  additional  set  of Bm-3c promoter-luciferase reporter gene  constructs  were 
devised  that  carried  allele  SNPG2  at  position  -3432  together  with  the  native  5’ 
haplotype at -3457 and -3495  [(GA)2 and (GT)2i; respectively]  that also differed in the 
number  of  dinucleotide  repeats  at  position  -566.  Briefly,  a  pGEM®-T  easy  clone 
carrying  a  398bp  genomic  DNA  insert  with  allele  SNPG2  and  native  5’  haplotype 
defined  as  -3495(GT)2i  :  -3457(GA)2  :  -3432GGC(G)9  (see  section  3.2.2.4  for 
generation of 398bp fragment) was digested with SacI and Spel and the resultant 342bp 
fragment ligated into SacI and Spel cut p-Luc-SNPG1.566GTi6 and p-Luc-SNPGl_566G T 23 
to  form  constructs  p-Luc-SNPG2.566GTi6  and  p-Luc-SNPG2_566GT23,  respectively  (see 
Table 3.4, section 3.2.18). All constructs were sequenced to verify authenticity.
3.2.8.2  Expression constructs.
The  mammalian  expression  vector  pEVR2-Spl  that  contains  the  complete  human 
cDNA  for  SP1  has  been  described  previously  (Hagen  et  al,  1992)  and  was  kindly
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Spl  plasmid  was  digested  with Pvul and  then Xbal to  generate  a  SP1  cDNA  insert 
defined by Xbal overhangs  that  could be  clearly isolated  from  the pEVR2 backbone. 
This  was  ligated  into  Xbal  cut  pSi  (Promega)  to  form  the  mammalian  expression 
construct pSi-SPl.  The correct  (forward) orientation of the SP1  cDNA insert in pSi- 
SP1   was confirmed by BgUI digest (inserts in the forward orientation give two bands of 
4.6Kb and 3.0Kb).
The Drosophilia  expression vector pPac-USp3  containing the complete human 
SP3 cDNA has been described previously (Dennig et al, 1996) and was kindly provided 
by Professor G.Suske as before. The SP3 cDNA insert was digested from pPac-USp3 by 
Spel / Xhol cleavage.  The pSi  mammalian  expression  vector  (Promega)  was  cleaved 
with Xbal / Sail to generate compatible 5’ overhangs for acceptance of the Spel / Xhol 
SP3  cDNA insert upon ligation. This formed the mammalian expression construct pSi- 
SP3.  The  correct  (forward)  orientation  of  the  SP3  cDNA  insert  in  pSi-SP3  was 
confirmed by Bglll digest (inserts in the forward orientation give two bands of 4.4Kb 
and 1.6Kb).
The mammalian dominant negative human SP1  expression vector pEBGN-SPl 
encoding a fusion protein of glutathione S-transferase (GST) linked to the DNA binding 
domain (DBD) of SP1  has been described previously (Petersohn and Thiel,  1996; Lietz 
et  al,  2003)  and  was  kindly  provided  by  Professor  Gerald  Thiel,  University  of the 
Saarland Medical Centre, Germany. Using plasmid pEBGN-SPl  as a template, primer 
SplDomNeg-S: 5' ATGCTGGTTCCGCGTGGATCAC 3' designed to include a 5’ATG 
for  an  in-frame  methionine  and  primer  SplDomNeg-AS:  5  ’
CCCTCACTCTAGAGTCGC 3' were used to amplify a fragment containing the cDNA 
for the  SV40  nuclear localisation  signal  (NLS)  linked to  the  DBD  of SP1.  PCR was 
performed using the BD  Advantage ™   2  PCR  Kit  (BD  Biosciences)  for high  fidelity 
PCR  (see  section  3.2.2.5).  The  resultant  fragment  was  gel  purified  (QIAquick  gel 
extraction  kit,  QIAGEN),  sub-cloned  into  the  pGEM®-T  easy vector  (Promega)  and 
sequenced  to  ensure  correct.  The  SV40  NLS  -  SP1-DBD  cDNA  chimera  was  then 
cleaved  from  pGEM®-T  easy vector by EcoRI digest  and  ligated  into EcoRl cut pSi 
(Promega); this formed the mammalian dominant negative expression vector for human 
SP1  termed, pSi-DBD-SPl. The correct  (forward) orientation of the DBD-SP1  cDNA 
insert in pSi-DBD-SPl was confirmed by Bglll digest (inserts in the forward orientation 
give two bands of 3.0Kb and 1.3Kb).
1093.2.8.3  pGL3-promoter constructs.
Oligonucleotides with 5’ overhangs (either Bgl II or Nhe I) spanning: common sequence 
variants  in  the  Bm-3c  promoter;  containing  a  consensus  transcription  factor binding 
site;  or  a  mutated  transcription  factor binding  site,  were  5’-end  phosphorylated  in  a 
standard  T4  polynucleotide  kinase  reaction  (see  section  3.2.9.5).  Phosphorylated 
oligonucleotides were purified by ethanol precipitation (Sambrook et al,  1989), diluted 
in ddthO and ligated into Bgl II or Nhe I digested pGL3-promoter vector (Promega) as 
appropriate.  Insertion  of the required oligonucleotide into pGL3-promoter vector was 
confirmed  by  replica-plating  of recombinant  clones  and  hybridisation  with  [y- 32  P] 
labelled single stranded oliogonucleotide as probe. Recombinant clones confirmed with 
oligonucleotide insert were screened for copy number of insert (oligonucleotides with 
5’-overhangs  will  ligate  to  each  other in  addition  to  the  linearised  vector  during the 
ligation reaction) by double restriction enzyme digest with either Nhe I and Nco I or Sac 
I and Nco I as appropriate (see Table 3.5, section 3.2.18).
3.2.9  DNA manipulations.
3.2.9.1  TA-clonina.
Post-PCR  amplified  fragments  were  directly  cloned  into  the  pGEM®-T  easy  vector 
(Promega)  for  sequencing.  The  pGEM®-T  easy  vector  is  linearised  at  the  multiple 
cloning region with single 3'-thymidine overhangs that facilitates the insertion of PCR 
products  with  adenosine  appendages  at  their  3'-ends.  DNA  polymerases  such  as  Taq 
have terminal transferase activity and characteristically append the 3'-ends of amplified 
fragments  in  a  manner  that  is  independent  of template.  Typically,  the  PCR  reaction 
products were chloroform extracted for purification (Sambrook et al, 1989) and purified 
amplicons sub-cloned into the pGEM®-T easy vector using the 2x rapid ligation buffer 
kit (Promega).  Briefly,  a 2pi  aliquot of the purified PCR product was mixed with 5pi 
rapid ligation buffer, 25ng pGEM®-T easy vector and  lpl T4 DNA ligase in a reaction 
volume  of  lOpl.  Contents  were  incubated  at  room  temperature  for  2-3  hours  or 
overnight at 4°C.
3.2.9.2 Restriction endonuclease digestion.
Restriction endonuclease digest was generally used to prepare staggered or blunt ends of 
insert  and  vector plasmid  DNA  for  sub-cloning  or to  screen  for insert  orientation  in
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restriction  enzyme  (maximum  amount  1 0%  v/v)  in  lx  of the  appropriate  restriction 
enzyme buffer (Promega) in a total volume of 20-3 Opl.  For double restriction enzyme 
digests  if the  two  restriction  enzymes  were  not  compatible  in  the  same  restriction 
enzyme  buffer  or  the  multicore  buffer  (Promega),  the  digests  were  performed 
sequentially.  Ethanol precipitation (SamBrook et al,  1989) was used to precipitate the 
DNA after the first digest and the precipitated DNA was re-suspended in ddFhO for the 
second digest. Reactions were left for 1-2 hours or overnight at 37°C (or at the required 
temperature  as  appropriate)  and  analysed  by  agarose  gel  electrophoresis  (see  section
3.2.12.1).
3.2.9.3 Phosphatasinq of plasmid vectors.
Phosphatase treatment was used to facilitate vector DNA for acceptance of insert DNA 
prior  to  ligation.  After  restriction  endonuclease  digest  vector  DNA  was  de- 
phosphorylated with calf intestinal alkaline phosphatase (AP) to help prevent re-ligation 
of digested vector DNA;  AP  catalyses the hydrolysis of the  5'-phosphate groups from 
DNA. Typically,  lpl of AP was added direct to the digested vector DNA (ensuring that 
the total  enzyme content did not exceed  10 % v/v) with  lx AP buffer (Promega) in a 
total  volume  of  25pl  and  incubated  at  55°C  for  45  minutes.  The  AP  was  then 
deactivated by heating to 65°C for 15 minutes.
3.2.9.4 Ligation of DNA.
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Digested, purified  vector and insert DNA were ligated using a molar ratio of either 1:3 
or 1:7 DNA molecules, respectively with lx T4 DNA ligase buffer (Promega) and 3U of 
T4 DNA ligase in a total volume of lOpl. Ligations were incubated at 16°C overnight. 
‘Vector and  insert DNA were purified by recovering  from  low melting  point agarose  gels,  see  section 
3.2.11.14.
3.2.9.5 Phosphorylation of oligonucleotides.
5’-end phosphorylation was used to prepare oligonucleotides for sub-cloning. Annealed 
oligonucleotides  were  5’end  phosphorylated  in  a  standard  T4  polynucleotide  kinase 
reaction with dATP. Briefly, 5pg of annealed oligonucleotide was combined with 2ul of 
lOmM dATP, 5U of T4 polynucleotide kinase and lx standard kinase buffer (Promega) 
in a total volume of 20pl and left to incubate at 37°C for 30 minutes.
Ill3.2.9.6  Bacterial transformation.
Competent  Escherichia  Coli  (E.  Coli)  XL 1-Blue  cells  were  prepared  according  the 
method  of Hanahan,  1985  with  minor  modifications.  For  transformation,  5pl  of the 
ligation mix was pipetted into 50pl of freshly thawed competent cells and incubated on 
ice for 45  minutes.  Cells were subject to a heat-shock by incubating for 2 minutes at 
42°C, 200pl of LB medium was added followed by incubation at 37°C for 30 minutes in 
a  rotating  shaker  at  200rpm.  Cells  were  plated  onto  standard  LB  agar-AMP  plates 
containing  50pg/ml  ampicillin  or if recombinant  clones  were to  be  selected  by blue- 
white  colour  screening,  LB  agar-AMP  plates  containing  50pg/ml  ampicillin 
supplemented with 0.02mM IPTG,  and 20pg/ml X-gal.  Plates were incubated at 37°C 
overnight.
3.2.10  Screening of recombinant clones.
Recombinant  clones  were  screened  by  blue-white  colour  screening,  restriction 
endonuclease  digest  (see  section  3.2.9.2),  by  PCR  reaction  or  by  hybridisation  as 
appropriate.
3.2.10.1  Bv blue-white colour screening coupled with PCR.
Recombinant clones were identified on indicator plates by blue-white colour screening. 
The cloning of an insert into the pGEM®-T easy vector (Promega) results in insertional 
inactivation  of  the  a-peptide  coding  region  of  the  enzyme  P-galactosidase. 
Consequently recombinant clones  containing the required insert  give rise to white (or 
pale blue) colonies on indicator plates.  Routinely several white (or pale blue) colonies 
were picked  and  streaked out onto  a master plate (typically a standard  LB-agar AMP 
plate) and screened for plasmids containing the relevant insert by PCR direct from the 
bacterial  colonies  using primers that were used in the original  PCR  amplification  for 
that insert. Positive clones were grown up from the master plate at 37°C in 5ml of LB 
medium containing 50pg/ml ampicillin, in a rotating shaker at 200rpm, overnight.
3.2.10.2 Bv PCR-screeninq.
To  confirm  insertion  of the required  insert  and  /  or insert  orientation  in pGL3-Basic 
vector (Promega) recombinant clones were screened by PCR reaction. Routinely several 
white colonies were picked  and  streaked  out onto  a master plate (a standard LB-agar
112AMP plate) and screened for plasmids containing the relevant insert by PCR direct from 
the  bacterial  colonies  using  primers  as  appropriate  (see  Table  3.4,  section  3.2.18). 
Positive clones were grown up from the master plate at 37°C as before.
3.2.10.3  Bv hybridisation.
To  confirm  insertion  of  the  required  oligonucleotide  into  pGL3-promoter  vector 
recombinant  clones  were  screened  by  replica-plating  and  hybridisation  with  [y-  P] 
labelled single stranded oliogonucleotide as probe. Routinely, recombinant clones were 
replica-plated  to  a  Hybond™-N+  nylon  membrane  (Amersham  Biosciences)  on  a 
standard  LB-agar  AMP  plate  and  incubated  at  37°C  overnight.  The  membrane  was 
removed from the LB-AMP plate and placed on top of two sheets of Whatman 3MM 
paper pre-wetted with  10% SDS and left for 3  minutes, transferred to Whatman 3MM 
paper pre-wetted with lx denaturing solution and left for 7 minutes, quickly rinsed in 3x 
SSC  and  DNA  was  cross-linked  to  the  membrane  with  an  UV  stratalinker.  The 
membrane was air-dried and stored in Saran wrap at 4°C until ready to hybridise.
The hybridisation solution was freshly prepared and pre-warmed to the required 
hybridisation  temperature.  The  membrane  was  carefully  rolled  and  placed  inside  a 
hybridisation  bottle  and  pre-wetted  with  3x  SCC.  The  SCC  was  discarded  and  the 
membrane  covered  with  pre-warmed  hybridisation  solution  (5-10mls  for  a  small 
hybridisation  bottle)  and  set  on  a  carousel  in  a  hybridisation  oven  at  the  required
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hybridisation temperature, [y-  P] labelled double stranded oliogonucleotide (50ng) was 
denatured by heating to 95°C  for 3  minutes and placed on ice ready for use as single 
stranded probe.  Probe was pippetted into the hybridisation bottle and left to hybridise 
overnight.  Post-hybridisation,  probe  was  discarded  and  membrane  rinsed  with  pre- 
warmed wash solution (3x SSC, 0.1% SDS). In order to remove non-specific binding of 
probe the membrane was incubated with a new aliquot of pre-warmed wash solution for 
15 minutes, the wash solution was discarded and this step repeated. The membrane was 
removed  from the hybridisation bottle  and  excess  liquid removed with  a paper towel 
without allowing the membrane to dry out. The membrane was wrapped in Saran wrap 
and  insertion  of required  oligonucleotides  into  pGL3-promoter  vector  confirmed  by 
autoradiography of the membrane with Hyperfilm™ MP film (Amersham Biosciences) 
at -80°C.  Recombinant clones containing the empty pGL3-promoter vector were used 
as  a  negative  control  to  confirm  binding  of  [y-32  P]  labelled  probe  was  due  to
113recombinant  clones  containing  the  required  insert  cross-linked  to  the  membrane. 
Positive clones were grown up from the master plate at 37°C as before.
3.2.11  DNA preparation.
3.2.11.1  Genomic DNA preparation from human blood.
Blood was thawed at room temperature. 3mls of thawed blood was diluted to 25mls in a 
50ml  Falcon®  tube with cold  Sucrose-Tris  lysis buffer (0.32M  Sucrose,  lOmM Tris- 
HC1 pH 7.5, 5mM MgCh and 1% Triton X-100), inverted to mix and spun at 2500rpm 
at 4°C for 10 minutes. The supernatant was discarded and traces of lysis buffer removed 
from the tube with a paper tissue. The pellet was re-suspended in 68mM NaCl, 22mM 
EDTA pH 8.0, 0.5% SDS with lmg proteinase K in a total volume of 5mls, transferred 
to  a  12ml  Falcon®  tube  and  incubated  at  37°C  overnight.  After  which,  5mls  of 
equilibrated  phenol  was  added,  the  tube  inverted  gently  several  times  and  spun  at 
2000rpm for 5 minutes. The upper aqueous phase was carefully removed to a clean tube 
and  mixed  with  5mls  of  phenol:chloroform:isoamyl-alcohol  (25:24:1;  ReadyRed, 
Qbiogene)  and  spun as before.  The aqueous phase was removed to  a new tube,  5mls 
chloroform:isoamyl-alcohol (24:1; ReadyRed, Qbiogene) added and the tube was mixed 
and  spun  as  before.  The  aqueous  phase  was  removed  to  a  new  tube,  0.5ml  of 3M 
sodium acetate added, the tube was swirled to mixed and 12.5ml of cold ethanol quickly 
added. The tube was gently inverted several times until DNA precipitated. Precipitated 
DNA was transferred to an eppendorf tube, centrifuged at  13,000rpm for  1   minute and 
excess liquid removed. The pellet was air dried for  10-15 minutes and re-suspended in 
200pl  ddH20  on  a rotator  for  2  days  at  4°C.  DNA  concentration  was  determined  by 
spectroscopy at 260nm  and DNA was  stored  at -20°C with concentrated DNA stocks 
stored at -80°C.
3.2.11.2 Small-scale preparation of plasmid  DNA from transformed E.Coli. 
Plasmid  DNA  was  purified  from  3-5ml  of  overnight  bacterial  culture  using  the 
Nucleon®  plasmid  mini-prep  kit  (Nucleon  Biosciences)  or the QIAprep®  spin mini- 
prep kit (QIAGEN) according to the manufacturer’s instructions.  DNA was quantified 
by spectrophotometry at 260nm and running an aliquot on an agarose gel. If required a 
glycerol stock was prepared of the liquid culture by vortexing 1ml of culture with 500pl 
of autoclaved glycerol and storing at -80°C.
1143.2.11.3  Medium-scale preparation of plasmid  DNA from transformed E.Coli.
Plasmid  DNA  was  purified  from  50ml  of  overnight  bacterial  culture  using  the 
QIAGEN® plasmid midi  purification kit according to  the manufacturer’s instructions 
with minor modifications. DNA was quantified by spectroscopy at 260nm and running 
an  aliquot  on  an  agarose  gel.  If required  a  glycerol  stock  was  prepared  as  described 
previously  (3.2.11.2).  Plasmid  integrity  was  confirmed  by  restriction  endonuclease 
digest.
3.2.11.4  Purification of DNA from low melting point agarose gels.
Prior to  ligation  a  specific PCR product,  digested plasmid  insert or vector DNA  was 
recovered from a standard low melting point agarose gel. 0.71-2.4% low melting point 
agarose  gels  were  prepared  with  lx  TAE  buffer  containing  0.25pg/ml  ethidium 
bromide.  DNA  to  be  recovered  was  loaded  with  lx  DNA  loading  buffer  and 
electrophoresed alongside 3-5pl of 1KB DNA ladder (Invitrogen) as appropriate.  DNA 
was  briefly  visualised  with  a  3UV™  transilluminator  GelDoc-It  imaging  system 
(Jencons-PLS) and the required fragments excised from the gel  and purified using the 
QIAquick  gel  extraction  kit  (QIAGEN)  with  a  microcentrifuge  according  to  the 
manufacturer’s instructions.
*0.7% low melting point agarose gels were prepared and electrophoresed at 4°C.
3.2.12  Electrophoresis.
3.2.12.1  Agarose gel electrophoresis of DNA.
0.7-3% agarose gels were prepared with lx TAE buffer containing 0.25pg/ml ethidium 
bromide.  Samples  were  loaded  with  lx  DNA  loading  buffer  and  electrophoresed 
alongside 3-5pl of 1KB DNA ladder (Invitrogen) as appropriate. DNA was visualised at 
302nm with a 3UV™ transilluminator GelDoc-It imaging system (Jencons-PLS).
3.2.12.2 SDS-polvacrvlamide qel electrophoresis (SDS-PAGE).
SDS-polyacrylamide  gel  electrophoresis  (SDS-PAGE)  was  performed  using  the 
Jencons-PLS  vertical  electrophoresis unit  (Model  V10-CDC).  Resolving  and  stacking 
gels  were  prepared  with  the  Jencons-PLS  gel-casting  unit  according  to  the 
manufacturer’s instructions. OC-2 nuclear extract (24 pg) and lOpl Rainbow™ coloured 
protein molecular weight markers (Amersham Biosciences) were made up to 20 pi with 
lx SDS gel-loading buffer, heated at 95°C for 2 minutes, immediately loaded onto a 5%
115stacking gel and electrophorised on an 8% resolving gel at 150V in lx western running 
buffer until the appropriate pre-stained molecular weight markers had separated within 
the gel. The gel was immunoblotted as described in section 3.2.13.
3.2.13 Western Immunobloting.
Following  SDS-PAGE,  the  protein was  transferred  from  the polyacrylamide  gel  to  a 
Hybond™-C  nitrocellulose  membrane  using  a  Bio-RAD  Trans-Blot®  electrophoretic 
transfer  cell.  The  cassette  containing  the  gel  and  nitrocellulose  membrane  was 
assembled with  3 MM  Whatman paper and  submerged in blotting buffer according to 
the manufacturer’s guidelines. Transfer was performed at a constant current of 210mA 
for  3  hours;  successful  transfer  of  proteins  was  confirmed  by  visualisation  of the 
Rainbow™  coloured protein molecular weight markers on the membrane. Post-transfer 
the membrane was blocked for  1   hour at room temperature in TBS-T containing  10% 
non-fat  milk  powder  (Marvel),  washed  for  5  minutes  in  TBS-T  and  subsequently 
incubated  for  1   hour  at room  temperature  with  primary antibody,  mouse  monoclonal 
anti-SPl  antibody [SP1  (1C6) X, Santa Cruz Biotechnology Inc.], diluted 1:10,000 fold 
in TBS-T containing 5% non-fat milk powder. After which, the membrane was rinsed 
twice in TBS-T followed by two 5 minute incubations in TBS-T containing 5% non-fat 
milk  powder  and  then  incubated  for  1   hour  at  room  temperature  with  secondary 
antibody, horseradish peroxidase (HRP)-conjugated goat anti-mouse antibody (DAKO) 
diluted  1:1000 fold in TBS-T containing 5% non-fat milk powder. The membrane was 
then rinsed in TBS-T for 15 minutes followed by two 5 minute washes. All procedures 
were performed on a mixer platform with gentle agitation. Protein bound with anti-SPl 
antibody  on  the  membrane  was  identified  by  detecting  HRP  activity  with  a 
chemiluminescence system (ECL Plus Western blotting detection reagents, Amersham 
Biosciences)  according to  the manufacturer’s  instructions  and  visualised by exposing 
the membrane to autoradiography film, Hyperfilm™ ECL™ (Amersham Biosciences).
3.2.14 Transient transfection and luciferase assay.
The day before transfection,  OC-2 cells were plated into 6-well plates at 2 x  105  cells 
per  well.  Cells  were  transfected  according  to  the  calcium  phosphate  precipitation 
method  (Gorman,  1985).  Typically,  0.5pg  of firefly  luciferase  reporter  plasmid  was 
transfected with  10 or  lOOng Renilla  expression plasmid (pRL-SV40 or phRL-null  as
116appropriate) as an internal control to normalise for differences in transfection efficiency. 
In  co-transfections  0.5pg -  3pg of expression plasmid  (either pSi-SPl,  pSi-SP3,  pSi- 
DBS-SP1  or  CMV5-Gfi-1)  was  titrated  in  as  appropriate  and  the  empty  expression 
plasmid (either pSi or pCi as appropriate) was used as a negative control to ensure that 
regulation was not due to the plasmid backbone and to standardise DNA concentrations 
between wells. Additional experiments were performed with the empty firefly luciferase 
reporter plasmid to  ensure that regulation was  specific to  the Bm-3c promoter insert. 
Twenty-four hours after transfection the medium was removed and a standard glycerol 
shock was performed (15% glycerol).  Cells were harvested 24 hrs after glycerol shock 
and luciferase activities determined according to the Dual-Luciferase® Reporter Assay 
System (Promega).  Luminescence was measured using a Turner TD-20e luminometer. 
Each  experiment  was  performed  in  triplicate  and  repeated  at  least  twice  with  two 
different preparations of DNA.  Error bars on charts represent the standard error of the 
mean.
3.2.15  Genotvpinq -3432polv-G polymorphism.
The  -3432poly-G-polymorphsim  was  genotyped  by  direct  sequencing  in  combination 
with PAGE analysis of radioactive PCR products to size poly-G alleles both procedures 
were optimised to produce the protocol described below.
3.2.15.1  Direct sequencing.
Primers  3cPll-S  (5 ’-GCATAAATGCCCACATAGTCC-3 ’)  and  3cP12-AS  (5*- 
GCAATTTGTAACAGCCTCTATGC-3’)  were  used  to  amplify  a  285bp  fragment* 
containing  the  -3432poly-G  polymorphism.  PCR  was  carried  out  in  96-well  format 
using  lOOng genomic DNA per reaction.  Each PCR reaction comprised 0.2pM of each 
primer, 200pM dNTPs,  lx GeneAmp PCR Gold buffer (Applied Biosystems), 2.0mM 
MgCb, and 0.625U of AmpliTaq Gold (Applied Biosytems) in a total volume of 25pl. 
Thermal  cycling  was  performed  with  an  Eppendorf Mastercycler  Gradient  using  an 
initial denaturation step of 95°C for 10 minutes followed by denaturation at 94°C for 30 
seconds,  annealing at 59°C for 30 seconds,  extension at 72  °C for 30 seconds, for 30 
cycles,  with  a final  extension of 70°C  for  10 minutes.  Post-PCR,  PCR products were 
purified  using  the  QIAquick  PCR  purification  kit  (QIAGEN)  with  a microcentrifuge 
according  to  the  manufacturer’s  instructions  and  5pi  of the  purified  PCR  mix  was
117electrophoresed on a 1.5% agarose gel to check successful amplification of the required 
band.  Purified  samples  were  diluted  in  ddH20  as  appropriate,  and  lOOng  of each 
purified sample was sequenced on an ABI 3730 DNA analyser with BigDye terminator 
chemistries version 3.1, MRC geneservice (Babraham Bioincubator, Cambridge, U.K.) 
using primer 3cP12-AS in the sequencing reaction.
3.2.15.2  PAGE analysis of radioactive PCR products.
Length of poly-G alleles was determined by incorporating a [a  P]-dCTP radiolabel in 
the amplification of an  18 lbp product* spanning the -3432poly-G polymorphism using 
primers  G3cP13-S  (5 ’ -GATT  GT  A  ATTT  A  AT  GCC  AT  GGT  G-3 ’)  and  3cP12-AS  (5’- 
GCAATTTGTAACAGCCTCTATGC-3 ’)  in  the  PCR  reaction.  Each  PCR  reaction 
comprised  lOOng  genomic  DNA,  0.2pl  [a32P]-dCTP,  0.2pM  of each  primer,  200jiiM 
dATP,  200pM  dGTP, 200jaM dTTP  and  lOOpM dCTP  with  lx GeneAmp PCR Gold 
buffer (Applied Biosystems), 2.0mM MgCh,  and 0.625U of AmpliTaq Gold (Applied 
Biosytems)  in  a  total  volume  of  25pi.  Thermal  cycling  was  performed  with  an 
Eppendorf Mastercycler Gradient as  described  above (3.2.15.1) but with an annealing 
temperature  of  56°C.  Post-PCR,  5pl  of  the  PCR  reaction  was  mixed  with  5pl 
formamide gel-loading buffer, heated to 95 °C for 5 minutes and immediately placed on 
ice  prior  to  loading  on  a  6%  denaturing  polyacrylamide  gel  (SequaGel  6,  National 
Diagnostics)  in  lx TBE  alongside plasmid markers**  of known length.  Samples were 
electrophorised using a Life technologies Inc. vertical electrophoresis unit (Model S2) at 
60Watts  for 2  hours  30 minutes and bands were visualised by autoradiography of the 
dried gel on BioMax MR film (Kodak) at -80°C.
‘based on containing poly-G allele (G)n which is of equivalent length to alleles SNPG4 and SNPG5 ( see 
Reference sequence: Ensembl transcript ID ENST00000230732; Appendix B).
“ Plasmid  markers  were  produced  by using  lOOng  plasmid  DNA  in  the  PCR  reaction.  Plasmids  were 
pGEM®-T easy constructs carrying specific -3432poly-G alleles that had been confirmed by sequencing.
3.2.16  Genotvping -1391A>C.
The  -1391A>C  single nucleotide  substitution  was  genotyped by FCR-TaqI restriction 
digest. Initially the PCR reaction was optimised for production of a single, intense band 
of the required size by varying the following parameters: the magnesium concentration 
and annealing temperature of the reaction, the DNA template concentration, the number 
of PCR cycles, the length of the annealing and extension stage of the PCR reaction and
118the type of DNA polymerase used [Taq DNA polymerase (Promega) versus AmpliTaq 
Gold (Applied Biosystems). The optimised protocol  consisted of a 25pi  PCR reaction 
per sample with  lOOng genomic DNA.  PCR was  carried  out in 96-well  format using 
0.2juM each primer (3cPl-S and 3cP3-AS; for sequence see Table 3.1, section 3.2.18), 
200pM dNTPs,  lx GeneAmp PCR Gold buffer (Applied Biosystems), 2.0mM MgCh, 
and 0.625U of AmpliTaq Gold (Applied Biosystems). Thermal cycling was performed 
as described previously (3.2.15.1) but with an annealing and an extension stage of 45 
seconds.  Specificity  of the  PCR  reaction  was  confirmed  by  electrophoresing  a  5pi 
aliquot  of a  few  samples  on  a  1.5%  agarose  gel  and  visualisation  of a  single  596bp 
band. Post-PCR the TaqI digest was performed by adding an aliquot of TaqI directly to 
the  PCR  reaction mix  at  a  final  concentration  of 4%  and  incubating at  65°C  for 2Vi 
hours.  Restriction  fragments  were  then  visualised  on  a  2%  agarose  gel  stained  with 
ethidium bromide (0.25pg/ml) and genotypes allocated according to the bands present: 
homozygous  wild-type  (AA)  81,  123  and  392bp,  homozygous  variant  (CC)  204  and 
392bp and heterozygous 81, 123, 204 and 392bp.
3.2.17  Statistics.
Paired or unpaired /-tests, as appropriate, were performed to compare data sets obtained 
from transient transfection assay; a p-value <0.05 was considered significant. Analysis 
was performed using SPSS 12.0.1  statistical software package.
The Chi-square (%  ) test was used to compare genotype and allelic frequencies between 
patient and general population sample groups for the preliminary association study; a p- 
value  <0.05  was  considered  significant  (for  % 2  probability  table  see  Swinscow  and 
Campbell, 2002). %   analysis was performed using the formula:
X2=(0-E)*/E
Where  O  is  the  observed  frequency  distribution  and  E  is  the  expected  frequency 
distribution (see Swinscow and Campbell, 2002)
119Genotype distribution assuming Hardy-Weinberg equilibrium was calculated using the 
Hardy-Weinberg equation:
P2 (AA) +2pq (Aa) + q2 (aa) = 1
Where A and a are two alleles of gene; A is the dominant allele in the population and a 
is the recessive allele.
The frequency of the A allele = p and the frequency of the a allele = q 
Where p + q = 1.
Statistical  levels  of  significance  for  deviation  from  expected  Hardy-Weinberg 
equilibrium were tested by %   analysis as described previously and a p-value <0.05 was 
considered significant.
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Table 3.1: Summary of primers for PCR-SSCP analysis of the Brn-3c gene.
3cPl-S Promoter 5* CTCTCAGCGGAGGCAGTGG 3’ 1 216 62.3 -
3cPl-AS 5' TGAGGGCTCTCGAGGTTAGC 3'
3cP2-S Promoter 5* GCAGTGCTAACCTCGAGAGC 3’ 2 210 62.3 -
3cP2-AS 5’ CCACCGTATGGAGTAGGTGATGT 3'
3cP3-S Promoter 5’ AACATCACCTACTCCATACGGTG 3' 3 220 62.3 -
3cP3-AS 5' CCGTCTAAGGAAGCTTGTGGAG 31
3cP4-S Promoter 5’ CTCCACAAGCTTCCTTAGACG 3' 4 276 62.3 -
3cP4-AS 5' CCAAGCTGTCCACCAGAGTC 3’
3cP5-S Promoter 5' GGACTCTGGTGGACAGCTTG 3’ 5 209 63.4 -
3cP5-AS 5* TGTCCCAGCTCGAACTGCC 3'
3cP6-S Promoter 5’ GGCAGTTCGAGCTGGGACA 3’ 6 256 62.3 4-
3cP10-AS 5' TCACGCGCCGGGGACTCG 3’
3cP9-S Promoter 5* AAGGCGCGCCGCTAGCTG 3* 7 295 54.2 +
3cP7-AS 5’ GAAAGGCTGCTTGGAGTTCAT 3'
3cP7-S Promoter 5’ CTTCCTGGCAGGCTGCTTGT 3’ 8 205 62.3 -
3cP7-AS 5' GAAAGGCTGCTTGGAGTTCAT 3’
3cPll-S Promoter* 5’GCATAAATGCCCACATAGTCC3’ 15 130 57.5 -
3cPll-AS 5’ CCACCACCATGGCATTAAA 3’
Exl-S Exon 1 5* AAGCCTOATTCCATOTCACC 3’ 9 228 58 -
Exl-AS 5’ CATGAAGCTAGTGCCTGTCAA 3'
3cI-S Intron 5* GAGCATAATTACCGCTCTAAGGC 3* 10 287 62.3 -
3cI-AS 5' ACAGCACGGTCAGTAGGGAATAC 3'
Ex2Fl-S Exon 2 5’ TTCCCTACTGACCGTGCTGT 3' 11 302 58 -Ex2Fl-AS 5' ACTCAGCGTGGGCGAGATGT 3'
Ex2F2-S Exon 2 5’ TTCGTCCACCGTGCCCATCT 3’ 12 271 63 -
Ex2F2-AS 5* CTCCACGTCGCTGAGGCATG 3’
Ex2F3-S Exon 2 5’ TCAGCGACGTGGAGTCAGA 3* 13 254 63 -
Ex2F3-AS 5’ CTCTCGGTAGGCGGCCTCG 3'
Ex2F4-$ Exon 2 5’ cxjAGGccgcctaccoagag y 14 261 63 -
Ex2F4-AS 5’ TGCCGCAATCAGTGGACAG 3’
'Fragment 15 spans -3495(GT)n within the Bm -3c promoter. All other promoter fragments are within 1.5Kb based on the first A of 
the ATG translation start for Bm -3c as +1.Table 3.2: Summary of oligonucleotides used in EMSA analysis.
Oligonucleotide name Type: allele oligonucleotide 
spans / consensus sequence
Sequence
(5’ overhangs are denoted in red).
Length
(bp)
(G)9-S -3432 (G)9* 5' GAT  CTGGTGGTGGGGGGGGGTGGGT  AAGT 3’ 29
(G)9-AS -3432 (G)9* 5' GATCACTTACCCACCCCCCCCCACCACCA 3' 29
(G)10-S -3432 (G)io 5’ GATCTGGTGGTGGGGGGGGGGTGGGTAAGT 3’ 30
(G)10-AS -3432 (G)10 5’ GATCACTTACCCACCCCCCCCCCACCACCA 3’ 30
(G)ll-S -3432 (G)„ 5’ GATCTGGTGOTGGGGGGGGGGGTGGGTAAGT 3’ 31
(G)11-AS -3432 (G)i, 5’ GATCACTTACCCACCCCCCCCCCCACCACCA 31
(G)12-S -3432 (G)12 5’ GATCTGGTGGTGGGGGGGGGGGGTGGGTAAGT 3’ 32
(G)12-AS -3432 (G)12 5’ GATCACTTACCCACCCCCCCCCCCCACCACCA 3’ 32
SNPG1-S -3432 SNPG1 5' GATCTGGTGGTGGGGGGGGCGTGGGTAAGT 3' 30
SNPG1-AS -3432 SNPG1 5' GATCACTTACCCACGCCCCCCCCACCACCA  3' 30
SNPG2-S -3432 SNPG2 5' GATCTGGTGGTGGCGGGGGGGGGTGGGTAAGT 3' 32
SNPG2-AS -3432 SNPG2 5* GATCACTTACCCACCCCCCCCCGCCACCACCA  3' 32
SNPG4-S -3432 SNPG4 5’ GATCTGGTGGTGGTGGGGGGGGTGGGTAAGT 3’ 31
SNPG4-AS -3432 SNPG4 5’ GATCACTTACCCACCCCCCCCACCACCACCA 3’ 31
SNPG5-S -3432 SNPG5 5’ GATCTGGTGGTGGGGCGGGGGGTGGGTAAGT 3’ 31
SNPG5-AS -3432 SNPG5 5’ GATCACTTACCCACCCCCCGCCCCACCACCA 3’ 31
1391C-S -1391 C 5* GATCAGCGTAGTCGCGGTCCAGGATTCC 3' 28
1391C-AS -1391 C 5' GATCGGAATCCTGGACCGCGACTACGCT 3' 28
1391A-S -1391 A 5' GATCAGCGTAGTCGAGGTCCAGGATTCC 3' 28
1391A-AS -1391 A 5’ GATCGGAATCCTGGACCTCGACTACGCT 3' 29CPBP-S CPBP consensus site1 5' GATCTGACCCCACCCATGAGCCTGAGAAGTGC 3' 32
CPBP-AS CPBP consensus site1 5' GATCGCACTTCTCAGGCTCATGGGTGGGGTCA 3’ 32
SP1-S SP1 consensus site 5' GATCATTCGATCGGGGCGGGGCGAGC 3' 26
SP1-AS SP1 consensus site 5' GATCGCTCGCCCCGCCCCGATCGAAT 3' 26
SP1 Mut-S Mutated SP1 binding site 5' GATCATTCGATCGGTTCGGGGCGAGC 3' 26
SP1 Mut-AS Mutated SP1 binding site 5' GATCGCTCGCCCCGAACCGATCGAAT 3' 26
Egr-S Consensus Egr binding site 5’ CTAGGGATCCAGCGGGGGCGAGCGGGGGCGA 3’ 30
Egr-AS Consensus Egr binding site 5’ CTAGTCGCCCCCGCTCGCCCCCGCTGGATCC 3’ 30
Egr Mut-S Mutated Egr binding site 5’ CTAGGGATCCAGCTAGGGCGAGCTAGGGCGA 3’ 30
Egr Mut-AS Mutated Egr binding site 5’ CTAGTCGCCCTAGCTCGCCCTAGCTGGATCC 3’ 30
Gfi-l-S Consensus Gfi-1 binding site 5’ CTAGACCATCACCACATAAATCACTGCCTATCCTGTG 3’ 37
Gfi-l-AS Consensus Gfi-1 binding site 5’ CTAGCACAGGATAGGCAGTGATTTATGTGGTGATGGT 3’ 37
Gfi-1 Mut-S Mutated Gfi-1 binding site 5’ CTAGACCATCACCACATAACTCACTGCCTATCCTGTG 3’ 37
Gfi-1 Mut-AS Mutated Gfi-1 binding site 5’ CTAGCACAGGATAGGCAGTGAGTTATGTGGTGATGGT 3’ 37
Bar-Exl-S Section of exon 1 of Barhll 5’ AGCGACTGCTCTTCGCCAG 3’ 19
Bar-Exl-AS Section of exon 1 of Barhll 5’ CTGGCGAAGAGCAGTCGC 3’ 18
* (G)9 was later determined to be a sequencing error and not a true allele. GATC: Bglll 5’overhang; CTAG: Nhel 5’ overhang. Alleles are 
highlighted in black and blue bold. Where mutated binding sites are used, mutated nucleotides are highlighted in black bold.  Koritschomer 
et al, 1997.Table 3.3: Summary of primers used in sequencing analysis.
Primer Sequence Reason for use
Rvprimer3* 5’ CTAGCAAAATAGGCTGTCCC 3’ Confirm -3495(GT)n, -3457(GA)nand -3432poly-G 
polymorphism genotype in Bm-3c promoter inserts.
GLprimer2*
3cP4-S
3cP5-S
5’ CTTTATGTTTTTGGCGTCTTCCA 3’ 
5' CTCCACAAGCTTCCTTAGACG 3’
5' GG  ACT  CT  GGT  GG  AC  AGCTT  G 3'
Confirm -566(GT)n and -386C>A genotypes in Bm-3c promoter 
inserts. Also provides sequence of GC box and TATA box in 
Bm-3c promoter inserts.
3cP2-AS
3cPl-S
5' CCACCGTATGGAGTAGGTGATGT 3' 
5' CTCTCAGCGGAGGCAGTGG 3'
Confirm -1391 A>C genotype in Bm-3c promoter inserts.
SP6** 5’ TATTTAGGTGACACTATAG 3’ Confirm sequence in pGEM®-T easy inserts.
T7 forward* 5’ T  AAT  ACG  ACT  C  ACT  AT  AGGG 3’ Confirm sequence in pGEM®-T easy inserts.
*  Purchased from Promega.
"Provided by the sequencing service (for details see section 3.2.7).Table 3.4: Summary of human Brn-3c promoter constructs
Construct -3495(GT)n -3457(GA)„ -3432poly-G
polymorphism
-1391A>C -566(GT)„ -386C>A Construct origin.
clones.
Primers used in 
sequencing analysis 
to confirm 
construct integrity*
pg!3b-Brn3c-3.6
(p-Luc-1391C)
15 2 SNPG1
t(G)8CG]
C 20 C Human PAC library 
RPCI1  (HGMP, 
MRC, U.K.)
RVprimer3
GLprimer2
3cPl-S
P-LUC-SNPG1-566GT20
(p-Luc-1391A)
15 2 SNPG1
[(G)gCG]
A 20 C p-Luc-1391C by site- 
directed mutagenesis.
Primers: 3cPl-S 
and 3cP3-AS 
followed by Taq I 
digest.
RVprimer3
GLprimer2
3cP2-AS
3cPl-S
P-LUC-SNPG 1-S66GT16 15 2 SNPG1
[(G)gCG]
A 16 C p-LuC-SNPG 1-566GT20 
by Sac  I  I digest.
JPrimers: 3cP5-S 
and 3cP6-AS.
GLprimer2
3cP4-S
p-LuC-SNPG1.5toGT23 15 2 SNPG1
[(G)gCG]
A 23 C p-LuC-SNPG 1-566GT20 
by SacI  I digest.
2Primers: 3cP5-S 
and 3cP6-AS.
GLprimer2
3cP4-S
P-LUC-SNPG2.S66GT16 21 2 SNPG2
[GGC(G)9]
A 16 C p-LuC-SNPG 1-566GT16 
by SacI and Spel 
digest.
3Primers: 3cP12-S 
and 3cP12-AS
RVprimer3
P-LUC-SNPG2.566GX23 21 2 SNPG2
[GGC(G)9]
A 23 C p-LuC-SNPG 1-566GT23 
by SacI and Spel 
digest.
3Primers: 3cP12-S 
and 3cP12-AS
RVprimer3
1   PCR was performed under standard conditions as described in section 3.2.2.1  with 0.2pM of each primer (3cPl-S and 3cP3-AS), 2mM  MgCl2 at an annealing temperature of 60.3°C with an annealing 
and  extension  stage of 45  seconds.  Post-PCR  12pl  of the PCR mix was used  in  a  Taq I digest under standard conditions (see section  3.2.9.2  ) to  identify the wild-type allele,  A (the wild type allele 
produces 3 bands of 81,  123 and 392bp; the variant allele 2 bands of 204 and 392bp).
2 PCR was performed under standard conditions (see section 3.2.2.1) with 0.2pM of each primer (3cP5-S and 3cP6-AS), 2mM  MgCl2, 5% DMSO at an annealing temperature of 54°C.  Only constructs 
carrying the SacIJ insert in the correct (forward) orientation produce a 490bp product upon PCR.
3  PCR was performed under standard conditions (see section 3.2.2.1) with 0.2pM  of each primer (3cP12-S and 3cP12-AS), 2mM  MgCl2at an annealing temperature of 59°C.  Only constructs carrying 
the SacI/ Spel insert produce a 400bp product upon PCR.  * See Table 3.3 for information on sequencing primers.
to
OsTable 3.5: Summary of pGL3-promoter constructs to detail restriction enzymes 
used to confirm copy number of inserts.
O ligonucleotide
nam e*
Tm  (°C) H ybridisation 
tem perature (°C)
D ouble restriction 
enzym e digest screen
pG L3- prom oter 
construct form ed
SNPG 1 75.57 71 Nhe /, Nco I pGL3 -P(SNPG 1 )2
SNPG 2 77.46 71 Nhe /, Nco I pGL3-P(SNPG2)2
(G)io 75.57 71 Nhe I, Nco I pGL3-P(G10)2
(G )n 76.54 71 Nhe I, Nco I pGL3-P(Gll)2
SP1 74.05 70 Nhe I, Nco I pGL3-P(SPl)2
SP1 M ut 70.90 66 Nhe /, Nco I pGL3-P(SP 1 Mut)2
1391A 75.00 71 Nco /, Sac I pGL3-P(1391A)2
1391C 78.60 71 Nco I, Sac I pGL3-P(1391C)2
G fi-1 70.22 66 Nco /, Sac I pGL3-P(Gfi-l)2
Gfi-1 M ut 71.33 66 Nco /, Sac I pGL3-P(Gfi-lMut)3
* Oligonucleotide sequence and 5’-overhang is given in Table 3.2. 
** Lower case denotes copy number of oligonucleotide insert.4.0 Identification And Characterisation Of Genetic 
Variation At The Brn-3c Locus.
4.1  Introduction.
The overall  aim of this project is to investigate whether common sequence variants in 
the Bm-3c gene, a hair cell POU domain transcription factor, underlie susceptibility to 
late onset sensorineural hearing loss (a discussion of the term late onset hearing loss is 
reviewed  in  section  1.5.1).  Late  onset  hearing  loss  is  an  extremely  common  and 
complex trait. Audiometrically, it is characterised by an elevation of hearing thresholds 
in  the high  frequencies  and  at the  cellular level  a loss  of hair  cells  in the cochlea is 
widely regarded to underlie the pathology (for reviews  see Jennings  and Jones,  2001; 
Fransen  et  al,  2003;  Gratton  and  Vazquez,  2003;  Ohlemiller  et  al,  2004;  Gates  and 
Mills, 2005).
At  the  onset  of this  project  Bm-3c  was  one  of the  very  few  genes  that  had 
emerged as a good candidate gene for susceptibility to late onset hearing loss.  During 
the course of this project several additional promising candidate genes for susceptibility 
to late onset hearing loss have come to light including Cdh23  (involved in stereocilia 
integrity), Barhll  (involved in hair cell survival), PMCA2 (involved in maintenance of 
calcium  homeostasis  in  the  cochlea)  and  some  genes  involved  in  regulation  of ROS 
homeostasis in the cochlea (see section  1.7). However, Bm-3c still remains one of the 
strongest candidates.  Bm-3c is one of three highly homologous genes that constitute a 
small gene family, the Bm-3 family that is categorised under division IV of the widely 
characterised  POU  protein  family  (for  review  see  Latchman,  1999).  The  additional 
members  of the  Bm-3  family are important  developmental  regulators  involved  in  the 
maintenance and survival of specific neuronal cell sub-types (Erkman et al,  1996; Gan 
et al,  1996; McEvilly et al,  1996; Xiang et al,  1996; Eng et al, 2001; see section 1.9.2). 
Within the inner ear Bm-3c is the only Bm-3  factor expressed in hair cells (Erkman et 
al,  1996; Xiang et al,  1997; Xiang et al,  1998). Importantly, evidence from Bm-3c (-/-) 
mice  suggests  that  Bm-3c  functions  in  hair  cell maturation  and  maintenance  during 
development; in the absence of Bm-3c the molecular cues that direct formation of the 
highly organised  stereociliary hair bundle are lost and  a lack of Bm-3c results  in the 
progressive degeneration of incompletely differentiated hair cells by apoptosis such that
128the total  loss of these cells is  evident in the sensory epithelia of the inner ear shortly 
after birth (Erkman et al,  1996; Xiang et al, 1997; Xiang et al, 1998). Moreover, an 8bp 
deletion in the POU homeodomain of Bm-3c in humans results in adult onset hearing 
loss,  DFNA15  thus  suggesting  that  Bm-3c  is  essential  for  maintenance  of hair  cell 
function in the long term (Vahava et al, 1998). Collectively, these features make Bm-3c 
a very strong  candidate  gene  for  susceptibility to  late  onset hearing loss  (see  section
1.8.1  for a comprehensive discussion of the evidence that Bm-3c is a good candidate 
gene for late onset hearing loss).
Predisposition  to  late  onset  hearing  loss  as  with  many  traits  of a  common, 
complex nature is thought to be due to multiple genetic and environmental risk factors 
and  the  relative  risk  contributed  by  any  one  factor  is  expected  to  be  moderate  (for 
reviews see Jennings and Jones, 2001; Fransen et al, 2003; Gratton and Vazquez, 2003; 
Ohlemiller  et  al,  2004;  Gates  and  Mills,  2005).  Specifically,  genetic  susceptibility to 
complex traits such as late onset hearing loss is thought to be due to moderate variations 
in  gene  expression  or  function  at  multiple  loci  and  the  DNA  sequence  variants 
responsible for such effects are thought to be common in the general population. This 
concept that common sequence variants (with a rare allele frequency of or greater than 
1%) underlie susceptibility to common diseases is the basis of the CD:CV hypothesis 
(for  reviews  see  Smith  and  Lusis,  2002;  Wright  et  al,  2003).  Therefore,  given  the 
paramount  role  of Bm-3c  in hair  cell  survival  it  is  hypothesized  that  common  inter­
individual sequence variants in the Bm-3c gene or within the regulatory regions of this 
gene that have a subtle affect on function or expression of Bm-3c respectively, could be 
a risk factor for susceptibility to this disease.
4.1.1  Genetic  variation  at the  Brn-3c  locus  reported  at the  onset of this 
project.
It is  hypothesised that  common inter-individual  sequence variants  in the Bm-3c  gene 
predispose to late onset hearing loss. At the onset of this project an 8bp deletion within 
the coding region of Bm-3c located in the POU homeodomain had been identified in 
one  family,  a large  Israeli-Jewish  family and  found  to  cause  adult onset hearing loss 
DFNA15  with  an  autosomal  dominant  mode  of progressive  late  onset  hearing  loss 
(Vahava et al, 1998; see section 1.8.1  and 1.8.2). This 8bp deletion in the Bm-3c gene is 
sufficient to  cause adult onset hearing loss manifesting between ages  18-30 years and 
appears  to  be  rare  but  it  raises  the  possibility that  there  may be  common  sequence
129variants within the Bm-3c gene that have a more subtle effect on phenotype and hence, 
are  only  phenotypically  significant  in  the  later  decades  of  life.  Common  sequence 
variants in the Bm-3c gene that predispose to late onset hearing loss, albeit with a subtle 
effect  on  phenotype  could  manifest  within  the  coding  region,  intron  or  regulatory 
regions of the gene. Vahava et al have previously examined the coding region of Bm-3 c 
for sequence variation in their search for a mutation in Bm-3c that is responsible for 
DFNA15. However, this analysis was restricted to the Israeli-Jewish family and hence, 
a  small  number  of samples.  It  gives  no  information  as  to  the  existence  of common 
sequence variants in the Bm-3c coding region that could predispose large numbers of 
the general population to late onset hearing loss.
At the time of commencing this project minimal information was reported in the 
public SNP databases for the Bm-3c gene (see Table 4.1) and the international HapMap 
project which aims to characterise the common patterns of DNA sequence variation in 
the human genome had not been formed (International HapMap Consortium, 2003; see 
section  1.6.2.1).  At the onset of this project three single nucleotide substitutions were 
reported  within  the  vicinity  of  the  Bm-3c  coding  region.  An  A>C  substitution  at 
position -1391  in the Bm-3c promoter (NCBI SNP Cluster ID: rs 1368402) and a G>A 
and  C>T  substitution  at 230  and 424  nucleotides respectively,  beyond the translation 
termination codon in the Bm-3c gene  [hereafter referred to  as  *230G>A (NCBI  SNP 
Cluster ID:  rs891969)  and  *424C>T (NCBI  SNP  Cluster ID: rs891970) according the 
guidelines issued by the Human Genome Variation Society www.hgvs.org/mutnomen/; 
the 3’ end of the mRNA transcript for the Bm-3c gene has not been defined in humans]. 
However,  none of these sequence variants  had been validated  and the significance of 
these sequence variants with respect to Bm-3c regulation and / or expression was not 
known. Furthermore, little was known about how Bm-3c is regulated or maintained in a 
tissue  specific manner in  sensory hair cells  of the  inner ear.  No  functional  cis-acting 
elements had been characterised within the Bm-3c promoter.  Had any such regulatory 
elements been identified, they would have formed an ideal basis within which to search 
for common sequence variants in the Bm-3c gene that lead to inter-individual variations 
in regulation and / or expression of Bm-3 c.
Therefore,  in  the  absence  of known  functional  cis-acting  elements  within  the 
Bm-3c  promoter  or  the  first  intron  of  the  Bm-3c  gene ^coupled  with  a  lack  of 
comprehensive information regarding genetic variation at the Bm-3c locus at the time of 
undertaking  this  project  it  was  decided  to  perform  mutation  scanning  of the  Bm-3c 
locus in an attempt to identify common sequence variants in this gene. For the purpose
130of this project  all  regions  of the Bm-3c gene including the coding region,  intron  and 
promoter were considered.
Table 4.1: Genetic variation at the Brn-3c locus reported in 
NCBI SNP database at the onset of this project
V ariant Position N ature N C BI SN P C luster ID
-1391A >C Promoter A  >C rsl 368402
*230G >A 3’-flanking region G >A rs891969
*424C >T  3’-flanking region  C >T  rs891970
4.1.2  Mutation  scanning:  single  strand  conformational  polymorphism 
(SSCP) analysis and other methods.
Mutation scanning is a form of mutation detection whereby specific genes are scanned 
for the presence of novel  sequence variants.  There are many technologies available to 
perform mutation scanning to search for novel  sequence variants including denaturing 
gradient-gel  electrophoresis  (DGGE),  chemical  cleavage  of  mismatch  (CCM), 
heteroduplex  analysis  (HA),  denaturing  high  performance  liquid  chromatography 
(dHPLC),  single  strand  conformational  polymorphism  (SSCP)  analysis  and  direct 
sequencing  (for  reviews  see  Ellis  et  al,  1998;  Nataraj  et  al,  1999;  Xiao  and  Oefher, 
2001; Knapp, 2004; Suh and Vijg, 2005). Each method has its own potential advantages 
and  disadvantages  and  these must be  taken  into  consideration  together with practical 
considerations such as the size of the gene to scan, the number of samples to be scanned 
and the availability or cost of equipment when deciding which procedure to use.
The purpose of this project is to identify common sequence variants (with a rare 
allele  frequency of or greater than  1%) in the Bm-3c gene that may predispose large 
numbers  of the  ageing population  to  late  onset  hearing  loss.  Rare  sequence  variants 
(with a rare allele frequency of less than  1  %) although may be functionally significant 
with  respect  to  Bm-3c  in  a  limited  number  of individuals  are  not  the  focus  of this 
project. Therefore, since only a modest number of DNA samples needed to be scanned 
at the onset of this project in order to identify common sequence variants in the Bm-3c 
gene^ this  was  an  important  factor  when  deciding  upon  the  mutation  scanning 
methodology.
131SSCP analysis originally developed in  1989 by Orita et al, is a very simple and 
rapid technique that has been widely used for mutation detection in genes responsible 
for  genetic  disease  (Castellvi-Bel  et  al,  1999;  Majores  et  al,  2002;  Shinahara  et  al,
2004).  A  variety  of mutations  can  be  detected  by  SSCP  including  single  nucleotide 
substitutions, insertions and deletions the former of which are the most common type of 
DNA  sequence variation in the human genome;  single nucleotide substitutions with a 
rare allele frequency of at least 1% are estimated to occur every 200-3OObp (for reviews 
see Salisbury et al, 2003; Wright et al, 2003). At the onset of this project SSCP analysis 
was  considered  as one of the most practical,  rapid  and reliable methods  for mutation 
scanning  of the  Bm-3c  gene.  The  principle  of SSCP  analysis  will  be  discussed  and 
compared alongside additional methods for mutation scanning.
SSCP analysis involves the amplification of sample DNA by PCR, denaturation 
followed by electrophoresis on a non-denaturing polyacrylamide gel.  It is based upon 
the  principle  that  under  non-denaturing  conditions,  the  secondary  structure  of single 
stranded DNA molecules is directly related to their primary structure, their nucleotide 
composition. This effectively means that single stranded DNA molecules that differ in 
sequence  by  even  a  single  nucleotide  have  the  ability  to  fold  into  two  different 
conformations. These “conformers” can manifest in electrophoretic mobility shifts or in 
the  presence  or  absence  of specific  bands  upon  non-denaturing  polyacrylamide  gel 
electrophoresis and can be visualised by autoradiography (for reviews see Nataraj et al, 
1999; Suh and Vijg, 2005). Classically, the PCR product of an individual heterozygous 
for a specific sequence variant such as a single nucleotide substitution should generate 
at least four bands, two with mobility identical to that of the wild-type allele and two 
that are characteristic of the sequence change (this is illustrated in Fig 4.1). However, it 
is important to realise that this is not always the case. One sequence of DNA can give 
rise to more than two conformations termed, iso-conformers.  Iso-conformers can arise 
for many reasons; the two complementary strands of a DNA molecule can each fold into 
more than one conformer. In addition, the ability of Taq DNA polymerase to randomly 
append  the  3’  end  of double  stranded  DNA  fragments  with  an  extra residue,  usually 
adenine means that single strands that carry the appendage have the ability to fold into 
different conformers compared to those that lack the appendage (Sugano et al, 1996). In 
a similar manner the ability of excess primers to interact with amplicons can also induce 
the  formation  of  iso-conformers  (Cai  and  Touitou,  1993).  However,  despite  this 
anomaly, in general unincorporated primers are not removed prior to SSCP analysis as 
presence of excess primers can lead to sharper SSCP bands (Hennessy et al, 1998). It is
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Figure  4.1  A schem atic  to  illustrate the principle of SSC P analysis,  (a)  Subject  1   homozygous wild type (one allele shown),  subject 2 
homozygous variant (one allele shown) and subject C heterozygous for the variant allele (both alleles shown), (b)  SSCP gel for samples 1-3 
in (a) to illustrate a classical example of the migration pattern that may be produced by a subject heterozygous for a single sequence variant 
compared to subjects homozygous wild-type and variant. Four bands are seen for the heterozygous subject, 3, two with mobility identical to 
that of the wild-type allele and two characteristic of the sequence change.
u>thought that unincorporated primers enhance the formation of stable conformers most 
probably by decreasing or abolishing minor or metastable conformations.
When  considering  SSCP  analysis  for  mutation  detection  it  is  important  to 
consider that a main limitation of SSCP analysis lies in its sensitivity;  100% mutation 
detection is rarely achieved (for reviews see Nataraj  et al,  1999;  Suh and Vijg, 2005). 
However, all methods of mutation detection including direct sequencing are not  100% 
effective (for reviews see Ellis et al,  1998; Nataraj et al,  1999; Franca et al, 2002;  Suh 
and  Vijg,  2005).  The  sensitivity of SSCP  analysis  is  influenced by many parameters 
including  ionic  strength  of  the  electrophoresis  buffer,  acrylamide-to-bis-acrylamide 
ratio  and  addition  of reagents  to  the  gel  matrix  (for review  see Nataraj  et  al,  1999). 
Importantly, varying these parameters can enhance the sensitivity of mutation detection 
by  SSCP  analysis.  Addition  of  denaturants,  urea  or  formamide  to  create  a  mildly 
denaturing environment in the gel can reduce smearing and sharpen SSCP bands (Yip et 
al,  1999).  Similarly,  addition  of  additives  for  example  glycerol  to  electrophoresis 
buffers containing borate can also improve mutation detection.  Glycerol is reported to 
lower the pH of the electrophoresis buffer and as a consequence stabilises the secondary 
conformers  of  single  stranded  DNA  molecules  (Kukita  et  al,  1997).  It  is  common 
practice to  scan for novel  sequence variants  at more than one temperature to enhance 
sensitivity; the secondary structure conformation of single stranded DNA molecules is 
very sensitive to variations in temperature (Orita et al,  1989).  For this reason accurate 
control  of temperature  during  electrophoresis  is  paramount  to  avoid  dissociation  of 
intrastrand  base  pairs,  formation  of  unstable  conformers  and  ultimately  loss  of 
resolution. The sensitivity of SSCP analysis is strongly dependent upon the size of the 
fragment used in the analysis (Sheffield et al,  1993). There are conflicting estimates in 
the literature regarding the optimum size fragment to use in order to achieve maximum 
sensitivity (see reviews by Cotton, 1992; Hayashi and Yandell, 1993; Nataraj et al, 1999 
and references within).  In general it appears that SSCP  analysis can detect 70-95% of 
mutations  in  PCR  products  of 200bp  or  less,  but  less  than  50%  when  fragments  of 
greater  than  400bp  are  analysed  (Michaud  et  al,  1992;  Grompe,  1993).  Restriction 
digest of PCR products can improve the sensitivity of SSCP analysis for large fragments 
(Liu and  Sommer,  1995;  Jugessur et al,  2000)  although this  can  sometimes lead to  a 
complex  SSCP  banding  pattern  within  which  to  decipher  abnormal  conformers.  It 
should  also  be  considered  that  coupling  SSCP  analysis  with  HA  analysis,  a  related 
technique,  has  long been  known  to  increase  the  sensitivity of mutation  detection  by 
SSCP analysis (Ravnik-Glavac et al, 1994; Rossetti et al, 1995).
134HA analysis is based upon the conformation of duplex DNA fragments in native 
gels.  It  exploits  the  fact  that  samples  heterozygous  for  a  given  allele  can  form 
heteroduplexes  upon  denaturing  and  re-annealing;  for  a  heterozygous  sample  four 
duplex DNA species should form: two perfectly matching homoduplexes (one wild-type 
the other variant) and two heteroduplexes containing a mismatch (formed by annealing 
of either the wild-type sense strand with the variant anti-sense strand or vice-versa). To 
facilitate formation of heteroduplexes in samples homozygous for the rare allele of any 
given  sequence  variant  samples  to  be  analysed  are  mixed  with  wild-type  DNA  as  a 
reference.  Heteroduplex  DNA  fragments  containing  a  mis-match  generally  exhibit  a 
retarded  electrophoretic  mobility  compared  to  the  corresponding  homoduplex  DNA 
fragments formed by the annealing of complementary strands (for review see Nataraj et 
al,  1999).  During SSCP  analysis single stranded DNA fragments denatured post-PCR 
prior to loading on SSCP gels often renature to a certain extent. Hence, if this occurs in 
a heterozygote sample heteroduplexes can form between wild-type and mutant strands; 
these heteroduplexes can often be resolved from the homoduplexes in a lower position 
from  the  single  stranded  conformers  on  SSCP  gels  and  facilitate  the  detection  of 
sequence variants (Gerrard and Dean,  1997). When used as the sole means of mutation 
scanning the sensitivity of HA analysis is similar to that of SSCP analysis (for reviews 
see  Grompe  1993;  Nataraj  et  al,  1999)  but  a drawback  of HA  analysis  compared  to 
SSCP analysis is that sensitivity appears greater for detection of insertions and deletions 
compared to base substitutions (Wikman et al, 2000).
Similar to HA analysis dHPLC and DGGE are two additional mutation scanning 
techniques that exploit inherent properties of heteroduplex DNA fragments compared to 
homoduplexes; both DGGE and dHPLC exploit the differential denaturation kinetics of 
hetero-  compared  to  homo-duplex  DNA  fragments.  In  DGGE  double  stranded  DNA 
fragments  are  electrophorised  through  a  gradient  gel  of  increasing  denaturant 
concentration  or  temperature  (temperature  gradient  gel  electrophoresis,  TGGE).  This 
effectively  causes  the  double  stranded  DNA  fragments  to  denature  in  a  step-wise 
fashion  as  discrete melting domains  unfold,  the domains  of low melting temperature 
denaturing  first.  A  single  difference  in  nucleotide  composition  between  two  double 
stranded DNA fragments is sufficient to alter the denaturation kinetics for the melting 
domain  within  which  the  variant  nucleotide  resides  such  that  altered  electrophoretic 
mobilities  are  observed  (for  reviews  see  Knapp,  1994;  Suh  and  Vijg,  2005).  The 
sensitivity of DGGC  is  enhanced by  applying heteroduplexing  and by attachment  of 
GC-rich clamps to the fragments under analysis the later of which ensures detection of
135sequence  variants  occurs  within  regions  of  relatively  low  melting  temperature. 
Compared  to  SSCP  analysis  DGGC  is  a  highly  sensitive  method,  but  it  is  arguably 
technically more difficult to perform and thorough optimisation of the conditions for gel 
electrophoresis is required (Suh and Vijg, 2005).
dHPLC  utilises  ion-pair reverse  phase  liquid  chromatography to  differentially 
retain homo- and hetero-duplex DNA fragments; the heteroduplex DNA fragments elute 
more rapidly from the column due to their ability to denature more readily (for reviews 
see  Xiao  and  Oefiner,  2001;  Suh  and  Vijg,  2005).  One  of the  main  advantages  of 
dHPLC is that complete automation can be achieved using the WAVE DNA fragment 
analysis system, which is adapted for 96-well throughput.  Samples are detected by on­
line UV absorbance at 260nm and can be visualised as an elution profile; heterozygous 
samples  typically  displaying  four  chromatographic  peaks:  two  representing  the 
homoduplexes  and  two  representing  the  heteroduplexes  (Donohoe,  2004).  However, 
current drawbacks of this system compared to SSCP analysis are that only one sample 
can be analysed at a time resulting in a modest throughput.  In addition, the operating 
temperature has to be optimised for each fragment to be assayed and initial set-up costs 
are high due to the need to purchase specialist equipment (for review see Suh and Vijg,
2005).
SSCP  analysis  is  limited  in  that  it does  not define the nature of the  sequence 
variant or the location of the sequence variant within the fragment examined. However, 
this  anomaly  is  not  limited  to  SSCP  analysis  many  methods  of mutation  scanning 
including  HA,  DGGE  and  dHPLC  pin-point  putative  sequence  variants  without 
identifying the position or nature of the sequence variant within the fragment of DNA 
under  analysis.  Therefore,  abnormal  bands  identified  by  SSCP  or  these  alternative 
mutation scanning techniques must be followed up by sequencing analysis in order to 
identify  the  sequence  change.  Indeed,  direct  sequencing  is  considered  the  ‘Gold 
standard’ amongst mutation detection techniques because it defines precisely the nature 
and  location  of the  sequence  change  (for review  see  Suh  and Vijg,  2005).  However, 
direct sequencing,  as the sole means of mutation  scanning may not be the most cost- 
effective  approach.  Even  with  the  use  of the  current  genetic  analysers  that  utilise 
capillary  arrays  and  fluorescent  dye  deoxy  terminator  methodology  for  example,  the 
ABI  Prism 3100 Genetic Analyser fitted with a standard 50cm capillary array and used 
in  combination  with  BigDye  terminator  chemistries  (Applied  Biosystems)  mutation 
scanning of large,  complex,  multi-exon  genes by direct  sequencing can be very time
136consuming and costly, especially if a large number of samples have to be processed (for 
reviews see: Franca et al, 2002; Suh and Vijg, 2005).
Besides  direct  sequencing,  one  of the  few  mutation  scanning  techniques  that 
localises  the  sequence variant within the fragment under examination  is  CCM.  CCM 
was  originally  described  by  Cotton  in  1988  and  similar to  HA,  dHPLC  and  DGGE, 
utilises  heteroduplex  formation  between  wild-type  and  variant  DNA  fragments. 
Typically, the wild-type DNA is given a label (a radiolabel or fluorescence label) and 
added  to  all  sample  DNA  to  be  scanned.  Heteroduplex  formation  is  followed  by 
chemical modification at the sites of the mismatched bases; osmium tetroxide is used to 
chemically modify mismatched thymines and hydroxylamine for mismatched cytosines. 
Piperidine is then used to  cleave the modified  strand  at the  site of the mismatch and 
cleavage  products  detected  by  denaturing  gel  electrophoresis  followed  by 
autoradiography  or  fluorescence  detection,  as  appropriate  (for review  see  Ellis  et  al, 
1998). However, drawbacks of the CCM method compared to SSCP are the use of toxic 
chemicals and it is technically more difficult to perform. CCM is probably most useful 
when  large  and  complex  genes  have  to  be  examined  as  fragments  over  1Kb  can be 
screened at a time (for review see Ellis et al, 1998).
SSCP  analysis  is  a  popular  choice  for  mutation  scanning  and  the  main 
advantages of SSCP analysis particularly when compared to dHPLC, DGGE and CCM 
most  probably lie  in  its  speed  and  /  or  simplicity.  The  use  of pre-cast  gels  that  can 
examine up to 48  samples at a time (Pharmacia Biotech) and the application of silver 
staining  to  visualise  SSCP  bands  eliminates  the  need  for  radioactivity  and  has  been 
reported to increase resolution (Dockhom-Dwomickzak et al,  1991).  Enhancements in 
SSCP analysis over recent years have lead to the incorporation of fluorescent labels and 
the  separation  of  fragments  by  automated  capillary  array  electrophoresis  using 
automated genetic analysers such as the ABI PRISM 3100 (PE Applied Biosystems); a 
procedure which has greatly streamlined the mutation detection process and increased 
the turn-around time (Baba et al, 2003; for review see Suh and Vijg, 2005).
Finally, attention should be drawn to the fact that SSCP analysis as with many 
techniques used in mutation detection (eg: dHPLC, DGGE, HA and CMC) is based on 
PCR amplification of sample DNA prior to analysis. Consequently, it is very important 
to  validate  reports  of novel  mutations  that  have  been  obtained  via  these  techniques 
particularly the identification of single nucleotide substitutions.  Taq DNA polymerase 
introduces errors into the newly synthesized strand during PCR and does not have 3’-5’ 
exonuclease proofreading activity; Cline et al,  1996 report an error rate of 8.0 xlO'6 for
137Taq DNA polymerase (expressed as mutation frequency/bp/duplication). Therefore, if a 
sequence change is only detected in one individual, this should always be confirmed in 
a second PCR from the same individual to rule out the possibility of a PCR artefact.
In  summary,  given  the  small  size  of the  Bm-3c  gene  (in  humans  the  coding 
region spans  1017bp;  NCBI GenBank Accession:  NM  002700)  coupled with the fact 
that only a modest number of samples needed to be scanned it was decided that SSCP 
analysis in combination with non-radioactive silver staining would be an ideal mutation 
scanning method with which to examine the Bm-3c gene for the presence of common 
sequence variants. The relatively high sensitivity of SSCP analysis when more than one 
condition of electrophoresis is used and the relative ease and speed of the method plus 
the  low-reagent  cost  made  mutation  scanning  of the  Bm-3c  gene  by  SSCP  a  rapid, 
reliable, cost-effective and most appealing approach.
4.1.3  Reporting DNA sequence variation: nomenclature.
DNA  sequence  variation  can  manifest  in  various  forms  including  single  nucleotide 
substitutions, deletions or insertions of one, several or even hundreds of base pairs and 
simple  sequence  repeats  (SSRs)  which  are  tandem  repeats  of  nucleotide  motifs 
commonly  referred  to  as  micro-  or  mini-  satellites  depending  on  the  length  of the 
repeating  motif.  Single  nucleotide  substitutions  are  the  most  common  type  of DNA 
sequence variation  in the human  genome,  they are mainly located within non-coding 
regions  and  it  is  estimated  that  there  are  greater  than  10  million  single  nucleotide 
substitutions with rare allele frequencies above 1% (for review see Wright et al, 2003). 
Single nucleotide substitutions are often referred to in the literature as single nucleotide 
polymorphisms (SNPs). However, this later term is misleading. The classical definition 
of a  polymorphism  states  a  polymorphism  is:  “a  Mendelian  trait  that  exists  in  the 
population in at least two phenotypes, neither of which occurs at a frequency less than 
1%” (Vogel  and Motulsky,  1986) and hence, it has an effect on phenotype.  However, 
the term polymorphism is also used to describe a neutral change in the DNA sequence 
that has no affect on phenotype and is often used to simply refer to a change in the DNA 
sequence present at a frequency of 1  % or higher in the population regardless of whether 
it may have an affect on phenotype (see Cotton and  Scriver,  1998).  Clearly, many of 
these  terms  are  not  well  defined  and  are  used  ambiguously  in  the  literature.  A 
polymorphism can have a functional affect on gene regulation and / or function of the 
encoded protein and hence, be of phenotypic significance or it can be neutral without
138phenotypic effect. Therefore, for the purpose of this thesis the term  'sequence variant ’ 
as  opposed  to  ‘polymorphism’  was  adopted  as  the  nomenclature  of  choice  when 
reporting  sequence  variation  identified  at  the  Bm-3c  locus  and  knowledge  of  the 
frequency and functional effect(s) of the sequence variant was unknown. This concept is 
in  agreement  with  the  current  guidelines  set down by the  Human  Genome Variation 
Society (www.hgvs.org/mutnomen/). Where the term polymorphic or polymorphism is 
used  within  the  text  in  this  thesis  this  represents  a  variable  DNA  element  and  no 
indication of functional  significance is  intended to be inferred;  it could be neutral  or 
disease causing.
1394.2  The PCR-SSCP screen of the Brn-3c gene.
To  search  for  common  sequence  variants  at  the  Bm-3c  locus  mutation  scanning  by 
PCR-SSCP  analysis  was performed using DNA  isolated  from  45  random  individuals 
(see method section: 3.2.1, 3.2.2.1  and 3.2.3). In humans the coding region of the Bm- 
3c gene is contained within two exons of 120bp (NCBI GenBank Accession: U 10060.1) 
and  897bp (NCBI GenBank Accession:  U10061.1) respectively, intervened by a small 
intron of 315bp (NCBI GenBank Accession: AF043452.1). The small size of this gene 
facilitated rapid  analysis by PCR-SSCP  analysis.  To  enhance the  sensitivity of SSCP 
analysis  PCR  primers  were  designed  to  generate  fragments  that  on  average  spanned 
250bp (see Table 3.1, section 3.2.18). In the quest to achieve maximum sensitivity PCR 
primers were placed to generate fragments in any given region that overlapped as much 
as was possible,  so that segments of DNA were examined in the context of more than 
one PCR product as much as was feasible within the limitations of the DNA sequence 
on primer design.  It is particularly important to consider searching for novel  sequence 
variants in the context of more than one PCR product if possible and / or practical as if a 
sequence variant exists in one allele at the site of primer annealing then this allele may 
not  be  amplified  in  the  PCR  pre  SSCP  analysis.  Accordingly  this  sequence  variant 
would go undetected in heterozygous samples.  Furthermore,  sequence variants located 
near the end of DNA fragments but not within the sites of primer annealing are not as 
well  detected  as  those  within  or  closer to  the  middle  of the  fragment under  analysis 
(Rossetti et al, 1995).
A total of 14 overlapping PCR fragments were examined at the Bm-3c locus: 6 
covering  the  coding  region  and  intron  of the  gene  and  8  spanning  1.5Kb  of the  5’- 
flanking region (Fig. 4.2). An additional fragment designed to include the dinucleotide 
(GT)n repeat  at  position  -3495bp  within  the  5’-flanking  region  of the  gene  was  also 
examined (Fig. 4.2). The PCR was optimised by varying the magnesium concentration 
and  the  annealing  temperature  for  each  of the  15  PCR  reactions  to  ensure  specific 
amplification of the required fragment for subsequent SSCP analysis. Specificity of the 
PCR  analysis  was  confirmed  by electrophoresing  an  aliquot  from  each  sample  to  be 
analysed on an agarose gel.  In order to stand the best chance of detecting all sequence 
variants at the Bm-3c locus within the region under examination the SSCP screen was 
performed  at three  different  temperatures  of 4,  10  and  20  °C  for  each  fragment  (see 
method  section  3.2.3).  Samples  displaying  abnormal  conformers  in  the  SSCP  screen 
indicative of putative sequence variants were sub-cloned into the pGEM®-T easy vector
140(Promega)  alongside  samples  that  did  not  display  the  abnormal  conformers.  The 
pGEM®-T easy vector has  single  3'-thymidine overhangs  at the multiple cloning site 
that  facilitates  insertion  of PCR products with  adenosine appendages  at their 3'-ends. 
Several  clones  were  sequenced  for  each  sample  in  both  directions  on  an  ABI  3100 
genetic  analyser  and  compared  to  the reference  sequence  (for reference  sequence  see 
Appendix B) to confirm and to identify the nature of the variation. Using this approach 
five novel sequence variants were identified at the Bm-3c locus and the presence of two 
previously reported sequence variants was confirmed.  Identification of these sequence 
variants is discussed in the following sections: 4.3 -  4.4.
141-3495(GT)„  -1391A>C -566(GT),
Figure 4.2 Schem atic of PC R  fragm ents designed for SSC P analysis at the B rn-3c locus.  Exons  1   and 2 are numbered and the intron is 
shown as a red shaded box (not to scale). The position of the previously reported but non-validated -1391A>C single nucleotide substitution 
(NCBI  SNP  Cluster  ID:  rsl368402)  and  the  location  of two  dinucleotide  (GT)  repeats  at  -566  and  -3495  are  all  indicated  by  arrows. 
Numbering is with respect to the first A of the ATG translation start site as +1  (indicated by a small black arrow). Fragments generated by 
PCR for  SSCP  analysis  are  numbered  in blue  and  their locations  defined by the thick black  lines below.  Sequences  of primers  for each 
fragment are shown in Table 3.1 Method section 3.2.18. For simplicity the region of the Bm-3c promoter between -1391 and -3495 has been 
omitted as indicated by the two hatched lines.4.3  Identification of single nucleotide substitutions at the Brn-
3c locus.
4.3.1  Identification of-1391A>C.
Prior to undertaking the PCR-SSCP  screen to search for novel and common sequence 
variants at the Bm-3c locus three non-validated single nucleotide substitutions had been 
reported  in the NCBI  SNP  database  for Bm-3c  (see Table 4.1  section 4.1.1).  One of 
these was  an A  >C  substitution in the 5’-flanking region of Bm-3c  at position -1391 
(NCBI  SNP  Cluster ID:  rs 1368402), but this sequence variant had not been validated 
and no report of allele frequency was available. Therefore, it was decided to begin the 
PCR-SSCP screen of Bm-3c with a fragment spanning the -1391 locus. Confirmation of 
the -1391  sequence variant would validate the original report and confirm the presence 
of a single nucleotide substitution within the 5’-flanking region of Bm-3c. This analysis 
would also help affirm the suitability and sensitivity of this PCR-SSCP  screen for the 
detection of sequence variants.
A 216bp fragment (termed fragment  1) spanning the -1391  locus was subjected 
to  PCR-SSCP  analysis  at 4,  10  and 20°C  as described in method  section  3.2.2.1  and 
3.2.3. The results of this analysis revealed the presence of abnormal conformers at 4 and 
10°C but not 20°C (see Fig. 4.3  for comparison of the SSCP banding pattern at  10 and 
20°C).  This  illustrates  the  importance  of  using  more  than  one  temperature  when 
scanning for sequence variants by SSCP. Upon closer examination of the SSCP gels at 4 
and  10°C  it  was  evident  that  each  of the 45  subjects  examined  could be  categorised 
under one of three distinct classes based on the  SSCP banding pattern (Fig.  4.3). The 
most frequent pattern,  group A,  (found in 26 of 45  subjects) was characterised by the 
presence of a single lower band,  band A  (Fig.  4.3,  arrow A).  This was followed by a 
subset of individuals, group AB, (found in  13  of 45 subjects) that displayed this single 
lower band, A,  in addition to another immediately below, band B, hence forming two 
closely spaced  lower bands, A  and B  (Fig.  4.3,  arrow AB).  Finally a small  subset of 
individuals,  group B,  (found in 6 of 45  subjects) lacked the upper of these two lower 
bands {band A) and was characterised by the existence of band B alone (Fig. 4.3, arrow 
B). Based on the principle of SSCP analysis these results suggest that the genotypes of 
the  individuals  within  groups  A,  AB  and  B  may  be  homozygous  wild-type, 
heterozygous  and homozygous  variant respectively,  for  a particular  sequence variant. 
Indeed, for a common sequence variant one would generally expect individuals that are
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Figure  4.3  SSCP  results for fragment  1  spanning the -1391  locus  in  the Brn-3c  5’-flanking 
region,  (a) Section of the SSCP gel electrophoresed at  10°C compared to the same section in (b) 
electrophoresed  at  20°C.  Results  are  shown  for  15  individuals.  The  presence  of  abnormal 
conformers can be observed at  10°C but not 20°C.  Subjects can be categorised into three distinct 
groups shown by arrows A, B, and AB based on the SSCP banding pattern observed in (a). Bands a 
and b are indicated. Primer sequences for fragment 1 are shown in Table 3.1 Method section 3.2.18.
homozygous  wild-type  to  exhibit  the  most  frequent  banding  pattern  and  individuals 
homozygous  for  the  variant  allele  to  exhibit  the  least  frequent  banding  pattern  with 
individuals that are heterozygous exhibiting a banding pattern at frequency intermediate 
between the two. However, as discussed previously (section 4.1.2) a limitation of SSCP 
analysis is that it does not define the nature of the sequence variant or the location of the 
sequence variant within the fragment under analysis.  Therefore,  SSCP is not an accurate 
method  by  which  to  assign  genotypes.  Indeed,  two  distinct  single  nucleotide 
substitutions  at  the  same  position  can  result  in  identical  SSCP  shifts;  different  base 
substitutions at  any particular nucleotide position do not necessarily mean that distinct 
SSCP migration patterns will be observed (Sheffield et al,  1993).  Therefore, to identify 
the sequence change(s) within fragment 1  and to assess whether the -1391 A > C
144130  140  1 5 0
C  G T AG T C GAG G T C CA GGATTCCCC
1 4 0   150
COTAGTCG AG G T C CAO G ATT CCCC
(b)
130  140  150
COTAG TCOCGGTCCAGO AT TCCCC
140  15 0
CGTAGTCGC GGTCCAGGATTCCCC
(c)
130  140  150  130  14 0   1 5 0
CGTAG TCG AG G T C  CAG GATTCCCC  CO TAGTCGCGO TCCAGGATTCCCC
Figure 4.4 Sequencing results for fragment  1  spanning the -1391  locus in the Bm-3c 5’- 
flanking  region.  Representative  sequencing chromatograms  obtained from  sequencing DNA 
cloned from a single individual within each of the three SSCP groups A in (a), B in (b) and AB 
in (c).  The -1391  A>C substitution was confirmed as the only sequence change in fragment  1  
and the genotypes of the individuals within groups  A (a), B (b) and AB (c) were verified as 
homozygous wild-type A/A, homozygous variant C/C and heterozygous A/C, respectively. The 
single nucleotide substitution is underlined in black in each chromatogram. Numbers above each 
sequencing chromatogram represent the automatic base numbering from the start of readable 
sequence using BioEdit Sequence Alignment Editor software.
substitution is responsible^several clones of an individuals DNA within pGEM®-T easy 
vector were sequenced for one individual within each of the three groups: A, B and AB. 
The  results  of this  analysis  confirmed  the  -1391  substitution  as  the  only  sequence 
change within  fragment  1   (see Fig.  4.4).  In addition,  the genotypes of the individuals 
within groups A, B,  and AB were verified as homozygous wild-type AJA, homozygous 
variant  C/C  and  heterozygous  A/C,  respectively.  This is  consistent with the predicted 
genotypes based on SSCP banding patterns. Based on this data one could estimate that 
the -1391  sequence variant is a common sequence variant with a rare allele frequency of 
0.28 (see Table 4.2).  However,  as discussed previously SSCP is not a reliable method 
with  which  to  perform  genotyping.  Without  verifying  the  genotypes  of each  sample 
within a particular group by a direct means for example, sequencing analysis one cannot 
conclude equivocally that each sample within a particular group has the same genotype.
145An alternative single nucleotide substitution to that of the -1391  sequence variant may 
be present  within  one  or  several  samples  within  any of the  groups  that produces  the 
same  banding  pattern  to  that  of  the  -1391  sequence  variant.  Therefore,  the  allele 
frequency figures quoted in Table 4.2 for the -1391  single nucleotide substitution should 
be taken  as  a guide only,  but this  data is  suggestive that the  -1391  single nucleotide 
substitution is a common sequence variant in the general population.
Table 4.2: Genotype and allelic frequencies of the -1391 A>C single nucleotide 
substitution based on SSCP analysis in 45 random individuals.
SSCP
Class
Number of 
observations
Genotype
(SSCP)
Genotype
frequency
Allele Allele
frequency
A 26 AA 0.58 A 0.72
AB 13 AC 0.29 C 0.28
B 6 CC 0.13
4.3.2  Identification of +9QOT.
Six overlapping PCR fragments (numbers 9-14, Fig 4.2, page  142) were designed to 
examine the complete coding region of Bm-3c and the only intron for the presence of 
novel sequence variants. Each of these fragments was examined by PCR-SSCP analysis 
at 4,  10 and 20°C as described in method section 3.2.2.1  and 3.2.3. The results of this 
analysis showed the presence of abnormal conformers for fragment nine only (Fig. 4.5). 
Fragment nine spans the whole of exon 1  of the Bm-3c gene (Fig. 4.2, page 142). SSCP 
analysis of fragment nine at 20°C revealed the presence of abnormal conformers in the 
form of an extra upper band in two of the 45 subjects examined (Fig. 4.5, arrows A and
B).  The remaining subjects  all  confer  to the same banding pattern that lacked the 
presence of this  extra band  (Fig.  4.5,  comparing arrows A  and  B  with  C).  Abnormal 
conformers were not evident for fragment nine when examined at 4 or 10°C.
To identify the sequence change(s) within fragment nine several clones obtained 
from  cloning  this  fragment  into  pGEM®-T  easy  vector  from  both  individuals  that 
displayed  the  extra conformer  (Fig.  4.5,  subjects  indicated by arrows  A  and  B) were 
sequenced  and  compared  with  clones  from  one  individual  who  did  not  display  the 
presence  of the  abnormal  conformer  (Fig.  4.5,  subject  indicated  by  arrow  C).  The 
results  of this  analysis  identified  a  C  to  T  substitution  at  position  +90  in  subjects 
displaying the abnormal conformer; these subjects were both confirmed by sequencing
146Figure  4.5  SSCP  results  for fragment  9  spanning exon  1  of Brn-3c.  Sections  of the  SSCP gel 
electrophoresed at 20°C to show the two subjects containing the abnormal conformer (arrows A and 
B).  All  remaining  subjects  displayed  the  same  banding  pattern  as  indicated by  arrow  C.  Primer 
sequences for fragment 9 are shown in Table 3.1 Method section 3.2.18.
analysis as heterozygous for the C to T substitution (Fig. 4.6a and b).  The subject who 
did not display the abnormal conformer (indicated by arrow C, Fig. 4.5) was determined 
homozygous  wild  type,  C/C  (Fig.  4.6c).  Further  analysis  revealed  that  the  +90C>T 
substitution is a  synonymous variant;  both wild-type (GCC)  and variant  alleles (GCT) 
encode for the amino acid alanine (Fig.  4.6). This sequence variant is discussed further 
in section 4.5.(a)
580  590
TGOCTCCGAGGCCATGCGCCGAGT
GGC  TCC  GAG  GCC  ATG  CGC  CGA
180  190  200
TGGCTCCG AG GCTATGCGCCOAGT
GGC  TCC  GAG  GCT  ATG  CGC  CGA
M M
(b)
620  630
TGGCT CCGAGGCCATGCGCCGAGT
GGC  TCC  GAG  GCC  ATG  CGC  CGA
560  570
TGGCTCCGAGGCTATGCGCCGAGT
GGC  TCC  GAG  GCT  ATG  CGC  CGA
M M
(C)
200  210 
TGGCTCCGAGGCCATGCGCCGAGT
GGC  TCC  GAG  GCC  ATG  CGC  CGA
610  620  630
TGGCT CCGAOOCCATGCOCCGA OT
GGC  TCC  GAG  GCC  ATG  CGC  CGA
M M
Figure  4.6  Sequencing  results  for  fragment  9  spanning  exon  1  of  Bm-3c.  All  sequencing 
chromatograms were obtained from sequencing cloned PCR products in pGEM®-T easy vector, (a) 
and  (b)  representative  sequencing  chromatograms  for  subjects  heterozygous  for  the  +90OT 
substitution (subjects displaying the extra conformer as indicated by arrows A and B in Fig. 4.5). 
(c) Representative sequencing chromatograms for a subject homozygous wild-type,  C/C (subject 
lacking the extra conformer as indicated by arrow C in Fig. 4.5). The single nucleotide substitution 
is underlined in black in each chromatogram. The +90OT substitution is a synonymous variant as 
illustrated by  the  amino acid  sequence  shown  under each chromatogram.  Numbers above each 
sequencing  chromatogram  represent  the  automatic  base  numbering  from  the  start  of readable 
sequence using BioEdit Sequence Alignment Editor software.
4.3.3 Identification of -386Q A .
Eight overlapping PCR fragments (numbers  1   -  8, Fig 4.2, page  142) were designed to 
examine  approximately  1.5Kb  of the immediate  5’-flanking region of the Brn-3c gene 
for the presence of novel sequence variants.  Each of these fragments was examined by 
PCR-SSCP analysis at 4,  10 and 20°C as described in methods section 3.2.2.1 and 3.2.3. 
The  results  of this  analysis  confirmed  the  previously  reported  -1391A>C  sequence 
variant  within  fragment  one  as  discussed  in  section  4.3.1.  In  addition,  an  abnormal
148SSCP  migration  pattern  was  evident  following  PCR-SSCP  analysis  of fragment  five 
(the  PCR-SSCP  results  of  fragment  five  are  discussed  further  in  section  4.4: 
Identification of multi- allelic sequence variants) and fragment six (see Fig.  4.7). None 
of the additional fragments covering  1.5Kb of the 5’-flanking region of Bm-3c showed 
an  abnormal  SSCP  migration  pattern  to  suggest  the  presence  of a  novel  sequence 
variant(s).  SSCP  analysis  of fragment  six  at  4  and  10,  but  not  20°C  revealed  an 
abnormal migration pattern in one of the 45 samples examined; this sample displayed an 
abnormal conformer in the form of an extra lower band that was absent in all the other 
samples examined (Fig. 4.7, arrow A).
To  identify the  sequence change(s) within fragment  six several  clones obtained 
from cloning this fragment into pGEM®-T easy vector for the individual that displayed 
the  extra  conformer  (Fig.  4.7,  subject  indicated  by  arrow  A)  were  sequenced  and 
compared  with  clones  from  one  individual  who  did  not  display  the  presence  of the 
abnormal conformer (Fig. 4.7, subject indicated by arrow B).  The results of this analysis 
identified a C to A substitution at position -386 and revealed that the subject displaying 
the  abnormal  conformer  was  heterozygous  for this  sequence  variant  (Fig.  4.8a).  The 
subject lacking the abnormal conformer (indicated by arrow B, Fig. 4.7) was determined 
homozygous wild type,  C/C (Fig.  4.8b).  Since the -386C>A variant was only identified 
in  one  individual  this  raises  the  possibility  that  the  -386C>A  variant  may  have  risen 
from a PCR error. To rule out the possibility that the -386C>A variant was an artefact of 
the  PCR  amplification  the  PCR  amplification  was  repeated  with  DNA  from  the 
individual displaying this abnormal conformer.  SSCP analysis at 4°C on this second
A  B
Figure 4.7  SSCP  results for fragment 6  within  the 5’-flanking region  of Brn-3c.  Section of the 
SSCP gel electrophoresed at 4°C to show the subject containing the abnormal conformer (arrow A). 
All remaining subjects confirmed to the banding pattern as indicated by arrow B. Primer sequences for 
fragment 6 are shown in Table 3.1 Method section 3.2.18.
149(a)
670  680
OAA GGGAAGT CCACGAAGAAGAAA
690  700
G  A AGO  GA A GT  CCAAGAAGAAOAAA
(b)
630  640
GAAGGGAAGTCCACOAAGAAOAAA
670  680
OA A OGGA A GT  C CA C GAA OA A GA A A
Figure  4.8  Sequencing  results  for  fragment  6  within  the  Brn-3c  5’-flanking  region.  All
sequencing chromatograms were obtained from sequencing cloned PCR products in pGEM®-T 
easy vector,  (a) Representative sequencing chromatograms for the subject heterozygous for the - 
386C>A substitution (subject displaying the extra conformer as indicated by arrow A in Fig. 4.7). 
(b) Representative sequencing chromatograms for a subject homozygous wild-type, C/C (subject 
indicated by arrow B in Fig. 4.7). The single nucleotide substitution is underlined in black in each 
chromatogram.  Numbers  above  each  sequencing  chromatogram  represent  the  automatic  base 
numbering  from  the  start  of  readable  sequence  using  BioEdit  Sequence  Alignment  Editor 
software.
PCR sample of fragment  six confirmed the presence of the abnormal  conformer in the 
form of the extra lower band (Fig. 4.9a).  Sequencing several clones generated from this 
second PCR amplification confirmed the C to A substitution at position -386 in the Bm- 
3c promoter was not an artefact of the PCR amplification (Fig. 4.9b).  Collectively, the 
results of this analysis suggest that the -386C>A substitution is a rare variant; the C to A 
substitution  was  only  identified  in  one  of the  45  subjects  examined  and  no  subjects 
homozygous  for  the  variant  allele  were  identified  from  the results  of this PCR-SSCP 
screen. This sequence variant is discussed further in section 4.5.
150(a)
A
(b)
740  750
GGA A GGGAAGT  CCA C GA A GAA GA AA
680  690
GAA GGGAAGT  C C A _A  GA A GA A GA A A
Figure 4.9 Confirmation of -386C >A by repeat PCR-SSCP analysis followed by sequencing, (a) 
Repeat SSCP results for fragment 6 within the 5’-fIanking region of Brn-3c. Section of the SSCP 
gel  electrophoresed  at  4°C  to  show the  subject  containing the abnormal  conformer  (arrow A),  (b) 
Repeat  sequencing  results for fragment 6 within the  Brn-3c 5’-flanking  region.  Representative 
sequencing chromatograms obtained from sequencing cloned PCR products in pGEM®-T easy vector 
for  the  subject  confirmed  by  repeat  PCR-SSCP  analysis  to  display  the  extra  conformer  [subject 
indicated by arrow A in (a)].  Sequencing analysis confirms that the subject is heterozygous for the - 
386C>A  single  nucleotide substitution.  The single nucleotide substitution is underlined  in black  in 
each  chromatogram.  Numbers above  each  sequencing  chromatogram  represent the  automatic  base 
numbering from the start of readable sequence using BioEdit Sequence Alignment Editor software.
1514.4  Identification of multi-allelic sequence variants at the Brn-3c
locus.
4.4.1  Identification of -566(GT)n repeat variation.
Examination of the 5’-flanking region of Bm-3c using the reference sequence (Ensembl 
transcript  ID:  ENST00000230732;  Appendix B)  revealed  a  (GT)n  dinucleotide  repeat 
with  21  GT  repeats  at  position  -566.  Dinucleotide  repeats  such  as  these  are  often 
polymorphic  exhibiting  multiple  alleles  with  sequence  variation.  Moreover,  there  is 
increasing  evidence  that  polymorphic  dinucleotide  repeats  have quantitative  effects on 
gene  expression  (Akai  et  al,  1999;  Gebhardt  et  al,  1999;  Borrmann  et  al,  2003; 
Tadokoro  et  al,  2004).  To  examine  the  possibility  that  the  -566(GT)n  repeat  is 
polymorphic  PCR-SSCP  analysis  was  performed  using  primers  3cP5-S:  5’
GGACTCTGGTGGACAGCTTG  3’  and  3cP5-AS:  5’  TGTCCCAGCTCGAACTGCC 
3’ designed to flank the -566(GT)n repeat (Fig. 4.2, fragment 5, page 142).
At  each  of three  temperatures  examined  (4,  10  and  20°C)  a  variable  SSCP 
banding pattern was observed across the 45 subjects scanned.  At 4 and  10°C the SSCP 
banding pattern was complex consisting of many extra bands.  However, three common 
banding patterns appeared evident at 20°C (Fig.  4.10,  as indicated by arrows A, B and
C)  in  addition  to  a  few  less  frequent  banding  patterns.  These  SSCP banding  patterns 
mainly  resulted  from  slight  shifts  in  the  migration  of  specific  bands  (for  example, 
comparing the banding pattern indicated by arrows B and C in Fig. 4.10). Consequently,
A  B  C
Figure 4.10 SSCP results for fragment 5 spanning the -566(GT)n repeat in the Brn-3c 5’-flanking 
region.  Section  of the  SSCP gel  electrophoresed at 20°C to  show the three  main banding patterns 
observed as indicated by arrows A, B and C. Subtle differences in the migration pattern can be observed 
between samples B and C. Primer sequences for fragment 5 are shown in Table 3.1  Method section
3.2.18.
152classifying  all  the  samples  into  particular  subsets  as  performed  for  the  -1391A>C 
sequence  variant  (section  4.3.1)  was  not  considered  reliable  and  so  not  undertaken. 
Using the  SSCP  results  obtained  at  20°C  as  a guide,  five  subjects were  selected that 
clearly  exhibited  differential  SSCP  banding  patterns.  Sequencing  several  clones  of an 
individuals DNA within pGEM®-T easy vector for each of these five subjects revealed 
that  the  -566(GT)n  repeat  varied  in  length  from  16  to  23  dincucleotide  repeats  [- 
566(GT)i6-23]  (see  Fig.  4.11).  No  additional  sequence  variants  were  identified  within 
fragment  5  in 20  clones  sequenced.  Taken together with the PCR-SSCP  results these 
results suggest that the -566(GT)n repeat is a common sequence variant in the general 
population.
v   '  4 4 0   4 5 0   4 6 0   4 7 0   4 8 0
COA CGGAOT OT OT OT GT GT GT GT GT GT OT GT GT OT GT OTOOT GGAGA GGGG
1 3 0   1 4 0   1 5 0   1 6 0   1 7 0   1 8 0
CGACGG AGTGTGTOTGTGTGTGTGTGTGTOTGTOTOTOTOTOTOTOTOOTOGAGAOGOO
(c)
4 0 0   4 1 0   4 2 0   4 3 0   4 4 0   4 5 0   4 6 0
CGA CGGAGTOT GT OT GT GT GT OT GT OT OT GT GT OT GT OT OT GT GT GT GT OT GTOGTOGA OAOOGO
Figure 4.11  Sequencing results for fragment 5 spanning the -556(GT)„ repeat in the Bm-3c 5’- 
flanking region. Sequencing several clones of an individuals DNA within pGEM®-T easy vector for 
five  subjects  that  exhibited differential  SSCP  banding  patterns  revealed that  the  -566(GT)n repeat 
varied in length from 16 to 23 dincucleotide repeats. Sequencing chromatograms representative of 16 
(a), 20 (b) and 23 (c) repeats are shown. Numbers above each sequencing chromatogram represent the 
automatic base  numbering from the start of readable sequence using BioEdit  Sequence Alignment 
Editor software.
1534.4.2  Identification  of  -3495(GT)n.  -3457(GA)n   and  -3432poly-G
polymorphism.
Having  established  that  the  -566(GT)n repeat  is  a  multi-allelic  sequence  variant  this 
prompted  an  examination  of  a  wider  region  of  the  published  Bm-3c  5’-flanking 
sequence for the presence of additional simple sequence repeats to see if these too may 
be polymorphic. Another (GT)n dinucleotide repeat was located at position -3495 with 
19  GT repeats in the reference sequence (Ensembl transcript ID:  ENST00000230732; 
see  Appendix  B  and  Fig.  4.12).  Therefore,  PCR-SSCP  analysis  was performed using 
primers  3cPll-S:  5’  GCATAAATGCCCACATAGTCC  3’  and  3cPll-AS:  5’ 
CCACCACCATGGCATTAAA 3’  designed to flank the -3495(GT)n  repeat (fragment 
15,  Fig.  4.2, page  142)  in order to  assess whether this region of the Bm-3c promoter 
(from -3431  to -3561bp) was variable (see Fig. 4.12). PCR-SSCP analysis of the region 
spanning the -3495(GT)n repeat revealed  a very complex  SSCP banding pattern  at all 
three temperatures  examined  (4,  10  and 20°C)  across  all  45  individuals  scanned  (see 
Fig. 4.13 for SSCP banding pattern at 10°C). Using the SSCP banding pattern produced 
at  10°C  as  a  guide  two  of the  45  subjects  that  displayed  differential  SSCP  banding 
patterns  (Fig.  4.13,  subjects  indicated  by arrows  A  and  B)  were  selected  and  several 
clones obtained from cloning fragment 15 into pGEM®-T easy vector for each of these 
individuals  were  sequenced.  The  results  of this  analysis  showed  that the  -3495(GT)n 
repeat was variable; alleles of length 15,  16 and 20 (GT)n repeats were identified within 
these two subjects. In addition, the -3495(GT)n repeat was not the only sequence variant 
identified within fragment 15. The first two nucleotides downstream of the -3495(GT)n 
repeat, GA (see Fig. 4.12) were found to constitute another variable dinucleotide repeat, 
termed -3457(GA)n;  alleles of 1, 2  and 3  (GA)n repeats were identified.  Searching the 
NCBI SNP database revealed that the -3457(GA)n sequence variant had been previously 
reported but not validated (NCBI SNP Cluster ID: rsl3162234).
A stretch of eleven guanine residues is located at position -3432 adjacent to the - 
3495(GT)n and -3457(GA)n repeats; this poly-G repeat is only 23 bp downstream from 
the  -3457(GA)n  repeat  (see  Fig.  4.12).  Mononucleotide  repeats  as  with  dinucleotide 
repeats  are  abundant  in  the  human  genome  and  are  a  common  source  of sequence 
variation  often  exhibiting multi-allelic variation  (Cohen  et  al,  2004).  Given  the close 
proximity of the -3432 poly-G repeat to the -3457(GA)n and -3495(GT)n repeats it was 
decided to investigate this highly repetitive region of the Bm-3c 5’-flanking region in 
greater detail. Primers 3cP12-S: 5’ GAGCTCCTGAAGCAGTGTCT 3’ and 3cP12-AS: 
5’ GC A  ATTT  GT  A  AC  AGCCT  CT  ATGC 3’ were designed to amplify a larger
154GGAGGATATGGTGCTTTGTGCCCTGACTTCACCTTACATGTGGCAAATCTATGTCCCTACTAGACTCTGA  - 3 7 4 2   t o  
CCTCCTATACCACGAAACACGGGACTGAAGTGGAATGTACACCGTTTAGATACAGGGATGATCTGAGACT  - 3  67 3
GCTCCTGAAGCAGTGT^TTCTGTATCTTCAAGGCCTTCCACAAGACTCTGCTGTTAGTAGGTATTTGGAA  - 3 6 7 2   t o  
CGAGGACTTCGTCACAGAAGACATAGAAGTTCCGGAAGGTGTTCTGAGACGACAATCATCCATAAACCTT  -3 6 0 3
ATGCTTATCGAATGGGGAAAATTCTTCCTTCAATGCCACTTGCATAAATGCCCACATAGTCCTTACATGG  - 3 6 0 2   t o  
TACGAATAGCTTACCCCTTTTAAGAAGGAAGTTACGGTGAACGTATTTACGGGTGTATCAGGAATGTACC  - 3 5 3 3
ACCTTCACATATTTTGTTTGGCCCATAAATGGTATGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG  - 3 5 32  t o  
TGGAAGTGTATAAAACAAACCGGGTATTTACCATACTCACACACACACACACACACACACACACACACAC  -3 4  63
TGTGTGATTGTAATTTAATGCCATGGTGGTGGGGGGGGGGGTGGGTAAGTGCTCTCTAGTTTACCACAGT  - 3 4 6 2   t o  
ACACACTAACATTAAATTACGGTACCACCACCCCCCCCCCCACCCATTCACGAGAGATCAAATGGTGTCA  -3 3 9 3
M---------------------
TTCAATCTTTCCTTTTATCCACCCAGATAAAGTTGCTCAATTTTATTTTACTAGTTTTGCACCTTATAGA  - 3 3 9 2   t o  
AAGTTAGAAAGGAAAATAGGTGGGTCTATTTCAACGAGTTAAAATAAAATGATCAAAACGTGGAATATCT  - 3 3 2 3
ATTTAAGTTTACAAATTCTGGAAAGCATAGAGGCTGTTACAAATTGCCGTCTAAGGCTGTCCTTCCAATT  - 3 3 2 2   t o  
TAAATTCAAATGTTTAAGACCTTTCGTATCTCCGACAATGTTTAACGGCAGATTCCGACAGGAAGGTTAA  - 3 2 5 3
<--------------------------
GCTTTTTCTATGGTCTTTTCCCTCTTTTCTTCTCCAGTCTCCAGTCTGTTATCTCCAAGGCCTTCTCAAA  - 3 2 5 2   t o  
CGAAAAAGATACCAGAAAAGGGAGAAAAGAAGAGGTCAGAGGTCAGACAATAGAGGTTCCGGAAGAGTTT  - 3 1 8  3
Figure  4.12  Section  of  the  Brn-3c  5’-flanking  region  with  loci  for  the  -3495(GT)„  repeat,  - 
3457(GA)n repeat and -3432 poly-G element highlighted. The -3495(GT)n repeat and -3432 poly-G 
element are shown in black bold, the -3457(GA)n repeat in red bold. Sequence of primers 3cPl 1-S and 
3cPll-AS  used  in  the  original  PCR-SSCP  screen  are  highlighted  in  blue  with  direction  of primer 
extension  defined  by  the  blue  arrows.  Sequence  of primers  3cP12-S  and  3cP12-AS  designed  to 
amplify a larger fragment of the Bm-3c 5’-flanking region incorporating the -3432 poly-G element are 
highlighted in green with direction of primer extension defined by the green arrows.
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Figure  4.13  SSCP  results  for  fragment  15  spanning  the  -3495(GT)„  repeat  in  the  Brn-3c  5’- 
flanking  region.  Section  of the  SSCP  gel  electrophoresed  at  10°C  to  show the  complex differential 
banding  pattern;  two  subjects  with  distinct banding patterns  are  indicated  by  arrows A  and  B  as  an 
example. Primer sequences for fragment 15 are shown in Table 3.1  Method section 3.2.18.
fragment (from  -3276 to -3674bp) that in addition to the -3495(GT)n and -3457(GA)n 
repeats also contained the poly-G repeat at -3432 (Fig.  4.12;  see also  Method section 
3.2.2.4). Genomic DNA from six subjects that originally displayed a differential SSCP 
banding  pattern  for the  -3431  to  -3561 bp  region encompassing the  -3495(GT)n and  - 
3457(GA)n repeats (Fig. 4.12) was amplified by PCR using primers 3cP12-S and 3cP12-
155AS  and  several  clones  obtained  from  cloning  this  larger  fragment  (from  -3276  to  - 
3674bp)  into  pGEM®-T  easy  vector  for  each  of these  six  different  individuals  were 
sequenced.  These  results,  coupled  with  subsequent  genotyping  analysis  for  a 
preliminary association study (see Chapter 8) showed that the -3495(GT) repeat ranged 
in length from  15  to  21  dinucleotides,  with an additional  allele of 24 dinucleotides  [- 
3495(GT)15.21,.24] and the -3457(GA) repeat from 1  to 3 dinucleotides \-3457(GA)j.j]. In 
addition the -3432poly-G repeat located just 23bp downstream of the -3457(GA)n repeat 
(see Fig. 4.12) was found to constitute a highly complex and common sequence variant 
exhibiting  multiple  variations  in  length  together  with  single  nucleotide  substitutions 
within the poly-G repeat (see Fig.  4.14).  Originally, five different alleles were identified 
for the -3432poly-G repeat as part of the initial PCR-SSCP screen (see Table 4.3; poly- 
G  alleles  that  are  highlighted  in  blue)  and  eventually  a  total  of nine  different  alleles 
were  identified  based  on  the  subsequent  genotyping  analysis  for  a  preliminary 
association  study  (see  Table 4.3).  This  sequence variant was termed the -3432poly-G 
polymorphism.  Four  of the  alleles  identified  are  simple  variations  in  mononucleotide 
length termed (G)x where x was found to vary between  10 and  13 guanine repeats. The 
remaining  five  alleles  all  display  single  nucleotide  substitutions  termed  SNPGX  in 
addition to varying in length (see Table 4.3)
Table 4.3: The polymorphic alleles identified at position -3432 within the
Brn-3c 5’-flanking region.
Allele DNA sequence Abbreviation Length of allele
(G),0 5’ TGGTGGTGGGGGGGGGGTGGGTA 3’ (G)io 10
(G)„ 5’ TGGTGGTGGGGGGGGGGGTGGGTA 3’ (G)n 11
(G),2 5’ TGGTGGTGGGGGGGGGGGGTGGGTA 3’ (G)12 12
(G )l3 5’ TGGTGGTGGGGGGGGGGGGGTGGGTA 3’ (G )i3 13
SNPG1 5’ TGGTGGTGGGGGGGGCGTGGGTA 3’ (G)8CG 10
SNPG2 5’ TGGTGGTGGCGGGGGGGGGTGGGTA 3’ GGC(G)9 12
SNPG4 5’ TGGTGGTGGTGGGGGGGGTGGGTA 3’ GGT(G)g 11
SNPG5 5’ TGGTGGTGGGGCGGGGGGTGGGTA 3’ (G)4C(G)6 11
SNPG6 5’ TGGTGGTGGGGGGGGGGGGGTGGGT  A 3’ GGC(G)io 13
Alleles  identified  are based on PCR-SSCP analysis  in 45  random individuals predominantly  of Caucasian 
ethnicity in addition to 142 patients characterised with late onset hearing loss and 145 general population samples 
genotyped  for  a  preliminary  association  study.  All  subjects  used  in  the  preliminary association  study  are 
Caucasian (see Chapter 8 for details of the association study). Alleles highlighted in blue were initially identified 
as part of the PCR-SSCP screen. Alleles identified either vary in poly-guanine repeat length or exhibit single 
nucleotide substitutions (shown in red bold) within the poly-guanine repeat.
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Figure 4.14 Representative sequencing chromatograms to illustrate three multi-allelic sequence 
variants  in  the  Bm-3c  5’-flanking  region:  -3495(GT)„,  -3457(GA)n   and  -3432poly-G 
polymorphism.  Sequencing  chromatograms  shown  were  obtained  from  sequencing  cloned  PCR 
products in pGEM®-T easy vector for different individuals as part of an initial PCR-SSCP screen and 
a  subsequent preliminary association study.  The sense strand of sequence is shown.  Numbers above 
each  sequencing chromatogram represent the automatic base numbering from the  start  of readable 
sequence using BioEdit Sequence Alignment Editor software.
(a)  -3495(GT)15: -3457(GA)2: -3432(G)8CG,  (b)  -3495(GT)]6: -3457(GA)j: -3432GGT(G)8,
(c)  -3495(GT)20: -3457(GA)3: -3432GGC(G)9,  (d)  -3495(GT)21: -3457(GA)2: -3432GGC(G)9,
(e)  -3495(GT)24: -3457(GA)2: -3432GGC(G),0.
157For example  allele  SNPG1  although the  same length  as the  shortest  allele identified, 
allele (G)io, contained a G to C substitution on the 9th nucleotide (counting the first G of 
the  poly-G  repeat  as  nucleotide  one)  (see  Fig.  4.15).  Similarly,  alleles  SNPG4  and 
SNPG5 were of equivalent length to allele (G)n, but allele SNPG4 contained a G to T 
substitution on the 3rd nucleotide, and allele SNPG5 contained a G to C substitution on 
the 5th nucleotide. Interestingly, the G to T substitution in allele SNPG4 also extended 
the trinucleotide repeating motif TGG immediately upstream of the guanine repeat from 
three to  four repeats  (see  Fig 4.15).  Allele  SNPG2  was of equivalent length to  allele 
(G)i2,  differing only in  the  G to  C  substitution  at the  3rd  nucleotide.  Whereas,  allele 
SNPG6 although equivalent in length to allele (G)n, also appeared to be an extension of 
allele SNPG2, in that it contained the same G to C substitution on the 3rd nucleotide but 
with an additional guanine in the mononucleotide repeat. Sequencing chromatograms of 
all alleles are shown in Fig. 4.15 on the following page and sequence is summarised in 
Table 4.3, page 156.
This  line of genetic  analysis  incorporating the initial  PCR-SSCP  screen and  a 
subsequent preliminary association  study (see  Chapter 8  for details of the association 
study) also revealed that the -3432poly-G polymorphism appears to be in strong linkage 
disequilibrium with the -3495(GT)n repeat and the -3457(GA)n repeat; for the region of 
the  Bm-3c  promoter  encompassing  -3495(GT)n,  -3457(GA)n  and  -3432poly-G 
polymorphism specific haplotypes could be defined (a section of the Bm-3c 5’-flanking 
region  with  loci  for  the  -3495(GT)n repeat,  -3457(GA)n repeat  and  the  -3432poly-G 
polymorphism  highlighted  is  illustrated  in  Fig.  4.12,  page  155).  However,  the 
complexity of this  region  of the  Bm-3c  promoter resulting  from  the  high  amount  of 
variation identified, the close proximity of the variation and the repetitive nature of the 
sequence  variants  meant  that  detailed  characterisation  of  all  haplotypes  was  not 
possible. This was mainly due to difficulties in sequencing analysis caused by the high 
heterozygosity  for  each  dinucleotide  repeat  at  -3495  and  -3457  (full  details  of the 
problems  encountered  in  characterisation  of haplotypes  are  discussed  in  Chapter  8 
section 8.4.4 as part of the genotyping analysis performed for a preliminary association 
study). However, some haplotypes could be clearly defined based on genetic analysis of 
subjects homozygous for the -3432poly-G polymorphism.  For example, it was evident 
that  if allele  SNPG1  was  present  at  position  -3432  the  native  5’  haplotype  detected 
always  consisted  of -3457(GA)2  :  -3495(GT)is  (Fig.  4.14a,  page  157).  Similarly,  if 
allele  SNPG2  was  present  at  position  -3432  the  common  5’  haplotype  detected  was 
always -3457(GA)2 : -3495(GT)20or2i (Fig. 4.14d, page 157). Haplotypes that it was
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Figure 4.15: Sequencing chromatograms to illustrate the multi-allelic -3432poly-G polymorphism in the Brn-3c 5’-flanking region. Alleles are grouped according 
to  length  of the  poly-G  repeat,  which  is underlined for each allele.  Chromatograms  shown  represent  sequencing of cloned PCR products  except for allele  (G)i3  the 
chromatogram shown represents direct sequencing of genomic DNA from an individual heterozygous for allele (G)i3: genotype (G)i3/(G)i2. The correct base calls for this 
sequence are  shown below the chromatogram for each allele.  In all cases  sequencing was performed using primer 3cP12-AS but for convenience the  sense  strand is 
shown.  Numbers above each sequencing chromatogram represent the automatic base numbering from the start of readable sequence using BioEdit Sequence Alignment 
Editor software.
1120  1130  1140
TOOTOGTOOOOGOGOCOTOGOTApossible  to  decipher  are  summarised  in  Table  4.4  and  discussed  in  greater  detail  in 
Chapter 8 section 8.4.4.
Table 4.4: Haplotypes of multi-allelic sequence variants identified at -3495, -3457 
and -3432 within the Brn-3c 5’-flanking region.
Haplotype -3495(GT)„ -3457(GA)„ -3432poly-G,
3 c/A 15 2 (G)8CG  (SNPG1)
3c/B 20 2 GGC(G)9  (SNPG2)
3c/C 21 2 GGC(G)9  (SNPG2)
3c/D 20 3 GGC(G)9  (SNPG2)
3c/E 16 1 GGT(G)8  (SNPG4)
3c/F - 1 (G)4C(G)6 (SNPG5)
3c/G 24 2 GGC(G)k) (SNPG6)
3c/H 19 1 (G),0
3c/I 19 1 (G)„
3c/J - 1 (G),2
Haplotypes identified are based on sequencing of cloned PCR products in pGEM®-T easy vector as part of an 
initial PCR-SSCP screen in 45 random individuals predominantly of Caucasian ethnicity and direct sequencing 
of  genomic  DNA  to  genotyped  the  -3432poly-G  polymorphism  for  a  preliminary  association  study.  All 
subjects used in the preliminary association study are Caucasian (see Chapter 8 for details of the association 
study).  It was not possible to establish  haplotype frequency due to difficulties in sequencing analysis; this is 
discussed in Chapter 8 section 8.4.5. Dashed line -  allele type inconclusive.
1604.5  General discussion.
To assess the extent of genetic variation at the Bm-3c locus and to search for common 
sequence variants mutation  scanning by PCR-SSCP  analysis  was performed on DNA 
isolated  from 45  random individuals.  A total of 15  PCR fragments were examined:  6 
covering the coding region and intron of the gene, 8 spanning 1.5Kb of the 5’-flanking 
region,  plus  one  fragment  designed to  include the dinucleotide (GT)n repeat  at -3495 
within the distal  5’-flanking region.  Using this  approach five novel  sequence variants 
were identified at the Bm-3c locus and the presence of two previously reported but non­
validated  sequence  variants  were  confirmed.  Thus,  confirming  the  suitability  of the 
PCR-SSCP  screen for detection of sequence variation.  Genetic variation at the Bm-3c 
locus is summarised in Fig. 4.16 and was deposited in the NCBI SNP database (NCBI 
SNP Cluster ID for each sequence variant is given in the legend to Fig. 4.16).
Of the novel sequence variants identified at the Bm-3c locus, two are simple bi- 
allelic single nucleotide substitutions: +90C>T within exon  1   and -386C>A within the 
5’-flanking region of the gene. The remaining novel variants are multi-allelic sequence 
variants:  two  variable  dinucleotide  (GT)n  repeats  -566(GT)n.23  and  -3495(GT)i5_2i, 24 
both within the 5’-flanking region of the gene and a highly complex polymorphism, a 
guanine repeat at position -3432 that in addition to displaying variations in length also 
exhibits  single  base  substitutions  within  the  repeat  (-3432poly-G  polymorphism).  A 
third dinucleotide repeat consisting of 5 CT repeats in the intron of Bm-3c (for reference 
sequence  see Appendix  B)  was  not  found  to  be variable based  on the results  of this 
PCR-SSCP  screen.  Analysis  of the  Bm-3c  locus by PCR-SSCP  analysis  followed by 
sequencing analysis also confirmed two previously reported but non-validated sequence 
variants:  a  single  nucleotide  substitution  at  -1391,  A>C  (NCBI  SNP  Cluster  ID: 
rsl368402) and a variable dinucleotide repeat at -3457, (GA)i-3 (NCBI SNP Cluster ID: 
rsl 3162234); both are within the 5’-flanking region of the Bm-3c gene.
The aim of this project is to  assess whether common  sequence variants in the 
Bm-3c gene are a risk factor for late onset hearing loss exhibited by a large proportion 
of  the  ageing  population  by  using  only  those  sequence  variants  where  there  is 
experimental  evidence  to  suggest  they  are  functional  in  subsequent  case-control 
association  analysis.  The  results  of this  PCR-SSCP  screen  coupled  with  sequencing 
analysis suggest that five sequence variants identified at the Bm-3c locus are common 
in the general population: -3495(GT)i5.2i,24,-3457(GA)i.3)-3432poly-G polymorphism, - 
1391A >C and -566(GT)  17.23;  all are within the 5’-flanking region of the Bm-3c gene.
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Figure 4.16 A schematic illustration of genetic variation identified at the Brn-3c locus.
Variants are numbered with respect to the first A of the ATG translation start site as +1  (indicated by a curved black arrow). Novel variants 
are highlighted in red.  Variants reported but  non-validated  at the onset  of this project are highlighted in black; of these -1391A >C and - 
3457(GA)n were confirmed as part of the PCR-SSCP screen and  *230G>A and  *424C>T were confirmed independently (the nature of the 
sequence variation is indicated below). Exons  1   and 2 are numbered and shown as pale yellow boxes, the intron as a red shaded box (not to 
scale). For simplicity the region of the Bm-3c promoter between -1391 and -3495 has been omitted as indicated by the two hatched lines. The 
sequence containing the three multi-allelic sequence variants at -3.4Kb is shown: the -3495(GT)n repeat and -3432poly-G polymorphism are 
highlighted in bold, the -3457(GA)n repeat in red bold, the allele shown is: -3495(GT)i9 : -3457(GA)!  : -3432(G)n which forms haplotype 3c/I 
(see Table 4.4). NCBI  SNP Cluster ID:  -3495(GT)n (rs28994882),  -3457(GA)n  (rs28994881), -3432poly-G polymorphism (rs29001168), - 
1391A>C  (rsl368402),  -566(0^  (rs28987086),  -386C>A  (rs28994880),  +90C>T  (rs28994879),  *230G>A  (rs891969)  ,  *424C>T 
(rs891970).Therefore,  in  accord  with  the  aim  of this  project  (see  section  2.0)  these  sequence 
variants  were  considered  candidates  for  subsequent  functional  analysis  and  are 
discussed further in the following Chapters, 5 to 7.
The two novel single nucleotide substitutions +90C>T and -386C>A were only 
identified in 2 and  1   subjects respectively, of the 45  subjects examined by PCR-SSCP 
analysis and in each case in the heterozygous  state.  This suggests that these sequence 
variants  are  rare  in  the  general  population  and  since  the  purpose  of this  project  is 
common genetic variation these sequence variants were not pursued further within this 
project. It was considered that the -386C>A substitution could be an artefact of the PCR 
amplification since it was only identified in one individual. However, repeating the PCR 
amplification and subsequent sequencing analysis ruled out this possibility confirming it 
is a genuine sequence variant, albeit, a rare variant and unlikely to have much impact on 
late  onset  hearing  loss  risk  in  the  general  population.  The  +90C>T  substitution  is  a 
synonymous  sequence  variant  and  does  not  change  an  amino-acid  and  therefore,  is 
unlikely to have an affect on the function of Bm-3c.  Although, it cannot be ruled out 
that  this  sequence  variant  may  have  an effect  on  alternative  splicing  of Bm-3c  in 
individuals  who  carry  this  sequence  variant;  both  Bm-3a  and  Bm-3b  the  additional 
members  of the  Bm-3  family  are  known  to  undergo  alternative  splicing  (Liu  et  al, 
1996).  However,  the  +90C>T  sequence  variant  appears  rare  and  even if found  to  be 
functional its impact on late onset hearing loss risk in the general population would be 
small.
At the onset of this project two single nucleotide substitutions were reported 3’ 
of the translation termination codon in the Bm-3c 3’-flanking region:  *230G>A (NCBI 
SNP  Cluster  ID:  rs891969)  and  *424C>T  (NCBI  SNP  Cluster  ID:  rs891970).  These 
sequence  variants  were  non-validated  and  their  significance  with  respect  to  Bm-3c 
regulation was unknown. Due to the amount of common genetic variation identified at 
the Bm-3c  locus by the PCR-SSCP  screen that were  good  candidates  for subsequent 
functional analysis (2  sequence variants within  1.5Kb of the Bm-3c 5’-flanking region 
and  3  multi-allelic  sequence  variants  in  close  proximity  at  a  highly  repetitive  and 
polymorphic region of the Bm-3c promoter at -3.4Kb) it was decided not to pursue the 
non-validated sequence variants within the 3’-flanking region of Bm-3c further within 
the time constraints of this project.
During  the  course  of  this  project  both  *230G>A  (NCBI  SNP  Cluster  ID: 
rs891969)  and  *424C>T  (NCBI  SNP  Cluster  ID:  rs891970)  within  the  3’-flanking 
region of Bm-3c have been validated independently with a rare allele frequency of 0.27
163and  0.283  respectively,  in  samples  of Caucasian  ancestry  (see  NCBI  dbSNP  Human 
Build  126;  http://www.ncbi.nlm.nih.gov/project/SNP/).  Therefore,  given  that  these 
sequence variants are common it should be considered that they may be a risk factor for 
late  onset  hearing  loss  in  the  general  population.  It  is  possible  they  may  act  as 
downstream  modulators  of  Bm-3c  promoter  activity  and  cause  inter-individual 
differences in Bm-3c expression.  Indeed, recently a nuclear factor of activated T cells 
CCAAT/enhancer-binding  protein  (NFAT.C/EPB)  composite  element  has  been 
identified in the Bm-3c 3’flanking region (Yang et al, 2003). A search of the NCBI SNP 
database revealed that no previously reported single nucleotide substitutions intercepted 
this element but the *230G>A substitution is only 5bp downstream. The NFAT.C/EPB 
composite  element  was  originally  identified  as  a  novel  regulatory  enhancer  in  the 
immediate  upstream  region  of  the  peroxisome  proliferator-activated  receptor-y2 
promoter  and  it  was  through  subsequent  promoter  analysis  that  highly  similar 
derivatives  of  the  NFAT.C/EPB  composite  element  were  found  in  the  regulatory 
regions of several other genes including Bm-3c (Yang et al, 2003). Electromobility shift 
analysis  (EMSA)  using  nuclear  extracts  prepared  from  COS  cells  transfected  with 
NFATc4 and / or C/EBPa expression constructs suggests that both NFAT and C/EPB 
bind  to  the  NFAT.C/EPB  composite  element  in  the  Bm-3c  3’-flanking  region  and 
reporter gene analysis in BHK cells suggests that this element is functional (Yang et al, 
2003).  However, the significance of this element on Bm-3c expression in sensory hair 
cells  is  not  known.  Nevertheless,  these  findings  do  raise  the  possibility  that  the 
NFAT.C/EPB composite element in the Bm-3c 3’-flanking region could be functional 
in  sensory hair  cells  and  important  for regulation  of the  Bm-3c  gene.  Moreover,  the 
finding  that  the  common  *230G>A  substitution  is  only  5bp  downstream  raises  the 
possibility that this sequence variant could modify protein binding to the NFAT.C/EPB 
composite element and thus have an affect on regulation of Bm-3c; protein binding to 
cis-acting elements is influenced by adjacent flanking sequence (Dawson et al,  1996a). 
It  should  also be  considered that  *230G>A  and  *424C>T may be  important  in post- 
transcriptional  control  of Bm-3c regulation for example, by affecting mRNA stability. 
However, the 3’  end of the mRNA transcript for Bm-3c has not be defined in humans 
and it is not known whether *230G>A and  *424C>T are in the 3’-UTR of Bm-3c.  If 
*230G>A and  *424C>T are found to manifest in the 3’-UTR of Bm-3c it is possible 
they may affect stability of the Bm-3c mRNA transcript by modifying protein binding 
to important cis-acting elements within the 3’UTR of Bm-3c. However, this can only be 
speculated upon at present.
1644.6  Conclusion.
In conclusion, the data presented here within this thesis is the first comprehensive report 
of genetic  variation  in  the  Bm-3c  gene,  a  hair  cell  pro-survival  factor  and  a  good 
candidate  gene  for  late  onset hearing  loss.  Mutation  scanning of the Bm-3c  gene by 
PCR-SSCP analysis has identified five novel sequence variants at the Bm-3c locus and 
confirmed the presence of two that were previously reported but non-validated (see Fig. 
4.16, page  162).  Of the variants identified and confirmed,  five appear common in the 
general population and are candidates for functional analysis. Interestingly, all common 
variants are within the 5’-flanking region of the Bm-3c gene raising the possibility they 
could  modulate  regulation  of Bm-3c  leading  to  inter-individual  variations  in  Bm-3c 
expression.  Common  sequence  variants  that have  a  functional  affect on regulation of 
Bm-3c could be a risk factor for late onset hearing loss; this line of analysis is discussed 
in the following chapters.
1655.0 Functional Characterisation Of The -3432poly- 
G Polymorphism At The Brn-3c Locus.
5.1  Introduction.
Mutation  scanning  of the  Bm-3c  gene  by  PCR-SSCP  analysis  identified  five  novel 
sequence  variants  at  the  Bm-3c  locus  and  confirmed  the  presence  of two  that  were 
previously reported but non-validated (see Fig. 4.16, section 4.5, page  162). One novel 
sequence variant was identified within exon one of the Bm-3c gene, +90C>T, but this 
sequence variant appeared rare in the general population and was found to constitute a 
synonymous variant with both alleles  encoding for the amino acid alanine and so was 
not pursued further. The remaining six sequence variants were identified within the 5’- 
flanking region of the Bm-3c gene and of these five: -3495(GT)i5.2i, 24, -3457(GA)i-3, - 
3432poly-G polymorphism, -1391 A>C and -566(GT)n.23 appear common in the general 
population (based on PCR-SSCP analysis on 45 individuals; see section 4.5).
Common sequence variants are the basis of the CD:CV hypothesis that proposes 
they underlie susceptibility to common disease (for reviews see Smith and Lusis, 2002; 
Wright  et  al,  2003).  It  is  possible  than  any  or  a  combination  of common  sequence 
variants identified in the Bm-3c 5’-flanking region could be a risk factor for late onset 
hearing  loss  exhibited  by  a  large  proportion  of  the  ageing  population;  they  could 
modulate regulation of the Bm-3c gene leading to inter-individual variations in Bm-3c 
expression.  Indeed,  sequence variants that manifest within the promoter of a gene can 
have an adverse affect on expression of the downstream gene by disrupting existing or 
creating novel cis-acting elements and hence, modify the binding of trans-acting factors. 
Certainly,  there  is  increasing  evidence  that  functional  sequence  variants  involving  a 
single  nucleotide  change  in  the  DNA  sequence  within  gene  regulatory  regions  are 
involved  in  susceptibility  to  common,  complex  disease.  For  example,  a  C  to  T 
substitution  at  -1562  in  the  matrix  metalloproteinase-9  (MMP-9)  promoter  that  is 
associated with  severity of coronary atherosclerosis modifies the binding affinity of a 
nuclear protein at -1562 in the MMP-9 promoter such that greater promoter activity is 
observed  for the T allele compared to the C  allele when tested using a reporter gene 
assay (Zhang et al,  1999).  Similarly,  a G to A substitution at -112 in the uteroglobin- 
related protein 1   (UGRP1) promoter that modifies nuclear protein binding is associated
166with an increased risk of asthma (Niimi et al, 2002). The G allele has a greater affinity 
for  a  nuclear  protein  compared  to  the  A  allele  and  this  is  consistent  with  a  24% 
reduction  in  UGRP1  promoter  activity observed  for the  A  allele  compared  to  the  G 
allele when examined by reporter gene analysis. Likewise, a G to A substitution at -455 
in the p-fibrinogen promoter, which modifies nuclear protein binding, has a functional 
affect on interleukine-6 stimulated activity of the p-fibrinogen promoter and the -455A 
allele  has  been  consistently  associated  with  elevated  plasma  fibrinogen  levels  and 
atherothrombotic disease (for review see Green, 2001). Finally, genetic variation in the 
PAI-1  gene promoter has for some time been known to affect regulation of the PAI-1 
gene;  the  4G/5G  insertion  /  deletion  at  -675  is  thought  to  modify  binding  of  a 
transcriptional  repressor  (Dawson  et  al,  1993)  and  this  sequence  variant  has  been 
associated  with  susceptibility  to  cardiovascular  disease  (for  reviews  see  Nordt  et  al, 
2001; Dellas and Loskutoff, 2005).
Therefore, to determine whether any of the common sequence variants identified 
within  the  5’-flanking region  of the  Bm-3c  gene  underlie  susceptibility to  late  onset 
hearing  loss,  in  the  first  instance,  functional  analysis  will  be  performed  to  assess 
whether they have an affect on regulation of the Bm-3c gene. Measures will be taken to 
assess  whether  any  of  these  common  sequence  variants  modify  the  binding  of 
transcription  factors  and  whether this  translates  into  functional  differences  in  Bm-3c 
promoter activity.  Functional  sequence variants will then be used in subsequent case- 
control association analysis to assess whether they are a genetic risk factor for late onset 
hearing loss.
5.1.1  The electrophoretic mobility shift assay.
To assess whether common sequence variants identified within the promoter of the Bm- 
3 c  gene  modulate  the  binding  of  a  transcription  factor  or  factors,  protein-DNA 
interactions  will  be  investigated  by  use  of the  electrophoretic  mobility  shift  assay 
(EMSA).  Originally  devised  by  Fried  and  Crothers  (1981)  and  Gamer  and  Revzin 
(1981)  the  EMSA  assay  provides  a  rapid  and  simple  means  for  detecting  proteins 
binding  to  specific  DNA  sequences.  EMSA  analysis  involves  the  incubation  of 
radiolabelled DNA fragments as probes with whole cell or nuclear protein extracts and 
is  based  on  the  principle  that  protein-DNA  complexes  are  resolved  more  slowly by 
electrophoresis  through  non-denaturing  polyacrylamide  gels  than  free  DNA  probe 
alone. Oligonucleotide probes can be devised that contain either the wild-type or variant
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binding  can  be  assessed  and  visualised  by  autoradiography.  If  a  sequence  variant 
induces differential protein binding steps can then be taken to assess the specificity of 
the interaction and the relative affinity of each allele for the protein(s) involved.  This 
analysis  can  be  followed  by  measures  to  identify  the  protein(s)  binding  including 
competition  analysis  with  known  transcription  factor  consensus  sequences  and  /  or 
supershift analysis with specific antibodies.
5.1.2  The reporter gene assay.
EMSA  analysis  is  very useful  for determining  sequence-specific protein binding  and 
when  used  in  combination  with  supershift  analysis  identification  of  the  proteins 
involved.  However,  determination of sequence-specific protein binding does not mean 
that the  cis-acting  element in  question  is  functional.  Therefore,  if a sequence variant 
modulates the binding of a specific transcription factor this should always be followed- 
up with  functional  analysis to  assess whether the differential  protein binding actually 
has an affect on regulation or expression of the gene, or both. The examination of the 
effect  of sequence  variation  on  gene  regulation  can  be  achieved  in-vitro  by  use  of 
reporter gene  assays.  For a bi-allelic  sequence variant in the promoter of a gene this 
generally involves sub-cloning the promoter sequence under test upstream of a reporter 
gene carried in an expression vector and making two constructs, one containing the wild- 
type  allele  and  the  other  the  variant  allele.  These  reporter  gene  constructs  are  then 
transfected into a suitable cell line and assayed for reporter gene expression; in principle 
the amount of reporter gene expression being dependent on the regulatory sequence and 
hence,  the  allele  cloned  upstream  of  the  reporter  gene.  Although,  one  common 
drawback of the reporter gene assay is that differences in levels of reporter gene activity 
between two constructs can arise not because of functional differences in activity of the 
promoter  sequence  under  test  but  because  of  differences  in  transfection  efficiency 
between the constructs. However, this problem can be minimised by co-transfection of 
an internal  control reporter gene construct to normalise for differences in transfection 
efficiency  within  and  between  experiments.  There  are  many  different  types  of 
commercially available reporter gene systems to study gene regulation. One of the most 
common  reporter  genes  used  in  mammalian  cells  is  the  firefly  (Photinus  pyralis) 
luciferase enzyme (de Wet et al,  1987). Reporter gene systems incorporating luciferase 
enzymes  exploit  the  fact  that  these  enzymes  catalyse  bioluminescent  reactions  and
168produce photons of light, which can be quantified with a luminometer. Thus, producing 
rapid and  sensitive reporter gene assays.  For functional  analysis of common sequence 
variants  identified  within  the  Bm-3c  promoter  the  dual-luciferase®  reporter  assay 
system  (Promega)  was  chosen.  This  dual  system  has  an  added  advantage  in  that  it 
allows for the sequential assay of both firefly luciferase (the experimental reporter gene 
joined  to  the  promoter  sequence  under  test)  and  sea  pansy  (Renilla  reniformis) 
luciferase (the internal control reporter gene) within a single sample (Sherf et al,  1996; 
Wood,  1998).  Firefly and renilla luciferases are evolutionary diverse and are not alike 
structurally  nor  in  substrate  specificity.  Consequently,  it  is  possible  to  distinguish 
between their individual bioluminescent reactions in a single sample. By using the dual- 
luciferase®  reporter  assay  system  (Promega),  “the  luminescence  from  the  firefly 
luciferase reaction can be quenched while in parallel activating the luminescent reaction 
of renilla luciferase” (Sherf et al, 1996; Wood, 1998). Normalising the activity of firefly 
luciferase (the experimental  reporter)  to  that of renilla  luciferase (the internal  control 
reporter)  intra-  and  inter-  experimental  variation  resulting  from  differences  in 
transfection  efficiency  or  cell  viability  can  be  reduced  and  variability  arising  from 
preparation of extracts  for assay can be removed.  Thereby,  allowing  for accurate and 
reliable interpretation of experimental data generated.
It is important to  consider that this  in-vitro methodology incorporating EMSA 
analysis in combination with the reporter gene assay is limited in that it cannot provide 
evidence and  establish differences  in gene expression in-vivo (the limitations of these 
techniques are discussed further in section 5.8.1). However, this in-vitro approach does 
provide  insight  into  the  possible  functional  effect  of  sequence  variation  on  gene 
regulation and can shed light on the molecular pathway(s) involved.
5.1.3  The  OC-2  cell  line  used  for  functional  analysis  in  this  project: 
background.
The OC-2  (organ  of Corti-2)  cell  line derived  from inner ear sensory epithelium was 
used for functional analysis of common sequence variants in the Bm-3c gene and kindly 
provided  by  Professor  Matthew  Holley,  University  of Sheffield.  The  OC-2  cell  line 
along  with  the  OC-1  cell  line  is  derived  from  the  H-2Kb-teA58  transgenic  mouse, 
Immortomouse (Rivolta et  al,  1998).  Both OC-1  and OC-2  cell  lines  are of immense 
value  to  auditory  research.  Hair  cells  are  present  in  extremely  low  numbers  in  the 
mammalian  cochlea (in the region of 16,000  are present per cochlea in humans)  and
169experimentally they are inaccessible. These factors taken together with the fact that hair 
cells  do  not naturally proliferate  in-vitro have been  a major hindrance to progress  in 
auditory research.
The Immortomouse carries a conditional immortalizing transgene, a temperature 
sensitive  mutant  of the  tumour  antigen  from  the  simian  virus  40,  tsA58,  under  the 
control of the mouse major histocompatibility complex (MHC) H-2K  class 1  promoter. 
The  MHC  class  1   promoter  directs  expression  of the  immortalizing  gene  to  a broad 
range of tissues and expression can be stimulated to high levels in almost all cell types 
by  exposure  to  y-interferon  (y-IFN)  (Jat  et  al,  1991).  Hence,  cells  derived  from 
Immortomouse  and  cultured  under permissive  conditions:  33°C  in the presence  of y- 
IFN,  will  continue  to  proliferate.  If the  culture  conditions  are  changed  to  the  non- 
permissive conditions by withdrawal of y-IFN and increasing the temperature to 39°C, 
the  cells  will  cease  proliferation  and  start to  differentiate;  the  tsA58  gene product is 
degraded upon  change to the higher temperature (Jat et al,  1991).  The organ of Corti 
derived  cell  lines  were  isolated by inducing  expression  of the  immortalizing gene  in 
organotypic  cultures  of  developing  organ  of  Corti  (by  incubation  at  33°C  in  the 
presence of y-interferon, y-IFN) at El 3 immediately before hair cells undergo their final 
mitosis  (Rivolta et al,  1998).  Characterisation of the OC-1  and  OC-2  cell lines under 
immortalizing  and  differentiating  conditions  reveals  that  each  expresses  hair  cell 
specific  markers  (Rivolta  et  al,  1998).  Under  immortalising  conditions  OC-2  cells 
express Bm-3c, the a9 subunit of the nicotinic acetyl-choline receptor (a9AChR) and 
the cytoskeletal hair cell  components fimbrin, myosin VI and myosin Vila.  Under the 
same conditions in OC-1  cells, there is little expression of a9AChR and myosin Vila 
and  Bm-3c  mRNA  can  hardly  be  detected  however  under  differentiating  conditions 
these hair cell markers are upregulated. Consequently, it is suggested that OC-1  cells are 
derived  from  an  earlier  stage  of development  compared  to  OC-2.  In  particular,  it  is 
proposed that OC-1  cells were immortalized at a stage after specification of the hair cell 
fate but just before these committed hair cells begin to  express Bm-3c (Rivolta et al, 
1998).
Since their isolation in  1998, both OC-1  and OC-2 cell lines have been used in 
many aspects of functional auditory research (for review see Rivolta and Holley, 2002). 
OC-1  and OC-2 cells have been used to identify functional regions of Bm-3c to aid our 
understanding  of how  Bm-3c  may  function  in  inner  ear  sensory  hair  cells,  and  to 
examine the mechanism whereby Barhll, a hair cell survival factor, may regulate gene 
transcription in hair cells (Sud et al, 2005; see section 1.9.2). In humans, an 8bp deletion
170in Bm-3c is responsible for DFNA15 (Vahava et al, 1998), and use of the OC-2 cell line 
has helped elucidate the effect of the 8bp deletion on the function of the Bm-3c protein 
(Weiss et al, 2003, Clough et al, 2004; see section 1.8.2). Importantly, use of both these 
cell lines has helped provide evidence to suggest that Bm-3c directly regulates BDNF 
and NT-3  transcripts in hair cells (Clough et al, 2004;  see section  1.9.2).  Since OC-2 
cells strongly express Bm-3c under immortalizing conditions it was reasoned that trans­
acting factors needed for Bm-3c expression would be present. Therefore, the OC-2 cell 
line  was  regarded  a  suitable  medium  to  characterise  common  sequence  variants 
identified in the Bm-3c promoter and was used for preparation of nuclear extract for use 
in EMSA analysis and for performing transient transfection reporter gene assay.
In summary, identification of a common sequence variant or common haplotype 
in the Bm-3c promoter that is functional would be highly significant as it may be a risk 
factor for late onset hearing loss; a factor that can be tested by case-control association 
analysis.  It would also pave way for understanding how the Bm-3c gene, an important 
hair  cell  pro-survival  factor is  regulated  at the  level  of transcription -  something for 
which currently very little is known.
1715.2  The  -3432polv-G  polymorphism  in  the  Brn-3c  promoter: 
similarity to  a  complex  polv-G  length  polymorphism  identified 
in the tissue kallikrein promoter.
The  -3432poly-G  polymorphism  in  the  Bm-3c  promoter  is  extremely  complex 
exhibiting  multiple  variations  in  length  coupled  with  single  nucleotide  substitutions 
within  the  poly-G  repeat  (see  Table  4.3,  section  4.4.2,  page  156).  Given  the  unique 
complexity  of the  -3432poly-G  polymorphism  a  literature  search  was  undertaken  to 
establish whether any similar polymorphic  elements had been described.  This  line  of 
analysis revealed that the -3432poly-G polymorphism is very similar to a poly-G length 
polymorphism that has been identified at -121  to -13 lbp in the promoter of the tissue 
kallikrein (KLK1) gene (Song et al,  1997; Yu et al, 2002). The KLK1  gene encodes a 
serine proteinase and is the main enzyme responsible for kinin generation in the kidney. 
Kinins are potent vasodilators and have long been implicated in the pathophysiology of 
human  disease  including  essential  hypertension  (for  review  see  Campbell,  2001). 
Currently, on a mixed ethnic background 15 alleles have been identified for the poly-G 
length  polymorphism  in  the  KLK1  promoter  including  similar  poly-guanine  alleles 
(guanine  number  ranging  from  10  to  13)  and  alleles  that  exhibit  similar  single 
nucleotide substitutions to those identified in the Bm-3c promoter.  A summary of the 
poly-G  alleles  identified  in  the  KLK1  promoter  is  shown  in  Table  5.1  and  for 
comparison the similar poly-G alleles identified in the Bm-3c promoter are also shown.
Reporter gene assays in the human embryonic kidney 293  cell line have shown 
that the KLK1  poly-G polymorphism has a functional effect on KLK1  promoter activity 
with specific poly-G alleles exhibiting significantly lower promoter activities compared 
to  others.  In  addition,  case-control  association  analysis  has  shown  that  the promoter 
allele of the KLK1  gene containing a poly-G repeat of 12  guanines is associated with 
hypertensive  end  stage  renal  disease  (Yu  et  al,  2002).  These  findings  raise  the 
possibility that the similar poly-G polymorphism at -3432 in the Bm-3c promoter could 
be  functional  and  hence,  a  risk  factor  for  late  onset  hearing  loss.  To  explore  this 
possibility the -3432poly-G polymorphism was functionally characterised and this line 
of analysis is discussed in the subsequent sections of this chapter.
172KLK1 poly-G allele 
(name)
DNA Sequence Abbreviation Similar Brn-3c poly-G allele 
(abbreviation)
Brn-3c poly-G allele 
(name)
5’ AT  C GG  AGGGGGGGGGGC  A  ATT 3’ GGA(G)io (G)io (G)io
B 5’ ATCGGAGGCGGGGGGGCAATT 3’ GGA GGC(G)7 GGC(G)9 SNPG2
C 5’ ATC GGGGGGGGGGGGGC A  ATT 3’ (G)13 (G)i3 (G)i3
D 5’ ATC  GGGGC GGGGGGGGC  A  ATT 3’ (G)4C(G)8 (G)4C(G)6 SNPG5
E 5’ ATCGGAGGGCGGGGGGCAATT 3’ GGA (G)3C(G)6 (G)4C(G)6 SNPG5
F 5’ ATCGGAGCGGGGGGGGGCAATT 3’ GGA GC(G)9 GGC(G)9 SNPG2
G 5’ ATCGGAGCGGGGGGGGCAATT 3’ GGA GC(G)8 GGT(G)8 SNPG4
H 5’ ATC  GGAGGGGGGGGGGGC  AATT 3’ GGA (G)n (G)„ (G)n
I 5’ ATC GGAGGGGGGGGGC  AATT 3’ GGA (G)9
J 5’ ATC GG  A  GGGGGGGGC A  ATT 3’ GGA (G)8
K 5’ ATCGGAGGGGGGGGGGGGCAATT 3’ GGA(G)12 (G)i2 (G)12
M 5’ AT  C GG  AGGGGGGGGGGGGGC A  ATT 3’ GGA(G)13 (G)i3 (G)i3
P 5’ ATCGGAGGGCGGGGGCAATT 3’ GGA (G)3C(G)5 (G)4C(G)6 SNPG5
Q 5’ ATCGGGGGGGGGGGGCAATT 3’ (G)i2 (G),2 (G)l2
R 5’ ATCGGAGGGGGGGGGCAATT 3’ GGA (G)9CGG (G)8cg SNPG1
Table 5.1 A summary of the poly-G alleles identified at -131 in the KLK1 promoter and comparison with similar poly-G alleles identified at - 
3432  in  the  Brn-3c  promoter.  Poly-G  alleles  in the  KLK1  promoter  were  identified  on  a  mixed  ethnic  background;  alleles  found  in  Caucasian 
subjects are highlighted in red (Song et al,  1997; Yu et al, 2002). All poly-G alleles in the Bm-3c promoter were identified in Caucasian subjects.
u>5.3  The  -3432  polv-G  polymorphism  modulates  the  binding  of 
OC-2 nuclear proteins.
In order to investigate whether the -3432poly-G polymorphism modifies the binding of 
nuclear proteins to this region of the Bm-3c promoter EMSA analysis was performed 
using nuclear extracts from OC-2  cells;  an inner ear sensory epithelial cell line which 
expresses  Bm-3c  (further  information  on  the  OC-2  cell  line  is  discussed  in  section 
5.1.3).  Synthetic oligonucleotides spanning the -3432poly-G polymorphism in the Bm- 
3c promoter were devised to represent the most common alleles and annealed to form 
double stranded probes (see Table 3.2, method section 3.2.18).  For initial analysis two 
probes were used representing either poly-G allele SNPG1  or SNPG2, the two common 
alleles that were identified as part of the initial PCR-SSCP screen. To maximise chances 
of detecting  differential  protein  binding  the  temperature  of the  incubation  and  the 
amount of nuclear extract added to the binding reaction were varied (see Fig. 5.1).
Lanes  1-3  (Fig.  5.1)  show  free  probe  in  the  absence  of nuclear  extract;  no 
retarded  bands  are  visualised.  In  the  presence  of nuclear  extract  a  complex  banding 
pattern  is  observed  as  binding  of nuclear  proteins  to  free  probe  forms  protein-DNA 
complexes with a retarded migration compared to free probe alone (Fig. 5.1, comparing 
lanes  4-15  with  1-3).  At  room  temperature  a  multi-banded  shifted  protein-DNA 
complex of low mobility, labelled B (Fig.  5.1) and a shifted protein-DNA complex of 
greater  mobility,  labelled  E  (Fig.  5.1)  are  observed  at  analogous  positions  on  both 
SNPG1  and SNPG2 probes but, they are less prominent on probe SNPG2 compared to 
probe SNPG1  and only clearly visible on probe SNPG1 when a high amount of nuclear 
extract is used (Fig.  5.1  comparing lanes 7 and 8 with 4). This is in addition to several 
complexes of lower mobility, which appear common to both probes.  It is possible that 
the same protein(s) is binding to SNPG1  and SNPG2 probes to form complex B and a 
different protein of lower molecular weight is binding to both probes to form complex 
E.  However,  it is  important to  realise that two  different proteins  could  give identical 
mobility  shifts  depending  on  the  nature  of  their  respective  protein-DNA  complex 
conformations. In addition, a shifted protein-DNA complex does not necessarily consist 
of  one  protein  bound  to  DNA.  Proteins  can  bind  DNA  sequences  as  monomers, 
homodimers  or  heterodimers;  a  shifted  band  observed  upon  EMSA  analysis  could 
represent  any  of  these.  All  these  factors  must  be  taken  into  consideration  when 
interpreting data generated through EMSA analysis.
174In contrast to the observations at room temperature, when the binding reactions 
are performed on ice, a shifted protein-DNA complex, labelled A (Fig. 5.1) is observed 
on probe SNPG1  but not probe SNPG2. Instead a complex of greater mobility, labelled 
C (Fig. 5.1) is observed on the SNPG2 probe but not probe SNPG1 (Fig. 5.1 comparing 
lanes  10  and  11).  Increasing  the  protein  concentration  intensifies  the  formation  of 
complex A on probe SNPG1  and results in the formation of complex C, albeit to less 
extent (Fig. 5.1  comparing lanes 10 and 13). In contrast, although increasing the protein 
concentration intensifies the formation of complex C on probe SNPG2, complex A is 
not  observed  (Fig.  5.1  comparing  lanes  11  and  14).  Neither  complex  A  or  C  are 
observed on  SNPG1  or SNPG2 probes  if the binding reaction  is  carried out at room 
temperature  (shifted protein-DNA complex labelled D  is discussed in section 5.3.1.2, 
page 181 and 5.6, page 210).
Taken together,  these results show a complex banding pattern on  SNPG1  and 
SNPG2  probes  that  is  clearly  temperature-dependent  and  subject  to  the  amount  of 
nuclear extract used.  Moreover, they suggest that the different poly-G  alleles  SNPG1 
and  SNPG2  modulate  the  binding  of nuclear  proteins  to  this  region  of the  Bm-3c 
promoter.
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Figure  5.1  Differential  protein  binding  to  -3432poly-G  alleles  SNPG1  and  SNPG2.  Radiolabelled 
oligonucleotides  representing  poly-G  alleles  SNPG1  and  SNPG2  were  incubated  on  ice  or  at  room 
temperature in the presence of increasing amounts of OC-2 nuclear extract as indicated. In the absence of 
nuclear extract no retarded bands are visualised (lanes 1-3). In the presence of nuclear extract (lanes 4-15) 
shifted protein-DNA complexes are observed and are denoted by the arrows: A, B, C, D and E. [(G)9 was 
later determined to be a sequencing error and not a true allele].
175Initial  EMSA  analysis  on  the  -3432poly-G  polymorphism  shows  differential 
protein  binding  to  alleles  SNPG1  and  SNPG2  notably  formation  of nuclear protein- 
DNA complex A is only observed on probe SNPG1  and not probe SNPG2 (see Fig. 5.1 
lanes  10  and  11,  13  and  14).  To  investigate  this  further  radiolabelled  probes  of the 
additional  common  poly-G  alleles  were  incubated  with  OC-2  nuclear  extracts  (Fig. 
5.2a).  This  approach  showed  a  protein-DNA  complex  is  observed  on  the  additional 
poly-G probes, including probe SNPG2, at an analogous position to that of complex A 
on probe  SNPG1;  presumably all probes  are binding the  same protein.  However,  the 
intensity of complex A appears greater for probe SNPG1  compared to the other poly-G 
probes (Fig.  5.2a comparing lane  1   across all lanes). This is particularly evident when 
comparing  the  intensity  of  complex  A  on  probes  SNPG1  and  SNPG2  (Fig.  5.2a 
comparing lane  1   with 2) suggesting that the nuclear protein or proteins (for simplicity 
one protein will be assumed to bind hereafter referred to as nuclear protein A) involved 
in the formation of complex A has a greater affinity for allele SNPG1  compared to the 
other poly-G alleles examined. However, a shortcoming of EMSA analysis is that there 
is no internal  control  for gel loading.  When differences in band intensity are observed 
between  two  probes,  or more  such  as  observed here  for nuclear protein A  (Fig.  5.2a 
comparing band A across all lanes) the possibility of pipetting errors upon gel loading 
or  slight  differences  in  probe  concentration  must  be  taken  into  consideration  when 
attempting  quantitative  interpretations.  Therefore,  to  obtain  further  clarification 
competition  analysis was performed to test the relative affinity of alleles  SNPG1  and 
SNPG2 for nuclear protein A.
Increasing amounts of unlabelled probe SNPG1  (Fig 5.2b, lanes 2-4) or SNPG2 
(Fig. 5.2b, lanes 5-7) to compete with SNPG1 probe for binding nuclear protein A were 
examined.  If nuclear protein A has a greater affinity for the SNPG1  allele compared to 
SNPG2 one would expect a lower molar excess of unlabelled SNPG1  probe compared 
to unlabelled SNPG2 probe to compete with labelled SNPG1  probe for binding nuclear 
protein A. If the affinity of nuclear protein A for allele SNPG1  is particularly high even 
a high molar excess of unlabelled  SNPG2 probe (for example,  1000-fold excess) may 
not be able to  compete with labelled  SNPG1  probe for binding nuclear protein A.  In 
agreement with  these predictions  this  approach revealed that allele  SNPG1  is  able to 
strongly  compete  for  nuclear  protein  A;  the  shifted  complex  is  abolished  at  25-fold 
excess (Fig5.2b, comparing lanes 1   and 2). In contrast allele SNPG2 is unable to induce 
any significant reduction of the shifted complex at this level (Fig 5.2b, lanes  1   and 5). 
Even at 100-fold excess, the unlabelled SNPG2 probe showed only partial competition
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Figure  5.2  The  SNPG1  allele  of the  -3432poly-G  polymorphism  has  a  higher  affinity  for  OC-2 
derived  nuclear  protein  A  than  allele  SNPG2.  The  location  of nuclear protein-DNA  complex  A  is 
denoted by the arrow, (a) Radiolabeled oligionucleotides of the common poly-G alleles were incubated 
on ice with 8-lOpg of OC-2 nuclear extract, (b) The SNPG1  probe was incubated with 8-10pg of OC-2 
nuclear extract in the absence of competitor (lane  1), or in the presence of increasing amounts of either 
unlabeled SNPG1  (lanes 2-4) or unlabeled SNPG2 (lanes 5-7).
that  is  still  not  complete  at  500-fold excess  (Fig  5.2b,  comparing  lanes  1,  6  and  7). 
These  results  confirm  that  nuclear protein A  has  a greater affinity  for allele  SNPG1 
compared to  SNPG2 and indicate that the  interaction of nuclear protein A with allele 
SNPG1  is  sequence  specific  (the relative  affinity of the  additional  poly-G  alleles  for 
nuclear protein A is discussed further in section 5.3.2, page 186).
5.3.1  Identification of nuclear protein A that exhibits differential binding to 
the -3432 polv-G polymorphic site.
In  an  attempt  to  identify  nuclear  protein  A  Matlnspector  software 
(www.genomatix.de/products/MatInspector/index.html)  was  used  to  screen  poly-G 
allele SNPG1  and all common poly-G alleles for putative transcription factor binding 
sites.  Matlnspector  is  a  very  useful  bioinformatic  tool  to  search  any  specific  DNA 
sequence for potential transcription factor binding sites (Quandt et al,  1995; Cartharius 
et  al,  2005).  It  draws  on  a  large  database  of known  consensus  transcription  factor 
binding sites and nucleotide deviations from these as a set of weight matrices. Sequence 
similarity  between  the  input  sequence  and  the  consensus  binding  site  for  a  given 
transcription factor is recorded as a series of two scores: a core similarity and a matrix
177similarity score. The former is “the score of the highest conserved positions of a matrix 
match”  and  the  latter  is  “the  score  of the  complete  matrix  match”  (Cartharius  et  al, 
2005).  Analysis performed using this  software cannot be taken as definitive evidence 
that a transcription factor binds a particular DNA sequence but rather it provides a guide 
to the likelihood of transcription factor binding.
The results of this analysis did not reveal any transcription factor binding sites 
that exhibited a unique matrix similarity to the SNPG1  allele sequence compared to the 
other  poly-G  allele  sequences  (see  Appendix  C).  Therefore,  candidate  transcription 
factors  chosen  for  further  investigation  were  based  on  high  matrix  similarity  of the 
SNPG1  allele sequence and the additional poly-G allele sequences to known consensus 
sequences.  Two  candidates  were  selected  with  high  matrix  similarity  scores  to  the  - 
3432poly-G polymorphic region: stimulating protein 1   (SP1) and early growth response 
factor-1   (Egr-l/Krox-24/NGFI-A).  The  transcription  factor  core  promoter  binding 
protein (CPBP/ZBPF/ZF9/KLF6) was also selected, as this exhibited a matrix similarity 
to  the  -3432poly-G  polymorphic  region  but  not  the  SNPG1  allele  sequence  (see 
Appendix C). Interestingly, SP1  a well-characterised transcription factor known to bind 
to  GC-rich  elements  (for review  see  Kaczynski  et  al,  2003)  exhibited  a high  matrix 
similarity  across  all  poly-G  allele  sequences  examined  with  the  exception  of allele 
SNPG4 (see Appendix C).
In  the  first  instance,  in  an  attempt  to  identify  nuclear  protein  A  competition 
analysis  was  performed  using  synthetic  oligonucleotides  for  each  of the  following 
consensus  transcription  factor  binding  sites:  SP1,  Egr  and  CPBP  (for  sequence  see 
Table 3.2 method section 3.2.18). The SNPG1  probe was incubated with OC-2 nuclear 
protein extract in the presence of increasing amounts of: the unlabelled CPBP consensus 
sequence (Fig.  5.3, lanes  10 and 11), the unlabelled SP1  consensus sequence (Fig. 5.3, 
lanes  12 and  13) or the unlabelled Egr consensus sequence (Fig. 5.3, lanes  14 and  15). 
This approach showed that nuclear protein A is strongly competed from probe SNPG1 
by 25-fold excess of the unlabelled SP1  consensus sequence (Fig. 5.3, comparing lanes 
1   and 12). In comparison, little reduction in band intensity is observed if the competitor 
is changed to 25-fold excess of either the unlabelled CPBP or Egr consensus sequence 
(Fig.  5.3, comparing lanes  1,  10, and  14, respectively). This data suggests that nuclear 
protein A is a member of the SP1  transcription factor family.  Indeed, even at 200-fold 
excess, the Egr consensus sequence is unable to significantly compete indicating that a 
member of this transcription factor family is unlikely to be nuclear protein A (Fig. 5.3, 
lane 15). The consensus sequence for CPBP on the other hand does show some binding
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Figure  5.3  Competition  analysis  suggests  that  nuclear  protein  A  is  a  member  of  the  SP1 
transcription factor family. The SNPG1 probe was incubated with 8-10gg of OC-2 nuclear extract in the 
absence of competitor (lane 1) or in the presence of a molar excess of either unlabelled SNPG1  (lanes 2 & 
3), SNPG2 (lanes 4 & 5), (G)9 (lanes 6 & 7), unrelated sequence: a section of exon 1   from the Barhll gene 
(lanes 8 & 9), CPBP consensus sequence (lanes 10 &  11), SP1 consensus sequence (lanes 12 & 13) or Egr 
consensus sequence (lanes  14 &  15). The location of nuclear protein-DNA complex A is denoted by the 
arrow. [(G)9 was later determined to be a sequencing error and not a true allele].
affinity for nuclear protein A being able to compete at 200-fold excess (Fig.  5.3, lane 
11).  However, this may be expected  since CPBP, a Kruppel-like  factor,  belongs to a 
distinct subset of the SPl-like/KLF family and is capable of binding to SP1 sites (Ratziu 
et al,  1998).  The failure of 25- or 200-fold excess of an unrelated  sequence from the 
Barhll  gene to compete with SNPG1  probe for binding nuclear protein A confirms the 
sequence specificity of this interaction (Fig. 5.3, lanes 8 and 9).
5.3.1.1  Effect of SP1  consensus sequence as probe in EMSA assay.
To explore the possibility that nuclear protein A is a member of the SP1  transcription 
factor family further EMSA analysis was performed using the SP1  consensus sequence 
as the probe. In the absence of any competitors this approach showed binding of OC-2 
nuclear proteins  to  the  SP1  consensus  sequence  produces  a  near-identical  pattern  of 
nuclear protein-DNA complex formation to that obtained with the SNPG1  probe (Fig. 
5.4,  comparing  lanes  2  and  3).  In  particular,  the  location  and  intensity  of nuclear 
protein-DNA complex A suggests that both the SP1  consensus and SNPG1  probes are 
binding the same protein (Fig. 5.4, comparing lanes 2 and 3). Competition analysis is in
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Figure 5.4 The affinity of poly-G allele SNPG1  for nuclear protein A is comparable to that of the 
SPI  consensus sequence. The labelled SP1  consensus sequence (lanes 1-2 & 7-15) or the SNPG1  probe 
(lanes  3-6) were  incubated  in the  absence of nuclear extract (lane  1) or with  8-10pg of OC-2  nuclear 
extract (lanes 2-15) in the absence of competitor (lanes 1-3) or in the presence of a molar excess of either 
unlabelled  oligonucleotide  containing  a  mutated  SPI binding  site  (lanes  4-5  &  15),  SPI  consensus 
sequence (lanes 6-7 &  11), SNPG1  (lanes 8 &  12), SNPG2 (lanes 9 &  13), or (G)<, (lanes  10 &  14). The 
location of nuclear protein-DNA complex A is denoted by the arrow.  [(G)9 was later determined to be a 
sequencing error and not a true allele].
agreement  with  this  suggestion.  The  SPI  consensus  sequence  and  allele  SNPG1  are 
both able to  significantly compete nuclear protein A from the consensus SPI  binding 
site  at 25-fold  competition  (Fig.  5.4,  comparing  lanes  2,  7  and  8).  In contrast,  allele 
SNPG2 exhibits much weaker competition with shifted complex A still apparent even at 
200-fold competition (Fig.  5.4, comparing lanes 2, 9 and  13). Failure of an unlabelled 
oligonucleotide  containing  a  mutated  SPI  binding  site to  compete  nuclear protein A 
from either the  SPI  consensus  sequence (Fig.  5.4,  comparing lanes 2 and  15), or the 
SNPG1  probe  (Fig.  5.4,  comparing  lanes  3, 4  and  5) confirms the  specificity of this 
interaction, in that it is dependent on the presence of a functional SPI binding site.
Taken together these results confirm that both the SPI  consensus sequence and 
allele SNPG1 bind nuclear protein A with comparable affinities. Moreover, they suggest 
allele SNPG1 constitutes a high affinity SPI binding site and that the affinity of this site 
for SPI is modulated by the sequence variation present in the other -3432poly-G alleles.
1805.3.1.2  Effect of Zinc on binding of nuclear protein A.
SPI  is  a zinc  finger transcription  factor containing  a highly conserved  DNA-binding 
domain  at  the  C-terminus  characterised  by  three  tandem  (cystein)2(histidine)2  zinc 
finger motifs (for reviews see Cook et al,  1999; Kaczynski et al, 2003).  Cys2His2 zinc 
finger proteins such as SPI  use zinc to provide structural stability for sequence specific 
DNA  binding;  each  zinc  finger  is  tethered  to  a  zinc  ion  via  two  Cys  and  two  His 
residues such that the finger folds into a compact p(3a domain (for review see Wolfe et 
al, 2000).
To assess whether nuclear protein A is responsive to the presence of zinc ions in 
the EMSA binding reaction as would be expected for a member of the SPI transcription 
factor family a zinc titration was performed in the EMSA binding assay (see Fig. 5.5). 
This  approach  showed  that  binding  of nuclear  protein  A  is  strongly  augmented  at 
comparable amounts on SNPG1  and SPI  consensus probes as the concentration of zinc 
in the binding reaction is increased (Fig.  5.5  comparing lanes  1   and 2, 5  and 6, and 9 
and  10).  Additionally, presence of zinc in the binding reaction appears to promote the 
binding of nuclear protein A to probe SNPG2, although to a much less extent compared 
to either SNPG1  or SPI  consensus probes (Fig. 5.5 comparing lanes 3, 7 and 11). These 
results  are  consistent  with  previous  observations  that  allele  SNPG2  has  a  reduced 
affinity for nuclear protein A compared to allele SNPG1, and that allele SNPG1 and the 
SPI  consensus sequence exhibit comparable affinities for nuclear protein A. Moreover, 
they suggest that nuclear protein A is a zinc finger transcription factor; requiring zinc as 
a cofactor for enhanced binding.
Binding of SPI  to its recognition sequences can be abolished by zinc depletion 
(Westin  et  al,  1988).  With  this  in  mind  it  may  have  been  interesting  to  include  a 
chelating agent such EDTA in the binding assay to assess whether zinc ion depletion is 
consistent  with  absence  of nuclear protein  A  binding.  Although,  the  standard  Parker 
buffer used here in these EMSA assays contains EDTA, this is at a low concentration 
(ImM)  compared  to  those  used  for  metal  depletion  (Westin  and  Schaffiier,  1988). 
However, the results of the zinc titration, as shown in Fig.  5.5  are consistent with the 
notion that nuclear protein A is a member of the SPI  transcription factor family. The 
results  of this  zinc  titration  also  revealed  nuclear  protein-DNA  complex  C  and  an 
additional nuclear protein-DNA complex, termed D, to be affected by the presence of 
zinc in the EMSA binding reaction (see arrows C and D, respectively in Fig. 5.5). These 
results  are  discussed  further  in  section  5.3.3,  page  193  and  section  5.6,  page  210, 
respectively.
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Figure 5.5  Effect of Zinc on  binding of nuclear protein A. The labelled SPI  consensus sequence 
(lanes  1, 5 & 9), SNPG1  probe (lanes 2, 6 &  10), SNPG2 probe (lanes 3, 7 & 11) or (G)9 probe (lanes 
4, 8 & 12) were incubated with 8-10gg of OC-2 nuclear extract in the absence of zinc (lanes 1-4) or in 
the presence of lOpM zinc (lanes 5-8) or  100pM zinc (lanes 9-12). Arrows A, C & D denote shifted 
protein-DNA complexes that are affected by the presence of zinc in the EMSA binding reaction. [(G)9 
was later determined to be a sequencing error and not a true allele].
5.3.1.3  Supershift analysis to identify nuclear protein A.
In an attempt to confirm that OC-2 derived nuclear protein A is SPI, supershift analysis 
was  performed  by  incubating  a mouse  monoclonal  anti-SPl  antibody  [SPI  (1C6) X; 
Santa Cruz Biotechnology,  Inc.] with OC-2 nuclear extracts subsequent to addition of 
either the SNPG1  or SPI  consensus probe (Fig. 5.6a). If nuclear protein A is SPI  and 
the  epitope  to  which  the  anti-SPl  antibody  was  raised  is  exposed  upon  binding  of 
nuclear  protein  A  to  DNA  probe  one  would  expect  the  anti-SPl  antibody  to  bind 
forming  one  large  multimeric  complex.  Multimeric  complexes  such  as  these  possess 
retarded mobility compared to protein-DNA complex alone and can be visualised by the 
presence of a novel band high on the gel, termed a supershift. However, this approach 
did not induce a supershift of nuclear protein-DNA complex A on either the SNPG1  or 
SPI  consensus probes (Fig. 5.6a comparing lanes 1   and 2 with 3 and 4). Consequently, 
the supershift analysis was varied by incubating the anti-SPl  antibody prior to addition 
of labelled probe.  If the anti-SPl  antibody binds to a site on nuclear protein A that is 
essential for DNA binding this could block the ability of nuclear protein A to bind to 
labelled  probe  and  result  in  the  disappearance  of nuclear  protein-DNA  complex  A. 
Additionally, several attempts were made to optimise the supershift analysis by varying 
the temperature  and  length  of the  incubation  when  the  anti-SPl  antibody was  added 
prior to the probe (4°C  O/N, on ice for 30 minutes or on ice for 2hrs) and following 
addition of labelled probe (on ice for 30 minutes). However a positive result was not
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Figure 5.6 Supershift analysis to identify nuclear protein A. (a) The labelled SPI  consensus sequence or SNPG1 
probe were incubated with 8-lOpg of OC-2 nuclear extract in the absence of antibody (lanes 1-2) or in the presence 
of anti-SPl  antibody (lanes 3-4) or anti-ATF-1  antibody (lanes 5-6) as indicated.  The location of nuclear protein- 
DNA complex A is denoted by the arrow, A. (b) The labelled SPI consensus sequence (lane 1) or the SNPG1  probe 
(lane 2) were incubated with anti-SPl  antibody in the absence of OC-2 nuclear extracts, (a) and (b) In the presence 
of the anti-SPl  antibody lower complexes LC1  & LC2 can be observed lower down the gel. (c) The labelled SPI 
consensus  sequence  or  SNPG1  probe  were  incubated  with  258ng  recombinant  SPI  protein  in  the  absence  of 
antibody  (lanes  1-2)  or  in  the  presence  of anti-SPl  antibody (lanes  3-4)  or anti-ATF-1  antibody  (lanes  5-6)  as 
indicated. R denotes the complex formed by the binding of recombinant SPI  protein to labelled probe. SS denotes 
supershift of recombinant SPI protein. In the presence of the anti-SPl  antibody lower complexes (LC) are observed. 
In  each  case (a), (b) and  (c) antibody was added  subsequent to addition  of probe and  reactions were allowed to 
incubate for a further 30 minutes on ice.
183obtained under any of these conditions. It is possible that these results are due to the fact 
that  nuclear  protein  A  is  not  SPI.  It  could  be  a  different  member  of  the  SPI 
transcription factor family;  17  SPl-like/KLF genes have been identified in mouse (the 
OC-2  cell line used for preparation of nuclear extract is derived from Immortomouse; 
see section 5.1.3) (for review see Kaczynski et al, 2003). Alternatively, nuclear protein 
A may belong to a different transcription factor family or be a novel transcription factor, 
albeit one that exhibits high affinity for the SPI  consensus sequence. On the other hand, 
it should  also be  considered that these results are due to unsuccessful  supershifts and 
hence, nuclear protein A is SPI.  Certainly, the epitope to which the anti-SPl  antibody 
was  raised  may  not  be  not  exposed  on  nuclear  protein  A  and  thus,  accessible  for 
binding.  It may be masked by the presence of other nuclear proteins within the extract 
or the conformation of nuclear protein A under the conditions of these EMSA assays 
may not  expose  the  epitope  site  in  a  favourable position  for binding of the  anti-SPl 
antibody.  Alternatively,  it  is  possible  that  the  nuclear  extract  buffer  contains  a 
component  or  components  that  have  an  adverse  effect  on  binding  of the  anti-SPl 
antibody to nuclear protein A.
It is notable that in the presence of the anti-SPl  antibody two lower complexes 
(termed LC  1   and 2) are present on SNPG1  and SPI  consensus probe that are absent in 
the  absence  of the  anti-SPl  antibody  and  when  a  mouse  monoclonal  anti-activating 
transcription factor-1  antibody [ATF-1  (C41-5.1) X, Santa Cruz Biotechnology, Inc.] is 
used as a negative control (Fig.  5.6a comparing all lanes;  LC1  having a slightly lower 
mobility on probe  SNPG1  compared to  the  SPI  consensus  probe).  Lower complexes 
such as these that are shifted downwards can be induced when a specific antibody binds 
a nuclear protein and removes it from a multi-protein complex bound to labelled probe. 
However,  the  intensity of complex  A  is  not  reduced  in  the presence  of the  anti-SPl 
antibody as one might expect if a nuclear protein was being removed from a complex of 
proteins bound to labelled probe. Indeed, further analysis suggests that LC  1   and 2 are 
the result  of the  anti-SPl  antibody binding to  the  SNPG1  and  SPI  consensus probes 
direct;  incubating  the  anti-SPl  antibody  with  either  the  SNPG1  or  SPI  consensus 
probes in the absence of OC-2 nuclear extracts results in formation of complexes LC  1  
and 2 on both probes (Fig. 5.6b lanes 1   and 2). Hence, the supershift analysis appears to 
be confounded by the fact that free probe has the ability to bind the anti-SPl  antibody. 
To counteract the possible effect of free probe sequestering the anti-SPl  antibody the 
supershift  analysis  was  repeated  with  higher concentrations  of OC-2  nuclear  extracts 
(24pg), but this approach was not successful.
184In the  absence  of a  supershift with the  anti-SPl  antibody^ EMSA  experiments 
were  performed  with  affinity purified  recombinant human  SPI  protein  (Promega)  in 
place  of  OC-2  nuclear  extracts  in  order  to  establish  whether  the  -3432poly-G 
polymorphism does in fact modulate a high affinity SPI binding site. The results of this 
analysis  showed  that  recombinant  SPI  protein  can  bind  SNPG1  and  SPI  consensus 
probes and this is discussed in greater detail in the next section,  5.3.2.  Having shown 
that recombinant SPI protein can bind SNPG1  and SPI  consensus probes the supershift 
analysis  was  repeated  using  recombinant  SPI  protein  in  place  of the  OC-2  nuclear 
extracts  to  assess  whether  the  anti-SPl  antibody  used  in  supershift  analysis  was 
functional;  use  of a non-functional  antibody could  account  for the lack of a positive 
supershift of nuclear protein A (Fig.  5.6c).  However, from this analysis it is clear that 
the anti-SPl  antibody used can induce a complete supershift of recombinant SPI protein 
whether bound to the SPI  consensus or SNPG1  probes (Fig.  5.6c lanes 3 and 4) ruling 
out  the  possibility  that  the  anti-SPl  antibody used  in  these  assays  is  non-functional. 
However, the failure of the SPI  supershift analysis to produce positive results with the 
OC-2 nuclear extracts despite the use of an anti-SPl  antibody that was confirmed to be 
functional does not mean that nuclear protein A is not SPI. There are many reasons why 
the SPI  supershift analysis could have failed with the OC-2 nuclear extracts as has been 
discussed.  Importantly,  western  immunoblot  analysis  shows  that  the  OC-2  cell  line 
expresses  SPI  protein  (see  Fig.  5.12,  section  5.4,  page  201).  Hence,  in  light  of this 
observation one would expect the SPI consensus probe to bind endogenous SPI in these 
EMSA assays.  Consequently, the absence of a supershift on the  SPI  consensus probe 
suggests  that  the  results  obtained  probably  reflect  a  failure  of the  antibody  to  bind 
endogenous SPI under the assay conditions used.
5.3.2  The -3432  polv-G  polymorphism  creates a  high affinity SP1  binding 
site.
In the absence of a supershift with the SPI  antibody and in order to establish whether 
the -3432poly-G polymorphism does in fact modulate a high affinity SPI  binding site 
EMSA analysis was performed using affinity purified recombinant human SP1   protein 
(Promega) in place of OC-2 nuclear extracts. Use of purified protein in EMSA analysis 
can lead to spurious results through non-specific binding of the highly abundant purified 
protein.  However,  this  approach showed that recombinant SPI  protein is able to bind 
probe  SNPG1  to  form  a  shifted  protein-DNA  complex  that  appears  equivalent  in
185intensity,  if not  greater,  to  that  formed  on the  SPI  consensus probe  and importantly, 
much greater than that observed on probe SNPG2 (Fig.  5.7a, complex R in lanes 4, 8 
and  12). These observed differences in binding intensity to SNPG1  and SNPG2 probes 
presumably reflect differences in binding affinity between these two poly-G alleles for 
recombinant SPI  protein; they are similar to those observed with OC-2 nuclear extracts 
(see Fig. 5.7a, lanes 6 and 10, respectively for OC-2 nuclear extracts). It is notable that 
the  complex  formed by the binding of recombinant  SPI  protein has  greater mobility 
compared to that formed by the binding of OC-2 derived nuclear protein A to the same 
probes (Fig. 5.7a, comparing lanes 4, 8 and 12 with 2, 6 and 9). However, recombinant 
SPI  produced  in the baculovirus  expression  system does  not undergo the  same post- 
translational modifications as endogenous SPI  (molecular weight of 57kDa / 82kDa for 
recombinant  SPI  to 95 kDa /  106kDa for mammalian SPI, Promega, U.K) and is not 
expected to have the same mobility.
Competition  experiments  show  that  the  unlabelled  SNPG1  probe  is  able  to 
compete  recombinant  SPI  protein  from  its  consensus  binding  site  with  an  affinity 
similar to  that  of the  unlabeled  SPI  consensus  sequence  itself;  strong competition  is 
evident at 25-fold excess that progresses to the disappearance of the shifted complex at 
200-fold competition (Fig.  5.7b, comparing lanes  1, 2, 3 with 9 and  10). This suggests 
that allele SNPG1  is a high affinity SPI binding site not dissimilar to the consensus SPI 
binding  site.  Furthermore,  it  is  clear  from this  analysis  that  allele  SNPG2  is  a much 
lower affinity SPI  binding site;  only partial  competition is  evident at 200-fold excess 
(Fig.  5.7b,  lane  11).  This  is  a  similar level  of competition  exerted by the  consensus 
sequences  for  Egr  and  CPBP  (Fig.  5.7b,  comparing  lanes  1,  11,  14  and  15) both  of 
which are known to have a low affinity for SPI  (Ebert and Wong,  1995; Ratziu et al, 
1998). Failure of an unlabelled oligonucleotide containing a mutated SPI binding site to 
compete  recombinant  SPI  protein  from  its  consensus  binding  site,  even  at  200-fold 
excess (Fig.  5.7b, lane  13) confirms the sequence specificity of the interaction between 
recombinant SPI  protein and the consensus SPI  binding site in that it is dependant on 
the presence of a functional  SPI  binding site and further suggests that the interaction 
between  poly-G  alleles  and  recombinant  SPI  protein  is  likewise  dependent  on  the 
presence of a functional SPI binding site.
EMSA analysis using either recombinant SPI  protein or OC-2 nuclear extracts 
was  extended  to  the  rest  of the  poly-G  alleles  in  order  to  investigate  their  relative 
affinity for SPI.  The ability of each poly-G allele to compete with the consensus SPI 
binding site for either recombinant SPI protein (Fig. 5.8a) or nuclear protein A
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Figure 5.7 The -3432 poly-G polymorphism generates a high affinity binding site for SPI. (a) The
labelled consensus  SPI  sequence (lanes  1-4), SNPG1  probe (lanes  5-8) or SNPG2 probe (lanes 9-12) 
were incubated in the absence of extract (lanes 1, 5 & 9), in the presence of 8-10pg OC-2 nuclear extract 
(lanes 2, 6 & 10) or in the presence of increasing amounts of recombinant SPI protein,  129ng (lanes 3, 7 
&  11)  and  258ng  (lanes  4,  8  &  12).  Arrow  A  denotes  the  location  of shifted  nuclear protein-DNA 
complex A. Arrow R denotes the location of the shifted protein-DNA complex formed by the binding of 
recombinant SPI to labelled probes, (b) The labelled SPI  consensus sequence was incubated with 258ng 
recombinant SPI  protein in the absence of competitor (lane  1) or in the presence of a molar excess of 
unlabelled SPI  consensus sequence (lanes 2 & 9), SNPG1  (lanes 3 &  10), SNPG2 (lanes 4 &  11), (G)9 
(lanes 5 &  12), oligonucleotide containing a mutated SPI  binding site (lanes 6 &  13), CPBP consensus 
sequence (lanes 7 &  14) or Egr consensus sequence (lanes 8 &  15).  [(G)9 was later determined to be a 
sequencing error and not a true allele].
187(Fig. 5.8b) was examined. Data obtained using recombinant SPI  protein confirmed that 
allele SNPG1  has the highest affinity SPI binding site closely followed by allele (G)io; 
both  are  able  to  strongly  compete  at  25-fold  excess  (Fig.  5.8a,  lanes  1,  2  and  6). 
Whereas, allele SNPG2 and SNPG4 exhibit the lowest affinity for SPI binding; neither 
of these  unlabeled  oligonucleotides  appear  able  to  significantly  compete  at  25-fold 
excess  and  only  partial  reduction  of  the  shifted  complex  is  observed  at  100-fold 
competition (Fig.  5.8a, comparing lanes  1, 3, 4,  10 and  11). This is in agreement with 
analysis performed using Matlnspector software which showed that allele SNPG4 did 
not exhibit a strong matrix similarity to the SPI  consensus sequence (see section 5.3.1, 
page  177  and  Appendix  C).  It is possible that this may be due to the fact that allele 
SNPG4 contains a longer (TGG) motif and consequently is more GT-rich compared to 
the  other  poly-G  alleles  (see  Table  4.3,  section  4.4.2,  page  156);  SPI  is  known  to 
exhibit binding affinity for GC-rich sites compared to those that are GT-rich (for review 
see Kaczynski et al, 2003). The three remaining alleles, SNPG5, (G)n and (G)i2 exhibit 
intermediate affinity for SPI to that of SNPG1 and SNPG2 (see Fig. 5.8a, lanes 5, 7 and 
8). This data is similar to that obtained using OC-2 nuclear extracts, Fig.  5.8b. Alleles 
SNPG4,  SNPG5, (G)io,  (G)n  and (G)i2 all appear to exhibit a similar level of affinity 
for nuclear protein A at a level intermediate to that of alleles SNPG1  and SNPG2. This 
is particularly evident at 25  fold competition; the additional poly-G alleles moderately 
compete nuclear protein A  from the SPI  consensus binding site at levels intermediate 
between  alleles  SNPG1  and  SNPG2  which  exhibit  strong  and  weak  competition, 
respectively  (Fig  5.8b  comparing  lane  1   across  lanes  2-8).  Taken  together,  results 
obtained using recombinant SPI  protein are consistent with those obtained using OC-2
f
nuclear  extracts  and  demonstrate  that  the  different  poly-G  alleles  are  able  to  bind 
recombinant SPI  protein in a highly specific manner that is similar to their respective 
abilities  to bind  nuclear protein A.  This  lends  further support to  the fact that nuclear 
protein A is SPI.
In  summary,  the results  from  this  EMSA  analysis  show  that the  -3432poly-G 
polymorphism in the Bm-3c promoter modifies binding affinity for a specific nuclear 
protein  (protein  A)  expressed  in  OC-2  cells.  Of the  seven  common  poly-G  alleles 
examined,  allele SNPG1  has at least a 4-fold higher affinity compared to some of the 
other poly- G alleles for nuclear protein A (comparing relative levels of competition in 
Fig.  5.2b  and  5.8b).  Specific  competition with  a  SPI  consensus  sequence but not  an 
oligonucleotide  containing  a  mutated  SPI  binding  site  or  an  unrelated  sequence 
suggests that nuclear protein A is a member of the SPI transcription factor family (Fig.
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Figure 5.8 The different poly-G  alleles  bind  recombinant SPI  in  a  highly specific manner that is 
similar to their respective abilities to bind nuclear protein A. The labelled SPI  consensus sequence 
was incubated with either (a) 258ng recombinant SPI  protein or (b) 8-10pg of OC-2 nuclear extract in 
the absence of competitor (lane  l) or in the presence of a molar excess of unlabelled SNPG1  (lanes 2 & 
9), SNPG2 (lanes 3 &  10), SNPG4 (lanes 4 &  11), SNPG5 (lanes 5 &  12), (G)1 0  (lanes 6 &  13), (G)u 
(lanes 7 &  14) or (G)t2 (lanes 8 &  15).  Arrow A denotes the  location of shifted nuclear protein-DNA 
complex A. Arrow R denotes the location of the shifted protein-DNA complex formed by the binding of 
recombinant SPI to labelled probe.
1895.3  and 5.4). The finding that the SPI consensus probe produces a near-identical pattern 
of protein-DNA complex formation to that observed on probe SNPG1, in particular, the 
location and intensity of protein-DNA complex A is in agreement with this suggestion 
(Fig.  5.4).  In addition, the enhanced binding of nuclear protein A to SNPG1  and SPI 
consensus probes in the presence of zinc is consistent with nuclear protein A being a 
zinc finger transcription factor such as SPI. Further confirmation that nuclear protein A 
is SPI  was not obtained from supershift analysis with an anti-SPl  antibody (Fig. 5.6a). 
However, this does not rule out the possibility that nuclear protein A is SPI. Successful 
interaction  of  an  antibody  with  a  protein  bound  to  labelled  DNA  probe  (or  even 
antibody-protein interaction prior to addition to labelled DNA probe) is subject to the 
assay conditions and there are many reasons why the SPI  supershift could have failed 
as previously discussed.  Had time permitted Shift-Western blotting of nuclear protein- 
DNA  complexes  formed  with  the  SNPG1  and  SPI  consensus probes may have been 
useful to gain further evidence that nuclear protein A is  SPI.  However,  Shift-Western 
blotting which combines the EMSA gel shift technique with that of the Western transfer 
of proteins (immunoblotting) can be notoriously difficult to perform (see Demczuk et al, 
1993).  Similarly,  matrix-assisted  laser  desorption  ionisation  time-of-flight  mass 
spectrometry (MALDI-TOF) a powerful technique that identifies isolated proteins by a 
combination of accurate mass determination and peptide mass fingerprinting (Chaurand 
et al,  1999) may have confirmed that nuclear protein A is  SPI.  MALDI-TOF has the 
added advantage of being able to discriminate from several proteins in a mixture when 
the complete isolation of a single protein is not possible (Jenson et al,  1996). However, 
it  was  not  possible  to  pursue  this  line  of analysis  within  the  time  constraints  of the 
project. In any case, analysis with recombinant SPI protein shows that recombinant SPI 
can bind to the SNPG1  allele sequence to produce a bandshift pattern that is identical to 
that observed with the SPI  consensus sequence (Fig. 5.7a). Moreover, recombinant SPI 
protein  appears  to  bind  to  allele  SNPG1  with  an  affinity  comparable  to  that  of the 
consensus SPI binding site (Fig. 5.7b). Furthermore, the relative affinity of recombinant 
SPI  protein  for  the  SPI  consensus  sequence,  allele  SNPG1  and  additional  poly-G 
alleles  is  very  similar  to  that  of nuclear  protein  A  for  these  sequences  (comparing 
Fig.5.8a and b). Hence, the results obtained using recombinant SPI  protein are in good 
agreement with those obtained using OC-2 nuclear extracts. Therefore, collectively the 
data suggest that allele SNPG1  is indeed a high affinity SPI  binding site and are highly 
indicative  that  OC-2  derived  nuclear protein  A  that  exhibits  high  binding  affinity to 
allele SNPG1 of the -3432poly-G polymorphism in the Bm-3c promoter is SPI.
1905.3.3  Identification of nuclear protein C that exhibits differential binding to 
the -3432polv-G polymorphic site.
Initial  EMSA analysis with OC-2 nuclear extracts revealed a complex banding pattern 
on -3432poly-G probes SNPG1  and SNPG2 (see Fig.  5.1, page  175).  In particular, the 
complex  formed  by  the  binding  of  nuclear  protein  A  to  poly-G  probes  is  more 
prominent on probe SNPG1  compared to probe SNPG2 whereas, in contrast, a shifted 
protein-DNA complex termed C is more prominent on probe SNPG2 compared to probe 
SNPG1  (Fig.  5.1,  page  175,  comparing  lanes  10  and  11  and  13  and  14).  Subsequent 
analysis  has  confirmed  that  nuclear protein  A has  a greater affinity for poly-G  allele 
SNPG1  compared to the other poly-G alleles and suggests that nuclear protein A is the 
transcription factor SPI  (section 5.3.1  and 5.3.2). The preliminary data presented in Fig
5.1  (page 175) suggests that the nuclear protein or proteins involved in the formation of 
shifted protein-DNA complex C (hereafter referred to as nuclear protein C) has a greater 
affinity for poly-G  allele SNPG2  compared to allele SNPG1; this is in contrast to the 
affinity of nuclear protein A for these two poly-G alleles. Hence, raising the possibility 
that nuclear proteins A and C are distinct.
To explore this possibility analysis was performed using Matlnspector software 
(www.genomatix.de/products/MatInspector  /index.html)  for  putative  transcription 
factor binding sites that exhibited a unique or high matrix similarity to the SNPG2 allele 
sequence  compared  to  allele  SNPG1  (see  Appendix  C).  The  results  of this  analysis 
showed that the transcription factor Egr-4 (NGF1-C) exhibits a high matrix similarity to 
the SNPG2 allele sequence compared to allele SNPG1  (see Appendix C). Egr-4 belongs 
to  the  Egr  transcription  factor  family,  which  consists  of a  group  of immediate  early 
response genes that are transiently activated in response to  environmental  signals (for 
reviews  see  O’Donovan  et  al,  1999;  Thiel  and  Cibelli  et  al,  2002).  In  light  of these 
findings  and  to  seek  further  clarification  a  limited  set  of preliminary  competition 
experiments were performed in the EMSA assay as far as was possible to investigate 
within the time constraints of this project (see Fig. 5.9).
To  assess whether the binding of nuclear protein C to poly-G allele SNPG2 is 
sequence specific and in order to assess whether nuclear protein C may be a member of 
the Egr transcription factor family the Egr consensus sequence and an oligonucloetide 
containing a mutated Egr binding site were used as competitors in EMSA analysis (Fig. 
5.9a).  This  line of analysis  showed  that nuclear protein  C  is  strongly competed  from 
probe SNPG2 by 100- and 500-fold excess of the unlabelled SNPG2 probe (Fig.  5.9a, 
comparing lanes 1, 7 and 8) and by 500-fold excess of the unlabelled Egr consensus
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Figure 5.9  EMSA  analysis  to  identify  nuclear  protein  C.  (a)  The  SNPG2 probe (lanes  I,  7-10) or 
SNPG1  probe (lanes 2-6) were incubated in the presence of 16fig OC-2 nuclear extract in the absence of 
competitor (lanes  1   & 2) or in the presence of a molar excess of unlabelled SNPG1   (lanes 3 & 4), an 
oligonucleotide containing a mutated Egr binding site (lanes 5 & 9), Egr consensus sequence (lanes 6 & 
10) or SNPG2 (lanes 7 & 8). (b) The SNPG2 probe was incubated with 8pg OC-2 nuclear extract in the 
absence  of competitor  (lane  1)  or  in  the  presence  of a  molar  excess  of unlabelled  CPBP  consensus 
sequence  (lanes  2  &  3)  or  SPI  consensus  sequence  (lanes  4  &  5).  (c)  The  labelled  Egr  consensus 
sequence was incubated either in the absence (lane  1) or in the presence (lane 3) of OC-2 nuclear extract 
(8pg)  and  the  pattern  of shifted  nuclear  protein-DNA  complex  formation  was  compared  to  labelled 
SNPG2  probe  in the  presence  of OC-2  nuclear extract,  8fig  (lane 2).  Arrows A,  C  and  F  denote the 
location of shifted nuclear protein-DNA complexes A, C and F, respectively.
192sequence (Fig.  5.9a, lane  10); the shifted complex for nuclear protein C is abolished in 
each  case.  In  contrast,  competition  with  500-fold  excess  of  an  unlabelled 
oligonucleotide containing a mutated  Egr binding site failed to induce any significant 
reduction of complex C (Fig. 5.9a, lane 14). These results suggest that the interaction of 
nuclear protein C with allele SNPG2 is sequence specific and that nuclear protein C is a 
member of the Egr transcription factor family. Although, the amount of unlabelled Egr 
consensus sequence used, as competitor DNA in this EMSA experiment is high (500- 
fold excess)  and could arguably lead to non-specific binding.  However, it is clear that 
500-fold excess of an unlabelled oligonucleotide containing a mutated Egr binding site 
cannot compete at this level. Hence, suggesting this is not the case. In addition, similar 
results were obtained when 500- and 1000-fold excess of the unlabelled CPBP and SPI 
consensus sequences were used as competitors; the shifted complex for nuclear protein 
C is not abolished in either case  (Fig.  5.9b comparing complex C in lane  1   across all 
lanes). Therefore, taken together these data confirm that interaction of nuclear protein C 
with  allele  SNPG2  is  sequence  specific  and  suggest that  nuclear protein  C may be  a 
member  of the  Egr  transcription  factor  family.  (The  EMSA  data  shown  in  Fig.  5.9a 
lanes  2-6,  represent  preliminary  competition  data  generated  through  part  of  the 
investigations into the sequence specificity of nuclear protein A binding to poly-G allele 
SNPG1.  This data in Fig.  5.9a,  lanes 2-6 is very similar to that already shown in Fig. 
5.2b  (page  177)  and  Fig.  5.3  (page  179)  and  therefore,  will  not be discussed  further 
here).
The Egr family are zinc finger transcription factors (for review see O’Donovan 
et al,  1999).  From the zinc titration experiment (Fig.  5.5, page  182) it is evident that 
nuclear protein  C  is  sensitive to  the presence of zinc in the  EMSA binding reaction; 
notably  forming  a  shifted  protein-DNA  complex  of  increasing  intensity  on  probe 
SNPG2 as the concentration of zinc in the binding reaction is increased (Fig. 5.5, page 
182, comparing lanes 3, 7 and 11). This suggests that nuclear protein C is a zinc finger 
transcription factor.  Additionally,  in these experiments it is evident that complex C is 
not observed on the SPI  consensus probe either in the absence or presence of zinc (Fig. 
5.5  lanes  1,  5  and  9).  This  is  in  agreement  with  subsequent  competition  analysis; 
competition with the SPI consensus sequence suggests that nuclear protein C is unlikely 
to be a member of the SPI  transcription factor family (Fig. 5.9b comparing lane 1   with 
4  and  5).  Instead,  collectively  these  EMSA  data  suggest  that  OC-2  derived  nuclear 
proteins C and A are distinct proteins.
193To obtain further clarification as to whether nuclear protein C is a member of the 
Egr  transcription  factor  family,  the  Egr  consensus  sequence  was  radiolabelled  and 
incubated with OC-2 nuclear extracts (Fig. 5.9c). This approach showed that formation 
of shifted protein-DNA complexes on the Egr consensus probe is not analogous to those 
on probe SNPG2 (Fig. 5.9c). In particular, when the Egr consensus sequence is used as 
probe no band is visible at the site where complex C forms on probe SNPG2.  Instead, 
on the Egr consensus probe a unique complex of slightly greater mobility, termed F, is 
observed  lower down the gel  (Fig.  5.9c,  comparing lanes 2  and 3). This suggests that 
formation of complex C on probe SNPG2 may not be due to the binding of a member of 
the Egr transcription factor family. However, in the absence of further analysis such as 
supershift analysis with an anti-Egr antibody it is not possible to rule out that nuclear 
protein C is Egr.
In  summary,  these  data  suggest  that  nuclear  protein  C  is  a  zinc  finger 
transcription factor but more analysis than was possible within the scope of this project 
is  needed  to  clarify  whether  nuclear protein  C  is  a  member  of the  Egr  transcription 
factor  family.  However,  the  data  is  strongly  suggestive  that  nuclear  protein  C  is  a 
different protein to nuclear protein A and not a member of the SPI  transcription factor 
family.
5.3.3.1  Effect  of  Zinc  on  binding  of  nuclear  proteins  A  and  C  to  common  - 
3432poIv-G alleles.
The data suggest that OC-2 derived nuclear proteins A and C are distinct proteins and in 
the  absence  of competitors  exhibit  a binding  affinity for alleles  SNPG1  and  SNPG2, 
respectively (see Fig. 5.1, page 175, lanes 10,  11, 13 and 14; Fig. 5.5, page 182, lanes 2, 
3, 6 and 7 and Fig. 5.16a lanes  1   and 2). This differential binding of nuclear proteins A 
and C to SNPG1  and SNPG2 probes is particularly evident under conditions of the zinc 
titration (Fig.  5.5) and suggests that the nature of the poly-G allele at position -3432 in 
the Bm-3c promoter modulates the binding of at least two, distinct nuclear proteins. To 
obtain further clarification this line of analysis was extended to the rest of the poly-G 
alleles and emphasis was placed on the binding of nuclear proteins A and C.
Radiolabelled  probes  for  each  of the  common  poly-G  alleles  were  incubated 
with OC-2  nuclear extracts in the presence of increasing amounts of zinc (Fig.  5.10). 
This approach showed that in the presence of zinc nuclear protein A binding is evident 
on  probe  SNPG5  in  addition  to  probe  SNPG1  with  little  if any binding  of nuclear 
protein C observed on these probes (Fig. 5.10 lanes 1   and 4). If the concentration of zinc
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Figure 5.10 Effect of zinc on  binding of nuclear proteins A and C to common -3432 poly-G alleles.
Probes:  SNPG1  (lanes  1   & 8), SNPG2 (lanes 2 & 9), SNPG4 (lanes 3 &  10), SNPG5 (lanes 4 &  11) (G)i0 
(lanes 5 &  12), (G)M  (lanes 6 &  13) or (G)i2 (lanes 7 &14) were incubated with 8pg OC-2 nuclear extract 
in the presence of lOpM zinc (lanes  1-7) or  lOOpM zinc (lanes 8-14). Arrows A and C denote the location 
of shifted nuclear protein-DNA complexes A and C, respectively.
in the binding reaction is increased this effect is augmented (Fig.  5.10 lanes 8 and 11). 
These results suggest that poly-G alleles SNPG1 and SNPG5 have a greater affinity for 
nuclear protein A compared to nuclear protein C.  In contrast,  in the presence of zinc, 
nuclear  protein  A  binding  in  concert  with  nuclear protein  C  binding  is  enhanced  at 
comparable  amounts  on  poly-G  probes  SNPG2,  SNPG4,  (G)i0, (G)n  and  (G)n  (Fig. 
5.10 comparing lanes 3, 5, 6, 7, 10,  12, 13 and 14); this is particularly evident on probe 
(G)i2 (Fig.  5.10,  lane  14).  Hence,  suggesting that the affinity of each of these poly-G 
alleles for nuclear proteins A and C is comparable in the presence of zinc. These data 
are in agreement with previous observations (Fig. 5.1, page 175; Fig. 5.5, page 182, and 
Fig. 5.9a) suggesting that the nature of the -3432poly-G allele plays an important role in 
determining the binding of two OC-2 derived nuclear proteins A and C to this region of 
the  Bm-3c promoter.  Nuclear protein  C  is discussed further in section 5.8.2  and for 
clarity an alternative exposure of the gel presented in figure 5.10 is shown in Appendix 
D.
1955.4  Effect  of  the  -3432poIv-G  polymorphism  on  basal  Brn-3c 
promoter  activity  and  activity  of  the  Brn-3c  promoter  in 
response to exogenous SP1.
It  has  been  established  that  the  -3432poly-G  polymorphism  in  the  Bm-3c  promoter 
modifies the binding affinity of at least two OC-2 derived nuclear proteins, A and C; the 
affinity of poly-G  alleles  for nuclear protein A being very similar to  their respective 
abilities to bind purified recombinant SPI protein. However, this does not mean that the 
-3432poly-G polymorphism is functional nor does it mean that the differential affinity 
in  the  -3432poly-G  alleles  for  SPI  actually has  a  functional  effect  on  regulation  or 
expression  of the  Bm-3c  gene.  Indeed,  sequence  specific  binding  of  SPI  does  not 
necessarily correlate with promoter activity.
To assess whether the -3432poly-G polymorphism is functional  and modulates 
transcriptional  activity  of Bm-3c  a  series  of transient  transfection  experiments  were 
performed in OC-2 cells. The pGL3-Basic vector (Promega) contains a modified firefly 
luciferase  gene  {Flue)  and  vector  backbone  both  designed  to  optimise  expression  in 
mammalian  cells  and  to  help  reduce  anomalous  expression  (see 
http://www.promega.com/tbs/tm033/tm033.pdf).  The  pGL3-Basic  vector  does  not 
contain  a  eukaryotic  promoter;  transfecting  cells  with  the  empty  pGL3-Basic  vector 
(which  lacks  insertion  of  a  putative  regulatory  sequence)  produces  only  very  low 
background  luciferase  expression driven by the vector backbone or cryptic regulatory 
elements present within the Flue gene itself.  Hence,  efficient luciferase expression in 
cells transfected with pGL3-Basic vector results from sub-cloning a functional promoter 
fragment upstream of the Flue gene. Thus, making the pGL3-Basic vector suitable for 
identifying  putative  regulatory  sequences  and  for  examining  the  effect  of sequence 
variation on gene expression. The pGL3-Basic vector carrying a 3.6Kb fragment of the 
human  Bm-3c  promoter  (bases  -80bp  to  -3670bp  with respect  to  the  A  of the ATG 
translation  start  as  +1)  was  already  cloned  in  our  laboratory  from  the  human  PAC 
library  RPCI1  (HGMP,  MRC,  U.K.)  and previous  experiments  have  shown  that  this 
fragment of the Bm-3c promoter is of sufficient length to drive Flue expression in the 
inner ear sensory epithelial cell line, OC-2 (Jagutpal et al, unpublished data).
The region of the Bm-3c promoter upstream of the -3432poly-G polymorphism 
is extremely complex.  Two repetitive sequence variants are present in close proximity 
with  the  -3432poly-G  polymorphism:  -3457(GA)i_3  and  -3495(GT)  15.21,24  and  all
196sequence variants  at -3432,  -3457  and  -3495  appear in  strong linkage disequilibrium. 
Thus,  forming native haplotypes  5’  of the -3432poly-G polymorphism (see Table 4.4, 
section 4.4.2,  page  160  and Fig.  4.16,  section 4.5, page  162). The complexity of this 
region  of  the  Bm-3c  promoter  in  the  vicinity  of  the  -3432poly-G  polymorphism 
resulting  from  the  high  amount,  the  proximity  and  repetitive  nature  of  variation 
identified limited the nature of functional analysis that could be performed.
For initial functional analysis -3432poly-G alleles SNPG1  and SNPG2 that were 
originally identified  as  part  of the  PCR-SSCP  screen  were  focussed  on.  It is  evident 
from EMSA analysis that -3432poly-G alleles  SNPG1  and SNPG2 exhibit a high and 
low affinity respectively, for both OC-2 derived nuclear protein A and recombinant SPI 
protein  (see  section  5.3)  raising  the  possibility  that  these  two  alleles  may  have  a 
differential  functional  effect(s)  on  activity  of the  Bm-3c  promoter.  To  explore  this 
possibility  the  firefly  luciferase  reporter  vector  pGL3-Basic  (Promega)  was  used  to 
generate  two  Bm-3c  promoter-luciferase  reporter  gene  constructs.  Each  construct 
contained  3.6Kb  of the  human  Bm-3c  promoter  sub-cloned  upstream  of the  firefly 
luciferase gene with either allele SNPG1  or allele SNPG2 at position -3432 in the Bm- 
3c  promoter  insert:  p-Luc-SNPG1.566GT23  and  p-Luc-SNPG2.566GT23,  respectively  (a 
clear illustration of the variation present in the constructs is given in Fig.  5.11a, page 
199;  see method section 3.2.8.1  for details of construct formation).  It was not possible 
to  generate  by  site-directed  mutagenesis  or  restriction  digest  sub-cloning  Bm-3c 
promoter-luciferase reporter gene constructs that only varied in the nature of the poly-G 
allele at position -3432. The proximity and repetitive nature of the sequence variants at - 
3457  [(GA)i.3],  -3432  [poly-G polymorphism] and  -3495  [(GT) 15.21,24]  (see Fig.  4.16, 
section  4.5,  page  162)  made  any  attempts  to  alter  appropriate  Bm-3c  promoter- 
luciferase reporter gene constructs by site-directed mutagenesis extremely problematic 
if not impossible.  Site-directed mutagenesis is  a PCR based  technique and  success is 
dependent  on  suitable  DNA  sequence  flanking  the  target  site  for  specific  primer 
annealing;  the  highly repetitive  nature  of the  -3432poly-G  polymorphism  (the  target 
site) and surrounding promoter sequence prevented this line of analysis. In addition, no 
suitable restriction enzyme sites were found adjacent to the -3432poly-G polymorphism 
and  prior  to  the  -3457(GA)n  repeat  to  facilitate  sub-cloning  of  Bm-3c  promoter- 
luciferase  reporter  gene  constructs  by  restriction  enzyme  digest.  Therefore,  Bm-3c 
promoter-luciferase reporter gene constructs that differ in the nature of the poly-G allele 
(p-Luc-SNPGl -566GT23  and p-Luc-SNPG2_566GT23) also differ in the length of the -3495 
(GT)n repeat according to their native 5’-haplotypes (see Fig. 5.1 la, page  199). For the
197purpose of these experiments the GT repeat at -566 in the Bm-3c promoter [-566(GT)n. 
23,  see  Fig.  4.16,  section  4.5,  page  162]  was  standardised  at  23  repeats  and  this  is 
reflected in the construct labelling: p-Luc-SNPGl_566G T 23 and p-Luc-SNPG2_566GT23 (the 
importance of the 5’haplotype in the Bm-3c promoter on regulation of the Bm-3c gene 
is  explored  further  in  Chapter  6  and  is  illustrated  by  analysis  of the  effect  of the  - 
566(GT)n variant on Bm-3c promoter activity).
To examine whether the nature of the poly-G allele at position -3432 in the Bm- 
3 c  promoter  has  an  effect  on  basal  expression  levels  of Bm-3c,  Bm-3c  promoter- 
luciferase reporter gene constructs p-Luc-SNPGl-566G T 23  and p-Luc-SNPG2_566GT23 (the 
experimental reporter gene constructs) were transfected into OC-2 cells along with the 
renilla  luciferase  expression  vector pRL-SV40  (Promega)  as  an  internal  control  (Fig.
5.1  lb). The renilla luciferase expression vector, pRL-SV40 contains the simian virus 40 
(SV40) early enhancer / promoter region to provide strong constitutive expression from 
the renilla luciferase  gene  (Rluc)  in transfected mammalian cells.  By normalising the 
activity of Flue  from the experimental  reporter gene constructs  (p-Luc-SNPGl_566G T 23 
and p-Luc-SNPG2.566GT23) to that of Rluc (the internal control reporter gene) intra- and 
inter-  experimental  variation  resulting  from  differences  in  transfection  efficiency and 
cell  viability is minimised.  Furthermore, because Flue and Rluc activities  are assayed 
sequentially within  a  single  sample under conditions  of the dual-luciferase®  reporter 
assay  system  (Promega;  see  section  5.1.2)  intra-  and  inter-  experimental  variation  is 
reduced with a high degree of accuracy and variability manifesting from preparation of 
extracts for assay is eliminated. This line of analysis showed that basal activity between 
Bm-3c promoter-luciferase reporter gene constructs that differ in the nature of the poly- 
G allele at -3432 does not differ significantly;  activity from both p-Luc-SNPGl^Gra 
and  p-Luc-SNPG2_566GT23  is  approximately  3-fold  higher  than  that  from  the  empty 
pGL3-Basic vector alone (Fig.  5.11b; mean RLV: 272.04 ± 7.34 versus 281.80 ± 8.87, 
respectively). These results suggest that the nature of the poly-G allele at position -3432 
and  native  5’-haplotype  does  not  appear to  modulate basal  transcriptional  activity of 
Bm-3c,  at  least  under  these  culture  conditions.  Indeed,  the  results  imply  that  the 
differential  affinity  between  poly-G  alleles  SNPG1  and  SNPG2  for  OC-2  derived 
nuclear protein A and / or C (section 5.3) has no  affect on basal promoter activity of 
Bm-3c.
In the absence of observing an effect of the nature of the poly-G allele on basal 
promoter activity of Bm-3c and in order to assess whether the high affinity SPI binding 
site, allele SNPG1 or the low affinity SPI binding site, allele SNPG2 has a functional
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Figure  5.11  Effect  of  the  -3432  poly-G  polymorphic  on  basal  Brn-3c  promoter  activity  and 
activity of the Bm-3c promoter in response to exogenous SPI. (a) A schematic diagram (not to scale) 
to  illustrate  the  5’  haplotype  of the  3.6Kb  Bm-3c  promoter-luciferase  reporter  gene  constructs  that 
contain either allele SNPG1  or allele SNPG2 at position -3432.  (b) OC-2 cells were transfected with 
500ng of either p-Luc-SNPGl5660T23, p-Luc-SNPG2566oT23 or the empty pGL3-Basic vector. The renilla 
expression vector pRL-SV40  (lOOng)  was  used as an  internal  control  to  normalise for differences in 
transfection efficiency.  (C) OC-2 cells were co-transfected with 500ng of either p-Luc-SNPGl5660T 23 or 
p-Luc-SNPG2566oT23 in the presence of increasing amounts (0, 0.5,  1, 2 & 3pg) of SPI expression vector 
(pSi-SPl). The empty pSi expression vector was used to standardise DNA concentrations between wells 
and  the  renilla  expression  vector phRL-null  (10ng)  was used as an  internal  control  to  normalise for 
differences in transfection efficency. Error bars on charts represent the standard error of the mean. RLV: 
relative  luciferase value.  Luciferase activities shown on charts are expressed:  (b) relative to the empty 
vector or (C):  relative to each construct in the absence of stimulation by assigning a RLVof 100. Each 
experiment was performed in triplicate and  repeated  at least twice with two different preparations of 
DNA.
effect on Bm-3c promoter activity, activity of p-Luc-SNPG1.566GT23 and p-Luc-SNPG2. 
566G T 23  in  response  to  exogenous  SPI  from  an  SPI  expression  vector was  examined 
(Fig.5.11c).  The  mammalian  expression  vector  pEVR2-Spl  containing  the  complete 
human cDNA for SPI has been described previously (Hagen et al,  1992) and was kindly 
provided by Professor Guntram  Suske, University of Marburg,  Germany.  Using vector 
pEVR2-Spl  the  cDNA  for  SPI  was  sub-cloned  into  the  pSi  mammalian  expression 
vector (Promega) for constitutive expression in the OC-2 cell line (see method section 
3.2.8.2).  In  these  experiments  the  renilla  luciferase  expression  vector  phRL-null
199(Promega) that lacks eurkaryotic promoter and /or enhancer sequences was selected for 
use as an internal control. The SP1  transcription factor was originally identified via its 
ability to transactivate the SV40 early promoter as a virtue of its ability to recognise and 
specifically bind multiple GC-rich sites within this promoter (Dynan and Tjian,  1983; 
Gidoni  et  al,  1984).  Accordingly,  the pRL-SV40 vector that  contains the  SV40  early 
enhancer  /  promoter  region  and  which  was  used  as  an  internal  control  in  initial 
experiments  to  examine basal  Bm-3c promoter activity (Fig.  5.11b)  is unlikely to be 
suitable  for  co-transfections  with  an  SP1  expression  vector.  The  expression  of Rluc 
from the pRL-SV40 vector may be subject to anomalous regulation by exogenous SP1. 
In contrast the phRL-null vector not only lacks known eurkaryotic promoter / enhancer 
sequences but is from the ‘second generation’ phRL series of Renilla luciferase vectors 
and  contains  a  synthetic  Renilla  luciferase  gene  (hRluc)  that  lacks  the  majority  of 
mammalian  transcription  factor  binding  sites  exhibited  by  the  native  gene  including 
consensus sites for SP1. These features make the phRL-null vector much more suitable 
as a control reporter gene for co-transfection experiments incorporating exogenous SP1.
Preliminary  experiments  were  performed  to  examine  the  effect  of  the  SP1 
expression  vector,  pSi-SPl,  on  the  backbone  of the  empty  pGL3Basic  vector  (see 
method  section  3.2.14).  Having ascertained  that pSi-SPl  had  negligible  effect  on the 
backbone  of the  empty  pGL3Basic  vector  increasing  amounts  of pSi-SPl  were  co­
transfected  into  OC-2  cells  alongside  Bm-3c  promoter-luciferase  reporter  gene 
constructs  that  carried  either  the  high  affinity  SP1  binding  allele  SNPG1  (p-Luc- 
SNPGI-566G T 23) or the low affinity SP1  binding allele SNPG2 (p-Luc-SNPG2_566GT2) at 
position -3432 (see, Fig.  5.11c).  In each titration experiment the empty pSi expression 
vector  (Promega)  was  used  to  standardise  DNA  concentrations  between  wells  to 
minimise  the  possible  affect  of  inter-well  variation  in  DNA  concentration  on 
transfection  efficiency.  This  line  of analysis  showed  that  SP1  has  little  effect  on  the 
Bm-3c promoter construct carrying allele SNPG1; two, four and six-fold excess of pSi- 
SP1  vector  only increases  Bm-3c promoter  activity by  14,  19  and  35%,  respectively 
(Fig.  5.11c).  In  contrast  a  somewhat  greater,  although  not  significantly  different 
response is observed if allele SNPG2 is present; two,  four and six-fold excess of pSi- 
SP1  vector  increases  expression  from  p-Luc-SNPG2.566GT23  by  25,  41  and  96%, 
respectively  (Fig.  5.11c;  these  results  are  not  significantly  different  when  tested  by 
paired  t-test  analysis).  These  results  show  that  neither  Bm-3c  promoter-luciferase 
reporter  gene  construct  that  carries  allele  SNPG1  or  allele  SNPG2  is  strongly 
transactivated  by  exogenous  SP1.  Hence,  suggesting  that  SP1  has  little  effect  on
200regulation of Bm-3c promoter activity. This is despite the finding that EMSA data show 
allele  SNPG1  to  contain  a high  affinity SP1  binding site (section  5.3.2).  It is possible 
that the  SP1  binding  site  at  -3432  in the  Bm-3c promoter,  which is  modulated by the 
nature  of the  poly-G  alleles,  does  not  play  an  important  role  in  Bm-3c  regulation. 
Alternatively,  it  is possible that  endogenous  SP1  expression in OC-2  cells may not be 
limiting under these experimental  conditions  and hence adding  a source of exogenous 
SP1  into  these  cells  does  not  influence  Bm-3c  promoter  activity.  Indeed,  SP1  is  a 
housekeeping gene and expression is thought to be ubiquitous (for reviews see Philipsen 
and Suske,  1999; Kaczynski et al, 2003; Zhao and Meng, 2005).  In the mouse, levels of 
SP1  vary greatly during embryonal  development; depending on the cell  type and stage 
of development the levels of SP1  mRNA vary at least  100-fold  and this is reflected at 
the protein  level  (Saffer et  al,  1991).  However, it has not been ascertained whether the 
OC-2  cell  line  that  is  derived  from  inner  ear  sensory  epithelia  in  the  H-2Kb-taA58 
Immortomouse at E l3  immediately before hair cells undergo their final mitosis express 
SP1.
In  light of these findings western immunoblot analysis was performed on OC-2 
nuclear  extracts  to  assess  whether  the  OC-2  cell  line  expresses  SP1  (Fig.  5.12).  The 
mouse monoclonal  anti-SPl  antibody  [SP1  (1C6)  X,  Santa  Cruz  Biotechnology,  Inc.] 
used  in  supershift  analysis  (section  5.3.1.3)  was  used  at  a  dilution  of  1:10,000.  In 
mammalian  cells  SP1  exists  in  two  isoforms of 95  and  106Kda.  Western  immunoblot 
analysis of OC-2 nuclear extracts revealed a clear band immediately below the standard 
Rainbow™  coloured  protein  molecular  weight  marker  band  of 97.4  kDa  (Fig.  5.12). 
This is in agreement with the 95kDa isoform for SP1  and confirms SP1  is expressed in 
the  OC-2  cell  line.  Although,  attempts  were  not made  to  quantify the amount  of SP1 
protein  expressed  it  is  clear  that  the  OC-2  cell  line  expresses  SP1  and  therefore,  it  is 
possible that SP1  is not limiting in OC-2 cells under the culture conditions used.
Marker band 
97.4kDa
Figure  5.12  Western  immunoblot  of OC-2  nuclear  extracts with  anti-SPl  antibody.  24pg  OC-2 
nuclear  extract  was  resolved  via  8%  SDS-polyacrylamide gel  electrophoresis,  transferred  to  a  Hybond 
™-C nitrocellulose membrane and probed with primary antibody (diluted  1:10,000):  mouse monoclonal 
anti-SPl  antibody [SP1  (1C6) X,  Santa Cruz Biotechnology Inc.].  Secondary antibody HRP-conjugated 
goat  anti-mouse  antibody (DAKO)  was  used  at a  1:1000  dilution.  Arrow denotes  the presumptive  SP1 
band. Position of the 97.4kDa Rainbow™ protein molecular weight marker band is indicated.
Presumptive 
SP1  band
201Accordingly,  it  is  feasible  that  the presence  of endogenous  SP1  in  OC-2  cells  could 
have  confounded  analysis  using  an  SP1  expression  vector  and  masked  any effect  of 
exogenous SP1 on Bm-3c promoter activity.
5.4.1  A  dominant  negative  approach  to  assess  whether  the  differential 
affinity for SP1  at the  -3432  polymorphic  site  has  a functional  affect on 
Brn-3c promoter activity.
It is possible that endogenous SP1  levels are not limiting in OC-2 cells and that this is 
responsible  for  the  limited  effect  observed  when  an  SP1  expression  vector  is  co­
transfected  with  Bm-3c promoter-luciferase reporter gene  constructs  containing either 
the high affinity SP1  binding allele, SNPG1  (p-Luc-SNPGl-566GT 23) or the low affinity 
SP1  binding allele, SNPG2 (p-Luc-SNPG2_566GT23) (Fig- 5.11c, page 199). In agreement 
with  this  suggestion  Western  immunoblot  analysis  confirms  that  the  OC-2  cell  line 
expresses  SP1  (Fig.  5.12).  Therefore,  a dominant negative approach using a truncated 
form of SP1  was undertaken in an attempt to assess the affect of the differential affinity 
for SP1  at the -3432 polymorphic site when SP1 levels are limiting.
The dominant negative SP1  expression vector pEBGN-SPl  has been described 
previously  (Petersohn  and  Thiel,  1996)  and  has  been  successfully  used  in  transient 
transfection assays to establish the role of SP1  in gene regulation (Lietz et al, 2003; Al- 
Sarraj  et al, 2005). The pEBGN-SPl  vector encodes a fusion protein of glutathione S- 
transferase (GST) linked to the DNA binding domain (DBD) of SP1  under the control 
of the human polypeptide chain elongation factor 1  a promoter. It is not known whether 
this promoter is active in OC-2 cells. In order to use this truncated form of SP1 in OC-2 
cells PCR primers were designed to amplify a fragment from the pEBGN-SPl  vector 
that contained the cDNA for the SV40 nuclear localisation signal  (NLS) linked to the 
DBD of SP1  (see method section 3.2.8.2) and this fragment was subcloned into the pSi 
mammalian  expression  vector (Promega)  for constitutive  expression  in the  OC-2  cell 
line (pSi-DBD-SPl).  The dominant negative mutant SP1  protein lacks the N-terminal 
activation domain; the bipartite glutamine rich activation domain is absent (Courey and 
Tjian,  1988) (Fig. 5.13a). Hence, although the truncated SP1 protein is able to recognise 
and bind to  its cognate sites  it is unable to activate gene expression.  This means that 
exogenous dominant negative SP1  protein has the ability to compete with endogenous 
SP1  for SP1 DNA-binding elements and once bound to render these sites inaccessible to 
endogenous SP1 and block activation.
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Figure 5.13 A dominant negative approach to assess whether the differential affinity for SP1 at the 
-3432 polymorphic site has a functional affect on Bm-3c promoter activity, (a i & ii) A schematic 
diagram (not to scale) to illustrate dominant negative SP1 expression vector compared to SP1 expression 
vector.  Features of the pSi expression vector backbone (Promega) are shown as black shaded boxes,  i. 
SP1 expression vector illustrating the N-terminal glutamine rich activating domains and C-terminal zinc 
finger DNA binding domain of SP1 (Hagen et al,  1992). ii. Dominant negative SP1 lacks the N-terminal 
portion of the protein (Petersohn and Thiel,  1996). The SV40 nuclear localisation signal (NLS) is 5’ to 
the zinc finger DNA binding domain (orange shaded box), (b) OC-2 cells were co-transfected with 500ng 
of either p-Luc-SNPGl566G T23 or p-Luc-SNPG2566G T 23 in the presence of increasing amounts (0, 0.5,  1,2 
& 3pg) of dominant negative SP1  expression vector (pSi-DBD-SPl). The empty pSi expression vector 
was used to standardise DNA concentrations between wells and the renilla expression vector phRL-null 
(lOng) was used as an internal control to normalise for differences in transfection efficency. Error bars on 
charts  represent  the  standard  error of the  mean.  Luciferase  activities  are  expressed  relative  to  each 
construct in the absence of stimulation by assigning a relative value of 100 (RLV). The experiment was 
performed in triplicate and repeated at least twice with two different preparations of DNA. The difference 
in activity between p-Luc-SNPGlseeom and p-Luc-SNPG2566oT23 constructs is significantly different at 
p<0.05 (paired t-test; d.f. = 4).
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transfected  in  OC-2  cells  with  Bm-3c  promoter-luciferase  reporter  gene  constructs 
containing either the high affinity SP1 binding allele, SNPG1  (p-Luc-SNPGl_566G T 23) or 
the  low  affinity  SP1  binding  allele,  SNPG2  (p-Luc-SNPG2.566GT23) (Fig-  5.13b).  This 
line  of analysis  showed  that  activity  of both  Bm-3c  promoter  constructs  is  clearly 
affected  by  the  presence  of  dominant  negative  SP1.  Six-fold  excess  of  dominant 
negative  SP1 expression vector reduces Bm-3c promoter activity by 40%  from p-Luc- 
SNPG1-566G T 23- In comparison, this reduction in promoter activity is induced on p-Luc- 
SNPG2-566GT23 with as little as 2-fold excess of dominant negative SP1. Indeed, at 4-fold 
excess, dominant negative SP1   reduces expression from p-Luc-SNPG2_566GT23 by 60% 
(Fig.  5.13b);  this  reduction  in  activity  is  equivalent  to  the  basal  level  of  activity 
exhibited by the empty pGL3-Basic vector alone (Fig.  5.11a).  These results show that 
the  Bm-3c  promoter  construct  that  carries  the  high  affinity  SP1  binding  site,  allele 
SNPG1,  is  less  sensitive  to  the  activity  of dominant  negative  SP1  compared  to  that 
containing  allele  SNPG2,  a much  lower  affinity  SP1  binding  site.  This  difference  is 
statistically significant p<0.05 (paired t-test) and suggests that the nature of the poly-G 
allele and native 5’-haplotype is important for Bm-3c regulation when  SP1  levels are 
limiting.  Moreover, when taken together with EMSA analysis (section  5.3) these data 
suggest  that  the  nature  of the poly-G  allele  at  -3432  is  a  critical  determinant  of this 
response;  the differential binding affinity between poly-G  alleles  SNPG1  and SNPG2 
for SP1  alters the regulation of the Bm-3c promoter when SP1  levels are limiting in a 
way which is consistent with their respective binding affinities for SP1.
In summary, a possible model to explain this result is: under standard OC-2 cell 
culture conditions endogenous SP1  levels are probably not limiting. Endogenous SP1 is 
present in excess and therefore, the differential affinity for SP1  between poly-G alleles 
SNPG1  and SNPG2 does not have an effect on basal transcriptional activity of Bm-3c 
(Fig.  5.11b).  Consequently,  adding  exogenous  SP1  in  the  form  of  the  pSi-SPl 
expression  vector  has  very  little  effect  on  Bm-3c  promoter  activity  (Fig.  5.11c). 
However, if the culture conditions are changed such that SP1  levels are limiting by co­
transfection of dominant negative  SP1  mutant  (pSi-SPl-DBD) the differential  affinity 
for SP1  between poly-G alleles SNPG1  and SNPG2 has an affect on Bm-3c promoter 
activity (Fig.  5.13b).  The high  affinity SP1  binding site,  allele  SNPG1  is presumably 
able to retain endogenous SP1, or at least for longer periods compared to allele SNPG2 
and therefore is not readily susceptible to the presence of excess dominant negative SP1 
(Fig.  5.13b).  In  contrast,  under these  culture  conditions  the  low  affinity  SP1  binding
204site,  allele  SNPG2  is probably less able to  retain endogenous  SP1  binding and  hence, 
readily  succumbs to the  presence  of excess  dominant  negative  SP1  (Fig.  5.13b).  This 
putative model is summarised in Fig. 5.14.
SP1  levels not limiting
— X--------------   --------------X—
SNPG1  SNPG2
(b) SP1  levels limiting
SNPG1 SNPG2
Figure  5.14  A  putative  model  to  illustrate  how  the  differential  binding  affinity  between  poly-G 
alleles SNPG1 and SNPG2 for SP1 alters the regulation of the Brn-3c promoter when SP1 levels are 
limiting,  (a)  When  SP1  levels are not limiting the differential affinity for SP1  between poly-G alleles 
SNPG1  and SNPG2 (illustrated by thick and thin black shaded arrows,  respectively) does not have an 
affect  on  Bm-3c  promoter  activity;  the  high  affinity  SP1  binding  allele,  SNPG1,  readily  binds  SP1 
(shown as a red shaded circle) and the low affinity SP1 binding allele, SNPG2, can bind SP1 albeit with 
lower affinity,  (b)  When SP1  levels are limiting, the high affinity  SP1  binding allele,  SNPG1,  retains 
endogenous SP1, or at least for longer periods compared to allele SNPG2 and is not readily susceptible to 
the presence of excess dominant negative SP1  (shown as a blue shaded arc). In contrast, the low affinity 
SP1 binding allele,  SNPG2, is less able to retain endogenous SP1 binding and readily succumbs to the 
presence of excess dominant negative SP1. X denotes the -3432 poly-G polymorphic site in the Bm-3c 
promoter.
2055.5  The  -3432poIv-G  polymorphism  modulates  the  binding  of
SP3.
SP1  has  been  shown  to  competitively  interact  with  other  transcription  factors  for 
binding  to  the  same  cis-acting  motifs  including  Egr-1  (Ackerman  et  al,  1991; 
Thottassery et al,  1999) and MAZ (Her et al, 2003); the competitive interplay between 
SP1  and opponents such as these for cis-element occupation is regarded as an important 
mechanism in the control of gene expression. Within the SP family the ability of SP1 to 
competitively interact with SP3 for the same binding elements is well documented (for 
reviews  see  Suske,  1999;  Kaczynski  et  al,  2003).  Indeed,  SP1  and  SP3  share  95.1% 
amino  acid  homology  within  the  zinc  finger  DNA  binding  domain  and  all  residues 
predicted to interact with DNA are identical (see Kaczynski et al, 2003). Therefore, the 
ability of SP3  to bind  to  the Bm-3c promoter within the  vicinity of the  -3432poly-G 
polymorphism was investigated.
To  expedite  this  analysis,  EMSA  analysis  using  in-vitro  translated  SP3  was 
performed with poly-G alleles known to contain the highest and lowest affinity for SP1 
(Fig.  5.15). This approach showed that SP3 binds to probe SNPG1  (a high affinity SP1 
binding site) to form a shifted protein-DNA complex that appears equivalent in intensity 
to that observed when the consensus SP1  binding site is used as the probe (Fig.  5.15a, 
lanes  1   & 2  respectively).  In contrast no  SP3  binding is observed to probe SNPG2  (a 
low affinity SP1 binding site) (Fig. 5.15a lane 3), presumably because allele SNPG2 has 
a  much-reduced  affinity  for  SP3.  Competition  analysis  with  25-fold  excess  of the 
unlabelled  SNPG1  probe  induces  a moderate reduction  in the  intensity of the  shifted 
complex  formed  by  the  binding  of  in-vitro  translated  SP3  to  the  SP1  consensus 
sequence,  with  the  total  disappearance  of this  shifted  complex  evident  at  200-fold 
competition (Fig.  5.15b, lanes  1, 3  and 6).  In comparison, the unlabeled SNPG2 probe 
does not appear to induce any significant reduction of the shifted complex (Fig. 5.15b, 
lanes  1,  4  and  7).  Taken  together,  these  results  confirm  that  the  high  affinity  SP1 
binding allele, SNPG1  has a much greater affinity for SP3 compared to the low affinity 
SP1  binding  allele,  SNPG2.  Similar  analysis  was  performed  using  in-vitro  translated 
SP1  and this was in agreement with the data obtained using OC-2 nuclear extracts and 
recombinant SP1 protein (section 5.3).
Having established that allele SNPG1,  a high affinity SP1  binding site, is also 
capable of binding SP3, the ability of SP1  and SP3 to competitively interact at this site 
was examined. The SNPG1 probe was incubated with increasing amounts of in-vitro
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Figure 5.15 Effect of -3432 poly-G polymorphism on binding of SP3. (a) The labelled SP1  consensus 
sequence (lanes  1   & 4), SNPG1  probe (lanes 2 & 5) or SNPG2 probe (lanes 3 & 6) were incubated in the 
presence of 5pl  SP3  in-vitro translate  (lanes  1-3) or 5pl  T7  in-vitro translate  as a negative control  for 
endogenous protein binding (lanes 4-6). The T7 in-vitro translate contains a luciferase encoding plasmid 
under the control of the T7 RNA polymerase promoter (Promega). The arrow denotes the location of the 
shifted protein-DNA complex formed by the binding of IVT SP3 to the labelled probes, (b) The labelled 
SP1  consensus  sequence was  incubated  in the presence of 5pl  SP3  in-vitro translate  in the absence of 
competitor (lane  1) or in the presence of a molar excess of unlabelled SP1 consensus sequence (lanes 2 & 
5), SNPG1 (lanes 3 & 6) or SNPG2 (lanes 4 & 7). (c) The SNPG1 probe was incubated in the presence of 
3.5pl  SP1  in-vitro translate (lanes  1-3) in the presence of increasing amounts of SP3  in-vitro translate: 
lpl (lane 2) and 2pl (lane 3); lpl SP3 in-vitro translate (lanes 4-6) in the presence of increasing amounts 
of SP1  in-vitro translate: 3.5pl (lane 5) and 7pi (lane 6) or 8pl T7 in-vitro translate as a negative control 
for endogenous protein binding. Figure 5.15c is reproduced in full in Appendix E.
translated SP3 as the amount of in-vitro translated SP1  in the binding reaction was held 
constant  (Fig.  5.15c).  This  line  of analysis  showed  that  the  complex  formed  by  the 
binding of in-vitro translated SP1 to probe SNPG1 progressively diminishes in intensity
207as  the  complex  formed  by  the  binding  of in-vitro  translated  SP3  to  probe  SNPG1 
intensifies.  Hence  suggesting that  SP3  is  able to  competitively displace  SP1  from the 
high  affinity  SP1  binding  site  on  allele  SNPG1.  When  the  reverse  experiment  was 
performed and the amount of in-vitro translated  SP3  in the binding reaction was held 
constant as the amount of in-vitro translated SP1 was increased (Fig. 5.15c) the complex 
formed by the binding of in-vitro  translated  SP3  to  probe  SNPG1  did  not  appear to 
diminish  in  intensity  although  the  complex  for  in-vitro  translated  SP1  clearly 
intensified. These results suggest that SP3 is somewhat effective at displacing SP1  from 
probe SNPG1  but clearly, SP1  shows little ability to displace SP3, at least under these 
assay conditions.  In light of these preliminary observations it is possible that SP1  and 
SP3  competitively interact  for  SNPG1  allele binding.  However,  based  on the limited 
preliminary data available it is not possible to ascertain whether this is the case.
2085.6  Effect  of  the  differential  affinity  for  SP3  at  the  -3432
polymorphic site on Brn-3c promoter activity.
It is widely recognised that SP1 functions as a transactivator of transcription, and SP3 as 
a repressor, able to repress SP1-mediated transactivation (Hagen et al,  1994; for review 
see Suske,  1999). EMSA analysis using in-vitro translated SP3 shows that SP3 can bind 
with high affinity to  allele  SNPG1,  a high affinity SP1  binding site  and  similarly the 
low affinity SP1  allele,  SNPG2,  shows a much-reduced affinity for SP3  (section 5.5). 
To assess whether the differential affinity for SP3  at the -3432 polymorphic site has a 
functional  affect  on  regulation  of  the  Bm-3c  gene  a  titration  experiment  with  an 
expression vector for SP3 was performed in OC-2 cells.
The Drosophilia  expression vector pPac-USp3  containing the complete human 
SP3 cDNA has been described previously (Dennig et al, 1996) and was kindly provided 
by  Professor  Guntram  Suske,  University  of Marburg,  Germany.  Using  vector  pPac- 
USp3  the  cDNA  for  SP3  was  sub-cloned  into  the pSi  mammalian  expression  vector 
(Promega) for constitutive expression in the OC-2 cell line (see method section 3.2.8.2). 
Preliminary experiments were performed to  examine the  effect of the  SP3  expression 
vector, pSi-SP3,  on the backbone of the empty pGL3Basic vector (see method section 
3.2.14).  Having ascertained that pSi-SP3  had negligible effect on the backbone of the 
empty pGL3Basic vector increasing amounts of SP3  expression vector (pSi-SP3) were 
co-transfected  with  Bm-3c  promoter-luciferase  reporter  gene  constructs  containing 
either the high affinity SP binding site, allele SNPG1  (p-Luc-SNPGl-566G T 23) or the low 
affinity SP binding site, allele SNPG2 (p-Luc-SNPG2.566GT23) in the presence of phRL- 
null vector as an internal control (Fig. 5.16). This approach showed that SP3 has only a 
moderate effect on the Bm-3c promoter construct carrying allele SNPG1; two, four and 
six-fold excess of pSi-SP3  vector reduced Bm-3c promoter activity by 5, 21  and 34% 
respectively (Fig.  5.16).  In contrast no appreciable reduction in activity is observed if 
the Bm-3c promoter construct contains allele SNPG2, even at six-fold excess pSi-SP3 
vector  expression  is  not  significantly reduced  from  p-Luc-SNPG2.566GT23  (Fig.  5.16). 
These  observations  are  consistent  with  the  respective  binding  affinities  of  alleles 
SNPG1  and SNPG2 for SP3 in EMSA analysis (see section 5.3, Fig.  5.15a and b) but 
are not significantly different when tested by paired t-test analysis. Taken together, this 
data  suggests  that  the  differential  affinity  for  SP3  at  the  -3432  polymorphic  site has 
some effect,  albeit  subtle,  on  regulation  of Bm-3c  promoter  activity although  not  at 
statistically significantly different levels (paired t-test analysis). Expression of SP3
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Figure  5.16  Effect  of  the  -3432poly-G  polymorphism  on  activity  of  the  Brn-3c  promoter  in 
response to exogenous SP3. OC-2  cells were co-transfected with  500ng  of either p-Luc-SNPG 1  566g t 23 
or  p-Luc-SNPG2 566GT23  in  the  presence  of increasing  amounts  (0,  0.5,  1,  2  &  3pg)  of SP3  expression 
vector  (pSi-SP3).  The  empty  pSi  expression  vector  was  used  to  standardise  DNA  concentrations 
between  wells  and  the  renilla  expression  vector  phRL-null  (lOng)  was  used  as  an  internal  control  to 
normalise  for differences  in  transfection efficency.  Error bars  on  charts  represent  the  standard error of 
the mean.  Luciferase  activities are  expressed relative to each construct in the absence of stimulation by 
assigning  a  relative  value  of  100  (RLV).  The  experiment  was  performed  in  triplicate  and  repeated  at 
least twice with two different preparations of DNA.
similar  to  that  of its  sister  factor,  SP1,  is  thought  to  be  ubiquitous  (for  reviews  see 
Kaczynski et al, 2003; Zhao and Meng, 2005). Accordingly, it is possible that the subtle 
differences in Bm-3c promoter activity as observed are due to endogenous expression of 
SP3 in OC-2 cells.
Interestingly,  a  zinc  titration  in  the  EMSA  binding  assay  revealed  enhanced 
formation  of a  nuclear  protein-DNA  complex,  designated  D,  on  probes  SNPG1  and 
SNPG2 as the concentration of zinc in the binding reaction was increased; this complex 
is  arguably more prominent on probe SNPG1  compared to probe SNPG2 (see Fig.  5.5 
comparing  lanes  2  and  3  with  6  and  7,  and  10  and  11,  page  182).  These  findings 
suggests the presence of a nuclear protein(s) (hereafter referred to as nuclear protein D) 
that may be a zinc finger transcription factor and which may have a greater affinity for 
allele SNPG1  compared to allele SNPG2.  It was not possible to investigate the identity 
of nuclear protein D further within the scope of this project but from this limited data it 
is tempting to speculate that it may be SP3.
Depending  on  the  promoter  and  cellular  context,  SP1-mediated  promoter 
activity  can  be  attenuated  by  SP3  (Hagen  et  al,  1994;  for  review  see  Suske,  1999). 
Indeed,  for  some  SP1-responsive  genes  the  nuclear  SP1:SP3  ratio  appears  to  be 
important in regulating gene expression (Hoppe and Francone,  1998; Hata et al,  1998).
210From the limited competitive interaction studies presented in this thesis using in-vitro 
translated SP1  and SP3  (Fig.  5.15c, page 207) it was not possible to confirm that SP1 
and  SP3  competitively  interact  for  SNPG1  allele  binding.  However,  it  would  be 
interesting to investigate this possibility further and to extend this line of analysis to the 
rest of the -3432poly-G alleles in particular the low affinity SP binding allele SNPG2. 
At present it is clear that the nature of the poly-G allele at position -3432 in the Bm-3c 
promoter is  a determinant of SP1  (Fig.  5.8a,  page  189)  and  SP3  binding (Fig.  5.15b, 
page 207) but whether this translates into competitive interplay between SP 1   and  SP3 
for binding  site  occupation  and  whether the  nature  of the poly-G  allele modifies  the 
dynamics  of this  interaction is not yet clear.  If this  occurred  it would be tempting to 
speculate  that  the  nuclear  SP1:SP3  ratio  is  at  least  one  mechanism  whereby  the  - 
3432poly-G polymorphism modulates  expression  of the Bm-3c gene.  To  explore this 
notion,  extended  competitive  interaction  studies  would  need  to  be  performed  and 
supported with transient transfection assays using SP1  and  SP3  expression vectors.  In 
this  regard  Drosophila  Schneider’s  SL-2  cells  may  prove  useful  (Schneider,  1972). 
Unlike  the  sensory  epithelial  OC-2  cell  line  derived  from  the  inner  ear  of 
Immortomouse,  SL-2  cells  are  an  embryonic  cell  line  derived  from  Drosophila  and 
hence, do not resemble the physiological context of hair cells. However, SL-2 cells are 
devoid of endogenously expressed SP proteins and have been widely used to investigate 
the affect of SP1  and / or SP3  on the control of human gene expression (Courey and 
Tjian, 1988; Hoppe and Francone, 1998; Suske, 2000; Koutsodontis et al, 2001).
2115.7  Effect of the -3432poIv-G  polymorphism  in the context of a 
heterologous promoter.
The transient transfection assays designed to investigate the effect of the -3432poly-G 
polymorphism on Bm-3c promoter activity have so far focussed on using 3.6Kb Bm-3c 
promoter  fragments  containing  conserved  haplotypes  5’  of  the  -3432  poly-G 
polymorphism (the -3495(GT)n repeat and -3457(GA)n  repeat appear in strong linkage 
disequilibrium with the -3432 poly-G polymorphism; see Table 4.4, section 4.4.2, page 
160).  Consequently it  is  important to  remember that  Bm-3c promoter constructs that 
differ  in  the  nature  of  the  poly-G  allele  (p-Luc-SNPGl_566G T 23  and  p-Luc-SNPG2. 
566G T 23) also  differ in the length of the -3495(GT)n repeat  according to their native  5’ 
haplotype (see Fig.  5.11a for haplotype of Bm-3c promoter constructs, page  199). The 
precise contribution, if any, of the -3495(GT)n repeat on basal promoter activity of Bm- 
3c  (Fig.  5.11b,  page  199)  or  on  activity  of  Bm-3c  promoter  constructs  when  co­
transfected with an expression vector for SP1  (Fig. 5.1 lc, page 199), dominant negative 
SP1  (Fig.  5.13b,  page  203)  or  SP3  (Fig.  5.16b,  page  210)  cannot be delineated  from 
these data.  Indeed, it is impossible to exclude that the -3495(GT)n repeat has an affect 
on the  significantly different  activity of the Bm-3c  promoter when  constructs  p-Luc- 
SNPG1-566G T 23  and  p-Luc-SNPG2.566GT23  are  co-transfected  with  an  expression  vector 
for dominant negative SP1  (Fig. 5.13b, page 203). The repetitive nature of the sequence 
variants and their close proximity meant it was not possible to generate constructs that 
only varied  at  the  -3432  poly-G  position.  However,  the  EMSA  data is  very  strongly 
suggestive that the region  spanning the -3432poly-G polymorphism  is responsible  for 
the altered response of the Bm-3c promoter to  SP1  and SP3  (see section 5.3  and 5.5). 
EMSA  analysis  using  different  lengths  of the  -3495(GT)n repeat  as  probe  to  assess 
whether  SP1  and  SP3  can bind  to  this  sequence  and whether binding is  modified by 
repeat  length may have been  informative.  However,  there  is  very little  evidence that 
transcription factors can bind dinucleotide repeats compared to much evidence they can 
bind tri-, tetra-, and penta-nucleotide repeat motifs (Albanese et al, 2001; Contente et al, 
2002; Iglesias et al, 2004). Certainly a search of the literature revealed no evidence that 
SP1  or SP3 can bind GT dinucleotide repeats. Therefore, in an attempt to obtain further 
clarification of this issue the functional significance of the -3432poly-G polymorphism 
was  examined  in  the  context  of the  SV40  heterologous  promoter  in  contrast  to  the 
native Bm-3c promoter and conserved 5’-haplotype, see Fig. 5.17.
2 1 2The  pGL3-Promoter  vector  (Promega)  contains  an  SV40  promoter  cloned 
upstream of the firefly luciferase gene (Flue); DNA fragments suspected of containing 
putative  enhancer  elements  can  be  examined  by  sub-cloning  them  upstream  or 
downstream  from  the  SV40 promoter  and  assaying for transcriptional  activity.  Using 
the synthetic oligonucleotides that were designed for EMSA analysis of the -3432poly- 
G  polymorphism  (see  method  section  3.2.18,  Table  3.2)  a  series  of pGL3-Promoter 
constructs were devised that contained two concatenated copies of either allele SNPG1 
[pGL3-P(SNPG 1  )2],  allele  SNPG2  [pGL3-P(SNPG2)2],  allele  (G)io  [pGL3-P(G10)2], 
allele  (G)n  [pGL3-P(Gl 1)2],  the  consensus  sequence  for  SPl[pGL3-P(SPl)2]  or  an 
oligonucleotide  containing  a  mutated  SP1  binding  site  [pGL3-P(SPlMut)2]  cloned 
upstream  of the  SV40  promoter  (see  method  section  3.2.8.3  for  details  of construct 
formation;  a  schematic  illustration  of the  constructs  is  shown  in  Fig.  5.17a).  These 
constructs  were  co-transfected  into  OC-2  cells  with  either  pSi-SPl  or  pSi-SP3 
expression  vectors  and  activity was  compared  to  basal  levels  in  the  presence  of the 
empty pSi expression vector (Fig. 5.17b). The phRL-null vector (Promega) was used as 
an internal control to adjust for intra-experimental variation.
This line of analysis showed that in the absence of exogenous SP1  or SP3, basal 
activity from pGL3-Promoter constructs containing two concatenated copies of poly-G 
alleles  SNPG1,  SNPG2,  (G)io or (G)n is very similar and does not differ appreciably 
from  that  of the  empty  pGL3-Promoter  vector  alone  (Fig.  5.17b).  Similarly,  in  the 
presence  of  pSi-SP3  expression  vector  activity  of  each  poly-G-  pGL3-promoter 
construct  does  not  differ  significantly  compared  to  basal  levels  observed  for  each 
construct.  In  response  to  exogenous  SP1  subtle  increases  in  promoter  activity  are 
observed for constructs that contain high affinity SP1 binding alleles; pGL3-P(SNPGl)2 
and pGL3-P(G10)2  exhibit 34% and 21% more activity respectively,  compared to the 
empty  pGL3-Promoter  vector  alone.  In  contrast,  constructs  pGL3-P(SNPG2)2  and 
pGL3-P(Gll)2 that  contain much weaker affinity SP1  binding alleles  show negligible 
increases in activity;  only 6% in each case.  In comparison, in the presence of pSi-SP 1  
expression  vector  activity  of  constructs  pGL3-P(SPl)2  and  pGL3-P(SPlMut)2  that 
contain  two  concatenated  copies  of the  SP1  consensus  sequence  and  a mutated  SP1 
binding site respectively, does not differ significantly from each other nor from that of 
the empty pGL3-Promoter vector alone. It is possible that this lack of enhanced activity 
from construct pGL3-P(SPl)2 containing the  SP1  consensus  sequence may in part, be 
due to the fact that the OC-2 cell line expresses SP1  under standard culture conditions 
(see Fig. 5.12, page 201) and hence, masks any effect of adding exogenous SP1 (pSi-
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Figure 5.17 Effect of the -3432 poly-G polymorphism in the context of a heterologous promoter, (a)
Schematic  diagram  (not  to  scale)  to  illustrate  pGL3-Promoter  luciferase  reporter  gene  constructs  that 
differ  in  the  nature  of the  -3432  poly-G  allele.  Constructs  contain  two  concatenated copies of either the 
SP1  consensus  sequence,  a  mutated  SP1  binding  site,  allele  SNPG1,  SNPG2,  (G)|0  or  (G)u  cloned 
upstream  of the  heterologous  SV40  promoter in pGL3-promoter vector (Promega).  (b)  OC-2  cells  were 
co-transfected  with  500ng  of  either  pGL3-P(empty),  pGL3-P(SPl)2,  pGL3-P(SPlMut)2  pGL3- 
P(SNPG1)2 pGL3-P(SNPG2)2 pGL3-P(G10)2 or pGL3-P(Gll)2 in  the  presence  of 500ng  of either  SP1 
expression vector (pSi-SPl), SP3 expression vector (pSi-SP3) or the empty pSi expression vector. Renilla 
expression  vector  phRL-null  (lOng)  was  used  as  an  internal  control  to  normalise  for  differences  in 
transfection efficency.  Error bars on charts represent the standard error of the mean.  Luciferase activities 
are  expressed  relative  to  pGL3-P(empty)  in  the  absence  of stimulation  by  assigning  a relative  value  of 
100  (RLV).  The  experiment  was  performed  in  triplicate  and  repeated  at  least  twice  with  two  different 
preparations of DNA.
214SP1  expression  vector)  to  these  cells.  Moreover,  it  is  possible  that  these  results  are 
confounded by the fact the  SV40 promoter present in vector pGL3-Promoter contains 
several binding sites for SP1  thus, meaning that the SV40 promoter is already activated 
by endogenous SP1. Therefore, it is very hard to be convinced of any specific effects of 
the  poly-G  alleles  from  this  data  alone  particularly  since  only  subtle  differences  in 
promoter  activity are  observed.  Indeed,  similar  experiments  designed  to  test  putative 
SP1  elements  in  the  context  of a heterologous  promoter  show  SP1  responsive  sites 
exhibit up  to  nine-fold  increased  activity in the presence  of a  SP1  expression vector 
(Hirano et al,  1998).  However, these experiments were performed in Drosophila SL-2 
cells.  Therefore,  in hindsight  it  is  possible that more reliable  and  informative results 
may be obtained by cloning the -3432poly-G alleles in the context of a minimal Bm-3c 
promoter or in the context of a heterologous promoter that lacks multiple SP1  sites such 
as those  exhibited by the  SV40 promoter although,  most  if not  all  promoters  contain 
putative SP1  elements.  Finally, it should be considered that performing these transient 
transfections  in  SL-2  cells  as opposed to  OC-2  cells may yield more clear-cut results 
due to a lack of endogenous SP protein expression.
2155.8  General discussion.
5.8.1  Limitations of functional data generated in-vitro.
The results  of the  EMSA  analysis  and transient transfection  assays  suggest that the - 
3432poly-G  polymorphism  in  the  Bm-3c  promoter  is  a  functional  polymorphism.  In 
particular  protein-DNA  investigations  show  that  the  nature  of  the  poly-G  allele 
modulates the binding of the SP1  transcription factor and there is convincing evidence 
that  this  alters  the  activity  of the  Bm-3c  promoter  when  SP1  levels  are  limiting. 
However,  it  is  important to  remember that  these  results  relate  to  an  in-vitro  context. 
Specific  binding  of a  trans-acting  factor  to  a  cis-acting  element  in-vitro  even  when 
supported  by  functional  studies  to  show  that  the  cis-acting  element  in  question  is 
transcriptionally active, does not mean that the same applies in-vivo. A binding site in- 
vitro may not be accessible in-vivo. EMSA studies are performed with DNA fragments 
of limited length these same regions in-vivo may be masked by the presence of histones 
and other DNA-binding proteins and accordingly may not be available for binding. To 
assess whether a specific transcription factor binds to a specific DNA sequence in-vivo 
chromatin  immunoprecipitation  (ChIP)  assays  can  be  performed  using  a  primary 
antibody specific to the transcription factor in question (see Shang et al, 2000;  Iype et 
al, 2005; for reviews see Spencer et al, 2003  and Das et al, 2004). This line of analysis 
would  be  useful  to  yield  information  on  the  chromatin  context  of the  -3432poly-G 
polymorphic site in the Bm-3c promoter in-vivo; to determine whether the -3432poly-G 
polymorphic site is accessible for transcription factor binding in-vivo and occupied by 
the  endogenous  SP1  protein  as the  EMSA  analysis  suggest  (section  5.3.2).  However, 
this line of analysis is severely hindered by the lack of human sensory hair cell lines and 
the difficulties in obtaining primary hair cells from the human inner ear.
In a similar manner, transient transfections to  investigate promoter activity are 
performed  with  a  DNA  fragment  of a  defined  length.  These  are  isolated  from  their 
normal  chromatin  context  and the influence of distal  enhancer or inhibitory elements 
that  could  further  modulate  promoter  activity  are  excluded  from  analysis.  Indeed, 
enhancer activity has been reported to influence transcription at a distance as great as 
85Kb from the transcription start site (Blackwood et al,  1998). Therefore, it should be 
considered that the size of the Bm-3c promoter fragments used in the luciferase reporter 
gene assays to examine the effect of the -3432poly-G allele on Bm-3c promoter activity 
is  3.6Kb  and  this  may  have  limited  the  magnitude  of  the  response  observed;  all 
promoter elements needed for expression of Bm-3c may not be present.
216Chromatin structure is central to the regulation of gene expression (for reviews 
see Kingston et al,  1996; Lee and Young et al, 2000, see also Biggin, 2001). The basic 
structural monomer of chromatin is the nucleosome comprising a core of 146bp of DNA 
wrapped  around  an  octamer  of histone  molecules;  it  is  the  packaging  of DNA  into 
nucleosomes that can repress or potentiate gene expression depending on the promoter 
context (for review see Lee and Young, 2000).  Hence, in this regard it should also be 
considered that transient transfection assays are limited in that the exogenous promoter- 
reporter gene constructs in the form of plasmid DNA are not integrated into the cellular 
genome  of  the  host  cell  but  instead  are  maintained  extra-chromosomally.  Some 
shortcomings  typical  of transient  transfection  assay can be  rectified by generation  of 
stable  transfectants  although  this  is  a very time  consuming  approach  (for review  see 
Knight, 2003).  Stable transfectants are integrated into the host genome, are “subject to 
position effects  from the surrounding chromatin”  and  accordingly are more typical  of 
the in-vivo DNA packaging than their transient counterparts (Smith and Hager,  1997). 
However, plasmid integration into the genome of a host cell is a random event and not 
necessarily representative of the native chromatin site in-vivo. Reporter gene expression 
can  be  subject  to  anomalous  regulation  by  the  influence  of host  genomic  regulatory 
elements near the site of plasmid integration that are absent from the native chromatin 
site. Consequently, this approach requires analysis of many clones in order to determine 
real  effects  and  the  value  of this  approach  when  looking  for  subtle  differences  in 
expression between two alleles is limited as variation between clones may mask such 
subtle effects (for review see, Knight, 2003). Analysis of mRNA expression profiles in 
different  individuals  that  each  carry  a  distinct  genotype  for  the  -3432poly-G 
polymorphism would allow one to conclude with more certainty whether differences in 
-3432 genotype manifest in differential expression of Bm-3c in-vivo. However, it is not 
possible to perform this line of analysis, as hair cells are experimentally inaccessible.
Thus,  although  transient  transfection  assay  in  OC-2  cells  to  characterise 
common  sequence  variants  in  the  Bm-3c  promoter  is  not  a  substitution  for  in-vivo 
functional  analysis  it  is  clear that this  line of analysis  can undoubtedly give valuable 
insight into the functional effect of sequence variation on Bm-3c regulation.
2175.8.2 Limitations of analysis using Matlnspector software: identification of
nuclear protein C as an example.
Analysis  using Matlnspector  software to  identify putative transcription  factor binding 
sites  within  a  particular  DNA  sequence  is  limited  by  the  comprehensiveness  of the 
database at the time the analysis is performed. Transcription factors yet to be identified 
and transcription  factors  identified but lacking experimental  verification of consensus 
binding site sequence are both unaccounted  for.  With this  in mind the  analysis using 
Matlnspector  software  was  repeated  on  the  poly-G  allele  sequences  during  the 
preparation of this thesis to see if any recent additions to the database would yield more 
informative results  as to  the identity of nuclear protein  C  (see section  5.3.3).  Results 
from this more recent search revealed that the transcription factor ZIC2 exhibits a high 
matrix  similarity to  all  poly-G  allele  sequences  examined  except  alleles  SNPG1  and 
SNPG5  (see Appendix C). These results are of particular interest as the results of the 
zinc titration experiment (Fig.  5.10, page  195) shows that both poly-G alleles SNPG1 
and SNPG5 appear to have a greater binding affinity for nuclear protein A compared to 
nuclear protein C.  In contrast the remaining poly-G alleles appear to have comparable 
affinities for nuclear proteins C and A, at least in the presence of zinc.
ZIC2  belongs to  the ZIC multigene  family of zinc  finger transcription  factors 
that play a crucial  role in neural  development  (for review  see Aruga,  2004;  Grinberg 
and Millen, 2005). Expression studies on the chick inner ear suggest that the ZIC gene 
family  plays  an  important  role  in  inner  ear  development  (Warner  at  al,  2003). 
Interestingly,  in the chick basilar papilla differential  display analysis  shows that ZIC2 
expression is up-regulated after exposure to acoustic trauma (Gong et al,  1996). Genes 
that  are  differentially  regulated  after  noise  exposure  in  the  chick  inner  ear  may  be 
involved in hair cell repair and survival.  Evidence suggests that Bm-3c functions as a 
pro-survival factor for hair cells of the inner ear (Erkman et al,  1996; Xiang et al,  1997 
and  Xiang  et  al,  1998).  Therefore,  if nuclear  protein  C  is  in  fact,  ZIC2  it  would be 
interesting to investigate whether ZIC2 is involved in Bm-3c regulation in hair cells and 
whether there is a connection between ZIC2 response to  acoustic trauma and the pro­
survival role of Bm-3c.  Furthermore, the possibility that OC-2 derived nuclear protein 
C is ZIC2 is of particular interest when coupled with the fact that ZIC2 has been shown 
to competitively interact with  SP1  and  SP3  for binding site occupation within the 5’- 
flanking region of the human Di a dopamine receptor gene (Yang et al, 2000). The 
-3432poly-G polymorphism constitutes a SP1  and SP3 binding site and the nature of the 
poly-G allele is a determinant of SP1  and SP3 binding (see Fig. 5.7 page  187; Fig 5.8,
218page  189  and  Fig.  5.15,  page  207).  Therefore,  it  would  be  interesting to  investigate 
whether ZIC2 may also interact at this site in the Bm-3c promoter although it was not 
possible to perform this analysis within the time constraints of this project.
2195.9  Conclusion
In  conclusion,  the  -3432poly-G  polymorphism  in  the  Bm-3c  promoter  modifies  the 
binding affinity of at least two OC-2 derived nuclear proteins, A and C. EMSA analysis 
is highly indicative that nuclear protein A is the transcription factor SP1 but attempts to 
identify nuclear protein  C  were not  as successful.  However,  EMSA  analysis  suggests 
that nuclear protein  C  is  a zinc  finger transcription  factor and  it  is  clear that nuclear 
protein C  is  distinct to  nuclear protein A.  Further investigation incorporating purified 
human  recombinant  SP1  protein  (Promega)  in  EMSA  analysis  and  Bm-3c  promoter- 
luciferase reporter gene constructs in transient transfection assay in OC-2 cells suggests 
that  the  -3432poly-G  polymorphism  in  the  Bm-3c  promoter  is  a  functional 
polymorphism; the nature of the poly-G allele modulates the binding of SP1 and there is 
convincing evidence  that  this  alters  the regulation of the  Bm-3c promoter when  SP1 
levels  are  limiting,  p<0.05  (paired  t-test).  It  is  well  established  that  SP1  can 
competitively interact with SP3  for binding to the same binding sites (for reviews see 
Suske,  1999  and  Kaczynski  et  al,  2003)  and  that  for some  SP1-responsive  genes  the 
nuclear  SP1:SP3  ratio  is  an  important  determinant  of  gene  regulation  (Hoppe  and 
Francone,  1998; Hata et al,  1998). With this in mind, attempts were made to establish 
whether SP1  and SP3 competitively interact at the -3432 polymorphic site in the Bm-3c 
promoter but it was not possible to  ascertain whether this is the case.  However,  from 
EMSA  analysis  using in-vitro  translated  SP3  it is  clear that  the nature  of the poly-G 
allele is a determinant of SP3 binding and transient transfection assays incorporating an 
SP3  expression  vector  suggest  this  has  an effect,  albeit  subtle,  on  Bm-3c  promoter 
activity  although  not  at  significantly  different  levels  when  tested  by  paired  t-test 
analysis.  Collectively,  these  findings  raise  the  possibility  that  the  -3432poly-G 
polymorphism  in the Bm-3c promoter may be a risk factor for late onset hearing loss 
exhibited  by  a  large  proportion  of  the  ageing  population;  this  line  of  analysis  is 
discussed  further  in  Chapter  8  as  part  of  a  preliminary  association  study.  The 
physiological  significance  of SP1  on  Bm-3c  regulation  in  hair  cells  is  not  known  at 
present. The role of SP1  in Bm-3c regulation is explored further in the next Chapter by 
analysis  incorporating  the  effect  of the  -566(GT)n  repeat  polymorphism  on  Bm-3c 
promoter activity.
2 2 06.0  Functional  Characterisation  Of  Dinucleotide 
Repeat Sequence Variation At The Brn-3c Locus.
6.1  Introduction.
DNA  sequence  variation  can  manifest  in  many  forms  from  single  nucleotide 
substitutions  to  DNA  elements  that vary only by changes  in the number of sequence 
repeats.  Sometimes  the  variation  is  much  more  complex  with  DNA  elements 
comprising both of these features such as the -3432poly-G polymorphism identified in 
the Bm-3c promoter (see Chapter 5).  Repetitive DNA elements,  also known as simple 
sequence repeats (SSRs) are tandem repeats of nucleotide motifs. Those that arise from 
short  motifs;  interactions  of  l-6bp  the  mono-,  di-,  tri-,  tetra-  and  penta-nucleotide 
repeats are commonly known as microsatellites. Whereas, those that form longer motifs, 
up  to  60bp  are termed minisatellites.  The  former  are  generally less  than  lOObp  long; 
repeat number ranging from 2 up to a couple of dozen. Whereas, the later can reach up 
to  20Kb  in  length  with  repeat  number  extending  into  the  hundreds  (for  reviews  see 
Kashi  et  al,  1997;  Li  et  al,  2002;  Ellegren,  2004).  The  majority  of microsatellite 
sequence variation arises with the short dinucleotide repeating motifs and is generally 
multi-allelic with a bimodal allelic distribution. The most abundant dinucleotide repeat 
is the (CA / TG)n motif; estimated to occur every 20-30Kb in mammals (Stallings et al, 
1991).  Dinucleotide  microsatellites  as  with  the  mono-,  tri-,  tetra-  and  penta- 
microsatellites are mainly located within non-coding regions of the eukaryotic genome 
and by comparison  are relatively rare within regions  that encode proteins  (for review 
see Li  et al,  2002).  Trinucleotide repeats are the exception to this rule;  they are often 
found within protein-coding regions and for some time have known to be linked with 
disease  (Stallings,  1994).  The  neurodegenerative  disorder  Huntington’s  disease  is  a 
good example; caused by an expansion of the triple repeat (CAG) in the coding region 
of the Huntington’s disease gene that is translated into expanded tracts of polyglutamine 
(for review see Zoghbi and Orr, 2000).
Originally  microsatellites  were  considered  to  be  just  ‘junk’  DNA  or 
evolutionarily neutral  genetic markers but there is now increasing evidence that some 
microsatellites  play  a  functional  role.  Their  involvement  has  been  documented  in  a 
range  of  cellular  processes  to  include  gene  regulation,  chromatin  organisation  and
221regulation of DNA metabolic processes such as recombination (for review see Li et al, 
2002).  Indeed,  there  is  substantial  evidence  that  polymorphic  dinucleotide  repeats 
located in non-coding regions have quantitative effects on gene expression able to both 
repress (Wu et al,  1994 and Gebhardt et al,  1999) and enhance gene expression (Akai et 
al,  1999,  Borrmann  et  al,  2003  and  Tadokoro  et  al,  2004).  However,  the  exact 
mechanism  as  to  how  they  do  so  is  still  not  well  understood.  The  ability  to  adopt 
alternative  secondary  structure  conformations  such  as  Z-DNA  (a  left-handed  double 
helix which lacks the major groove characteristic of the common right-handed B-DNA 
double helix  typically exhibited  by the  DNA  sequence)  appears  to  play an  important 
role  (Rothenburg  et  al,  2001).  Alternating  (CG)n repeats  most  readily  form  Z-DNA, 
followed  by  (CA  / TG)n and  (TA)n  repeats  (Rich  et  al,  1984).  In  addition,  evidence 
suggests that certain microsatellites may act as cis-regulatory elements by the binding of 
transcription factors (Albanese et al, 2001; Contente et al, 2002; Iglesias et al, 2004). In 
many  of these  cases  repeat  number  plays  a  key  role;  the  ability  of p53  to  strongly 
transactivate  the  p53-induced  gene  3  (PIG3)  is  dependent  on  the  length  of  a 
pentanucleotide repeat in the PIG3 promoter to which p53 binds (Contente et al, 2002). 
Furthermore, there is accumulating evidence that polymorphic dinucleotide repeats that 
modulate gene regulation may contribute to inter-individual differences in susceptibility 
to disease (Searle et al,  1999, Yamada et al, 2000, Kodama et al, 2004). For example, a 
polymorphic  dinucleotide  (GT)n  repeat in the  5’-flanking region of the human heme 
oxygenase-1   (HO-1)  gene  that  has  a  functional  affect  on  HO-1  gene  transcription  is 
associated with chronic pulmonary emphysema susceptibility  (Yamada et al, 2000).
Three polymorphic dinucleotide repeats have been  identified in the Bm-3c 5’- 
flanking  region  which  appear  common  in  the  general  population:  two  (GT)n 
dinucleotide  repeats  at  positions  -566  and  -3495  and  a  (GA)n  dinucleotide repeat  at 
position  -3457  (see  section  4.5  and  Fig.  4.16,  page  162).  It  is  possible that one or a 
combination  of these  dinucleotide  repeats  could  have  quantitative  effects  on  Bm-3c 
expression.  Indeed,  the human type I collagen a2  (COL1A2) gene is regulated by the 
combination of two polymorphic dinucleotide repeats: one in the 5’-flanking region and 
one in the first intron of the COL1A2 gene (Akai et al, 1999). Therefore, in the search to 
identify common  sequence variants  at the Bm-3c locus that are functional  and which 
may be a risk factor for late onset hearing loss exhibited by a large proportion of the 
ageing population  the  three  polymorphic  dinucleotide repeats  at  position  -566,  -3457 
and  -3495  in  the  Bm-3c  5’-flanking  region  were  considered  good  candidates  for 
functional analysis.
2 2 26.2  Strategy  to  investigate  the  significance  of  dinucleotide 
repeat sequence variation  at position -566, -3457 and -3495 on 
Brn-3c regulation.
There  is  increasing  evidence  that  polymorphic  dinucleotide  repeats  located  in  non­
coding  regions  can  modulate  gene  regulation  as  discussed  (section  6.1).  Three 
polymorphic dinucleotide repeats have been identified in the Bm-3c 5’-flanking region: 
-566(GT) 17.23, -3 4 5 7(GA)i_3 and -3 4 9 5 (GT)is.2i, 24 raising the possibility that either or a 
combination of these repeats may have quantitative effects on Bm-3c expression. The - 
3457(GA)n repeat and the -3495(GT)n repeat are located immediately adjacent to each 
other in the Bm-3c 5’-flanking region; the -3457(GA)n repeat begins immediately at the 
3-prime end of the -3495(GT)n repeat (see section 4.5, Fig.  4.16, page  162).  From the 
initial  PCR-SSCP  screen  and  subsequent  genotyping  analysis  of  the  -3432poly-G 
polymorphism  for  a  preliminary  association  study  it  was  clear  that  the  -3495(GT)n 
repeat  and  -3457(GA)n  repeat  appeared  in  strong  linkage  disequilibrium  with  the  - 
3432poly-G  polymorphism  thus  forming  native  haplotypes  5’  of the  -3432  poly-G 
polymorphism (see section 4.4.2, Table 4.4,  page  160 and section 4.5, Fig. 4.16, page 
162).  Due  to  the complexity of this region of the  Bm-3c promoter upstream  of the - 
3432poly-G  polymorphism  resulting  from  the  high  amount,  the  proximity  and  the 
repetitive nature  of the variation identified complete characterisation of haplotypes  at 
positions -3432,  -3457 and -3495 in all individuals examined was not possible (this is 
discussed  further  in  section  4.4.2,  page  158).  However,  where  it  was  possible  to 
decipher haplotypes were of definite combinations as far as could be determined from 
the analysis performed. For example, if poly-G allele SNPG1  was present at position - 
3432  then  the  corresponding  native  5’  haplotype  consisted  of  -3 4 5 7 (GA)2  and  - 
3 4 9 5 (GT)i5.  An  altered  haplotype  configuration  was  not  observed  5’  of the  poly-G 
polymorphism  if allele  SNPG1  was  present.  Similarly,  if poly-G  allele  SNPG2  was 
present  at  position  -3432  the  native  5’  haplotype  consisted  of  -3 4 5 7(GA)2  and  - 
3495(G T )2o or 21.  The -3 4 5 7 (GA)3 was very rare. To emphasise, a long -3495 GT repeat 
length was never observed in conjunction with allele SNPG1  and conversely a short - 
3495  GT repeat length was never observed in concert with allele SNPG2.  Haplotypes 
that it was possible to identify are summarised in Table 4.4, section 4.4.2, page 160.
Given the repetitive nature of the sequence variants at -3432, -3457 and -3495 
and  their  proximity  any  attempts  to  alter  appropriate  Bm-3c  promoter-luciferase
223reporter  gene  constructs  by  site  directed  mutagenesis  would  prove  extremely 
problematic  if not  impossible.  Furthermore,  no  suitable  restriction  enzyme  sites  are 
found between these sequence variants to facilitate sub-cloning of alternative haplotype 
combinations  by  restriction  digest.  The  complexity  of  this  region  of  the  Bm-3c 
promoter  in  the  vicinity  of  the  -3432poly-G  polymorphism  limited  the  nature  of 
functional  analysis  that  could  be  performed  (a  similar  discussion  of the  difficulties 
encountered with functional analysis is presented in section 5.4, page  197). Therefore, 
with these caveats in mind it was decided to assess the significance of the -566, -3457 
and -3495  dinucleotide repeats on Bm-3c promoter activity by examining the function 
of the  dinucleotide (GT)n repeat  at  position  -566  in  the  context  of the  -3432poly-G 
polymorphism and native 5’ haplotype at -3457 and -3495.
The  results  of the  PCR-SSCP  screen  of the  Bm-3c  locus  on  45  individuals 
suggests  that  the  -566  GT  dinucleotide  repeat  in  the  Bm-3c  promoter  is  a  common 
sequence  variant  and  repeat  alleles  ranging  in  length  from  16  to  23  repeats  were 
identified  through  subsequent  sequencing  analysis  (see  section  4.4.1,  page  152). 
However, the -566(GT)n repeat was not genotyped in our sample cohorts as part of the 
preliminary association study as genotyping the -3432poly-G polymorphism constituted 
a large part of this project (see Chapter 8). Therefore, it was not known which of the 
alleles (n =  16 to 23) identified from preliminary analysis of the -566(GT)n repeat were 
the  most  common  in  the  general  population.  Moreover,  with  the  exception  of the 
original PAC clone from which a 3.6Kb fragment of the Bm-3c promoter was isolated, 
it was not known in which context the -566(GT)n  repeat existed in nature with the - 
3432poly-G polymorphism and native 5’ haplotype at -3457 and -3495. Furthermore, of 
these  combined  haplotypes  incorporating  the  -566(GT)n  repeat,  -3432poly-G 
polymorphism, -3457(GA)n repeat and -3495(GT)n repeat it was not known which were 
the most common in the general population. The complexity of the Bm-3c promoter 5’ 
of  the  -3432poly-G  polymorphism  made  identification  of  the  naturally  occurring 
common haplotypes at -3495, -3457, -3432 and -566 technically difficult. Therefore, it 
was  decided  to  devise  controlled  haplotypes  5’of the  -566(GT)n repeat  based  on  the 
limited  allele  information  known  and  to  examine  the  significance  of the  -566(GT)n 
repeat in the  context of the -3432poly-G polymorphism  and  native  5’  haplotype (at - 
3495 and -3457) under these conditions.
In  some  cases  it  is  clear  that  the  actual  dinucleotide  repeat  number  is  a 
determinant of the effect of the dinucleotide repeat on gene regulation (Gebhardt et al, 
1999; Shimajiri et al,  1999). Often, the two extremes in dinucleotide repeat length have
224pronounced effects.  For example, using a nuclear run-off assay, transcriptional activity 
of  the  epidermal  growth  factor  receptor  (EGFR)  gene  was  found  to  decline  with 
increasing length of a highly polymorphic dinucleotide (CA)n repeat in the first intron of 
this gene; in particular the longest allele examined (n = 21) inhibited transcription of the 
EGFR gene by 80% compared to the shortest allele examined (n =  16) (Gebhardt et al, 
1999).  Similarly, luciferase-reporter gene assays designed to assess the importance of a 
dinucleotide (CA)n repeat at position -90 in the promoter of the matrix metalloproteinase 
9 (MMP-9) gene showed that in oesophageal carcinoma cell  lines an MM-9-luciferase 
reporter gene construct that carried the (CA)m allele exhibited only 50% of the activity 
of the MM-9-luciferase reporter gene construct that carried the (CA)2i  allele (Shimajiri 
et  al,  1999).  Consequently,  when  designing  Bm-3c  promoter-luciferase  reporter  gene 
constructs  to  examine  the  significance  of the  -566  dinucleotide  (GT)n repeat  in  the 
context  of  the  -3432poly-G  polymorphism  and  native  5’  haplotype,  emphasis  was 
placed on the two extremes of the -566(GT)n repeat length:  16 and 23 repeats.
The  common  -3432poly-G  alleles  SNPG1  and  SNPG2  that  were  originally 
identified as part of the PCR-SSCP  screen have native  5’  haplotypes that consist of a 
short  and  a  long  -3495(GT)n repeat,  respectively  (see  Table  4.4,  section  4.4.2,  page 
160). Therefore, poly-G alleles SNPG1  and SNPG2 and their native 5’ haplotypes at - 
3457  and  -3495  were  selected  to  form  the  distal  5’  haplotypes  of Bm-3c  promoter- 
luciferase  reporter  gene  constructs  designed  to  assess  the  significance  of  the  -566 
dinucleotide (GT)n repeat in the context of the -3432poly-G polymorphism and native 5’ 
haplotype. Using luciferase reporter vector pGL3-Basic (Promega) and a 3.6Kb Bm-3c 
promoter fragment that contained allele SNPG1 and native 5’ haplotype of -3457(GA)2: 
-3495(GT)i5  a  series  of constructs  were  generated  on  a  common  backbone  to  carry 
different lengths of the dinucleotide (GT)n repeat at position -566 (see method section 
3.2.8.1  for details of construct formation).  Specifically, repeat number varied from 23 
repeats  (p-Luc-SNPGl_566GT23) to  20 repeats  (p-Luc-SNPGl-566G T 2o)>  to  16  repeats  (p- 
Luc-SNPGl-566GTi6)  to  represent  constructs  containing  the  longest,  intermediate  and 
shortest lengths of the -566 dinucleotide (GT)n repeat, respectively (a clear illustration 
of the variation present in the constructs is given Fig 6.1a, page 228; of these constructs, 
construct p-Luc-SNPG1.566GT20 contains a naturally occurring haplotype at -3495, -3457, 
-3432  and  -566  as  it  was  derived  from  the  original  PAC  clone  containing  a  3.6Kb 
fragment of the Bm-3c promoter).  Similarly using poly-G allele SNPG2 with native 5’ 
haplotype -3457(GA)2: -3495(GT)2i, the dinucleotide (GT)n repeat at position -566 was 
varied from  23  (p-Luc-SNPG2.566GT23)  to  16  repeats  (p-Luc-SNPG2.566GTi6)  (a  clear
225illustration of the variation present in the constructs is given see Fig. 6.1a, page 228; see 
method  section  3.2.8.1  for details  of construct  formation).  This  formed  five different 
3.6Kb Bm-3c promoter-luciferase reporter gene constructs that each carried a distinct 5’ 
haplotype of the Bm-3c promoter for use in functional analysis.
2266.3  The significance of -566(GT)n repeat sequence variation on 
Brn-3c  promoter  activity  in  the  context  of  the  -3432poIv-G 
polymorphism and native 5’ haplotype.
In an attempt to examine the significance of the -566(GT)n repeat on Bm-3c promoter 
activity in the context of the -3432poly-G polymorphism and native 5’  haplotype five 
different luciferase reporter gene constructs that each carried a distinct 5’ haplotype of 
the  Bm-3c  promoter  were  generated:  p-Luc-SNPGl_566GT23,  p -L u c-S N P G 1.566GT20,  p- 
LU C -SN PG 1-566GT16,  p -L u c-S N P G 2 _566GT23  and  p -L u c-S N P G 2 -566GTi6  (see  Fig.  6.1a). 
Notably in these constructs the length of the dinucleotide (GA)n repeat at position -3457 
did not vary; both allele SNPG1  and SNPG2 have a native -3457(GA)n  repeat number 
of two. Accordingly, the effect, if any, of the -3457 dinucleotide (GA)n repeat on Bm-3c 
promoter activity could not be assessed in these experiments.
6.3.1  Effect of -566(GT)n  repeat sequence variation on basal activity of the 
Brn-3c  promoter  in  the  context  of  the  -3432polv-G  polymorphism  and 
native 5’ haplotype.
To  assess  whether  the  length  of the  -566(GT)n  repeat  allele  has  an effect  on  basal 
activity  of the  Bm-3c  promoter  each  of the  five  Bm-3c  promoter-luciferase  reporter 
gene constructs carrying a unique 5’ haplotype of the Bm-3c promoter were transfected 
into  OC-2  cells  along with the pRL-SV40 vector (Promega)  as  an  internal  control  to 
adjust for intra- and inter-experimental variation (Fig. 6.1b). The results of this analysis 
showed  that  changing  the  length  of the  -566(GT)  repeat  from  23  to  16  repeats  has 
negligible effect on basal  activity of the Bm-3c promoter if poly-G allele SNPG2  and 
the long native GT repeat at -3495 form the distal 5’ haplotype (Fig. 6.1b; mean RLV: 
281  ± 8.87 versus 286.06 ± 8.29, respectively).  In contrast, varying the length of the - 
566(GT)n repeat from 23 to 20 to  16 repeats has a subtle effect on basal activity of the 
Bm-3c promoter when the distal 5’ haplotype consists of poly-G allele SNPG1  and the 
short native GT repeat at -3495 (Fig. 6.1b). Most evidently, basal activity from construct 
p-Luc-SNPG 1-566G T 20  that  carries  a  -566(GT)n  allele  of  20  repeats  is  24%  greater 
compared  to  that  from  construct  p-Luc-SNPG1.566GT23 that  carries  a  -566(GT)  repeat 
length  of  23  repeats  (Fig.  6.1b;  mean  RLV:  338.04  ±  11.86  versus  272.09  ±7.34, 
respectively) and this difference is statistically significant, p<0.05 ( t-test).
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Figure  6.1  Effect  of  -566(GT)n   repeat  sequence  variation  on  basal  activity  of  the  Brn-3c 
promoter  in  the  context  of  the  -3432poly-G  polymorphism  and  native  5’  haplotype.  (a)  A
schematic diagram (not to scale) to illustrate the five 3.6Kb Bm-3c promoter-luciferase reporter gene 
constructs that each carry a distinct 5’haplotype of the Bm-3c promoter.  -3432 poly-G allele SNPG1 
and  native  5’  haplotype  is  highlighted  in  red  whereas  -3432poly-G  allele  SNPG2  and  native  5’ 
haplotype is highlighted in blue.  The length of the  -566 GT repeat was varied from  16 to 20 to 23 
repeats  as  indicated,  (b)  OC-2  cells were transfected with  500ng of either p-Luc-SNPG 1 566oti 6,  p- 
Luc-SNPG 1566OT20,  p-Luc-SNPG 1566gt23,  p-Luc-SNPG25660ti6,  P-Luc-SNPG2566gt23  or  the  empty 
pGL3-Basic  vector as  indicated.  The  renilla  expression vector pRL-SV40  (lOOng)  was  used  as  an 
internal control to normalise for differences in transfection efficiency. Error bars on charts represent 
the standard error of the mean.  Luciferase activities are expressed relative to the empty pGL3-Basic 
vector  (RLV).  The  experiment  was  performed  in  triplicate  and  repeated  at  least  twice  with  two 
different  preparations  of DNA.  *  p<0.05  (paired  t-test;  d.f.  =  22).  The  data for constructs  p-Luc- 
SNPG1566GT23 and p-Luc-SNPG2 566GT23 is reproduced from Fig. 5.1 lb section 5.4, page  199.
228It is also evident that varying the nature of the poly-G allele at -3432 in the presence of 
a fixed -566(GT)n repeat length has negligible effect on basal transcriptional activity of 
Bm-3c regardless of whether a long (Fig. 6.1b; mean RLV: 272.09 ± 7.34 versus 281.80 
±  8.87  for constructs p-Luc-SNPG 1-566G T23 and p-Luc-  SNPG2.566GT23, respectively)  or 
short (Fig.  6.1b; mean RLV:  305.55 ± 9.53 versus 286.06 ± 8.29 for constructs p-Luc- 
SNPG 1.  566GT 16  and  p-Luc-SNPG2-566GTi6,  respectively)  -566  GT  repeat  length  is 
present.  Taken together, this data suggests that the ability of the GT repeat at -566 to 
modulate basal transcriptional activity of Bm-3c is dependant on the nature of the poly- 
G  allele  at  -3432  and  native  5’  haplotype  at  -3495.  However,  it  is  important  to 
emphasise that where statistically significant differences in basal activity of the Bm-3c 
promoter are observed these results represent small  effects and it is questionable how 
relevant such small changes are to Bm-3c expression.
6.3.2  Effect  of  -566(GT)n   repeat  sequence  variation  on  Brn-3c  promoter 
activity  in  the  context  of  the  -3432polv-G  polymorphism  and  native  5* 
haplotype when SP1  levels are limiting.
Initial  analysis  suggests  that  the  -566(GT)n repeat  in  the  context  of the  -3432poly-G 
polymorphism  and  native  5’  haplotype  has  small  or  limited  effect  on  basal 
transcriptional activity of Bm-3c (Fig. 6.1b). However, it is difficult to be convinced of 
the validity of these results as where differences in basal activity of the Bm-3c promoter 
are observed they are only subtle. Therefore, the significance of the -566(GT)n repeat on 
Bm-3c promoter activity in the context of the -3432poly-G polymorphism and native 5’ 
haplotype was investigated further to obtain greater clarification.
It is established that the nature of the -3432poly-G allele and native 5’ haplotype 
appears  important  to  Bm-3c  regulation  when  levels  of SP1  are  limiting  (Fig.  5.11b, 
section  5.4.1, page  199). Transient transfection assays in OC-2  cells show that Bm-3c 
promoter-luciferase  reporter  gene  constructs  that  carry  allele  SNPG1  (and  native  5’ 
haplotype) are significantly less sensitive to the effect of dominant negative SP1 mutant 
compared  to  constructs  that  carry  allele  SNPG2  (and  native  5’  haplotyep)  p<0.05 
(paired t-test; Fig.  5.13b, section 5.4.1, page 203). Moreover, EMSA analysis is highly 
suggestive  that  it  is  the  nature  of the  poly-G  allele  at  position  -3432  in  the  Bm-3c 
promoter that co-ordinates  this response (see section  5.3).  Therefore,  in an attempt to 
validate the subtle differences in basal activity of the Bm-3c promoter as observed when 
the -566(GT)n repeat is examined in the context of the -3432poly-G polymorphism and
229native  5’  haplotype  (Fig.  6.1b)  this  line  of analysis  was  extended  to  incorporate  the 
effect, if any, of -566(GT)n repeat sequence variation on Bm-3c promoter activity in the 
context  of the  -3432poly-G  polymorphism  and  native  5’  haplotype  under  conditions 
where SP1 is limiting.
Bm-3c promoter-luciferase reporter gene constructs that each carry a distinct 5’ 
haplotype of the Bm-3c promoter were transfected into OC-2 cells alongside increasing 
amounts of dominant negative SP1  expression vector, pSi-DBD-SPl  (see Fig. 6.2). The 
phRL-null vector (Promega) was used as an internal control to adjust for differences in 
intra-  and  inter-experimental  variation.  This  line  of  analysis  showed  that  Bm-3c 
promoter-luciferase reporter gene constructs that carry poly-G allele SNPG1  and native 
5’ haplotype are only sensitive to the effect of dominant negative SP1  mutant when the 
long form of the GT repeat is present at position -566. Increasing amounts of dominant 
negative SP1  expression vector decreases transcriptional activity of the Bm-3c promoter 
in  a  dose-dependent  manner  when  -566(GT)n  contains  23  repeats  but  no  significant 
change in activity is observed if the length of the -566 GT repeat is modified to 16 or 20 
repeats  (Fig.  6.2b).  Moreover,  this  effect  is  not limited  to  Bm-3c promoter-luciferase 
reporter gene constructs that carry allele  SNPG1.  Construct, p-Luc-SNPG2_566GT23 that 
contains poly-G allele SNPG2  and native 5’  haplotype together with the long form of 
the GT repeat at position -566 is extremely sensitive to the effect of dominant negative 
SP1  mutant,  exhibiting  60%  less  activity  in  the  presence  of 4-fold  excess  dominant 
negative  SP1  expression  vector.  Yet,  the  ability of dominant  negative  SP1  mutant to 
reduce  expression  in  this  manner  is  lost  if the  GT  repeat  length  at  position  -566  is 
reduced  from  23  to  16  repeats  (Fig.  6.2b).  These  findings  show  that  regardless  of 
whether  the  poly-G  allele  at  -3432  contains  a  high  (allele  SNPG1)  or  low  (allele 
SNPG2)  affinity  SP1  binding  site  dominant  negative  SP1  mutant  can  only  reduce 
transcriptional  activity from Bm-3c promoter-luciferase reporter gene constructs if the 
long allele of the GT repeat is present at position -566.  However,  it is clear from the 
original analysis (see Fig 5.13b, section 5.4.1, page 203 and for comparison reproduced 
in Fig 6.2b) that in the presence of the long allele of the -566(GT)n repeat the actual 
extent of the reduction in Bm-3c promoter activity depends on the nature of the -3432 
poly-G allele and native 5’ haplotype. If the long allele of the (GT)n repeat is present at 
position -566 in concert with the low affinity SP1 binding allele, SNPG2, at -3432 Bm- 
3 c promoter activity is reduced to a greater extent than if the 5’ haplotype consists of the 
high  affinity  SP1  binding  allele,  SNPG1,  at position -3432.  Taken together,  this data 
suggests that both the length of the GT repeat at position -566 and the nature of the
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Figure  6.2  Effect  of -566(GT)n   repeat  sequence  variation  on  Brn-3c  promoter  activity  in  the 
context of the -3432poly-G polymorphism  and native 5’  haplotype when SP1  levels are limiting.
(a) A schematic diagram (not to scale) to illustrate the five 3.6Kb Bm-3c promoter-luciferase reporter 
gene  constructs  that  each  carry  a  distinct  5’haplotype  of the  Bm-3c promoter.  -3432  poly-G allele 
SNPG1 and native 5’ haplotype is highlighted in red whereas -3432poly-G allele SNPG2 and native 5’ 
haplotype  is highlighted in blue.  The length of the  -566  GT repeat was varied from  16 to 20 to 23 
repeats as indicated,  (b) OC-2 cells were transfected with 500ng of either p-Luc-SNPG 1566g t i6, p-Luc- 
SNPGl5 66O T 20,  p-Luc-SNPG 1566gt23.  P-LUC-SNPG25660T16,  p-Luc-SNPG25660T23  in  the  presence  of 
increasing amounts (0, 0.5,  1, 2 & 3pg) of dominant negative SP1 expression vector (pSi-DBD-SPl). 
The empty pSi expression vector was used to standardise DNA concentrations between wells and the 
renilla expression vector phRL-null (10ng) was used as an internal control to normalise for differences 
in  transfection efficiency.  Error bars on charts  represent  the  standard error of the mean.  Luciferase 
activities are expressed relative to each construct in the absence of stimulation by assigning a relative 
value of 100 (RLV). The experiment was performed in triplicate and repeated at least twice with two 
different preparations of DNA. The data for p-Luc-SNPG lsseora and p-Luc-SNPG2 5660T23 is reproduced 
from Fig. 5.13b, page 203.
p-Luc-SNPG1-  p-Luc-SNPG1-  p-Luc-SNPG1-  p-Luc-SNPG2-  p-Luc-SNPG2-
566GT16  566GT20  566GT23  566GT16  566GT23
231poly-G allele at -3432  and native 5’  haplotype at -3495  are important in regulation of 
the Bm-3c gene when SP1  levels are limiting. It also lends support to the notion that the 
small differences observed in basal activity of the Bm-3c promoter when the GT repeat 
at  -566  is  examined  in  the  context  of the  -3432poly-G  polymorphism  and  native  5’ 
haplotype (see Fig. 6.1b) are real effects.
2326.4  General discussion.
From this study it is not possible to delineate the molecular mechanism(s) by which the 
-566(GT)n  repeat  coupled  with  the  nature  of the  -3432poly-G  allele  and  native  5’ 
haplotype  influences  Bm-3c  regulation,  either  under  basal  conditions  (Fig.  6.1b)  or 
when SP1  levels are limiting (Fig. 6.2b). Indeed, from the limited data presented in Fig. 
6.1b  it  is  not  possible  to  draw  a  clear-cut  relationship  between  Bm-3c  5’  haplotype 
combination  and  corresponding basal  activity of the Bm-3c promoter.  Although,  it is 
evident that constructs that carry poly-G allele SNPG1  at -3432 and native 5’ haplotype 
are sensitive to a change in -566(GT)n repeat length compared to those that carry allele 
poly-G allele SNPG2  and native 5’  haplotype (Fig.  6.1b).  It should be considered that 
had a wider range of haplotype combinations been tested for constructs that carry poly- 
G allele SNPG2 at -3432 a difference in basal activity of the Bm-3c promoter may have 
been observed. However, it was not practical to test all possible haplotype combinations 
and selective haplotype combinations were chosen as discussed previously.
Interestingly,  the  basal  activity  of  Bm-3c  promoter-luciferase  reporter  gene 
constructs that carry poly-G allele SNPG1  at -3432 with the short native GT repeat at - 
3495  (p-Luc-SNPG 1  -566GT16,  p-Luc-SNPG 1  -566GT20  a n d   p-Luc-SNPGL566G T 23)  is  not 
linear with respect to  -566(GT)n repeat length (Fig.  6.1b).  This  suggests that it is the 
juxtaposition  of poly-G  allele  SNPG1  at  -3432  and  native  5’haplotype  with  the  - 
566(GT)n repeat allele that has an affect on basal activity of the Bm-3c promoter rather 
than  the  length  of  the  -566(GT)n  repeat  in  the  context  of  the  -3432poly-G 
polymorphism.  Indeed,  similar data has been observed for the COL1A2 gene (Akai et 
al,  1999).  Transcriptional  activity  of COL1A2  is  enhanced  by  the  presence  of two 
dinucleotide  repeats  (one  in  the  5’-flanking  region  and  one  in  the  first  intron  of the 
COL1A2 gene) and different allelic combinations of repeat length modulate this effect, 
but the quantitative changes in COL1A2 promoter activity are not linearly proportional 
to the length of each dinucleotide repeat. Accordingly, it is proposed that the differences 
in COL1A2 promoter activity are due to the different allele combinations rather than the 
length of each repeat.
In  comparison,  the  data  presented  in  Fig.  6.2b  is  strongly  indicative  that  the 
length of the -566(GT)n repeat in the context of the -3432 poly-G polymorphism  and 
native  5’  haplotype  plays  an  important  role  in  SP1-mediated  regulation  of Bm-3c. 
Specifically,  when  coupled  with  EMSA  analysis  (section  5.3)  the  data  suggest that  a 
functional interplay between the -566(GT)n repeat and the SP1 binding site in the -3432
233poly-G sequence is important to Bm-3c regulation, at least under conditions where SP1 
is limiting.  From this study it is not possible to delineate the molecular mechanism by 
which this may occur however, this data is consistent with several putative models for 
which  there  are  varying  degrees  of evidence  in  other  genes  and  these  will  now  be 
discussed.
6.4.1  Putative  models  to  explain  the  functional  interplay  between  the- 
566(GT)n  repeat and the SP1  binding site in the -3432 polv-G sequence.
SP1  is an extremely well  characterised transcription factor (for reviews see Phillipsen 
and Suske,  1999; Kaczynski et al, 2003; Chu and Ferro, 2005; Zhao and Meng, 2005). 
In addition to a well-known role in formation of the basal transcription complex (Gill et 
al,  1994),  SP1  interacts  with  a multitude of other transcription  factors  (Perkins et  al, 
1994,  Lin et al,  1996 and Lopez-Rodriguez et al,  1997) to play a more specific role in 
gene  expression.  It has been  suggested  that the  ability of SP1  to  confer flexibility to 
DNA upon binding SP1  -recognition motifs, enabling the DNA to bend may facilitate its 
interaction with proteins that are spaced far apart on the DNA sequence (Sjottem et al, 
1997).  Therefore,  it  is  tempting  to  speculate  that  the  shorter  allele  of the  -566(GT)n 
repeat  could  impair  the  binding  of  an,  as  yet  unidentified,  proximally  bound 
transcription factor that associates with SP1  bound at the distal -3432 site and is crucial 
for  SP1-mediated  regulation  of  Bm-3c  expression.  It  could  be  hypothesised  that  a 
proximal transcription factor may bind within the -566 GT dinucleotide repeat, itself. In 
agreement with this concept, the strength of nuclear protein binding to a polymorphic 
CA repeat within the promoter of the MMP-9 gene has been shown to be dependent on 
the  length  of the  CA  repeat;  with  longer  CA  repeat  alleles  showing  a  much  higher 
binding affinity than their shorter counterparts (Shimajiri et al,  1999). Although, in this 
study the nuclear protein was not identified and it may not be a transcription factor. Had 
time permitted EMSA analysis could have been performed with different lengths of the 
-566(GT)n repeat to see if repeat length modified the binding of a transcription factor or 
factors. However, on the whole evidence that transcription factors can bind dinucleotide 
repeats  is  lacking,  although  they  have  been  reported  to  bind  tri-,  tetra-  and  penta- 
nucleotide  repeat  motifs  (Albanese  et  al,  2001;  Contente  et  al,  2002;  Iglesias  et  al, 
2004). Alternatively, it could be hypothesised that a proximal transcription factor binds 
the DNA sequence adjacent to the -566 GT dinucleotide repeat. Certainly, it is feasible 
that an allele containing a shorter -566 GT repeat length could have a significant effect
234on binding of an adjacent transcription factor as flanking DNA sequences can influence 
the  context  and  configuration  of cis-acting elements  (for  example  see  Dawson  et  al, 
1996a).
On the other hand, it may not be the binding of a proximal transcription factor 
that  is  impaired  by  the  shorter  allele  of  the  -566(GT)n  repeat  but  rather  just  its 
association  with  SP1  bound  at  the  distal  -3432  site.  This  is  possible,  it  has  been 
suggested that dinucleotide repeats may serve to bring different regions of a promoter 
into  close proximity (for review see Li  et al,  2002).  Hence, polymorphic dinucleotide 
repeats that vary in length may fold into different secondary conformations that do not 
readily  favour  protein-protein  associations  (for  example  see  Gebhardt  et  al,  1999). 
DNA-bound SP1  is known to self-associate; looping out the intervening DNA such that 
SP1  bound  at  sites  distal  to  the minimal  promoter  can  exhibit  synergistic interaction 
with proximally bound SP1  to enhance transcription (Su et al,  1991, Mastrangelo et al, 
1991).  Consequently,  it  is  tempting  to  speculate  that  if SP1  bound  at  the  -3432  site 
associates  with  a  proximal  transcription  factor  that  this  proximal  transcription  factor 
may be SP1   itself. In support of this concept recent experiments in our laboratory have 
identified a functional  SP1  binding site within the minimal promoter region of Bm-3c 
(Jagutpal  et  al,  unpublished  data).  This  proximal  SP1  binding site  at position -345  is 
sufficiently close to the -566 GT dinucleotide repeat. Therefore, it is certainly possible 
that the shorter allele of the -566(GT)n repeat could hinder the binding or an association 
between SP1  at the proximal -345 site with SP1 bound at the distal -3432 site.
In summary, it is clear that the data suggest a functional interaction between the 
-566(GT)n  repeat  and the  -3432poly-G polymorphism  and native  5’  haplotype which 
associate to determine the response of the Bm-3c gene to  SP1  under conditions where 
SP1  is limiting. The molecular mechanism as to how this occurs is not known but it is 
clear that there are many possibilities, which are supported by evidence in other genes. 
The complexity and repetitive nature of the sequence variants identified (dinucleotide 
repeat  sequence  variation  at  -3495  and  -566  coupled  with  the  multi-allelic  poly-G 
polymorphism  at  -3432)  limited  the  nature  of  functional  analysis  that  could  be 
performed  and hindered  full  investigation of these  effects.  However,  collectively it is 
clear that there is  evidence of common variation in the Bm-3c promoter and there is 
convincing evidence that this has a functional effect on regulation of the Bm-3c gene.
2356.4  Conclusion.
In  conclusion,  transient  transfection  assay  in  OC-2  cells  suggests  that the  -566(GT)n 
repeat in the context of the -3432poly-G polymorphism and native 5’haplotype has an 
affect on basal transcriptional activity of Bm-3c.  Although, where differences in basal 
activity of the Bm-3c promoter are observed between different luciferase-reporter gene 
constructs that each carry a distinct 5’ haplotype of the Bm-3c promoter the differences 
are small and it is questionable how real these effects are. However, it is clear that the 
length  of the  -566(GT)n repeat  in  the  context  of the  -3432poly-G polymorphism  and 
native  5’haplotype has  an  affect  on Bm-3c regulation under conditions where  SP1  is 
limiting. Moreover, when taken together with EMSA analysis (section 5.3.2, page 185) 
the data suggest that a functional interplay between the -566(GT)n repeat and the SP1 
binding site in the -3432poly-G allele sequence is a determinant of this response. These 
results  also  lend  support to  the concept that subtle differences in basal  activity of the 
Bm-3c promoter as observed when the -566(GT)n repeat is examined in the context of 
the  -3432poly-G  polymorphism  and  native  5’haplotype  are  real  effects.  Collectively, 
these results are suggestive that the -566(GT)n repeat in the context of the -3432poly-G 
polymorphism and native 5’ haplotype is functional.
The physiological  significance  of these results  are unknown  and require more 
investigation than was possible within the time constraints of this project to identify the 
signalling  mechanisms  that  regulate  SP1  activity  in  auditory hair  cells.  Furthermore, 
with the exception of construct p-Luc-SNPG 1-566GT20 which carries a naturally occurring 
haplotype  spanning  sequence  variants:  -3495(GT)n,  -3457(GA)n,  -3432poly-G 
polymorphism and -566(GT)n it is important to consider that these results are based on 
data generated using controlled haplotypes 5’of the -566(GT)n repeat.  The complexity 
of the Bm-3c promoter 5’ of the -3432poly-G polymorphism made identification of the 
naturally occurring common haplotypes  at -3495,  -3457,  -3432  and -566 difficult and 
limited the nature of functional analysis that could be performed. It would be interesting 
to assess whether the common native haplotypes at these loci give similar results either 
under basal conditions or when SP1  levels are limiting although the genotyping required 
determining  the  naturally  occurring  common  haplotypes  would  be  technically 
challenging.
2367.0 Functional Characterisation O f-1391 A>C At 
The Brn-3c Locus.
7.1  Introduction.
At the onset of this project an A >C single nucleotide substitution at position -1391  in 
the  Bm-3c  5’-flanking  region  had  been  reported  in  the  public  NCBI  SNP  database, 
NCBI  SNP  Cluster ID:  rsl368402  (see Table 4.1,  section 4.1.1, page  131). However, 
this  sequence  variant  had  not  been  validated  and  the  significance  of  this  single 
nucleotide  substitution  with respect to  Bm-3c regulation  and / or expression was  not 
known.  Mutation  scanning  of the  Bm-3c  gene  by  PCR-SSCP  analysis  coupled  with 
sequencing  confirmed  the presence of the -1391A >C  substitution  and  suggested that 
the  -1391  sequence  variant  is  common  in  the  general  population  with  a  rare  allele 
frequency of 0.28  (based  on  SSCP  analysis  on  45  individuals;  see Table 4.2,  section
4.3.1,  page  146).  There  is  accumulating  evidence  that  common  sequence  variants 
involving a single base change in the nucleotide sequence which manifest within gene 
regulatory regions underlie susceptibility to common,  complex  disease (Dawson et  al, 
1993; Zhang et al,  1999; Jormsjo et al, 2000; Niimi et al, 2002; see also section  1.6.1, 
page  49  and  section  5.1,  page  166).  Consequently,  the  -1391A  >C  single nucleotide 
substitution in the Bm-3c 5’-flanking region could be a risk factor for late onset hearing 
loss exhibited by a large proportion of the ageing population; it may impair the binding 
of a transcription factor needed for regulation of the Bm-3c gene and thus lead to inter­
individual  variations  in  Bm-3c  expression.  Therefore,  as  part  of  the  aim  to  asses 
whether common  sequence variants in the Bm-3c gene are a risk factor for late onset 
hearing  loss  by  first  assessing  whether  they  are  functional,  functional  analysis  was 
performed  on  the  -1391  A  >C  substitution.  This  line  of analysis  is  explored  in  this 
chapter.
2377.2  Effect  of  the  -1391  A  >C  single  nucleotide  substitution  on
binding of OC-2 nuclear proteins .
In  order to  assess  whether the  -1391A >C  single  nucleotide  substitution modifies the 
binding  of nuclear proteins to this region of the Bm-3c promoter EMSA analysis was 
performed using nuclear extracts from OC-2  cells.  Synthetic oligonucleotides spanning 
each  allele  of the  -1391  sequence  variant  in  the  Bm-3c  promoter  were  devised  and 
annealed to  form  double  stranded  probes:  probes  A and  C  representing wild type and 
variant alleles, respectively (see Table 3.2, method section 3.2.18).
In the first instance in order to assess whether the A to C substitution at -1391 in 
the  Brn-3c promoter modifies nuclear protein binding probes A and C were incubated 
with  8-10pg  of OC-2  nuclear  extract  in  the  absence  of competitor  DNA,  Fig.  7.1. 
However, this approach did not reveal differential protein binding between alleles A and 
C  (Fig.  7.1).  Three  main  shifted  protein-DNA  complexes  are  observed  at  analogous 
positions  on  each  probe,  termed  G,  H  and  J  (Fig.  7.1).  The  intensity  of each  shifted 
protein-DNA complex appears similar between each probe suggesting that alleles A and 
C  have  similar  affinities  for the  protein  or proteins  involved  in  the formation  of each 
complex. However, it is possible that a difference in affinity for the protein(s) involved
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Figure 7.1  Binding of OC-2 derived nuclear proteins to alleles -1391A and -1391C. Radiolabelled 
oligonucleotides representing alleles -1391A (lane  1) and -1391C (lane 2) were incubated on ice with 
8-lOfj.g OC-2 nuclear extract. Three main shifted protein-DNA complexes are observed at analogous 
positions  on  each  probe  and  are  denoted by  the  arrows  G,  H  and  J.  The  intensity of each  shifted 
protein-DNA complex appears similar between each probe suggesting that alleles A and C have similar 
affinities for the protein or proteins involved in the formation of each complex.
238in the formation of complex G, H or J exists between alleles A and C but is too subtle to 
be observed directly in this manner (for simplicity one protein will be assumed to be 
involved in the formation of each complex hereafter referred to as protein G, H and J).
To test the possibility that a subtle difference in affinity for one of the proteins 
involved  in  the  formation  of complex  G,  H  or  J  exists  between  alleles  A  and  C 
increasing amounts (25-,  50-,  100-,  500- and  1000-fold excess) of unlabelled A probe 
(Fig. 7.2, lanes 3, 5, 7, 9 &  11) or unlabelled C probe (Fig. 7.2, lanes 4, 6, 8, 10 & 12) 
were used to compete with A probe for binding. This line of analysis showed that allele 
A is able to compete for nuclear protein J; the shifted complex J is reduced at 100-fold 
excess  and  is  further  reduced  in  intensity  as  the  amount  of unlabelled  A  probe  is 
increased 500- fold (Fig. 7.2, comparing lane  1   with 7 and 9). Although, as evident in 
Fig.  7.2,  lane  11  this competition does not proceed to completion; even at  1000-fold 
excess of the unlabelled A probe some nuclear protein J binding is still apparent on
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Figure 7.2 Competition analysis to show the relative affinity of alleles -1391A and -1391C for OC- 
2 derived nuclear proteins.  The -1391A probe was incubated in the absence of nuclear extract (lane 1) 
or in the presence of 8-10pg of OC-2 nuclear extract (lanes 2-13). Increasing amounts of unlabelled A 
probe (lanes 3, 5, 7, 9 & 11) or unlabelled C probe (lanes 4, 6, 8, 10 & 12) were used to compete with A 
probe for binding as indicated.  An unrelated sequence,  a section of exon  1   from the Barhll  gene was 
also used as competitor DNA to test for non-specific binding (lane  13). Shifted protein-DNA complexes 
G, H and J are denoted by the arrows.
239probe A  (Fig.  7.2,  lane  11).  However,  it is clear that when the unlabelled C probe is 
used  as  the  competitor,  the  C  allele  is  unable  to  induce  any  significant  reduction  of 
complex J,  even at  1000-fold competition (Fig. 7.2, comparing lane  1   with  12). These 
results  suggest  that  allele  A  has  a  greater  affinity  for nuclear protein  J  compared  to 
allele C, approximately 10-fold greater (comparing relative levels of competition in lane 
7 with lane 12, Fig. 7.2) and indicate that the interaction of nuclear protein J with alleles 
A and C is sequence specific. The failure of 1000-fold excess of an unrelated sequence 
from  the  Barhll  gene to  compete nuclear protein J  from probe  A  (Fig.  7.2,  lane  13) 
further confirms the sequence specificity of the interaction between allele A and nuclear 
protein J.
From  the  competition  experiment presented  in  Fig.  7.2  it  is  also  evident  that 
complexes  G  and  H  are  progressively  competed  from  probe  A  showing  a  gradual 
reduction in intensity as the amount of unlabelled excess A or C probe is increased (Fig.
7.2  comparing complex G and H in lanes 3-12 with lane 2). However, the intensity of 
complexes G and H, although progressively reduced, is similar between both probes at 
each level of competition. This suggests that alleles A and C have similar affinities for 
the proteins involved in the formation of complexes G and H. In addition, the ability of 
an  unrelated  sequence  from  the  Barhll  gene  to  compete  complex  G  and  to  a  lesser 
extent complex H, from probe A suggests that the interaction of nuclear proteins G and 
H  with probe A is not sequence specific (Fig.  7.2,  lane  13).  Therefore,  in subsequent 
analysis complex J was the focus of further experiments as the data suggest that allele A 
has a greater affinity for nuclear protein J compared to allele C and that the affinity of 
nuclear protein J for allele A is sequence specific.
Initial  EMSA  analysis  suggests that nuclear protein J has a greater affinity for 
allele A of the -1391  substitution compared to allele C (Fig. 7.2). This observation was 
investigated  in  more  depth  using  further  EMSA  analysis.  The  ability of probe  A  to 
retain nuclear protein J binding in the presence of an excess of either the unlabelled A or 
C  probe  was  observed  and  compared  to  the  ability of the  C  probe  to  retain  nuclear 
protein  J  binding  in  the  presence  of the  same  competitors  (Fig.  7.3).  This  line  of 
analysis showed that probe A is able to retain nuclear protein J binding in the presence 
of 500- and 1000-fold excess of the unlabelled C probe (Fig. 7.3 comparing lane 3 with 
6 and 8, respectively). In contrast, in the presence of 500- and  1000-fold excess of the 
unlabelled  A  probe  there  is  a  clear reduction  in  nuclear  protein  J  binding  (Fig.  7.3 
comparing lane 3  with 5  and 7).  These results are consistent with the original  EMSA 
observations, Fig. 7.2 suggesting that allele A has a greater affinity for nuclear protein J
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Figure 7.3 The wild-type allele, A, of the -1391  single nucleotide substitution has a greater affinity 
for OC-2 derived nuclear protein J compared to the variant allele, C. The -1391A probe (lanes 1, 3, 
5-9) or -1391C probe (lanes 2, 4,  10-14) were incubated in the absence of nuclear extract (lanes 1-2) or in 
the presence of 8-1 Opg of OC-2 nuclear extract (lanes 2-14); in the absence of competitor DNA (lanes 1- 
4) or with a molar excess of unlabelled: A probe (lanes 5, 7,  10 &  12), C probe (lanes 6, 8,  11  &13) or 
unrelated sequence, a section of exon  1   of the Barhll  gene (lanes 9 &  14) as indicated. Shifted protein- 
DNA complexes G, H and J are denoted by the arrows.
compared to allele C.  In comparison, when the C allele sequence is used as the probe 
and  the  competition  analysis  is  repeated probe  C  is unable to  strongly retain nuclear 
protein J binding in the presence of excess unlabelled A or unlabelled C probes (Fig. 7.3 
comparing lane 4 with 10-13). In addition, an excess of the unlabelled A probe appears 
to reduce nuclear protein J binding on the C probe to a greater extent than an equivalent 
excess of the unlabelled C probe (Fig. 7.3 comparing lanes  10 with 11  and  12 with 13). 
This is consistent with the data from the reverse experiment (Fig. 7.3 lanes 5-8) and the 
original observations (Fig. 7.2) suggesting that allele A has a greater affinity for nuclear 
protein J  compared to  allele C.  Taken together,  these observations (Fig.  7.2  and  7.3) 
confirm that the wild-type allele, A, of the -1391  substitution has a greater affinity for 
OC-2 derived nuclear protein J compared to the variant allele, C. The ability of 1000- 
fold excess of an unrelated sequence from the Barhll  gene to compete with the C probe 
but not the A probe for nuclear protein J binding (Fig. 7.3 comparing lanes 3 with 9 and 
4 with  14) is consistent with these observations and further suggests that the affinity of
241nuclear protein J for allele C is very low or that the interaction of allele C with nuclear 
protein J is non-specific.
In  summary,  from  initial  EMSA  analysis  performed  on  the  -1391  single 
nucleotide substitution it is evident that a difference in affinity between alleles A and C 
for nuclear protein J is only apparent if nuclear protein J binding on probe A or probe C 
is competed for with an excess of either the unlabelled A probe or unlabelled C probe 
(Fig.  7.2 and 7.3). This is presumably because nuclear protein J is an abundant protein 
in  the  OC-2  cell  line  and  therefore,  in  the  absence  of competitor  DNA  both  alleles 
exhibit  similar  levels  of binding.  However,  competition  analysis  (Fig.  7.2  and  7.3) 
clearly  illustrates  that  the  -1391  sequence  variant  in  the  Bm-3c  promoter  modifies 
binding affinity for OC-2  derived nuclear protein J.  Therefore, in subsequent analysis 
investigation was based on identification of nuclear protein J.
7.2.1  Identification of nuclear protein J.
Competition  analysis  has  shown  that  the  wild  type  allele,  A  of  the  -1391  single 
nucleotide substitution in the Bm-3c promoter has  a greater affinity for OC-2 derived 
nuclear protein J  compared to the variant allele,  C.  Therefore,  attempts were made to 
identify nuclear protein J. Matlnspector software (described in section 5.3.1, page  177; 
www.genomatix.de/products/MatInspector/index.html) was used to screen each allele of 
the -1391  sequence variant for putative cis-acting elements. The results of this analysis 
implicated  early  growth  response  gene  3  product  (Egr-3)  and  growth  factor 
independence-1   (Gfi-1) as possible candidates for nuclear protein J based on similarity 
of  the  sequence  in  the  vicinity  of the  -1391  sequence  variant  with  the  consensus 
sequences for these transcription factors (see Appendix F). A putative Gfi-1 binding site 
is located immediately 3’  of the -1391  sequence variant;  the 5’  nucleotide of the core 
sequence used by Matlnspector software to identify putative Gfi-1  binding sites is only 
8bp downstream of the -1391  sequence variant. Whereas, a putative Egr-3 binding site 
is located immediately 5’  of the -1391  sequence variant;  the 3’  nucleotide of the core 
sequence used by Matlnspector software to identify putative Egr-3 binding sites is only 
6bp upstream of the -1391 sequence variant (see Appendix F).
Egr-3  and Gfi-1  are both zinc finger transcription factors characterised by three 
(Patwardhan et al,  1991) and six (Gilks et al,  1993) copies of the (Cystein)2(Histidine)2 
type zinc finger motifs, respectively. Egr-3 belongs to the Egr family of immediate early 
response  genes  that  are  transiently  activated  in  response  to  environmental  signals
242includingsignals that induce proliferation, differentiation and apoptosis (for review see 
Thiel  and  Cibelli  et  al,  2002).  Gfi-1  is  a  cellular proto-oncogene  that  functions  as  a 
transcriptional  repressor via  a 20  amino-acid N-terminal  Snail/Gfi-1  (SNAG)  domain 
(Grimes et al,  1996a; Zweidler-Mckay,  1996; for review see Moroy, 2005).  Currently, 
only one other closely related homologue has been identified, Gfi-lb (Tong et al, 1998).
To  assess  whether  nuclear  protein  J  may  be  a  member  of the  Egr  or  Gfi-1 
transcription  factor  families  competition  analysis  was  performed;  the  A  probe  was 
incubated with OC-2 nuclear protein extracts in the presence of increasing amounts (25- 
,  100-, 500- and 1000-fold excess) of either the unlabelled Egr consensus sequence (Fig. 
7.4,  lanesl0-13)  or the unlabelled  Gfi-1  consensus  sequence  (Fig.  7.4,  lanes  5-8;  for 
consensus sequences see Table 3.2 method section 3.2.18). This approach showed that 
complex  J  is  not  competed  from  probe  A  by  the  addition  of excess  unlabelled  Egr 
consensus  sequence;  even  at  1000-fold  excess there is no  significant reduction in the 
intensity of complex J on probe A (Fig. 7.4, comparing lane 2 with 10-13). In contrast, 
partial competition of nuclear protein J  from probe A is evident at 500-fold excess of 
the unlabelled Gfi-1  consensus sequence (Fig. 7.4 comparing lane 2 with 7). However, 
this  competition does not appear to proceed to completion;  even when the amount of 
unlabelled  Gfi-1  consensus  sequence  as  competitor  is  raised  to  1000-fold  excess, 
protein J  although further reduced, is not abolished from probe A (Fig.  7.4 comparing 
lane 2 with 8). Taken together these results imply that nuclear protein J is unlikely to be 
a member of the Egr transcription factor family but suggest that nuclear protein J may 
be  a  member  of the  Gfi-1  transcription  factor  family.  The  failure  of an  unlabelled 
oligonucleotide  containing  a  mutated  Gfi-1  binding  site  to  induce  any  significant 
reduction of nuclear protein J  from probe A (Fig.  7.4,  comparing lanes 2  and 9) is in 
agreement with this suggestion as it implies that the interaction of nuclear protein J with 
the Gfi-1 consensus sequence is sequence specific in that it is dependent on the presence 
of a functional Gfi-1  binding site. However, compared with previous observations (Fig.
7.2  and  7.3  page  239  and  241,  respectively)  the  data  shows  that  nuclear  protein  J 
although having some affinity for the Gfi-1  consensus sequence, has a greater and more 
convincing affinity for allele A; possibly at least 2-fold more (comparing relative levels 
of competition in lane 5, Fig. 7.3 page 241  with lane 8, Fig.7.4). If nuclear protein J is 
Gfi-1  one would generally expect the relative affinity of nuclear protein J for the Gfi-1 
consensus  binding  site  to  be  greater than,  or at  least  equivalent  to  that  exhibited  for 
allele  A.  In  which  case  it  may be  that  nuclear  protein  J  is  not  Gfi-1  but  instead  a 
different member of this transcription factor family. It should also be considered that
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Figure 7.4 Competition analysis using consensus transcription factor binding sites as competitor to 
identify nuclear protein J. The -l 391A probe was incubated in the absence of nuclear extract (lane  1) or 
in the presence of 8-10pg of OC-2 nuclear extract (lanes 2-14) either in the absence of competitor (lanes 
1-2) or with a molar excess of unlabelled: A probe (lane 3), C probe (lanes 4), Gfi-1  consensus sequence 
(lanes 5-8), an oligonucleotide containing a mutated Gfi-1  binding site (lane 9), Egr consensus sequence 
(lanes  10-13) or an oligonucleotide containing a mutated Egr binding site (lane  14) as indicated.  Shifted 
protein-DNA complexes G, H and J are denoted by the arrows.
nuclear protein J could be a member of a different transcription factor family, albeit one 
that exhibits low affinity for the Gfi-1  consensus sequence.
7.2.1.1  Investigating binding of OC-2 derived nuclear proteins to the Gfi-1 
consensus sequence.
The  data  suggest  that  nuclear protein  J  could  be  a member of the  Gfi-1  transcription 
factor family.  However, evidence that nuclear protein J is Gfi-1  is not very convincing; 
competition with  1000-fold excess of the unlabelled Gfi-1  consensus sequence does not 
completely abolish the interaction of nuclear protein J with probe A (Fig. 7.4 comparing 
lane 2 with  8).  It is possible that this is due to the fact that nuclear protein J  is a very 
abundant  protein  within  the  OC-2  cell  line,  but  even  so  the  unlabelled  A  probe  can 
induce  more  convincing  competition,  even  when  present  at  a  lower  molar  excess 
compared  to  the  unlabelled  Gfi-1  consensus  sequence  (comparing  relative  levels  of
244competition in Fig.  7.3,  lane 5  with Fig.  7.4,  lane  8  page 241  and 244, respectively). 
Therefore,  to  seek further clarification EMSA analysis was performed using the Gfi-1 
consensus sequence as the probe.
OC-2  nuclear extracts were incubated with either the labelled Gfi-1  consensus 
sequence or probe A in order to compare the pattern of nuclear protein-DNA complex 
formation  between  these  two  sequences.  In  the  absence  of  competitor  DNA  this 
approach  revealed  shifted  nuclear  protein-DNA  complexes  on  the  Gfi-1  consensus 
probe that appear analogous to complexes G, H and J on probe A (Fig. 7.5, comparing 
lanes  1   &  2).  Hence,  suggesting that both these  sequences  bind  the  same protein(s). 
However,  in  addition  a  unique  complex  termed  K  is  also  observed  on  the  Gfi-1 
consensus  probe  that  is  not  observed  on  probe  A  (Fig.  7.5  comparing lanes  1   &  2). 
Competition analysis with an excess of the unlabelled Gfi-1  consensus sequence shows 
that  the  unlabelled  Gfi-1  consensus  sequence  can  compete  with  the  Gfi-1  consensus 
probe  for  binding  nuclear  protein  K  (for  simplicity  one  protein,  termed  K  will  be 
assumed  to  bind)  but  appears  unable  to  significantly  compete  for  nuclear  protein  J; 
complex  K  is  abolished  at  500-fold  competition  in  contrast  to  complex  J  that  still 
persists  at  1000-fold  competition  (Fig.  7.5  comparing lanes  2,  3  &  4).  Moreover,  an 
excess of the unlabelled A probe does not appear to compete with the Gfi-1  consensus 
probe for binding nuclear protein J; even at 1000-fold competition (Fig. 7.5 comparing 
lane 2 with 6). These results suggest that the nuclear protein involved in the formation 
of complex J on probe A may not necessarily be the same one involved in the formation 
of the  analogous  complex  J  on  the  Gfi-1  consensus  probe.  Indeed,  from  previous 
experiments it is clear that nuclear protein J that binds probe A has a greater affinity for 
allele A compared to the Gfi-1  consensus sequence (comparing levels of competition in 
Fig.  7.3, lane 5 with Fig.7.4, lane 8 page 241  and 244, respectively). Hence, if nuclear 
protein J that binds probe A is the same protein that binds at the equivalent position on 
the  Gfi-1  consensus probe one would generally expect  an  excess of the unlabelled A 
probe to compete with the Gfi-1 consensus probe for nuclear protein J.
Interestingly,  when the Gfi-1  consensus probe is incubated with OC-2  nuclear 
protein extract in the presence of an excess of either unlabelled A or C probe, a shifted 
protein-DNA complex termed SC, can be observed high on the gel (Fig. 7.5 lanes 5, 6, 8 
and 9).  This complex is not observed when OC-2 nuclear protein extract is incubated 
with the Gfi-1  consensus probe in the absence of competitor (Fig. 7.5, lane 2) nor if the 
competitors are changed to the Gfi-1  consensus sequence (Fig. 7.5, lanes 3  & 4) or an 
oligonucleotide containing a mutated Gfi-1 binding site (Fig. 7.5, lanes 10 & 11). Such
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Figure  7.5 Competition  analysis  using  the  Gfi-1  consensus  sequence  as  probe.  The -1391A  probe 
(lane  1)  or  labelled  Gfi-1  consensus  sequence  (lanes  2-11)  were  incubated  in  the  absence  of nuclear 
extract (lane 7) or  in the presence of 8-10pg of OC-2  nuclear extract (lanes  1-6 &  8-11) either in the 
absence of competitor (lanes  1-2) or with a molar excess of unlabelled: Gfi-1  consensus sequence (lanes 
3-4), A probe (lanes 5-7), C probe (lanes 8-9) or oligonucleotide containing a mutated Gfi-1  binding site 
(lanes  10-11) as  indicated.  Shifted protein-DNA complexes G,  H and J  are denoted by the arrows.  SC 
denotes a novel shifted protein-DNA complex (observed in lanes 5, 6, 8 & 9)
a complex is difficult to interpret, but it is possible complex SC is a result of a nuclear 
protein  binding to  both  the  Gfi-1  consensus  probe  and to  A  or C  competitor probes 
forming  one  large  complex  with  the  reduced  mobility  as  observed.  The  absence  of 
complex SC when 1000-fold excess of the unlabelled A probe is incubated with the Gfi- 
1   consensus  probe  in  the  absence  of OC-2  nuclear  extract  is  consistent  with  this 
suggestion (Fig. 7.5 lane 7); formation of complex SC on the Gfi-1  consensus probe is 
dependent on the presence of OC-2 nuclear extract in addition to an excess of either the 
unlabelled A or C probes.
In summary, evidence that nuclear protein J that binds probe A is Gfi-1  is not 
convincing.  Indeed, nuclear protein J appears to have only a low affinity for the Gfi-1 
consensus sequence (Fig.  7.4 comparing lane 2 with 8, page 244). It is possible this is 
because nuclear protein J is not Gfi-1 but instead a different member of the Gfi-1  family 
or a member of a different transcription factor family. In line with these observations it 
is  possible  that  nuclear protein  K,  which preferentially  binds  to  the  Gfi-1  consensus
246sequence compared to allele A may well be Gfi-1. Nuclear protein K is competed from 
the  Gfi-1  consensus  probe  by  500-fold  excess  of  the  unlabelled  Gfi-1  consensus 
sequence but is not competed from the Gfi-1  consensus probe by  1000-fold excess of 
either the unlabelled A or C probe (Fig. 7.5, comparing lane 2 with 6 & 9, respectively). 
Hence,  suggesting that the  interaction  of nuclear protein  K with the  Gfi-1  consensus 
sequence  is  sequence  specific.  However,  competition  is  also  evident  with  500-fold 
excess  of  an  oligonucleotide  containing  a  mutated  Gfi-1  binding  site  (Fig.  7.5 
comparing lane 2 with 10), which argues against sequence specificity of nuclear protein 
K with the Gfi-1  consensus sequence.
7.2.1.2 Supershift analysis to identify nuclear protein J.
Initial competition analysis suggests that nuclear protein J may be a member of the Gfi- 
1   transcription factor family (Fig. 7.4). In an attempt to clarify this data, EMSA analysis 
was  performed  using  the  Gfi-1  consensus  sequence  as  the  probe  (Fig.  7.5).  This 
approach  revealed  that  although  the  Gfi-1  consensus  sequence  can  bind  a  nuclear 
protein(s) in an equivalent position to that of complex J on probe A, nuclear protein J 
observed on probe A appears to be a different protein to that observed at the equivalent 
position on the Gfi-1  consensus probe. In addition, a unique complex, K, is observed on 
the Gfi-1  consensus probe, but not on probe A raising the possibility that this could be 
due to Gfi-1  binding. Although, the sequence specificity of nuclear protein K with the 
Gfi-1  consensus  sequence  is  questionable  when  tested  by  competition  analysis. 
Therefore, in an attempt to clarify unequivocally the identity of nuclear proteins J and K 
super  shift analysis was performed with a goat polyclonal anti-Gfi-1  antibody [Gfi-1  (N- 
20) X, Santa Cruz Biotechnology, Inc.].
The anti-Gfi-1  antibody was incubated with OC-2 nuclear extracts both prior to 
and subsequent to addition of either probe A or the Gfi-1  consensus probe (Fig. 7.6). In 
the presence of probe A, this line of analysis failed to either result in the disappearance 
of nuclear-protein DNA complex J, or induce a supershift of nuclear protein J (Fig. 7.6 
comparing  lanes  8,  10  and  9,  respectively).  Similarly,  in  the  presence  of the  Gfi-1 
consensus  probe  this  approach  did  not  result  in  the  disappearance  of nuclear-protein 
DNA complex K nor induce a supershift of nuclear protein K; the nuclear protein that is 
unique to the Gfi-1  consensus probe (Fig. 7.6 comparing lanes 3, 5 and 4, respectively). 
This  was  despite  several  attempts  to  optimise  the  supershift  analysis  by varying  the 
temperature and the length of the incubation when the anti-Gfi-1  antibody was  added 
prior to probe (4°C overnight or on ice for 30 minutes) and following addition of
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Figure 7.6 Supershift analysis of nuclear proteins J and K. The labelled Gfi-l  consensus sequence or 
-1391A probe were incubated in the absence of nuclear extract (lanes  1  & 2) or in the presence of 8-10|ng 
OC-2 nuclear extract (lanes 3-12) in the absence of antibody (lanes 3 & 9) or in the presence of anti-Gfi- 
1   antibody (lanes 4, 5, 9 &  10) or anti-OCT-2 antibody (lanes 6, 7,  11  &  12) as indicated. Antibody was 
added on ice either 30 minutes prior to probe or subsequent to probe and allowed to incubate for a further 
30 minutes on ice as indicated. Protein-DNA complexes G, H, J and K are denoted by the arrows.
labelled probe (on ice or at room temperature for 30 minutes or  1   hour). In addition to 
attempts  to  optimise  the  supershift  analysis  by  varying  the  amount  of  anti-Gfi-1 
antibody used; either 2, 3 or 4pg of anti-Gfi-1 antibody per binding reaction.
Collectively, these results do not suggest that either nuclear protein J or K is Gfi- 
1. However, it cannot be categorically excluded on the basis of this supershift analysis 
that  neither nuclear protein  J  or K  are  Gfi-1,  or a member of the  Gfi-1  family.  It is 
possible that the results obtained here are simply due to unsuccessful supershifts. There 
are  many  possible reasons to account  for the  lack  of a positive result with the  Gfi-1 
supershift. Steric interaction between the anti-Gfi-1  antibody and nuclear protein J or K 
could  be  prevented  if the  epitope to  which the  anti-Gfi-1  antibody was  raised  is  not 
exposed  on either of nuclear proteins  J  or K  and  hence,  accessible  for binding.  The 
presence of other nuclear proteins or the conformation of either nuclear protein J or K 
under these EMSA conditions could all hinder a positive interaction (see section 5.3.1.3, 
page  184 for a similar discussion on limitations of supershift analysis). Furthermore, in
248the  absence  of commercially available purified,  recombinant  Gfi-1  protein  it was  not 
possible  to  test  whether  the  anti-Gfi-1  antibody  used  in  these  assay  conditions  is 
functional.  If the anti-Gfi-1  antibody used in these  assay conditions  is  non-functional 
this would clearly explain the lack of a positive supershift.  In addition, the anti-Gfi-1 
antibody used in these assays only detects Gfi-1 not Gfi-lb, the only additional member 
of the  Gfi-1  family that has been  identified to  date.  In which  case it is possible  that 
nuclear protein J (or K) could be Gfi-lb. Use of an antibody that detects Gfi-lb would 
help  clarify this  issue  although due to  the time constraints  of this project this line of 
analysis  was  not  possible  because  functional  characterisation  of  the  -3434poly-G 
polymorphism constituted a large part of the study.
2497.3  Effect  of the  -1391  single  nucleotide  substitution  on  Gfi-1
binding.
Supershift  analysis  with  an  anti-Gfi-1  antibody  did  not  clarify  the  identification  of 
nuclear protein J (section 7.2.1.2) and therefore, it remains inconclusive whether nuclear 
protein J is Gfi-1  or a member of the Gfi-1  family. Consequently, it is unclear whether 
Gfi-1  binds  to  the  putative  Gfi-1  binding  site  3’  of  the  -1391  single  nucleotide 
substitution in the Bm-3c promoter (analysis using Matlnspector software suggests that 
the region 3’ of the -1391  single nucleotide substitution is a putative Gfi-1 binding site; 
see Appendix F). The -1391  sequence variant is 8bp upstream of the 5’ nucleotide of the 
core  sequence used  by Matlnspector  software  to  identify putative  Gfi-1  binding sites 
(see Appendix  F;  see also discussion of analysis using Matlnspector software,  section
7.2.1,  page 242).  Hence,  although EMSA  analysis  (section 7.2.1) has  failed to  clarify 
the  identity  of nuclear  protein  J  it  remains  possible  that  the  -1391  sequence  variant 
could modulate Gfi-1 binding to this putative Gfi-1 binding site in the Bm-3c promoter; 
protein binding to cis-acting elements can be influenced by adjacent sequence (Dawson 
et al, 1996a).
The  possibility  that  the  -1391  single  nucleotide  substitution  in  the  Bm-3c 
promoter could disrupt a functional  Gfi-1  binding site is important as recent evidence 
has shown that Gfi-1  plays an important pro-survival role in hair cells of the auditory 
system  (Wallis  et  al,  2003).  In  Gfi-1  mutant  mice  homozygous  for  a  severe  loss  of 
function  Gfi-1  allele  (due  to  deletion  of a  large  region  of the  Gfi-1  coding  region 
including the SNAG domain) hair cells are initially specified in both the vestibular and 
auditory system but fail to progress along their correct differentiation pathway (Wallis 
et  al,  2003).  Specifically,  the  organisation  of hair  cells  in  the  vestibular  organs  and 
organ of Corti is aberrant. The morphology of the vestibular hair cells is abnormal and 
outer hair cells of the auditory system exhibit ectopic expression of the neuronal marker 
TUJ1.  Ultimately,  a  loss  of  functional  Gfi-1  protein  in  the  cochlea  results  in  the 
progressive degeneration of hair cells. Interestingly, the outer hair cells appear the most 
susceptible and the degeneration progresses along a basal to apical gradient such that at 
P14  the  organ  of Corti  is  completely  destroyed.  Typical  morphological  features  of 
apoptosis  have  been  observed  in  some  of the  outer hair  cells  at  E l8.5  in  the  Gfi-1 
mutant mice. Leading the proposal that apoptosis may be the mechanism responsible for 
the hair cell death (Wallis et al, 2003). Clearly, presence of functional Gfi-1  protein is
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developmental  expression  pattern  of  Gfi-1  in  the  inner  ear  is  consistent  with  this 
concept; Gfi-1  mRNA and protein are reported to be expressed as early as El2.5 in the 
prospective  sensory  epithelia  in  the  otic  vesicle  and  when the  sensory organelles  are 
clearly defined,  around E l8.5, high expression levels of Gfi-1  protein are localised in 
hair  cells  (Wallis  et  al,  2003).  Furthermore,  recent  evidence  suggests that Gfi-1  is  a 
downstream target of Bm-3c in hair cells and that the survival of outer hair cells in the 
cochlea may depend to a large extent on Bm-3c maintaining Gfi-1 expression (Hertzano 
et al, 2004;  this evidence is discussed further in section 7.6 page 264). However, it is 
not known whether Bm-3c directly regulates Gfi-1, but whether by a direct or indirect 
mechanism the possibility that Gfi-1 may bind to the Bm-3c promoter particularly in the 
vicinity of the -1391  sequence variant is important. It is tempting to speculate that Gfi-1 
may regulate its own expression by binding to the Bm-3c promoter to form a positive or 
negative  feedback  loop.  Evidently,  the  -1391  sequence  variant  located  adjacent  to  a 
putative  Gfi-1  binding  site  has  the  potential  to  modulate  this  regulation.  Therefore, 
given  the  pro-survival  role  of Gfi-1  in  the  inner  ear  and  the  finding  that  this  gene 
appears to act downstream of Bm-3c in hair cells experiments were designed to clarify 
whether Gfi-1  binds to the Bm-3c promoter at the putative Gfi-1  binding site 5’ of the - 
1391 single nucleotide substitution.
7.3.1  Strategy.
It is not known whether the OC-2 cell line actively expresses Gfi-1. The OC-2 cell line 
was  isolated  from  the  H-2Kb-teA58  Immortomouse  at  E l3  immediately before  hair 
cells undergo their final mitosis (Rivolta et al,  1998). It has been established the OC-2 
cell line expresses Bm-3c (Rivolta et al,  1998) and therefore it could be reasoned that 
OC-2  cells  also  express  Gfi-1  based  on  the  evidence  suggesting  that  Gfi-1  is  a 
downstream target of Bm-3c (Hertzano et al, 2004). Indeed, Gfi-1 protein is reported to 
be expressed as early as  El2.5  in the prospective sensory epithelia in the otic vesicle 
(Wallis  et  al,  2003).  However,  semi-quantitative  RT-PCR  on  RNA  extracted  from 
cochlea  sensory  epithelia  at  several  developmental  time  points  did  not  detect  Gfi-1 
expression until  E l5.5  (Hertzano  et  al,  2004).  Moreover,  expression  of Gfi-1  in hair 
cells  of  the  inner  ear  does  not  appear  to  be  particularly  high  until  the  later 
developmental stages around E l8.5 (Wallis et al, 2003; Hertzano et al, 2004). Hence, it
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1  protein could be very low.
In  the  first  instance  attempts  were  made  to  characterise  endogenous  Gfi-1 
expression in OC-2 cells by performing western immunoblot analysis on OC-2 nuclear 
extracts  using  the  goat  polyclonal  anti-Gfi-1  antibody  [Gfi-1  (N-20)  X,  Santa  Cruz 
Biotechnology, Inc.] used in supershift analysis (section 7.2.1.2). It was reasoned that if 
the  OC-2  cell  line  is  confirmed  as  expressing  Gfi-1,  then  use  of more  concentrated 
nuclear extracts in EMSA analysis may help to clarify whether Gfi-1 binds to the region 
3’  of the -1391  sequence variant.  However, this approach was not successful; a single 
band  equivalent  to  the  55  kDa  polypeptide  for  Gfi-1  was  not  observed  with  many 
additional bands of higher and lower molecular weight also present presumably due to 
cross-reactivity  of the  anti-Gfi-1  antibody  used  (data  not  shown).  In  the  absence  of 
informative data regarding endogenous expression of Gfi-1   in OC-2 cells and a lack of 
commercially available purified recombinant Gfi-1  protein an alternative approach was 
sought to assess whether the region 3’ of the -1391  sequence variant constitutes a Gfi-1 
binding site; EMSA analysis was performed using OC-2 nuclear extracts that had been 
prepared from OC-2 cells transfected with an expression vector for Gfi-1.
7.3.2  EMSA  analysis  using  nuclear  extracts  prepared  from  OC-2  cells 
transfected with an expression vector for Gfi-1.
The  mammalian  expression  vector  containing  the  rat  cDNA  for  Gfi-1  subcloned 
downstream  of the  cytomegalovirus  5  (CMV5)  promoter,  termed  CMV5-Gfi-1,  has 
been described previously (Grimes et al,  1996b) and was kindly provided by Professor 
Horwitz (University of Washington, U.S. A). Briefly, OC-2 cells were plated into 90mm 
dishes (Nunclon™) and transiently transfected with either the CMV5-Gfi-1  expression 
vector or the empty pCi expression vector (Promega), which is under the control of the 
cytomegalovirus, CMV promoter. Cells were grown to 80% confluent and harvested for 
nuclear extract as described (see method section 3.2.4.3). This, in combination with the 
standard OC-2 nuclear extracts (see method section 3.2.4.2) formed three different types 
of OC-2  nuclear  extract:  standard  (OC-2  cells  not  transfected  with  any  expression 
vector), +CMV5-Gfi-1  (OC-2 cells transfected with the CMV5-Gfi-1 expression vector) 
and +pCi (OC-2 cells transfected with the empty pCi expression vector).
To  assess whether the -1391A >C  single nucleotide substitution modulates the 
binding of Gfi-1  to this region of the Bm-3c promoter the A probe and C probe were
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expression vector (+CMV5-Gfi-1) or empty expression vector (+pCi) as a control for 
aberrant  effects  induced  by  the  CMV backbone  in  the  empty  pCi  vector  (Fig.  7.7). 
However, this approach did not show a difference in protein-DNA complex formation 
between Gfi-1 transfected (+CMV5-Gfi-1) and non-transfected (+pCi) extracts on either 
probe A or C. (Fig.  7.7 comparing lanes 5 with 6 and 8 with 9). In addition, the same 
result  is  observed  when  the  probe  is  changed  to  the  Gfi-1  consensus  sequence  as  a 
positive control for binding of Gfi-1  under these EMSA conditions (Fig. 7.7 comparing 
lane 2  with  3).  It  is possible that these results are due to  a lack of Gfi-1  protein for 
example, due to either little or no expression from the CMV5-Gfi-1  expression vector. 
However, judging from the quality of the shifted protein-DNA complexes formed with: 
the standard OC-2 nuclear extracts, nuclear extracts that have been transfected with the 
CMV5-Gfi-1  expression vector (+CMV5-Gfi-1) or empty pCi expression vector (+pCi) 
it appears more conceivable that the results are due to poor quality nuclear extracts. The 
intensity of complexes J and G on probes A and C is faint compared to previous EMSA 
analysis (comparing complex J and G in Fig. 7.7, lanes 4-9 with for example, Fig. 7.5,
1391A ■1391C Probe
Figure 7.7  Effect of the -1391  single nucleotide substitution on Gfi-1  binding. The  labelled Gfi-1 
consensus sequence (lanes  1-3), -1391A probe (lanes 4-6) or -1391C probe (lanes 7-9) were incubated 
with  8-10pg of:  standard OC-2  nuclear extract (lanes  1,  4 &  7),  OC-2  nuclear extract that had been 
transfected with  the  empty  pCi  expression  vector,  which  is  under the control  of the  CMV promoter 
(lanes 2,  5  &  8) or OC-2  nuclear extract that had  been transfected with the CMV5-Gfi-1  expression 
vector (lanes 3, 6 & 9). Protein-DNA complexes G, J and K are denoted by the arrows.
253lane  1,  page  246  or  Fig.  7.6,  lane  8,  page  248)  and  complex  H  cannot be  observed 
(comparing lanes 4-9 in Fig. 7.7 with for example lane 1   in Fig. 7.5, page 246 or lane 8 
in Fig.  7.6, page 248). A western immunoblot of OC-2 nuclear extracts that have been 
transfected  with  the  CMV5-Gfi-1  expression  vector  (+CMV5-Gfi-1)  may  clarify  if 
these results are due to a lack of Gfi-1  protein. However, this approach has been tried 
previously  on  the  standard  OC-2  nuclear  extracts  in  an  attempt  to  characterise 
endogenous Gfi-1  expression and was not successful due to apparent cross-reactivity of 
the anti-Gfi-1  antibody used. Therefore, western immunoblot analysis of OC-2 nuclear 
extracts that have been transfected with the CMV5-Gfi-1  expression vector (+CMV5- 
Gfi-1)  was  not  undertaken.  Had  time  permitted  repeating  and  optimising  this 
experiment with more concentrated batches of OC-2  nuclear extracts may have given 
more  informative  results  as  to  whether  the  region  5’  of the  -1391  sequence  variant 
constitutes a Gfi-1  binding site, but it wasn’t possible to pursue this line of analysis as 
the  main  focus  of investigation  was  centred  around  the  -3434  poly-G  polymorphism 
(see Chapter 5).
2547.4  Effect  of the  -1391A  >C  single  nucleotide  substitution  on
basal  Brn-3c  promoter  activity  and  activity  of  the  Brn-3c 
promoter in response to exogenous Gfi-1.
It has been established that the single nucleotide  substitution at position -1391  in the 
Bm-3c  promoter  modifies  binding  affinity  for  a  specific  nuclear  protein  (protein  J) 
expressed in OC-2 cells. From EMSA competition analysis it is clear that the wild-type 
allele,  A,  of the  -1391  sequence  variant  has  a  higher  affinity  for  nuclear  protein  J 
compared to the variant allele, C. Using Matlnspector software (see section 7.2.1) two 
putative  cis-acting  elements  in  the  vicinity of the  -1391  sequence variant:  Egr-3  and 
Gfi-1  were identified and attempts were made to identify nuclear protein J. Competition 
analysis ruled unambiguously that Egr or a member of this transcription factor family is 
unlikely to be nuclear protein J and in contrast, suggested that nuclear protein J may be 
a member of the  Gfi-1  transcription  factor family.  Further analysis to  clarify whether 
nuclear protein J is Gfi-1  was not successful but it could not be ruled out unequivocally 
that nuclear protein J is Gfi-1, or a member of this transcription factor family.
The determination of sequence specific protein binding within the promoter of a 
gene does not mean that the protein binding site in question is a bona fide functional 
cis-acting element. Therefore, it needs to be clarified whether the difference in affinity 
between alleles A and C for nuclear protein J actually has a functional affect on activity 
of the Bm-3c promoter.  It is possible that the basal  activity of the Bm-3c promoter is 
modulated by the difference in affinity between A and C  alleles for nuclear protein J. 
Furthermore, regardless of whether nuclear protein J is a member of the Gfi-1  family, 
the  -1391  sequence variant may modulate a Gfi-1  binding  site  and this  could have a 
functional  affect  on  activity of the  Bm-3c promoter.  This  is  particularly important in 
light  of the  recent  evidence  that  Gfi-1  is  required  for  differentiation  and  survival  of 
inner  ear  hair  cells  (Wallis  et  al,  2003)  and  the  finding  that  Gfi-1  appears  to  be  a 
downstream target of Bm-3c in hair cells (Hertzano et al, 2004). Attempts to determine 
whether  Gfi-1  can  bind  to  the  putative  Gfi-1  binding  site  5’  of the  -1391  sequence 
variant using nuclear extracts prepared from OC-2  cells that were transfected with an 
expression  vector  for  Gfi-1  (+CMV5-Gfi-1)  were  not  conclusive  due  to  presumably 
poor quality nuclear extracts (see Fig 7.7, page 253). Therefore, in an attempt to clarify 
whether the -1391  sequence variant modulates basal activity of the Bm-3c promoter and 
whether the  region  5’  of the  -1391  sequence  variant  is  responsive  to  Gfi-1  transient
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gene constructs were generated that contained either allele A or C at position -1391  and 
the  activity  of these  constructs  was  observed  at  basal  levels  and  in  response  to  an 
expression vector for Gfi-1 (CMV5-Gfi-1).
The  firefly  luciferase  reporter  vector  pGL3basic  (Promega)  carrying  3.6Kb 
(bases -80bp to -3670bp) of the human Bm-3c promoter (termed: pgl3b-Bm-3c-3.6) had 
already been  cloned  in  our  laboratory  from  the  human  PAC  library RPCI1  (HGMP, 
MRC,  U.K.).  The genetic background of this construct at loci in the Bm-3c promoter 
established  from  the  PCR-SSCP  screen  to  be polymorphic  was  determined by direct 
sequencing  and  found  to  be:  -3495(GT)i5,  -3457(GA)2j  -3432(G)8CG,  -1391C,  - 
566(GT)2o  and -386C (see Table 3.4, method section 3.2.18). Hence, pgl3b-Bm-3c-3.6 
carries the variant allele, C at position -1391. Therefore, construct pgl3b-Bm-3c-3.6 (for 
simplicity  hereafter  referred  to  as  p-Luc-1391C)  was  used  as  a  template  in  a  site- 
directed  mutagensis  (SDM)  reaction  (QuikChange®,  Stratagene)  with  primers  - 
1391aSDM-S:  5’  GCAGCGTAGTCGAGGTCCAGGATTC 3’  and -1391tSDM-AS:  5’ 
GAATCCTGGACCTCGACTACGCTGC 3’ to modify the variant allele C at position - 
1391  to  the  wild  type  allele,  A,  to  form  construct p-Luc-1391A.  This  generated two 
different  Bm-3c luciferase-reporter gene constructs that differed in the nature of the - 
1391  allele; see Fig. 7.8a (see method section 3.2.8.1  for details in construct formation; 
for convenience  in  Chapter 6  construct p-Luc-1391A  is  referred  to  as p-Luc-SNPGl.
566GT2o).
To  assess  whether Gfi-1  has  an  affect on  activity of the Bm-3c promoter and 
whether  this  response,  if any  is  modulated  by  the  -1391  sequence  variant  the  Gfi-1 
expression  vector,  CMV5-Gfi-1,  was  co-transfected  into  OC-2  cells  with  Bm-3c 
promoter-luciferase reporter gene constructs that carry either allele A (p-Luc-1391 A) or 
allele  C  (p-Luc-1391C)  at  position  -1391  (Fig.  7.8b).  The  results  obtained  were 
compared with the respective basal levels of activity for each of these Bm-3c-luciferase 
reporter gene constructs in the presence of the empty pCi expression vector (Promega) 
as this vector is under the control of the CMV promoter (Fig.  7.8b). This ensured that 
the DNA concentration between wells in the absence of the Gfi-1  expression vector was 
standardised  to  minimise  any  possible  effect  of  inter-well  variation  in  DNA 
concentration  on  transfection  efficiency.  Similar  co-transfections  in  the  absence  and 
presence of the Gfi-1  expression vector, CMV5-Gfi-1, were performed with the empty 
pGL3basic vector as a control for activity of Gfi-1  on the backbone of the pGL3basic 
vector. In these experiments the renilla luciferase expression vector pRL-SV40
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Figure 7.8 Effect of the -1391  single nucleotide substitution on basal Brn-3c promoter activity and 
activity  of the  Bm-3c  promoter  in  response to exogenous Gfi-1.  (a) A schematic diagram (not to 
scale) to illustrate 3.6Kb Bm-3c promoter-luciferase reporter gene constructs that contain either the wild- 
type allele, A or the variant allele, C at position-1391. (b) OC-2 cells were co-transfected with 500ng of 
p-Luc-1391A,  p-Luc-1391C  or the  empty  pGL3Basic  vector  in  the  presence  of 500ng  of the  Gfi-1 
expression vector (CMV5-Gfi-1) or the empty pCi expression vector, which is under the control of the 
CMV promoter.  The renilla expression vector pRL-SV40 (lOOng) was used as an internal control to 
normalise for differences in transfection efficiency. Error bars on chart represent the standard error of the 
mean. RLV: relative luciferase value. Luciferase activities shown on chart are expressed relative to the 
empty pGL3Basic vector in the presence of pCi expression vector. The experiment was performed in 
triplicate and repeated at least twice with two different preparations of DNA. * p<0.05 (t-test; d.f. = 16), 
** p<0.05 (paired t-test; <Lf. = 1).
(Promega) was used as an  internal  control to adjust for intra-  and inter- experimental 
variation
This  approach  showed  that  in  the  absence  of exogenous  Gfi-1,  basal  activity 
between Bm-3c promoter-luciferase reporter gene constructs that differ in the nature of 
the -1391  allele is different.  Basal activity from construct p-Luc-1391C that carries the
257
o r^
co co
p-Luc-1391Avariant allele, C at position -1391 is 26% less than that from construct p-Luc-1391A that 
carries the wild-type  allele,  A  (Fig.  7.8b; mean RLV:  141.86 ± 8.54 versus  178.23  ± 
10.21,  respectively)  and  this  difference  is  statistically  significant,  p<0.05  (t-test). 
However,  this  difference  although  statistically  significant  does  not  represent  a  large 
difference  in  basal  transcriptional  activity  of Bm-3c.  Consequently,  it  is  hard  to  be 
convinced  from  this  data  alone  whether the  ability of the  -1391  sequence  variant to 
modulate  basal  activity  of the  Bm-3c  promoter  is  a  real  effect,  since  these  kind  of 
modest differences can arise by experimental error. However, the data presented in Fig. 
7.8b is reproducible;  the results  shown are the averages of three separate experiments 
and the inter-experimental variation is low as illustrated by the small error bars on the 
chart.  In  addition,  these  results  are  comparable  with  data  from  similar  experiments 
designed to examine the effect of single nucleotide substitutions within gene regulatory 
regions on gene expression; small differences in promoter activity comparable to those 
presented  here  have  been  reported  and  found  to  be  important  in  regulation  of other 
genes. For example a G >A single nucleotide substitution at position -112 in the human 
uteroglobin-related  protein  1   (UGRP1)  promoter that  is  associated  with  an  increased 
risk  of asthma  modulates  transcriptional  activity  of the  UGRP1  promoter  by only  a 
modest  amount  (Niimi  et  al,  2002).  Transient  transfections  in  a  human  lung 
adenocarcinoma  cell  line  showed  that  UGRP1  promoter-luciferase  reporter  gene 
constructs that carry the A allele at position -112 exhibit 24 % less activity compared to 
those that carry the G allele (Niimi  et al, 2002).  Similarly,  an A >C  single nucleotide 
substitution  at  position  -629  in  the  cholesteryl  ester  transfer  protein  (CETP)  gene 
promoter has been found to have a functional affect on activity of the CETP promoter 
such that presence of the A allele reduces promoter activity by 25 % compared to the C 
allele (Dachet et al, 2000). Moreover, the reduced basal activity observed with construct 
p-Luc-1391C that carries the variant allele, C at position -1391 is consistent with EMSA 
analysis; the variant allele C has a reduced affinity for OC-2 derived nuclear protein J 
compared to the wild-type allele, A (see section 7.2, Fig. 7.2 and 7.3 page 239 and 241, 
respectively).  Furthermore,  if quantitative differences  in  Bm-3c  expression  are  a risk 
factor for late onset hearing loss it is likely that one may only find subtle changes in 
Bm-3c promoter activity. Indeed, it must be remembered that late onset hearing loss is a 
complex trait; multiple loci are thought to underlie susceptibility and variation in gene 
expression  or  function  at  any  one  locus  is  thought  to  be  moderate  (for  review  see 
Fransen et al, 2003).
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showed that activity from construct p-Luc-1391A that carries the wild-type A allele and 
construct p-Luc-1391C  that carries the variant C  allele at position -1391  increases by 
56% and 61% respectively, compared to basal levels (Fig. 7.8b). This increase in Bm-3c 
promoter  activity  although moderate,  is  statistically  significant,  p<0.05  (paired t-test; 
Fig.  7.8b).  The  absence  of any  increased  activity  from  the  empty pGL3basic  vector 
when co-transfected with the Gfi-1  expression vector confirms that this response is not 
due to the backbone of the pGL3basic vector but specific to the Bm-3c promoter insert. 
Hence, it is clear that regardless of whether the wild type A allele or variant C allele is 
present at position -1391  Gfi-1  can transactivate the Bm-3c promoter (Fig. 7.8b). This 
increase  in  Bm-3c  promoter  activity  does  not  differ  significantly  between  Bm-3c 
promoter-luciferase reporter gene constructs that contain either allele A or C at position 
-1391.  Thus,  suggesting that the ability of the Bm-3c promoter to respond to  Gfi-1  is 
independent of the nature of the allele at position -1391. This could be explained if Gfi- 
1   does not bind to the putative Gfi-1 binding site 3’ of the -1391  sequence variant or if 
Gfi-1  bound  to  this  region  3’of the  -1391  sequence  variant but  the  single nucleotide 
substitution had no, or minimal, effect on the ability of Gfi-1 to bind. This is possible as 
the  -1391  sequence  variant  is  not  located  in  a  core  residue  of the  Gfi-1  consensus 
binding site (see Appendix F). Further investigation is needed to clarify this issue. It is 
possible that when Gfi-1  levels are limiting the -1391  sequence variant has an affect on 
Bm-3c promoter activity; this may account for the subtle, but significant difference in 
activity observed under basal  conditions  (Fig.  7.8b).  However,  it is  evident  from  this 
analysis  that  whether  through  a  direct  or  indirect  mechanism  Gfi-1  can  increase 
transcriptional  activity  of the  Bm-3c  promoter  (Fig.  7.8b).  This  finding  also  lends 
support to the proposal that the absence of a band indicative of Gfi-1  protein binding 
when  the  Gfi-1  consensus  probe  is  incubated  with  nuclear  extracts  that  have  been 
transfected with an expression vector for Gfi-1, +CMV5-Gfi-1, (Fig.  7.7, page 253) is 
due to poor quality or insufficient quantity of nuclear extract and not absence of Gfi-1 
expression from the CMV5-Gfi-1 expression vector.
2597.5  Effect  of  the  -1391  single  nucleotide  substitution  in  the 
context of a heterologous promoter.
Transient transfection assays using luciferase reporter gene constructs carrying a 3.6Kb 
Bm-3c promoter fragment have shown that Gfi-1  can transactivate the Bm-3c promoter 
(Fig. 7.8b, page 257). In these experiments the nature of the allele at position -1391 did 
not significantly modulate the response of the Bm-3c promoter to Gfi-1. It therefore still 
remains unclear whether Gfi-1 does actually bind to the putative Gfi-1 binding site 3’ of 
the -1391  sequence variant; both EMSA analysis and reporter gene assays have failed to 
clarify whether this is the case.  Hence, it is unclear whether the putative Gfi-1  binding 
site  3’  of the  -1391  sequence  variant  is  responsible  for  the  response  of the  Bm-3c 
promoter to Gfi-1.
In an attempt to establish whether the putative Gfi-1 binding site 3’ of the -1391 
sequence  variant  is  responsive  to  Gfi-1  the  isolated wild-type  allele,  A,  and  variant 
allele, C, were examined in the context of the SV40 heterologous promoter. The pGL3- 
Promoter vector (Promega)  contains an SV40 promoter cloned upstream of the firefly 
luciferase gene (Fluc+) and has been discussed previously (see section 5.7, page 213). 
Using the synthetic oligonucleotides that were devised for EMSA analysis of the -1391 
sequence  variant  (see  Table  3.2  method  section  3.2.18)  a  series  of pGL3-Promoter 
constructs  were  devised  that  contained  two  or three  concatenated  copies  of:  allele  A 
[pGL3-P(1391A)2],  allele  C  [pGL3-P(1391C)2],  the  consensus  sequence  for  Gfi-1 
[pGL3-P(Gfi-l)2] or an oligonucleotide containing a mutated Gfi-1 binding site [pGL3- 
P(Gfi-lMut)3]  cloned upstream of the heterologous  SV40 promoter (Fig.  7.9a).  These 
constructs  were  co-transfected  into  OC-2  cells  with  an  expression  vector  for  Gfi-1 
(CMV5-Gfi-1) and activity was compared to basal levels in the presence of the empty 
pCi expression vector as this is under the control of the CMV promoter (Fig. 7.9b). In 
these experiments the pRL-SV40 vector (Promega) was used as an internal  control  to 
adjust for intra- and inter- experimental variation.
This  line  of analysis  showed  that  in  the  presence  of CMV5-Gfi-1  expression 
vector  activity  from  the  empty  pGL3-Promoter  vector  increases  14-fold  (Fig.  7.9b). 
This suggests that the backbone of the pGL3-Promoter vector is subject to regulation by 
exogenous Gfi-1.  Hence, the validity of the remaining results obtained in the presence 
of  CMV5-Gfi-1  expression  vector  is  confounded  and  valid  conclusions  cannot  be 
drawn. In particular, it is not possible to ascertain whether the putative Gfi-1 binding
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Figure 7.9  Effect of the -1391A >C single nucleotide substitution in  the context of a heterologous 
promoter,  (a)  Schematic  diagram  (not  to  scale)  to  illustrate  pGL3-Promoter  luciferase  reporter  gene 
constructs  that  differ  in  the  nature  of the  -1391  allele.  Constructs  contain  two  or  three  concatenated 
copies of either allele A [pGL3-P(1391 A)2], allele C [pGL3-P(1391C)2], the consensus sequence for Gfi- 
1   [pGL3-P(Gfi-l)2]  or an oligonucleotide  containing a mutated Gfi-1  binding site [pGL3-P(Gfi-l  Mut)3] 
cloned  upstream  of the  SV40  promoter  in  pGL3-Promoter vector  as  indicated,  (b) OC-2  cells were co­
transfected with 500ng of either pGL3-P(empty), pGL3-P(1391 A)2, pGL3-P(1391C)2, pGL3-P(Gfi-l)2 or 
pGL3-P(Gfi-l  Mut)3  in  the  presence  of 500ng  of either  Gfi-1  expression  vector  (CMV5-Gfi-1)  or  the 
empty pCi  expression  vector  which  is  under  the  control  of the  CMV  promoter.  The  renilla  expression 
vector  pRJL-SV40  (lOOng)  was  used  as  an  internal  control  to  normalise  for  differences  in  transfection 
efficiency.  Error  bars  on  chart  represent  the  standard  error of the mean.  RLV:  relative  luciferase  value. 
Luciferase  activities  shown  on  chart  are  expressed  relative  to  pGL3-P(empty)  in  the  presence  of pCi 
expression vector by assigning a relative value of 100 (RLV). The experiment was performed in triplicate 
and repeated at least twice with two different preparations of DNA.
261site 3’ of the -1391  sequence variant is responsive to Gfi-1. However, from this analysis 
it  can be  inferred  that  levels  of Gfi-1  are  low  in  the  OC-2  cell  line  given the  large 
increase  in  transcriptional  activity  from  the  empty  pGL3-Promoter  vector  in  the 
presence  of  Gfi-1  expression  vector,  CMV5-Gfi-1.  Moreover,  in  the  absence  of 
exogenous  Gfi-1  it is clear that basal  activity between pGL3-Promoter constructs that 
carry  two  concatenated  copies  of  either  allele  A  [pGL3-P(1391A)2]  or  C  [pGL3- 
P(1391C)2],  does  not  differ  appreciably;  both  constructs  exhibit  around  7-fold  more 
activity compared to the empty pGL3-Promoter vector alone (Fig. 7.9b). This suggests 
that the -1391  sequence variant has no affect on basal activity in the context of the SV40 
heterologous promoter, at least under these experimental conditions. This is in contrast 
to the results obtained when the affect of the -1391  sequence variant on basal promoter 
activity is examined in the context of the Bm-3c promoter (see Fig. 7.8b).
2627.6  General discussion.
Gfi-1  was  originally characterised  as  a transcriptional repressor (Grimes  et al,  1996a; 
Zweidler-McKay et  al,  1996)  and  the majority of the published  data is  in agreement 
with this concept (Grimes et al,  1996b; Duan and Horwitz, 2003; McGhee et al, 2003). 
There appears little evidence in the literature for a role of Gfi-1  as a direct activator of 
transcription; Gfi-1  has only been reported to act as a direct transcriptional activator in 
the  context  of an  artificial  promoter  containing  four  copies  of the  Gfi-1  consensus 
sequence in an erythroid cell line (Osawa et al, 2002). However, it is conceivable that 
Gfi-1  can  function  as  a  dual  transcriptional  repressor  and  activator  of transcription. 
Binding of some  trans-acting  factors  to  their cognate  sites has  a positive or negative 
affect  on  transcription  depending on the  cell  type  and promoter context  as  co-factors 
needed for repression and / or activation can vary between cell type and flanking DNA 
sequences  can  greatly  influence  the  context  of  transcription  factor  binding  sites. 
Certainly,  there  is  evidence  that the  Gfi-1  homologue senseless  in Drosophilia has  a 
dual  role  as  a  transcriptional  repressor  and  activator  (for review  see  Jafar-Nejad  and 
Bellen,  2004).  Hence, the data presented in this thesis that Gfi-1  can transactivate the 
Bm-3c  promoter  is  interesting  although  the  extent  of  transcriptional  activation  is 
moderate and further investigation is required to  establish whether this is via a direct 
mechanism.  Repeating the  EMSA  analysis  as  described  in  section  7.3.2  with  in-vitro 
translated Gfi-1  protein may help clarify whether Gfi-1  can bind to the putative Gfi-1 
binding  site  3’  of  the  -1391  single  nucleotide  substitution.  This  data  would  help 
elucidate  whether the putative  Gfi-1  binding  site  3’  of the  -1391  sequence variant is 
directly responsible for the response of the Bm-3c promoter to Gfi-1. If it is established 
that the putative Gfi-1 binding site 3’ of the -1391  sequence variant does not bind Gfi-1 
foot-printing  analysis  with  a  source  of exogenous  Gfi-1  protein  may help  determine 
whether  Gfi-1  binds  to  an  alternative  region(s)  within  the  3.6Kb  Bm-3c  promoter 
fragment  used  for  transient  transfection  assays.  In  any  case,  subsequent  transient 
transfection  assays  incorporating  site-directed muatagensis  studies  of the region(s)  of 
the Bm-3c promoter shown to bind Gfi-1 would help clarify unequivocally the region of 
the Bm-3c promoter directly responsible for the observed response to Gfi-1. In addition, 
this  line  of  analysis  would  allow  one  to  establish  the  key  residues  of the  Bm-3c 
promoter crucial for Gfi-1 binding.
263Certainly,  it is  conceivable that  Gfi-1  positively regulates  Bm-3c.  It has  been 
reported that Gfi-1  is a downstream target of Bm-3c in hair cells (Hertzano et al, 2004). 
Consequently,  it  is  tempting  to  speculate  that  Gfi-1  regulates  its  own  expression by 
binding to the Bm-3c promoter to form a positive feedback loop, in effect, promoting its 
own  expression.  However,  it  must  be  emphasized  that  the  evidence  Gfi-1  is  a 
downstream target of Bm-3c in hair cells is not direct.  Bm-3c has not been shown to 
bind  to  and  have  a  functional  affect  on  the  Gfi-1  promoter,  but  rather  by  using  a 
comparative  approach mRNA  expression profiles  from  E l6.5  inner ears  of wild-type 
and Bm-3c mutant mice have shown that a deficiency in Bm-3c leads to a significant 
reduction  in  Gfi-1  expression  levels  (Hertzano  et  al,  2004).  Clearly,  whether Bm-3c 
directly regulates Gfi-1  awaits further investigation, but it seems likely that Gfi-1  acts 
downstream of Bm-3c in inner ear sensory hair cells. This is of great interest as one role 
of Gfi-1  at least in other cell types, is to prevent apoptosis. Over-expression of Gfi-1  in 
immortalized  IL-2-dependent  T  cells  and  in primary thymocytes  results  in  the  down- 
regulation of the pro-apoptotic genes Bax  and Bak  and in the inhibition of cell death 
(Grimes et al,  1996b). Furthermore, as discussed by Hertzano et al, Gfi-1  can promote 
STAT3  signals by a virtue of its ability to sequester the STAT3 inhibitor PIAS3 (Rodel 
et al,  2000),  and STAT3  signalling has been reported to transactivate members of the 
anti-apoptotic Bcl-2 family (Fukada et al,  1996; Catlett-Falcone et al,  1999). Therefore, 
based  on  this  evidence  it  is  tempting  to  speculate  that  Gfi-1  may  employ  similar 
survival mechanisms in cochlea hair cells of the inner ear.
2647.7  Conclusion.
In  conclusion,  transient  transfection  assays  in  OC-2  cells  with  Bm-3c  promoter- 
luciferase reporter gene constructs suggest that the -1391  single nucleotide substitution 
modulates basal activity of the Bm-3c promoter; presence of the variant C allele reduces 
basal transcriptional activity of Bm-3c by 26 % compared to the wild type A allele and 
this  difference  is  statistically  significant  p<0.05  (t-test;  Fig.  7.8b).  Importantly,  these 
results are consistent with EMSA analysis designed to examine the affect of the -1391 
sequence variant on binding of OC-2 derived nuclear proteins; the variant C allele has a 
reduced affinity for OC-2 derived nuclear protein J compared to the wild-type A allele 
(section  7.2).  The  agreement  between  the  affinity  of nuclear protein  J  for  the  -1391 
allele sequence and the extent of basal transcriptional activity supports the proposal that 
the observed differences in basal activity of Bm-3c are due to genuine effects induced 
by  the  nature  of the  -1391  allele  and  collectively,  these  data  suggest  that  the  -1391 
single  nucleotide  substitution  in  the  Bm-3c  promoter  could  have  a  functional  effect. 
However,  it is important to remember that these observations  are based within an in- 
vitro context. The significance of these results in terms of basal transcriptional activity 
of  Bm-3c  in-vivo  is  not  known,  but  it  is  possible  that  the  -1391C  allele  may  be 
associated with decreased basal  activity of Bm-3c in inner ear hair cells.  Indeed,  it is 
tempting to speculate that individuals who carry the variant C allele could have reduced 
expression of Bm-3c a hair cell pro-survival gene.
Attempts were made to identify nuclear protein J (see section 7.2.1). The results 
of this analysis although unable to confirm the identity of nuclear protein J, could not 
rule out that nuclear protein J is a member of the Gfi-1  transcription factor family.  In 
light of these observations  and the recent evidence that Gfi-1  plays an important pro­
survival role in cochlea hair cells (Wallis et al, 2003; Hertzano et al, 2004) experiments 
were  devised  to  establish  whether  the  putative  Gfi-1  binding  site  3’  of the  -1391 
sequence variant  constitutes  a functional  Gfi-1  binding site  (see section 7.3  and  7.4). 
This line of investigation did not clarify whether Gfi-1  could bind to the putative Gfi-1 
binding site 3’ of the -1391  sequence variant (see section 7.3) but, it is evident that Gfi- 
1   can increase transcriptional  activity of the Bm-3c promoter in OC-2  cells  (see Fig. 
7.8b). This finding that Gfi-1  can transactivate the Bm-3c promoter, albeit to moderate 
extent,  is  interesting;  it  raises  the  possibility  that  Gfi-1  a  well-characterised
265transcriptional repressor may function as a dual transcriptional repressor and activator 
of transcription.
2668.0  A  Preliminary  Association  Study  To  Assess 
Whether Common Sequence Variants At The Brn- 
3c  Locus  Are  A  Risk  Factor  For  Late  Onset 
Hearing Loss.
8.1  Introduction.
Delineating the genetic basis of late onset hearing loss is a difficult undertaking.  Late 
onset hearing loss is an extremely complex disease genetic susceptibility is confounded 
by  environmental  factors  including  acoustic  trauma  and  ototoxic  drugs  and  this  is 
exacerbated  by the polygenic nature of the disease;  a complex  genetic-environmental 
interplay is thought to underlie the aetiology (for reviews see Jennings and Jones, 2001; 
Fransen  et  al,  2003;  Gratton  and Vazquez,  2003;  Ohlemiller,  2004;  Gates  and Mills, 
2005).  In addition, the genetic determinants responsible for late onset hearing loss are 
likely  to  be  of  only  moderate  effect;  moderate  inter-individual  variations  in  gene 
expression  or  function  at  multiple  loci  masked,  hindered  or  augmented  by  epistatic 
interactions  and  compounded  by  environmental  interplay  are  thought  to  underlie 
susceptibility (for reviews see Jennings and Jones, 2001; Fransen et al, 2003). However, 
with careful  study design case-control association analysis provides  a powerful means 
to identify the genetic variants that underlie susceptibility to complex traits such as late 
onset  hearing  loss;  importantly  it  provides  great  power  to  detect  genes  of moderate 
effect  (Risch  and  Merikangas,  1996).  Certainly,  the  case-control  association  study 
approach  has been  used  successfully to  delineate the  genetic  risk  factors  involved  in 
other  similar complex  traits  cardiovascular disease being  a well-studied  example (for 
reviews  see  Daley  and  Cargill,  2001;  Green,  2001;  Herrmann  and  Paul,  2002; 
Humphries  et  al,  2004;  case-control  association  analysis  as a method to  decipher the 
genetic basis of complex disease is also discussed in section 1.6.2).
At the onset of this research project no studies had been published attempting to 
associate a candidate gene(s) with susceptibility to late onset hearing loss.  During the 
course of this PhD project a few studies have been published that have failed to find an 
association  between  sequence  variants  in  a  candidate  gene  and  susceptibility  to  late 
onset hearing  loss  (Van  Laer et  al,  2002;  Fransen  et  al,  2004).  Van  Laer et  al, 2002
267focussed  on  DFNA5  as  a  potential  candidate  gene  for  late  onset  hearing  loss.  A 
mutation  in  DFNA5  causes  progressive  sensorineural  hearing  loss  in  a Dutch  family 
which initiates in the high frequencies and is characteristic of late onset hearing loss, 
albeit manifesting at  an  earlier age of onset,  5-15  years  (Van Laer et al,  1998).  Two 
single  nucleotide  substitutions  in  the  DFNA5  coding  region  leading  to  amino-acid 
substitutions  were  examined  in  two  independent  association  based  studies  but  no 
significant  association  to  late  onset  hearing  loss  was  found  (Van  Laer  et  al,  2002). 
However, in recent years some studies have been published in the literature reporting a 
positive association between sequence variants in a candidate gene and susceptibility to 
late  onset  hearing  loss  (Fortunato  et  al,  2004;  Unal  et  al,  2005;  Yang  et  al,  2006). 
Specifically,  sequence variants in SOD2, PON2 and susceptibility to NIHL (Fortunato 
et al, 2004; see section 1.7.4), Cdh23 and susceptibility to NIHL (Yang et al, 2006; see 
section  1.7.1),  and  NAT2  and  susceptibility to  ARHL  (Unal  et  al,  2005;  see  section
1.7.4)  Although, in each of these studies a limited number of samples was used and the 
validity of these  findings  with  respect  to  late  onset hearing  loss  susceptibility in  the 
general population requires replication in a larger cohort for confirmation.
The long-term goal  of this research project is to use a case-control association 
study approach to investigate whether common sequence variants in the Bm-3c gene, an 
excellent candidate gene for late onset hearing loss are a risk factor for susceptibility to 
this  disease  (the evidence that Bm-3c is  a good candidate gene for late onset hearing 
loss is discussed in section  1.8). Delineation of discrete genetic variants that contribute 
only a small  amount to the overall phenotype of a complex disease such as late onset 
hearing loss is challenging.  Unless the gene under study has a major affect on disease 
phenotype  as  is  commonly observed  with  monogenic  traits,  a  small  sample  size  has 
limited  power to  detect  a positive  association  (Risch  and  Merikangas,  1996).  This  is 
important, as it is unlikely that any one gene contributes to late onset hearing loss by a 
large  extent  given  the  paradigm  of  genetic  heterogeneity  observed  for  monogenic 
deafness  (for reviews  see Van  Camp  et  al,  1997;  Petersen,  2002)  and the knowledge 
gained in analysis of other similar complex diseases (for review see Wright et al, 2003). 
However, use of moderately large and well-characterised sample cohorts in case-control 
association analysis of complex traits such as late onset hearing loss should in principle 
allow  detection  of even  small  genetic  effects  on  phenotype  (Risch  and  Merikangas, 
1996; for reviews see Cardon and Bell, 2001; Hirschhom et al, 2002 and Wright et al, 
2003).  Certainly,  the  merits  of using  moderately  large  sample  sizes  in  case-control 
association  studies  has  met  with  success  in  the  analysis  of other  similar  complex
268diseases  including  cardiovascular  disease  (Cambien  et  al,  1992;  for  review  see 
Herrmann  and  Paul,  2002),  type-2  diabetes  (Douglas  et  al,  2001)  and  schizophrenia 
(Shifman et al, 2002).
At the onset of this research project well-characterised patient cohorts  for late 
onset  hearing  loss  of any  size  were  lacking.  Hence,  it was  a major  aim  of the  PhD 
project to  initiate collection of a large, well-characterised patient cohort for late onset 
hearing  loss  that  could  be  used  in  subsequent  case-control  association  analysis  (see 
section  1.10).  It  was  accepted  at  the  outset  of the  PhD  project that the  likelihood  of 
finding a positive association would be limited by the power of the study, which in part 
would be dependent on the number of patients with late onset hearing loss it would be 
possible to recruit into this study within the time constraints of this project. Therefore, 
the case-control  association analysis performed for this PhD project was considered a 
preliminary  study  as  a  first  step  prior  to  undertaking  a  large-scale  population  based 
case-control association study, which is beyond the scope of the PhD project, but an aim 
of longer term research.
2698.2  Collection of a late onset hearing loss patient cohort.
At the onset of this project well-characterised patient cohorts for late onset hearing loss 
were scarce. Therefore, it was an important aim of this project to initiate collection of a 
large, well characterised patient cohort for late onset hearing loss that could be used in a 
preliminary  association  study  as  a  first-step  towards  undertaking  a  large-scale 
population based case-control  association study.  Patients characterised by a consultant 
audiologist as having a late onset sensorineural hearing loss (for definition see section 
1.5.1) were recruited from the adult hearing aid clinic at the Royal Free Nose, Ear and 
Throat Hospital, London, U.K (for more information see method section 3.2.1). Ethical 
approval  for this part of the project was  granted from the Royal Free Local  Research 
Ethics Committee (6202).
Patients were recruited from the forthcoming clinic appointments lists with the 
following  exclusions:  less  than  30  years  of age,  history of known  dementia  and /  or 
learning disability or patient identified as requiring an interpreter (which are likely to 
cause  problems  with  the  consent  procedure).  Data  sets  collected  on  patients  include 
gender,  age,  ethnicity,  diagnostic  audiogram,  age  of onset,  family history of hearing 
loss, history of noise exposure including both acute (sudden) and chronic exposure (for 
example,  occupational  noise  exposure)  in  addition  to  details  of  significant  medical 
problems (see questionnaire in Appendix A). Upon review of patient data sets, patients 
were  further  excluded  from  the  study if:  they were  non-Caucasians,  upon  diagnostic 
audiogram hearing loss was identified as conductive, a specific known aetiology of the 
sensorineural  hearing  loss  was  identified  for  example:  acoustic  neuroma  (a  non- 
cancerous  growth  near  auditory nerves),  Meniere’s  disease,  evidence  of head  trauma 
leading to sudden sensorineural hearing loss or evidence of acute noise exposure leading 
to sudden sensorineural hearing loss. Patients were not excluded from the study if there 
was an asymmetric hearing loss as long as the better hearing ear was consistent with the 
criteria for late onset sensorineural hearing loss. In these cases onset of hearing loss was 
dated from the better hearing ear characteristic of late onset sensorineural hearing loss 
and the worst hearing ear (due to hearing loss manifesting from childhood infections, 
mastoid surgery or Meniere’s disease) was ignored.
During the course of this PhD project 142 patients with late onset sensorineural 
hearing loss were recruited into this study that met the above inclusion criteria.  Blood 
was collected in EDTA and genomic DNA extracted using standard phenol-chloroform 
extraction procedure (see method section 3.2.11.1).
270The choice of the control population is a crucial factor in good study design for 
association-based analysis in complex disease (for review see, Cardon and Bell, 2001). 
Every effort was taken to use a control sample group as closely matched to the patient 
group as possible. However, recruitment of an aged- and ethnically- matched cohort of 
subjects with no medical history of hearing loss or any history of late onset hearing loss 
within  their  family  is  notoriously  difficult  to  achieve.  Use  of parental  family-based 
controls in association studies can be useful;  one advantage of this approach is that it 
reduces  the  effect  of population  stratification  resulting  from  ethnic  admixture  (for 
review, see Cardon and Bell, 2001). However, this approach is not appropriate given the 
late onset of the hearing loss phenotype and the likelihood of finding elder surviving 
family  members.  Therefore,  for  the  preliminary  case-control  association  study  the 
control  sample  group  consisted  of genomic  DNA  samples  that  were  obtained  from 
random, healthy members of the general population and have been described previously 
(see  Crawley  et  al,  1999).  Data  sets  available  on  subjects  include  gender,  age  and 
ethnicity.  For  the  preliminary  case-control  association  study  subjects  of  Caucasian 
ethnicity were  selected;  this  gave  145  ethnically matched  general  population  samples 
for use in association-based analysis.  It was accepted at the onset of this project that a 
general  population  sample  is  not  the  ‘ideal’  control  population but  the  145  random, 
healthy members of the general population are the closest matching ‘control’ sample to 
the  patient  cohort  that  it  was  possible  to  obtain  for  the  purpose  of the  preliminary 
association study.
8.2.1  Comparison  of  late  onset  hearing  loss  and  general  population 
cohorts.
The  late  onset  hearing  loss  patient  cohort  initiated  at  the  Royal  Free  Nose,  Ear  and 
Throat  Hospital,  London,  U.K  is  extremely  well  characterised.  However,  limited 
information was available for the general population sample; using information that was 
available data sets were compared between the two sample groups.
The  age  range  of  the  patients  with  late  onset  hearing  loss  included  in  the 
preliminary association study is from 39 to 90 years of age with an average age of 70-79 
years exhibited for 37% of patients  (see Table 8.1  and Fig.  8.1).  This is much higher 
than that observed  for subjects within the general  population sample group:  17  to  58 
years with an average age of 20-29 years exhibited for 61% of subjects (see Table 8.1 
and Fig. 8.1). This difference in average age between patients with late onset hearing
271Table 8.1: Comparison of age and gender between late onset 
hearing loss and general population cohorts.
Late onset hearing loss General population
Age range (years) 39-90 17-58
Average age (years) 70-79 20-29
Male (%) 49 44
Female (%) 50 50
Gender unknown (%) 1 6
All subjects were of Caucasian ethnicity. For more information on cohorts see figure legend 8.1
lLate onset hearing loss  ■General population
<20  20-29  30-39  40-49  50-59  60-69  70-79  80-89  90-99
Age (years)
Figure  8.1  Comparison  of age  between  late  onset  hearing  loss  and  general  population  cohorts.
Patients were recruited from the adult hearing aid clinic at the Royal Free Nose, Ear and Throat Hospital. 
London, U.K. All patients were characterised by a consultant audiologist as having a late onset hearing 
loss. General population samples were obtained from random, healthy members of the general population 
and have been described previously (see Crawley et al, 1999). All subjects were of Caucasian ethnicity.
loss and general population subjects is not ideal but an alternative control sample group 
was not available at the onset of this project.  For the general population sample group 
any family  history of late  onset  hearing loss was unknown and it was not  possible to 
measure the hearing of subjects within this sample group. Hence, it was acknowledged 
that  subjects  in  the  general  population  sample  group  could  be  or  may  go  on  to  be
272affected by late onset hearing loss. To overcome this short-coming for future association 
studies  recruitment  of age-matched  cohorts  characterised  with  late onset hearing loss 
and  good  hearing  is  now  underway  in  our  laboratory  (see  section  8.8  for  more 
information).  However, it is important to realise that this discrepancy between the two 
sample  groups  for  the  preliminary  association  study  is  more  likely  to  give  a  false- 
negative association rather than a false-positive association. Similarly, the likelihood of 
a  false-positive  association  resulting  from  population  stratification  due  to  ethnic 
admixture  is  likely to  be  low  in this  preliminary association  study as  great  care  was 
taken to  ensure that both patient and general population sample groups are ethnically 
matched. In addition, the likelihood of a false-positive association resulting from gender 
bias is unlikely to be encountered as both patient and general population sample groups 
contain  equivalent  proportions  of  each  gender:  approximately  50%  male  and  50% 
female subjects in each sample group (see Table 8.1).
8.2.2 Statistical evaluation of late onset hearing loss cohort.
Data sets collected on patients with late onset hearing loss include age of onset, family 
history  of hearing  loss  and  history  of noise  exposure  (all  are  self-reported).  These 
parameters are summarised in Table 8.2 and will be discussed.
Table 8.2: A summary of the main parameters measured within the 
late onset hearing loss patient cohort.
Years
Age at onset of late-onset 
hearing loss 
No.  %
Familial history of late 
onset hearing loss 
No.  %
Occupational noise 
exposure 
No.  %
20-29 9 6% 8 89% 6 67%
30-39 10 7% 9 90% 3 30%
40-49 27 19% 16 59% 10 37%
50-59 35 25% 17 49% 17 49%
60-69 43 30% 24 56% 18 42%
70-79 13 9% 6 50% 6 46%
80-89 3 2% 1 33% 1 33%
Unknown 2 2%
Total 81 /141’*  57 % 61 /142 43%
* One patient within group 70-79 years did not know if there was a family history of late onset hearing loss.
273Patients  were  categorised  according to  age  at  onset  of late-onset hearing  loss 
based  on  their  own  recollections  of hearing  loss  (self-reported).  The  results  of this 
analysis presented in Fig.  8.2a shows that in this patient sample the most common age 
for onset of late onset-hearing loss is 60-69 years of age, closely followed by 50-59 and 
40-49 years of age. This is in agreement with the general concept that late onset hearing 
loss is increasingly common with advancing age (Davis,  1995). The heritability of late 
onset hearing loss is estimated to be 35-55% (Karlsson et al,  1997; Gates et al,  1999). 
Of the  142 patients with late onset hearing loss recruited into this study,  141  patients 
were able to provide information on their family history of hearing loss (self-reported). 
Of those patients where information was available, 57% have at least one close family 
member (defined as a grandparent, parent or sibling) that is also affected by a late onset 
hearing loss (see Table 8.2). When the percent of patients classified as having at least 
one close family member that is also affected by a late onset hearing loss is compared to 
the patients own age at onset of late-onset hearing loss it is clear that the younger the 
age of the patient when hearing loss first became apparent the greater the likelihood that 
the patient has  at least one  close family member that is  also  affected  (Fig.  8.2b).  For 
patients with hearing loss onset within the 20-29  and 30-39 year age groups 89% and 
90%, respectively are classified as having at least one close family member that is also 
affected. In contrast, for patients with hearing loss onset within the elder age groups for 
example,  the  70-79  and  80-89  year  age  groups  only 46%  and  33%  respectively,  are 
classified as having at least one close family member that is also affected (Fig. 8.2b). It 
is  tempting to  speculate that in the younger age groups heritable genetic factors have 
accelerated onset of late onset hearing loss.
Acoustic trauma is a major factor in development of late onset hearing loss (for 
review see Lynch and Kil,  2005).  There is increasing evidence that ARHL and NIHL 
(hearing loss caused by prolonged exposure to moderate level  sound) are not separate 
pathologies but overlapping phenomena (for reviews  see Ohlemiller, 2004;  Gates and 
Mills, 2005). It is thought that combinations of additive and non-additive effects explain 
the interplay between chronic noise exposure and ageing in the cochlea (for review see 
Rosenhall,  2003;  for a more in-depth discussion see section  1.5.3, page 44).  Acoustic 
trauma is widely recognised  as a “global  occupational  health hazard” and worldwide, 
16%  of  adult  onset  hearing  loss  classified  as  disabling  is  estimated  to  be  due  to 
occupational noise exposure (based on figures scored in 2000; see Nelson et al, 2005). 
Therefore, given the major role of acquired acoustic trauma in development of late onset 
hearing loss patients recruited into this study were surveyed for a history of noise
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Figure 8.2:  Effect of family history of late onset hearing loss on patients own age at onset of late 
onset hearing loss  (self reported),  (a)  Age of patients at onset of late onset hearing loss.  Patients 
were categorised according to age at onset of late-onset hearing loss based on their own recollections of 
hearing loss, (b) Patient family history of late onset hearing loss. Percent of patients that have at least 
one close family member with a late onset hearing loss compared to patients own age at onset of late- 
onset hearing loss. For comparison the percent of patients with no family history of late onset hearing 
loss is also shown.
275exposure. For the purpose of this preliminary study attempts were not made to quantify 
the  degree  of noise  exposure  although  the  data  set  allows  this  to  be  done.  Instead, 
patients  were  simply  dichotomised  (yes  or  no)  according  to  whether  they  had  been 
subjected to occupational noise exposure.  Occupations of patients classified as having 
been exposed to noise include:  pilot,  soldier, construction worker, factory worker (eg: 
engineering industry, printing industry), miner and disc-jockey. Although attempts were 
not  made  to  quantify  the  degree  of noise  exposure  in  patients  the  majority  of the 
occupations listed are recognised as being an occupational noise hazard (Hong and Kim 
2001; Bohnker et al, 2002; Landen et al, 2004; Seixas et al, 2005); the majority of these 
occupations  exhibit  sound  pressure  levels  within the range  130-140dB  and  exposure 
periods of less than 5 minutes are sufficient to cause irreversible hearing damage (see 
Table 8.3).
Table 8.3 Sound pressure levels that can irreversibly damage hearing
Sound pressure level (dB) Duration Sound source Industry
140 < 1   minute Firearms, jet engine Military, aviation
130 >  1   minute Drop forge, jackhammers Manufacturing, mining, construction
120 > 5 minutes Amplified speaker Musicians, recreational
110 >  15 minutes Engines Rail, trucking
100 > 1   hour Woodshops, chainsaws Forestry
90 > 4 hours Motorcycles, lawnmowers Recreational
85 > 8 hours Interior plane cabins Aviation
Reproduced from Lynch and Kil, 2005.
Patients  classified  with  occupational  noise  exposure  were  compared  with  the 
patient’s  own  age  at onset of late-onset hearing loss  (self-reported) to  assess whether 
there  is  a  relationship  between  these  two  variables  (Fig.  8.3).  However,  no  clear 
relationship was observed.  For the majority of different age groups  at which onset of 
late-onset  hearing  loss  is  reported  similar  numbers  of  patients  are  classified  with 
occupational noise exposure;  30-50 % (Fig.  8.3). The exception to this is the youngest 
age group (20-29 years of age) nearly 70% of patients are classified with occupational 
noise exposure; it is possible that noise exposure has accelerated onset of hearing loss in 
this sample group. It would be interesting to extend this line of analysis. Recruitment of 
subjects into our late onset hearing loss cohort from the adult hearing aid clinic at the 
Royal Free Nose, Ear and Throat Hospital, London, U.K. has now accumulated to 500 
patients and a detailed history of noise exposure is available for each patient. It would 
be interesting to explore the relationship between age at onset of hearing loss and degree
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Figure 8.3  Percent  of patients  classified  with  occupational  noise exposure compared  to patients
own age at onset of late-onset hearing loss (self-reported). For comparison percent of patients with no 
history of occupational noise exposure is also shown.
of noise exposure in an attempt to delineate the effect of noise exposure on age at onset 
of hearing loss.
In  summary,  142  patients characterised by a consultant audiologist as having a 
late  onset  sensorineural  hearing  loss  were  recruited  into  the  preliminary  association 
study  within  the  time  constraints  of this  project.  Recruitment  of a  suitable  control 
sample  group  at  the  onset  of this  project  was  difficult  and  consisted  of 145  random, 
healthy  members  of  the  general  population.  Recruitment  of  age-matched  cohorts 
characterised  with  late  onset  hearing  loss  and  good  hearing  is  now  underway  in  our 
laboratory  and  will  be  a valuable  resource  for  future  association  studies.  All  subjects 
used in the preliminary association study are of Caucasian ethnicity.
2778.3  Common sequence variants at the Brn-3c locus selected for
the preliminary association study.
Mutation  scanning  of the  Bm-3c  gene  by  PCR-SSCP  analysis  identified  five  novel 
sequence  variants  at  the  Bm-3c  locus  and  confirmed  the  presence  of two  that  were 
previously reported, but non-validated (see Fig.  4.16,  section 4.5, page  162).  Of these 
the following appear common in the general population (based on PCR-SSCP analysis 
on 45  individuals):  an A>C  single nucleotide substitution at -1391, a complex poly-G 
polymorphism at -3432 and three polymorphic dinucleotide repeats at -566, -3457 and - 
3495. Interestingly, all are within the 5’-flanking region of the Bm-3c gene.
Common  sequence  variants  identified  at  the  Bm-3c  locus  could be neutral  or 
disease causing. To maximise chances of finding a positive association and identifying 
the casual sequence variant(s) a strategy was devised to perform functional analysis on 
common sequence variants identified at the Bm-3c locus and to use only those where 
there is evidence to implicate they are functional in subsequent case-control association 
analysis (see section  1.10). By using this functional screening approach a false-positive 
association  arising from  identification of a neutral  sequence variant that is  in linkage 
disequilibrium  with  the  casual  variant  at  the  same  or  another  locus  is  minimised.  In 
addition,  this  approach  also  allows  for  more  reliable  interpretation  of  case-control 
association  data as  it is  only when a casual  sequence variant(s) has been  functionally 
characterised that its pathogenic role can be fully assessed and its effect on disease risk 
can be elevated with confidence. Problems associated with multiple testing and finding 
an association by chance (type I error) are also minimised.
For  functional  screening  a  range  of in-vitro  analysis  was  performed  utilising 
EMSA analysis to assess whether common sequence variants in the Bm-3c 5’-flanking 
region  modify  the  binding  of transcription  factors  and  transient  transfection  reporter 
gene  assay  to  assess  whether  differences  in  binding  affinity translate  into  functional 
differences in Bm-3c promoter activity (see Chapters 5 to 7). The results of this analysis 
suggests that the following sequence variants could have a functional effect: -3432poly- 
G polymorphism, -1391A >C and the -566(GT)n repeat in the context of the -3432poly- 
G polymorphism and native 5’ haplotype.
The  -3432poly-G  polymorphism  modifies  the  binding  affinity  of  an  OC-2 
derived  nuclear protein  (protein  A)  and  there  is  convincing  evidence  that  this  is  the 
transcription factor SP1  or at least a member of this transcription factor family. Use of
278purified human recombinant SP1  protein, in-vitro translated SP1  and in-vitro translated 
SP3  confirms that the -3432polyG polymorphism modulates a high affinity SP family 
binding site and evidence suggests that this alters the regulation of the Bm-3c promoter 
when  SP1  levels  are  limiting,  P<0.05  (paired  t-test;  see  Fig.  5.13b,  page  203). 
Moreover,  the  data  suggest  a  functional  interaction  between  the  -3432poly-G 
polymorphism  and the -566(GT)n repeat which associate to determine the response of 
the  Bm-3c  gene  to  SP1.  Similarly,  the  -1391A  >C  single  nucleotide  substitution 
modifies the binding affinity of an OC-2 derived nuclear protein, protein J. The variant 
allele, C has a reduced affinity for nuclear protein J compared to the wild-type allele, A 
and this appears to have an affect, albeit subtle on basal activity of the Bm-3c promoter. 
Basal  activity from the Bm-3c promoter-luciferase reporter gene construct that carries 
the variant  C  allele  at position -1391  is  26%  less  compared to that which carries the 
wild-type A allele and this difference although subtle is statistically significant, P<0.05 
(t-test;  Fig.  7.8b,  page  257).  Therefore,  for  the  purpose  of this  PhD  project  it  was 
decided  to  genotype  both  the  -3432poly-G  polymorphism  and  the  -1391A>C  single 
nucleotide  substitution  for  the  preliminary  association  study  to  establish  allele 
frequency  and  to  assess  if either (or both)  of these  common  sequence variants  at the 
Bm-3c locus for which there is evidence to suggest they are functional, are a risk factor 
for  late  onset  hearing  loss  as  far  as  could  be  determined  within  the  power  of the 
preliminary study.
2798.4  Genotvpina the -3432poIv-G polymorphism.
8.4.1  Genotvpina strategy.
The  -3432poly-G  polymorphism  in  the  Bm-3c  promoter  is  an  extremely  complex 
polymorphism  exhibiting multiple variations  in length  coupled with  single nucleotide 
substitutions within the poly-G repeat (see Table 4.3, section 4.4.2, page 156). A search 
of  the  literature  revealed  that  the  -3432polyG  polymorphism  is  very  similar  to  a 
complex  poly-G  length polymorphism  that has been  identified in the promoter of the 
KLK1  gene  which  has  a  functional  affect  on  activity  of the  KLK1  promoter  and  is 
associated with hypertensive end stage renal disease (Song et al,  1997; Yu et al, 2002; 
see also section 5.2).
To genotype the poly-G length polymorphism in the KLK1  gene promoter Song 
et al, and Yu et al, used direct sequencing for primary analysis. However, distinct alleles 
were sometimes difficult to define in heterozygous individuals due to the complexity of 
the KLK1  poly-G polymorphism (multiple variations in length of the poly-G repeat in 
addition  to  multiple  single  nucleotide  substitutions  within  the  poly-G  repeat).  To 
overcome  the  difficulties  presented  when  genotyping  complex  heterozygotes  a  novel 
approach  was  devised  to  manually  interpret  the  sequencing  data  (Yu  et  al,  2002). 
Discrete alleles were elucidated by first locating an invariant sequence downstream of 
the KLK1  poly-G  polymorphism  and reading the sequencing chromatogram manually 
from this point in the direction 5’  to  3’;  once the sequence downstream of the KLK1 
poly-G  polymorphism  had  been  clarified  it  was  possible  to  manually  interpret  each 
poly-G allele in the direction 3’ to 5’.
From  examination  of  the  promoter  sequence  flanking  the  -3432poly-G 
polymorphism  (Fig.  8.4)  it  is  evident  that  any  technique  chosen  to  genotype  the  - 
3432poly-G  polymorphism  will  be  limited  by  the  proximity  of  the  multi-allelic 
dinucleotide repeats at positions -3457 and -3495: (GA)i-3 and (GT)i5_ 2i,24, respectively. 
Due to the success of Song et al, and Yu et al, with direct sequencing in their analysis of 
the  poly-G  length  polymorphism  in the KLK1  promoter  it  was  decided  to  use  direct 
sequencing to genotype the -3432poly-G polymorphism in the Bm-3c promoter and to 
adopt the method of Yu et al, to manually interpret the sequencing data in heterozygous 
subjects.
2808.4.1.1  Primer design and optimisation of genotyping.
The  design of primers for use in  genotyping the  -3432poly-G polymorphism by direct 
sequencing was complicated by the nature of the Brn-3c promoter in the vicinity of the - 
3432poly-G  polymorphism.  The  region  of  the  Bm-3c  promoter  surrounding  the  - 
3432poly-G  polymorphism  is  highly  repetitive;  in  addition  to  the  -3457(GA)n and  - 
3495(GT)n  dinucleotide  repeats  many  short  mononucleotide  repeats  are  evident  (Fig.
8.4).  This highly repetitive nature of the DNA sequence severely restricted the choice 
and  location  of possible  primers to  use  in  genotyping the -3432poly-G polymorphism 
by direct sequencing.
Given the complexity of the Bm-3c promoter in the vicinity of the -3432poly-G 
polymorphism  a  protocol  for  genotyping  the  -3432poly-G  polymorphism  by  direct 
sequencing  was  devised  and  optimised  using  predominantly  primers that were  already 
available in this region.  Using the primers originally devised for SSCP analysis of the - 
3495(GT)n repeat  (Fig.  8.4;  highlighted  in blue),  for  investigation  of the  -3432poly-G 
polymorphism  in  combination  with  the  -3495(GT)„ and  -3457(GA)n repeats  (Fig.  8.4 
highlighted in green) and a novel primer, G3cP13-AS (Fig 8.4; highlighted in purple on 
the anti-sense strand) several different primer combinations were tested to PCR up an
GGAGGATATGGTGCTTTGTGCCCTGACTTCACCTTACATGTGGCAAATCTATGTCCCTACTAGACTCTGA.  -3742  to  
CCTCCTATACCACGAAACACGGGACTGAAGTGGAATGTACACCGTTTAGATACAGGGATGATCTGAGACT  -3 67 3 
  ►
GCTCCTGAAGCAGTGTCTTCTGTATCTTCAAGGCCTTCCACAAGACTCTGCTGTTAGTAGGTATTTGGAA  -3672  to  
CGAGGACTTCGTCACAGAAGACATAGAAGTTCCGGAAGGTGTTCTGAGACGACAATCATCCATAAACCTT  -3603
  ►
ATGCTTATCGAATGGGGAAAATTCTTCCTTCAATGCCACTTGCATAAATGCCCACATAGTCCTTACATGG  -3602  to
TACGAATAGCTTACCCCTTTTAAGAAGGAAGTTACGGTGAACGTATTTACGGGTGTATCAGGAATGTACC  -3533
ACCTTCACATATTTTGTTTGGCCCATAAATGGTAT GAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG  -3  5 3 2  to  
TGGAAGTGTATAAAACAAACCGGGTATTTACCATACTCAGAGAGACACAGAGAGACACAGAGACACAGAC  -3 4 63
TGTGTGATTGTAATTTAATGCCATGGTGGTGGGGGGiSGGGGTGGGTAAGTGCTCTCTAGTTTACCACAGT  -34 62  to  
AGAGACTAACATTAAATTACGGTACCACCACCCCCCCCCCCACCCATTCACGAGAGATCAAATGGTGTCA  -3393
M-------------------------
TTCAATCTTTCCTTTTATCCACCCAGATAAAGTTGCTCAATTTTATTTTACTAGTTTTGCACCTTATAGA  -3392  to  
AAGTTAGAAAGGAAAATAGGTGGGTCTATTTCAACGAGTTAAAATAAAATGATCAAAACGTGGAATATCT  -3323
ATTTAAGTTTACAAATTCTGGAAAGCATAGAGGCTGTTACAAATTGCCGTCTAAGGCTGTCCTTCCAATT  -3322  to  
TAAATTCAAATGTTTAAGACCTTTCGTATCTCCGACAATGTTTAACGGCAGATTCCGACAGGAAGGTTAA  -3253
<    <------------------
(^TTTTTCTATGGTCTTTTCCCTCTTTTCTTCTCCAGTCTCCAGTCTGTTATCTCCAAGGCCTTCTCAAA  _3252  to  
CGAAAAAGATACCAGAAAAGGGAGAAAAGAAGAGGTCAGAGGTCAGACAATAGAGGTTCCGGAAGAGTTT  -318 3
Figure 8.4  Sequence of the Brn-3c promoter in the vicinity of the -3432poIy-G polymorphism to 
show  possible  primer  combinations  for  genotyping.  The  -3432poly-G  polymorphism  and  the  - 
3495(GT)n repeat are highlighted in black bold; the -3457(GA)n repeat in red bold. The region of the 
Bm-3c promoter in the vicinity of the -3432poly-G polymorphism is highly repetitive. In addition to the 
-3457  and -3495  dinucleotide repeats many short mononucleotide repeats are evident. This repetitive 
nature of the Bm-3c promoter hinders the  location of possible primers.  Sequence of primers already 
available  in this region are:  3cPll-S and  3cPll-AS used for PCR-SSCP analysis of the -3495(GT)n 
repeat (highlighted in blue with direction of each primer defined by the blue arrows; see also section 
4.2.2) and 3cP12-S and 3cP12-AS devised to investigate the -3432poly-G polymorphism in combination 
with the -3495(GT)n repeat and -3457(GA)n repeat (highlighted in green with direction of each primer 
defined  by  the  green  arrows;  see  also  section  4.2.2).  Sequence  of  novel  primer  G3cP13-AS  is 
highlighted in purple with direction of primer defined by the purple arrow.
281amplicon containing the -3432poly-G polymorphism (see Table 8.4).
For  each  PCR reaction with  a different primer combination genomic DNA of 
known  -3432  genotype  was  used  and  the  following  parameters  were  varied:  the 
magnesium  concentration,  the primer  concentration  and the  annealing temperature  of 
the reaction.  Sub-optimal results were obtained using Taq DNA polymerase (Promega) 
even when the PCR reaction was supplemented with 5-10% DMSO; the intensity of the 
PCR bands ranged from faint to moderate, or were not evident. However, excellent and 
consistent results were obtained when the DNA polymerase was changed to AmpliTaq 
Gold  (Applied  Biosystems);  an  intense  PCR  band  was  observed  for  all  primer 
combinations tested.
Having achieved specific and reproducible PCR amplification of genomic DNA 
for the  region  spanning the  -3432poly-G  polymorphism  with  several  different primer 
sets  the  PCR  products  were  purified  with  QiaQuick™  purification  columns  (Qiagen) 
and  different primers  (either  3cP12-AS,  G3cP13-AS  or 3cP12-S  as  outlined in Table
8.4)  were  tested  to  sequence  the  -3432poly-G  polymorphism  on  an  ABI  3730  DNA 
analyser using BigDye terminator chemistries version  3.1.  The results of this analysis 
revealed that the primer combination 3cPl 1-S and 3cP12-AS in the PCR followed with 
the  anti-sense  primer,  3cP12-AS,  in  sequencing  produces  clear  and  consistent 
sequencing results for the -3432poly-G polymorphism; good quality sequence data with 
a  strong  signal  is  obtained  18bp  from  the  3’  end  of primer  3cP12-AS.  Other primer 
combinations  that  were  tested  were  not  as  successful.  For  example,  the  primer 
combination  3cP12-S  and  3cP12-AS  (or  G3cP13-AS)  in  the  PCR  followed  with  the 
anti-sense  primer  3cP12-AS  for  sequencing  produces  sequencing  data  that  is 
confounded by a high background.  In  addition,  it became apparent from this  analysis 
that due to the proximity of the -3457(GA)n and -3495(GT)n repeats it is not possible to 
sequence the -3432poly-G polymorphism using a sense primer; the quality of the
Table 8.4: Primer combinations considered for genotyping the -3432poly-G 
polymorphism by direct sequencing.
Sense primer Anti-sense primer Size of PCR amplicon (bp) Sequencing primer
3cP12-S 3cP12-AS 398 3cP12-AS
3cP12-S G3cP13-AS 423 3cP12-AS
3cP12-S G3cP13-AS 423 3cP12-S
3cP12-S G3cP13-AS 423 G3cP13-AS
/•ScPll-S 3cP12-AS 285 3cP12-AS
3cPl 1-S G3cP13-AS 310 3cP12-AS
282sequence data 3’ of the -3495(GT)n and -3457(GA)n repeats and prior to the -3432poly- 
G polymorphism was consistently poor when this approach was tried. Once a successful 
primer  combination with which to  genotype the  -3432poly-G polymorphism by direct 
sequencing was  established final  adjustments were made to optimise this analysis.  The 
amount  of purified  PCR  product  per  sequencing  reaction  was  adjusted  for  optimum 
peak height of the sequencing chromatograms and lOOng of purified DNA was found to 
give optimum results.
In  summary,  by  careful  selection  of PCR  and  sequencing  primers  a  suitable 
protocol (described in detail in method section 3.2.15.1) was devised and optimised to 
genotype  the  -3432poly-G  polymorphism  by  direct  sequencing  and  problems  in 
sequencing  that  derived  from the  close  proximity  of the  -3457(GA)n and  -3495(GT)n 
repeats were minimised.
8.4.1.2  Manual interpretation of sequencing chromatograms.
To determine the -3432poly-G genotype in heterozygous subjects the method of Yu et 
al,  was  adopted  and  sequencing  chromatograms  were  interpreted  manually.  The 
methodology  for  manual  interpretation  of  sequencing  chromatograms  is  described 
below and for clarity the majority of this text is reproduced in figure legend 8.5.
Manual  interpretation  of sequencing  chromatograms  in  heterozygous  subjects 
was  aided  by  first  locating the  invariant  sequence  ‘TGGCATTAAATTA’  immediately 
downstream  of the  -3432  poly-G-polymorphism  (Fig.  8.5;  underlined  for  each  allele 
within  the  written  sequence  added  below  the  chromatogram).  By  identifying  this 
invariant  sequence  first  and  reading  the  chromatograms  3’  to  5’  across  the  poly-G- 
polymorphic  region  (shown  as  a  series  of  constitutive  C’s  in  Fig.8.5  as  sequence 
obtained  is  for  the  anti-sense  strand)  it  was  possible  to  categorise  homo-  and 
heterozygous  peaks  and  clarify  each  allele.  Specifically,  the  invariant  sequence  was 
located by identifying the initial three bases ‘TGG’ which in heterozygous individuals is 
easily identified as a region of either 3, 4 or 5 constitutive G’s (shown as 3 constitutive 
G’s  in  the  example  shown  in  Fig.  8.5).  Then  counting  from  the  3’  G  (Fig.  8.5; 
highlighted  in  blue  for  allele  1  within  the  written  sequence  added  below  the 
chromatogram;  also  highlighted  in  blue  for  allele  1   within  the  text)  the  first  (and 
longest)  allele  sequence  was  marked  off the  chromatogram  in  the  direction  3’  to  5’ 
using  the  reference  sequence  (Ensembl  transcript  ID:  ENST00000230732;  see 
Appendix B) and poly-G allele  sequences determined from the PCR-SSCP screen as a 
guide  (see  Table  4.3,  section  4.4.2,  page  156).  Referring  back  to  the  3’  G  of the
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Figure 8.5: Representative sequencing chromatogram to illustrate the methodology used to manually interpret discrete -3432poly-G alleles. The -3432poly-G polymorphism was genotyped by 
direct sequencing with anti-sense primer 3cP12-AS and sequence obtained was for the anti-sense strand. Chromatograms obtained from direct sequencing were manually interpreted in heterozygous 
subjects to elucidate discrete alleles. Manual interpretation of the sequencing chromatogram was aided by first locating the invariant sequence  ‘TGGCATTAAATTA’ immediately downstream of the 
-3432poly-G polymorphism (underlined in red for allele  1   and black for allele 2 within the written sequence added below the chromatogram).  Specifically, the invariant sequence was located by 
identifying the initial three bases ‘TGG’ which in heterozygous individuals consists of a region of either 3,4 or 5 constitutive G’s (shown as 3 constitutive G’s in above example). Then counting from 
the 3’ G (highlighted in blue for allele 1  within the written sequence added below the chromatogram) the first (and longest) allele sequence was marked off the chromatogram in the direction 3’ to 5’. 
Referring back to the 3’ G of the invariant sequence for allele 1 the rest of the invariant sequence ‘CATTAAATTA’ was marked off the chromatogram in the direction 5’ to 3’. Identification of this 
remaining invariant region was aided by clear distinction between homozygous and heterozygous peaks within this region (homozygous peaks that facilitated identification of each allele in the above 
example are indicated by the small red arrows). Identification of the invariant sequence was also aided by locating the 3’ C of the invariant sequence (shown in red bold for allele 1  within the written 
sequence added below the chromatogram) as this was characterised by a very low peak height on the sequencing chromatogram. Counting the length of the locus (L) for allele 1 defined from the 3’ G 
of the invariant sequence ‘TGGCATTAAATTA’ to the 3’A of the upstream sequence ‘TTACCCA’ (underlined in blue for the automatic base calls) helped determine whether allele 1  was (G)i2; if the 
(G)1 2  allele is present the length of the locus, L, is 23bp. In the example shown L = 22bp and allele one (the longest allele) is (G)n Once the first allele sequence had been marked off the chromatogram 
the second allele sequence was deduced in a similar manner by giving careful consideration to matching of homo- and heterozygous peaks across the invariant region. In the example shown for allele 2 
the 3’ G of the invariant sequence is highlighted in purple and the 3’ C of the invariant sequence is highlighted in black bold within the written sequence added below the chromatogram. The direct 
sequencing chromatogram shown is typical of the subjects assigned genotype (G)n / (G)i0.
to
00 4^invariant sequence for allele  1   the rest of the invariant sequence ‘CATTAAATTA’ was 
marked  off the chromatogram in the direction 5’  to 3’.  Identification of this remaining 
invariant  sequence  was  aided  by  the  clear  distinction  between  homozygous  and 
heterozygous peaks within this region; homozygotes are characterised by a single peak 
compared  to  heterozygotes  that  consists  of two  superimposed  peaks.  In  addition the 
heterozygous  peaks  consisted  of  half  the  signal  strength  compared  to  adjacent 
homozygous peaks (for example see homozygous peaks indicated by the red arrows in 
Fig.  8.5  and  compare to  adjacent  heterozygous  peaks).  Identification  of the  invariant 
sequence was also aided by locating the 3’  C of the invariant sequence (Fig. 8.5; shown 
in  red  bold  for  allele  1   within  the written  sequence  added  below the  chromatogram; 
‘TGGCATTAAATTA’) as this was always characterised by a very low peak height on 
the sequencing chromatogram.
Counting the length  of the locus  (L) for allele  1   defined from the 3’  G  of the 
invariant  sequence  ‘TGGCATTAAATTA’  to  the  3’A  of  the  upstream  sequence 
‘TTACCCA’  (see L in Fig.  8.5) helped determine whether allele  1   is (G)i2. If the (G)n 
allele was present the length of this locus, L, is 23bp.  Once the first allele sequence had 
been marked off the chromatogram, the second allele sequence was deduced in a similar 
manner by giving  careful  consideration to matching of homo-  and heterozygous peaks 
across the invariant region.  In the example shown (Fig.  8.5) the first allele sequence is 
(G)n  and  the  second  allele  sequence  is  (G)io;  the  3’  G  and  3’  C  of the  invariant 
sequence  highlighted  in  purple  and  black  bold  respectively,  for  allele  2  within  the 
written sequence added below the chromatogram.  The direct sequencing chromatogram 
shown in Fig. &S is typical of subjects identified genotype (G)n / (G)io.
8.4.2  Preliminary genotyping.
Having  devised  and  optimised  a  suitable  protocol  with  which  to  genotype  the  - 
3432poly-G polymorphism  by  direct  sequencing  a small  set  of preliminary genotyping 
was  undertaken  to  test  the  integrity  of this  approach  prior  to  genotyping  late  onset 
hearing loss and general population cohorts for the preliminary association study. From 
this  preliminary  genotyping  analysis  it  was  evident  that  genotyping  the  -3432poly-G 
polymorphism was a very difficult and time-consuming process.
For preliminary genotyping seventeen genomic DNA samples were subjected to 
PCR amplification using primers 3cPll-S and 3cP12-AS as described in method section 
3.2.15.1.  For each genomic DNA sample half of the PCR product was genotyped for -
285-3432poly-G  polymorphism  with  anti-sense  primer  3cP12-AS  according  to  method 
section  3.2.15.1  and  half  was  sub-cloned  into  a  T-Tailed  vector,  pGEM®-T  easy 
(Promega) (see method section 3.2.9.1) to allow sequence analysis of individual DNA 
molecules from the PCR product pool.  Several clones for each sample were sequenced 
for  -3432poly-G  polymorphism  using  primer  3cP12-AS  and  results  obtained  were 
compared with those obtained from direct sequencing.
Using  direct  sequencing  coupled  with  manual  interpretation  of  sequencing 
chromatograms it was evident that discrete poly-G alleles were sometimes difficult to 
elucidate  in  heterozygous  individuals  with  different  length  variants.  However,  it was 
clear  that  heterozygous  samples  could  be  grouped  according  to  genotype  based  on 
reproducible  and  consistently  similar  sequencing  chromatograms.  This  problem 
encountered in genotyping complex heterozygotes  for the -3432poly-G polymorphism 
by direct  sequencing is not unique;  it is similar to that described by Yu et al, in their 
analysis of the poly-G length polymorphism in the KLK1 promoter.
Sequencing of cloned PCR products did not aid elucidation of discrete poly-G 
alleles in complex heterozygotes. Similarly, neither did it prove to be a valuable method 
to  confirm  primary  genotyping  data  obtained  by  direct  sequencing  and  this  was 
especially  evident  if a  subject  was  heterozygous  for  the  -3432poly-G  polymorphism; 
poly-G  alleles  elucidated  from  sequencing  of cloned  PCR  products  did  not  always 
clearly agree with data obtained by direct sequencing. ‘Stutter’ alleles from the PCR had 
a  tendency  to  be  sub-cloned  alongside  the  bona-fide  genuine  alleles  making 
discrimination of genuine alleles from PCR artefacts difficult. Although, it was evident 
that  if a  subject  was  homozygous  for the  -3432poly-G  polymorphism  sequencing  of 
cloned  PCR  products  was  often  consistent  with  data  obtained  by  direct  sequencing 
particularly if the shortest poly-G alleles were present. A detailed discussion of this line 
of analysis is presented in Appendix G.
Given the overall unsuitability of sequencing cloned PCR products to confirm 
and / or to aid identification of -3432poly-G alleles determined by direct sequencing an 
alternative confirmatory technique was sought. In some heterozygous samples identified 
as having the same genotype based on reproducible and consistently similar sequencing 
chromatograms  it  was  evident  that  if the  size  of the  two  poly-G  alleles  could  be 
ascertained, then elucidation of the precise sequence for each allele would be facilitated. 
Therefore,  to  aid  genotyping  in  these  difficult  sample  groups  and  as  a  confirmatory 
method allele size was determined in each of the original  17 genomic DNA samples by
286polyacrylamide gel electrophoresis (PAGE) analysis of radioactive PCR products. This 
line of analysis is outlined in the next section.
8.4.2.1  PAGE  analysis  of radioactive  PCR  products  as  a  confirmatory  method 
for genotyping the -3432polv-G polymorphism by direct sequencing.
To facilitate identification of discrete -3432poly-G alleles in complex heterozygotes and 
as  a  confirmatory  method  for  genotyping  the  -3432poly-G  polymorphism  by  direct 
sequencing PAGE analysis of radioactive PCR products was used to size poly-G alleles 
in each of the original  17 genomic DNA samples selected for preliminary genotyping. 
This approach proved to be very valuable to aid elucidation of discrete poly-G alleles 
and to confirm genotypes identified by direct sequencing.
To  size poly-G alleles by PAGE analysis of radioactive PCR products a novel 
primer G3cP13-S:  5 ’ -G  ATT  GT  A  ATTT  A  AT  GCC  ATGGT  G-3 ’ was designed for use in 
combination  with  primer  3cP12-AS  to  amplify  a  181bp*  product  containing  the  - 
3432poly-G  polymorphism  (*based  on  containing  a  -3432poly-G  allele  of (G)n;  see 
Appendix  B  for  reference  sequence).  By  careful  placement  of  the  sense  primer, 
G3cP13-S, it was possible to generate PCR amplicons of length dependent on the nature 
of the -3432poly-G allele and not the proximal -3457(GA)n or -3495(GT)n polymorphic 
dinucleotide repeats (see Fig. 8.6). A summary of the different size -3432poly-G alleles 
generated is shown in Table 8.6 (sizes are shown for all nine alleles identified at the - 
3432 locus) and full details of the protocol is described in method section 3.2.15.2.
In summary, preliminary genotyping analysis suggested that direct sequencing is 
a reliable method with which to  genotype the -3432poly-G polymorphism if sizing of 
poly-G alleles by PAGE analysis of radioactive PCR products is used as an additional 
secondary technique to  aid elucidation and / or to confirm discrete alleles in complex 
heterozygotes.  Sequencing of cloned PCR products  as a confirmatory method did not 
prove  valuable.  Based  on  these  results  it  was  decided  to  genotype  the  -3432poly-G 
polymorphism  in  late  onset  hearing  loss  and  general  population  cohorts  using  direct 
sequencing  as  the primary analysis  and  then  where necessarily to perform  secondary 
analysis to size poly-G alleles to confirm or where appropriate facilitate identification of 
genotypes.
287GGAGGATATGGTGCTTTGTGCCCTGACTTCACCTTACATGTGGCAAATCTATGTCCCTACTAGACTCTGA  - 3 7  4 2  t o  
CCTCCTATACCACGAAACACGGGACTGAAGTGGAATGTACACCGTTTAGATACAGGGATGATCTGAGACT  -  3 6 7 3
GCTCCTGAAGCAGTGTCTTCTGTATCTTCAAGGCCTTCCACAAGACTCTGCTGTTAGTAGGTATTTGGAA  -3672  to 
CGAGGACTTCGTCACAGAAGACATAGAAGTTCCGGAAGGTGTTCTGAGACGACAATCATCCATAAACCTT  -3603
ATGCTTATCGAATGGGGAAAATTCTTCCTTCAATGCCACTTGCATAAATGCCCACATAGTCCTTACATGG  - 3 6 0 2   t o  
TACGAATAGCTTACCCCTTTTAAGAAGGAAGTTACGGTGAACGTATTTACGGGTGTATCAGGAATGTACC  - 3 5 3 3
ACCTTCACATATTTTGTTTGGCCCATAAATGGTAT GAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG  -  3  5 3  2  to 
TGGAAGTGTATAAAACAAACCGGGTATTTACCATACTCACAGACACACACACACACACACACACACACAC  -34  63
TGTGTGATTGTAATTTAATGCCATGGTGGTGGGGGGGGGGGTGGGTAAGTGCTCTCTAGTTTACCACAGT  - 3 4  6 2   to 
ACACACTAACATTAAATTACGGTACCACCACCCCCCCCCCCACCCATTCACGAGAGATCAAATGGTGTCA  - 3 3 9 3
TTCAATCTTTCCTTTTATCCACCCAGATAAAGTTGCTCAATTTTATTTTACTAGTTTTGCACCTTATAGA  - 3 3 9 2   to 
AAGTTAGAAAGGAAAATAGGTGGGTCTATTTCAACGAGTTAAAATAAAATGATCAAAACGTGGAATATCT  - 3 3 2 3
ATTTAAGTTTACAAATTCTGGAAAGCATAGAGGCTGTTACAAATTGCCGTCTAAGGCTGTCCTTCCAATT  -3322  to 
TAAATTCAAATGTTTAAGACCTTTCGTATCTCCGACAATGTTTAACGGCAGATTCCGACAGGAAGGTTAA  " 3 2 5 3
<-------------------------------
GCTTTTTCTATGGTCTTTTCCCTCTTTTCTTCTCCAGTCTCCAGTCTGTTATCTCCAAGGCCTTCTCAAA  - 3 2 5 2   to 
CGAAAAAGATACCAGAAAAGGGAGAAAAGAAGAGGTCAGAGGTCAGACAATAGAGGTTCCGGAAGAGTTT  - 3 1 8 3
Figure 8.6  Section of the Bm-3c  promoter surrounding the -3432 poly-G polymorphism to show 
sequence of primers for sizing poly-G alleles by PAGE analysis of radioactive PCR products. The
region of the  Bm-3c  promoter in the vicinity of the  -3432poly-G polymorphism  is  highly  repetitive 
consisting of two multi-allelic dinucleotide repeats: -3457(GA)n and -3495(GT)n highlighted in red bold 
and  black  bold,  respectively  (the  -3432poly-G  polymorphism  is  also  highlighted  in black bold).  By 
careful  primer  design  it  was  possible  to  size  poly-G  alleles  by  PAGE  analysis  of radioactive  PCR 
products and exclude the effect of the polymorphic dinucleotide repeats at -3457 and -3495  from the 
analysis.  Sequences of primers used are highlighted in green (3cP12-AS) and purple (G3cP13-S) with 
the  direction  of  each  primer  defined  by  the  arrows.  The  G3cP13-S  primer  includes  the  3’  two 
nucleotides of the -3457(GA)n repeat.
Table 8.5: A summary of the different sized -3432poly-G alleles generated by 
PCR amplification of genomic DNA.
Allele DNA sequence Abbreviation Length of allele (bp)*
(G)io 5’ TGGTGGTGGGGGGGGGGTGGGTA 3’ (G)io 181
(G)„ 5  TGGTGGTGGGGGGGGGGGTGGGTA 3’ (G)n 182
(G),2 5  TGGTGGTGGGGGGGGGGGGTGGGTA 3’ (G>2 183
(G)l3 5  TGGTGGTGGGGGGGGGGGGGTGGGTA 3’ (G)i3 184
SNPG1 5’ TGGTGGTGGGGGGGGCGTGGGTA 3’ (G)gCG 181
SNPG2 5  TGGTGGTGGt GGGGGGGGGTGGGTA 3’ GGC(G)9 183
SNPG4 5’ TGGTGGTGG1GGGGGGGGTGGGTA 3’ GGT(G)g 182
SNPG5 5’ TGGTGGTGGGG<: GGGGGGTGGGTA3’ (G)4QG)6 182
SNPG6 5  TGGTGGTGGt GGGGGGGGGGTGGGTA 3’ GGQG)10 184
* Allele length determined from using primers G3cP13-S and 3cP12-AS in the PCR reaction.
2888.4.3  Genotvpina the -3432polv-G polymorphism in late onset hearing loss 
and general population cohorts.
Having  devised  and  optimised  a  suitable  protocol  for  genotyping  the  -3432poly-G 
polymorphism by direct sequencing and having tested the integrity of this method and 
made  adjustments  the  -3432poly-G  polymorphism  was  genotyped  in  142  patients 
characterised  as  having  a  late  onset  sensorineural  hearing  loss  and  145  general 
population samples for a preliminary association study.
Direct  sequencing  was  used  as  the  primary  analysis.  Upon  direct  sequencing 
samples  were  initially  grouped  according  to  chromatogram  data  and  in  the  case  of 
complex  heterozygotes,  similar chromatogram patterns.  PAGE  analysis  of radioactive 
PCR products was performed in secondary analysis to  size poly-G alleles to  facilitate 
identification of discrete alleles in complex heterozygotes and to confirm the genotypes 
determined from primary analysis.  In all  samples where poly-G  alleles were sized the 
results  of sizing poly-G  alleles by PAGE  analysis of radioactive PCR products  aided 
elucidation of genotype by direct sequencing with a few exceptions. Firstly, for subjects 
assigned to chromatogram group 3 and identified as (G) 12 heterozygotes (see Table 8.6) 
it was not possible to discriminate between (G)u and (G)io as the second allele type and 
so in frequency analysis both possibilities were counted.  Secondly, it was not possible 
to  clarify  the  second  allele  type  for  subjects  with  genotype  SNPG4  /  ND  (Not 
Determined;  see Table 8.6) and therefore, this category of subjects was excluded from 
subsequent frequency analysis. In both these cases the presence of convincing ‘shadow’ 
bands  upon  PAGE  analysis  of radioactive  PCR products  confounded  accurate  sizing. 
Similarly, for a small number of samples (3 samples) identified SNPG2 homozygous by 
direct  sequencing  sizing  of  poly-G  alleles  by  PAGE  analysis  of  radioactive  PCR 
products did not agree with the data obtained by direct sequencing. The presence of a 
convincing secondary band upon PAGE analysis of radioactive PCR products prevented 
clarification  of genotype.  Consequently the  genotype  could  not be  identified  in these 
samples  and they were left unassigned (see Table 8.6) and excluded  from  subsequent 
frequency analysis. A detailed discussion of these problems encountered in genotyping 
the  -3432poly-G  polymorphism  is  discussed  further  in  Appendix  H:  elucidation  of 
problematic genotypes.
For some samples the quality of the data obtained from direct sequencing was 
poor;  either  a  high  background  or  loss  of sequencing  signal  after  the  poly-G  repeat 
confounded  reliability of the  data or made  accurate determination of discrete poly-G 
alleles impossible. These samples were immediately subjected to re-sequencing and if
289Table 8.6: A summary of -3432poly-G genotypes identified in late onset 
hearing loss and general population cohorts using direct 
sequencing coupled with secondary analysis.
Chromatogram
group
Genotype Late onset hearing loss 
(observed)
General population 
(observed)
1 (G)n /(G )1 0 69 52
2 (G)10/(G),„ 3 4
3 (G)i2 / (G)n or io 7 6
4 SNPG2 / SNPG2 22 27
5 SNPG2 / (G)io 2 1
6 SNPG1 / SNPG1 11 10
7 SNPG2 / SNPG6 8 5
8 SNPG4 / SNPG4 2 1
9 SNPG4 / ND* 4 3
10 SNPG4 / SNPG1 0 1
11 SNPG4 / (G)1 0 0 1
12 SNPG5 / SNPG5 3 4
13 SNPG1 / SNPG2 1 3
14 (G)13/(G )1 2 0 1
15 SNPG2 / SNPG4 3 5
16 SNPG1 / (G)n 0 3
Not assigned 1 2
Fail PCR 6 16
Total 142 145
*ND: second allele Not Determined.
good quality sequence data was obtained from repeat sequencing then this information 
was used to determine genotypes. If the sequencing data was consistently poor upon re­
sequencing then the samples were subjected to the initial PCR amplification again (see 
method section 3.2.15.1).  In the absence of good quality sequence data upon repeat of 
the initial PCR amplification a genotype was not determined for that sample.
Finally, to confirm further the genotypes identified^  random batch of samples of 
each  genotype  was  subject  to  repeat  sequencing  and  these results  were in  agreement 
with those obtained originally. In addition, the integrity of the method used to manually 
interpret the sequencing chromatograms and assign a genotype which was adopted from 
Yu et al, was tested in a blind study. A random batch of direct sequencing data for each 
genotype  was  selected  and  using  the  guidelines  as  described  previously (see  section 
8.4.1.2)  the  genotype  of  each  sample  was  determined  independently  by  a  second 
individual.  This  line  of analysis  showed  that  the results  of the genotypes  determined 
independently  by  a  second  individual  were  in  complete  agreement  with  those 
determined originally. Hence, confirming the reliability of the method used to manually 
interpret  discrete  poly-G  alleles  from  direct  sequencing  chromatograms  and  the 
accuracy  of  the  genotypes  determined,  particularly  in  the  case  of  complex
290heterozygotes. Given the complexity of the -3432poly-G polymorphism it was reasoned 
that  an  alternative  PCR  to  genotype  the  -3432poly-G  polymorphism  by  direct 
sequencing  using  PCR  and  sequencing  primers  different  from  those  used  originally 
would be  an  appealing approach  for further validation  of the original  data.  Especially 
since sizing poly-G alleles by PAGE analysis of radioactive PCR products would not be 
able to rule out loss of heterozygosity in the primary screen by direct sequencing due to 
a  mutation  within  the  annealing  site  of primer  3cP12-AS  leading  to  a  ‘null’  allele. 
Consequently,  attempts  were  made  to  optimise  an  alternative  PCR  reaction  using 
primers  3cP12-S  and G3cP13-AS  for the initial  PCR reaction and primer G3cP13-AS 
for sequencing (see Table 8.4,  page 282) but, this approach was besieged with a high 
background upon direct sequencing and so not pursued further.
In summary, a total of 16 different -3432poly-G genotypes were identified from 
genotyping samples for the preliminary association study (see Table 8.6). An overview 
of the steps taken that lead to confirmation of each genotype is shown in Fig. 8.7.
8.4.4  Identification of haplotvpes for -3495(GT)n^3457(GA)n and -3432polv- 
G polymorphism.
From  the  initial  PCR-SSCP  screen  and  genetic  analysis  to  genotype the  -3432poly-G 
polymorphism  it became  apparent  that  the  adjacent  dinucleotide  repeats:  -3457(GA)n 
and  -3495(GT)n  appear  in  strong  linkage  disequilibrium  with  the  -3432poly-G 
polymorphism.  This  was  particularly  clear  from  analysis  of subjects  homozygous  for 
the  -3432poly-G  polymorphism  where  sequencing  of  cloned  PCR  products  for  - 
3432poly-G  polymorphism  in  combination  with  direct  sequencing  analysis  revealed 
some very distinct haplotypes.  For example, it was strikingly evident that poly-G allele 
SNPG1,  one  of  the  shortest  poly-G  alleles  identified  was  always  detected  in 
combination with the shortest (GT)n dinucleotide repeat identified at position -3495;  15 
repeats and the -3457(GA)n repeat haplotype detected in these samples always consisted 
of two repeats (see Fig. 4.14a, page  157). In contrast, poly-G allele SNPG2 was always 
detected  in conjunction with  a much longer (GT)n repeat at position -3495  (20 or 21) 
and the common -3457(GA)n  haplotype observed in these samples was two repeats (see 
Fig. 4.14d, page  157).  Similarly, if poly-G allele SNPG4 was present at position -3432 
the  native  -3457  and  -3495  haplotype  detected  was  always  (GA)i  and  (GT)i6;  a  - 
3457(GA)n  repeat  greater  than  one  was  never  detected  from  the  genetic  analysis 
performed (see Fig. 4.14b, page 157).
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Figure  8.7:  An  overview  of  the  steps  taken 
that  lead  to  confirmation  of  different  - 
3432poly-G genotypes. Percentages refer to the 
number  of  samples  sized  by  a  secondary 
technique;  PAGE  analysis  of radioactive  PCR 
products using primers G3cP13-S and 3cP12-AS 
in  the  PCR  reaction  (see  method  section 
3.2.15.2). *ND: second allele Not Determined.
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292Elucidation  of  haploypes  at  -3495,  -3457  and  -3432  although  mainly  from 
subjects homozygous  for the  -3432poly-G polymorphism was by no means  limited to 
just  homozygotes.  Figure  8.8a  shows  the  direct  sequencing  chromatogram  typical  of 
SNPG2 / SNPG4 heterozygotes. It is clear from this chromatogram that the -3457(GA)n 
haplotype differs by one repeat between the two poly-G alleles present (shown as ‘TC’ 
versus ‘TCTC’ in Fig. 8.8a for the anti-sense strand). By locating the invariant sequence 
and  elucidating  the  discrete  alleles  it  is  evident  that  poly-G  allele  SNPG2  has  a  - 
3457(GA)n haplotype of two repeats and poly-G allele SNPG4 a -3457(GA)n haplotype 
of one repeat.  Similarly, figure 8.8b shows the direct sequencing chromatogram typical 
of SNPG2  /  (G)io heterozygotes.  By distinguishing the  discrete  alleles  it  is  clear that 
poly-G  allele  (G)io  has  a  -3457(GA)n  haplotype  of  one  compared  to  poly-G  allele 
SNPG2 which has a -3457(GA)n haplotype of two.
From the preliminary genotyping (section 8.4.2, page 285) it was evident that it 
would not be possible to  characterise the -3495,  -3457  and -3432 haplotypes  in every 
individual genotyped for -3432poly-G polymorphism; difficulties in sequencing limited 
this line of analysis. The close proximity of the variation at -3432, -3457 and -3495, the 
repetitive nature of the sequence variants and the high heterozygosity observed for each 
repeat variant made elucidation of haplotypes by direct sequencing extremely difficult. 
An  illegible  sequence was often observed  after sequencing the  -3495(GT)n repeat that 
was  very difficult to  interpret manually due to heterozygosity at the prior -3432  and - 
3457 repeats making elucidation of discrete  -3495(GT)n alleles problematic. Therefore, 
this  line  of work  was  not  undertaken.  However,  a  summary of the haplotypes  it  was 
possible to decipher are summarised in Table 8.7.
In summary, of 142 patients characterised with a late onset hearing loss and 145 
general  population  controls  that  were  genotyped  for -3432poly-G  polymorphism  95% 
and  88%  respectively,  were  successfully  assigned  a  distinct  genotype  (see Table  8.6, 
page  291).  By  combining  direct  sequencing  (primary  analysis)  with  sizing of poly-G 
alleles (secondary analysis) it was possible to elucidate discrete poly-G alleles for each 
genotype except two (see Table 8.6). These problems encountered with the genotyping 
the -3432poly-G polymorphism are very similar to those described by Yu et al, 2002 in 
their  analysis  of  the  similar  poly-G  polymorphism  within  the  KLK1  promoter  and 
exemplify  the  complexity  of  genotyping  this  particular  type  of  polymorphism. 
Moreover,  in  this  case  genotyping  of  the  -3432poly-G  polymorphism  was  further 
exacerbated because sequencing of the opposite DNA strand was not possible due to the 
closeness of the polymorphic -3457(GA)n and -3495(GT)n repeats.
293(a)
100  110  120  IX  14)  150  160
OTAAAC TA OAOAGCACT TACCCACCCCCCCCCC CAC CCCCCAOGGAT TAAAT TAC CAA CCCACACACACAC C
III 4
cgccfi  c   c   a   c  c   a   tggcattaaattac  a   a l
Allele 2: SNPG4
Allele 1: SNPG2
(b)
100  110  120  IX  14)  150  160
TAAAC TA 0 AOAOCAC TTACCCACCCCCCCCCCCCACCCCCOTOOTTTTATTTTACAATCTCACACACAC
Allele 2: (G ),„^
Allele 1: SNPG2
Figure  8.8  Direct  sequencing  chromatograms  representative  of  individuals  identified  SNPG2 
heterozygous, (a) and (b) The direct sequencing data obtained is for the anti-sense strand. Alleles were 
elucidated by reading 3’ to 5’ from the 3’ G within the invariant region (underlined). Clear distinction 
between  homozygous  and  heterozygous  peaks  facilitated  identification  of each  allele;  see  written 
sequence added below each chromatogram (homozygous peaks are indicated by the small red arrows). 
Haplotypes for -3432poly-G polymorphism and -3457(GA)n repeat can be observed on each allele. The 
region of the sequencing chromatogram representing the -3432poly-G polymorphism is underlined in 
blue  and  boxed  in  blue  for  the  -3457(GA)n repeat  within  the  written  sequence  added  below  each 
chromatogram, (a) Direct sequencing chromatogram representative of subjects identified SNPG2 / (G)i0 
heterozygous at -3432. The haplotype at -3432 and -3457 is SNPG2 : (GA)2 respectively, for allele 1  and 
SNPG4 : (GA)i respectively, for allele 2. (b) Direct sequencing chromatogram representative of subjects 
identified SNPG2 / SNPG4 heterozygous at -3432. The haplotype at -3432 and -3457 is SNPG2 : (GA)2 
respectively, for allele 1  and (G)i0 : (GA)i respectively, for allele 2.
294Table 8.7: Haplotypes of multi-allelic sequence variants identified at -3495, -3457 
and -3432 within the Brn-3c 5’-flanking region.
Haplotype -3495(GT)„ -3457(GA)„ -3432poly-G
3c/A 15 2 (G)gCG  (SNPG1)
3c/B 20 2 GGC(G)9   (SNPG2)
3c/C 21 2 GGC(G)9   (SNPG2)
3c/D 20 3 GGC(G)9   (SNPG2)
3c/E 16 1 GGT(G)8   (SNPG4)
3c/F - 1 (G)4C(G)6  (SNPG5)
3c/G 24 2 GGC(G)io (SNPG6)
3c/H 19 1 (G),0
3c/I 19 1 (G)„
3c/J - 1 (G)1 2
Haplotypes identified are based on sequencing of cloned PCR products in pGEM®-T easy vector 
as part of an initial PCR-SSCP screen in 45 individuals predominantly of Caucasian ethnicity and 
direct  sequencing  of  genomic  DNA  to  genotype  the  -3432poly-G  polymorphism  for  the 
preliminary  association  study.  All  subjects  used  in  the  preliminary  association  study  are 
Caucasian.  It was not possible to establish haplotype frequency due to difficulties in sequencing 
analysis; this is discussed in section 8.4.5. Dashed line -  allele type inconclusive.
2958.5  Association  analysis  to  asses  whether  the  -3432poIv-G
polymorphism is a risk factor for late onset hearing loss.
To assess whether the -3432poly-G polymorphism is a risk factor for late onset hearing 
loss  the -3432poly-G polymorphism was  genotyped in our late onset hearing loss and 
general  population  cohorts  for  a preliminary association  study.  It was  accepted  at the 
outset of this research project that the number of patients characterised with late onset 
hearing  loss  that  could be recruited  into  this  study within the time  frame of the PhD 
project  would limit the power of the association  analysis.  Therefore,  the main  aim of 
genotyping the -3432poly-G polymorphism for this PhD project was to establish allele 
frequency  and  to  perform  preliminary  association  analysis  as  a  first  step  prior  to 
undertaking  a  large-scale  population  based  case-control  association  study,  which  is 
beyond the capacity of the PhD project.
Due to the complexity of the -3432poly-G polymorphism: multiple variations in 
length of the poly-G repeat coupled with various single nucleotide substitutions within 
the poly-G repeat,  a dual approach was devised for genotyping.  Direct sequencing was 
used as the primary analysis and sequencing chromatograms were interpreted manually 
using  an  adaptation  of Yu  et  al,  2002.  Sizing of poly-G  alleles by PAGE  analysis of 
radioactive PCR products was used in secondary analysis to aid elucidation of discrete 
poly-G  alleles  in  complex  heterozygotes  and  to  confirm  data  obtained  by  direct 
sequencing.
Using  this  approach  95%  of patients  and  88%  of general  population  samples 
genotyped for -3432poly-G polymorphism were assigned a specific genotype (see Table 
8.8). A total of 16 distinct genotypes were identified and poly-G alleles were elucidated 
for each genotype except two.  For subjects with genotype (G)i2 / (G)n or 10 it was not 
possible to discriminate between (G)u  and (G)io as the second allele type. Whereas, for 
subjects with genotype SNPG4 / ND it was not possible to clarify the second allele type. 
In both these cases data obtained by PAGE analysis of radioactive PCR products did not 
prove useful when coupled with data obtained by direct sequencing (a full discussion of 
these problems  encountered in  genotyping the -3432poly-G polymorphism is given in 
Appendix H: elucidation of  problematic genotypes). Therefore, allele frequencies were 
determined accommodating these two limitations. For subjects identified as (G)i2 / (G)n 
or io both possibilities were counted as the second allele type and for subjects identified 
SNPG4 / ND this category was excluded from subsequent frequency analysis. It was
296Table 8.8: Genotype frequency of -3432poly-G polymorphism amongst 
Caucasian individuals in late onset hearing loss and 
general population cohorts.
Late onset hearing loss G eneral population
Genotype Observed Frequency Observed  Frequency
(G )„/(G )10 69 0.527 52 0.419
(G)io / (G)10 3 0.023 4 0.032
(G)12 / (G),, or 10 7 0.053 6 0.048
SNPG2 / SNPG2 22 0.168 27 0.218
SNPG2 / (G)io 2 0.015 1 0.008
SNPG1 / SNPG1 11 0.084 10 0.081
SNPG2 / SNPG6 8 0.061 5 0.040
SNPG4 / SNPG4 2 0.015 1 0.008
SNPG4 / ND* 4 - 3 -
SNPG4 / SNPG1 0 0.000 1 0.008
SNPG4 / (G)10 0 0.000 1 0.008
SNPG5 / SNPG5 3 0.023 4 0.032
SNPG1 / SNPG2 1 0.008 3 0.024
(G)i3 / (G)1 2 0 0.000 1 0.008
SNPG2 / SNPG4 3 0.023 5 0.040
SNPG1 / (G)n 0 0.000 3 0.024
Not assigned 1 2
Fail PCR 6 16
Total 142 145
*ND: second allele Not Determined.
acknowledged that this approach may lead to an over-representation of alleles (G)io and 
(G)n, and an under-representation of allele SNPG4 in the late onset hearing loss sample 
group examined. However, since the same criteria was applied to the general population 
sample  group  and  similar numbers  of samples were identified  as  (G)i2 / (G)n or  10 or 
SNPG4 / ND between both sample groups the possibility of these limitations leading to 
a false-positive association is unlikely.
From Table 8.8 it is evident that there is a skew towards certain genotypes. The 
most  common  genotype  in  both  the  late  onset  hearing  loss  and  general  population 
sample groups is  (G)u / (G)io heterozygous closely followed by SNPG2 homozygous. 
(G)n / (G)io heterozygotes account for around 40-50% of all genotypes identified within 
each sample group.  Given the high frequency of the (G)n / (G)io genotype across both 
sample groups the (G)n  and (G)io homozygotes  appear under-represented (Table  8.8). 
Indeed,  the  (G)u  homozygous  genotype  was  not  identified  during  the  course  of this 
analysis raising the possibility that some samples identified (G)n / (G)io heterozygous 
may have been wrongly identified. However, samples (G)n / (G)io heterozygous exhibit 
very  clear  and  distinctive  results  upon  direct  sequencing  as  illustrated  by  the 
chromatogram shown in Fig. 8.5 (page 284) and it is unlikely that any have been miss-
297assigned  on  sequencing  chromatogram  alone.  In  addition,  in  a proportion  of subjects 
(23%) assigned genotype (G)n / (G)io  allele size was determined by PAGE analysis of 
radioactive  PCR  products  and  this  was  found  to  be  in  complete  agreement  with  the 
original data obtained by direct sequencing (see Fig.  8.7 page 292). Hence, confirming 
the original genotype identified.
Due to the high proportion of subjects identified SNPG2 homozygous (17% and 
22%  in  late  onset  hearing  loss  and  general  population  sample  groups,  respectively) 
measures  were undertaken to help  exclude the possibility of loss of heterozygosity in 
the primary screen by direct sequencing. Allele size was determined by PAGE analysis 
of radioactive  PCR  products  in  each  sample  identified  from  direct  sequencing  to  be 
SNPG2 homozygous (see Fig.  8.7 page 292) as this would help exclude the possibility 
of non-amplification  of one  allele  in  the primary screen  by direct  sequencing due to 
stochastic hypoamplification leading to allele drop-out. This line of secondary analysis 
confirmed  the  original  SNPG2  homozygous  genotype  assignment  in  every  sample 
analysed  except  three;  for  three  samples  the  presence  of an  extra  band  upon  PAGE 
analysis of radioactive PCR products was observed that was too intense to be regarded 
an artefact from the PCR reaction.  It was not possible to clarify the genotype of these 
ambiguous samples; they were left unassigned and excluded from subsequent frequency 
analysis  (see  Table  8.8).  Since  similar  numbers  of ambiguous  samples  are  observed, 
between both late onset hearing loss and general population sample groups one and two 
samples respectively,  this  is unlikely to have an affect on subsequent allele frequency 
analysis.
It should also be remembered that many additional measures were undertaken to 
confirm all distinct poly-G genotypes identified.  In addition to sizing of poly-G alleles 
by PAGE analysis of radioactive PCR products repeat sequencing and a blind study was 
undertaken  and  the  results  of this  analysis  on  random  batches  of samples  for  each 
genotype including (G)n / (G)io and  SNPG2 homozygous were in complete agreement 
with  the  original  genotypes  identified.  Thus,  further  confirming  the  accuracy  of the 
methods undertaken to elucidate discrete poly-G alleles and the reliability of the original 
data.
A total of nine discrete alleles were identified for the -3432poly-G polymorphism using 
our late onset hearing loss  and general population cohorts of Caucasian ethnicity and 
allele frequencies are shown for both cohorts in Table 8.9. Alleles (G)io, (G)n, SNPG2 
and SNPG1  are the most common alleles observed in both late onset hearing loss and
298Table 8.9: Allele frequency of -3432poly-G polymorphism amongst 
Caucasian individuals in late onset hearing loss and 
general population cohorts
Late onset hearing loss Control
Allele Affinity of 
allele for SP1
Observed Frequency Observed Frequency
SNPG1 High 23 0.086 27 0.106
SNPG2 Low 58 0.216 68 0.268
SNPG4 Low 7 0.026 9 0.035
SNPG5 Intermediate 6 0.022 8 0.031
SNPG6 - 8 0.030 5 0.020
(G)io High 84 0.312 68 0.268
(G )n Intermediate 76 0.283 61 0.240
(G)i2 Intermediate 7 0.026 7 0.028
(G)l3 - 0 0.000 1 0.004
Total 269 254
Alleles were grouped according to affinity for SP1: high affinity (red), low affinity (blue) 
and intermediate affinity (green) based on the ability of each poly-G allele to compete 
with the consensus SP1 binding site for recombinant SP1 protein in EMSA analysis (see 
Fig.  5.7  section  5.3.2).  Dashed  line:  allele  was  not  included  in EMSA analysis  and 
affinity of allele for SP1  is unknown.
general population sample groups accounting for a similar proportion of alleles in both 
sample groups:  90%  and  80%  of total  alleles,  respectively.  The remaining five alleles: 
SNPG4,  SNPG5,  SNPG6,  (G)i2  and  (G)b  are  much  rarer  in  both  sample  groups. 
Although, the same poly-G alleles are either common or rare in both sample groups it is 
clear that  slight  differences in  allele frequency exist between these two  sample groups 
(see Table 8.9).
In-vitro  functional  characterisation  of the  -3432poly-G  polymorphism  shows 
that the -3432poly-G polymorphism modifies a high affinity SP family binding site and 
there  is  convincing  evidence that this  alters the activity of the Bm-3c promoter when 
SP1  levels are limiting (see Chapter 5,  sections 5.3 -  5.5).  Interestingly,  allele  SNPG2 
which  contains  a  low  affinity  SP1  binding  site  is  more  prevalent  in  the  general 
population  sample  group  whereas,  allele  (G)io  which  contains  a  high  affinity  SP1 
binding site is more prevalent in the late onset hearing loss sample group. However, the 
other high affinity  SP1  binding allele,  SNPG1,  does not follow this trend being slightly 
more  prevalent  in  the  general  population  sample  group  compared  to  the  late  onset 
hearing loss sample group.  Therefore,  from these observations there is no clear pattern 
between  affinity  of  poly-G  allele  for  SP1  and  allele  prevalence  between  patients 
characterised with late onset hearing loss compared to a general population sample.
Although,  no  clear trend  is  apparent  between  affinity  of poly-G allele for  SP1 
and  allele  prevalence  between  patients  characterised  with  late  onset  hearing  loss
a
compared to a general population sample a Chi (x ) square test was performed to assess
299whether the observed differences in poly-G allele frequency between these two sample 
groups  is  significant  (see method  section  3.2.17).  The results  of this  analysis  did not 
reveal  a significant difference in allele frequency between the two  sample groups;  the 
slight differences in poly-G  allele frequency observed between late onset hearing loss 
and  general  population  cohorts  are  too  small  to  reach  statistical  significance  in  this 
sample size. Hence, suggesting that there is no association between -3432poly-G allele, 
high  affinity  SP1  binding  allele  or  otherwise  and  susceptibility  to  late  onset  hearing 
loss, at least in the context of this preliminary association study. This result is discussed 
further in section 8.8: General discussion.
3008.6  Genotvpinq the -1391A>C single nucleotide substitution.
The  -1391A>C  sequence  variant  in  the  Bm-3c  promoter  is  a  single  nucleotide 
substitution.  At the time of commencing this project the -1391A >C  single nucleotide 
substitution had been reported  in  the public NCBI  SNP  database (NCBI  SNP  Cluster 
ID:  rs 1368402),  but  had  not  been  validated  and  no  report  of allele  frequency  was 
available.  Mutation  scanning  of the  Bm-3c  gene  by  PCR-SSCP  analysis  to  identity 
novel  sequence  variants  at  the  Bm-3c  locus  confirmed  the  -1391  single  nucleotide 
substitution  and  suggested  that  this  sequence  variant  is  common  in  the  general 
population  with  a  rare  allele  frequency  of  0.28  (based  on  SSCP  analysis  on  45 
individuals;  see Table 4.2,  section 4.3.1,  page  146).  However,  PCR-SSCP  analysis  is 
not  a reliable method  for  genotyping  as has been discussed previously (section 4.3.1, 
page 144) and therefore, the rare allele frequency of 0.28 was taken as an estimate only. 
Hence,  an  alternative  methodology  for  genotyping  the  -1391A>C  single  nucleotide 
substitution was sought.
One hundred and forty-two patiehts with late onset hearing loss and  145 general 
population  samples  were  available  for  genotyping  in  a  preliminary  association  study 
during the course of this project.  Given the moderate size of the sample cohorts it was 
decided  to  assess  whether the  -1391A>C  single  nucleotide  substitution  in  the  Bm-3c 
promoter alters the recognition  sequence for a restriction endonuclease for genotyping 
by PCR-restriction fragment length polymorphism (RFLP) analysis (for review see Gut, 
2001). PCR-RFLP analysis is a traditional and one of the most commonly used methods 
for  genotyping  single  nucleotide  substitutions  in  standard  laboratories.  Restriction 
endonucleases,  generally known as restriction enzymes recognise short,  specific, often 
palindromic  double  stranded  DNA  sequences  and  cleave  the  double  stranded  DNA 
either within or adjacent to the recognition site. Typically, a PCR fragment spanning the 
single  nucleotide  substitution  is  amplified  and  subjected  to  restriction  enzyme  digest 
using a restriction enzyme whose recognition site is modified by the single nucleotide 
substitution.  This  results  in  restriction  site  cleavage  only  for the  allele  that  does  not 
change the recognition site. Consequently, samples can be genotyped by observation of 
the restriction fragments produced upon agarose gel electrophoresis.  A small  sequence 
of DNA spanning the -1391  sequence variant was scanned against the known restriction 
enzyme  sites  using  Webcutter  software  version  2.0 
(www.firstmarket.com/cutter/cut2.html). The results of this analysis revealed that the -
3011391  sequence variant modifies the restriction site recognised by TaqL  TaqI recognises 
the  sequence  ‘TCGA’  and  cleaves  double  stranded  DNA  within  this  site;  the  variant 
allele,  -1391C modifies  the  TaqI site to  ‘TCGC’  preventing recognition by  TaqI (Fig. 
8.9a). Therefore, it was decided to genotype the -1391  single nucleotide substitution by 
PCR-TaqI digest for a simple, cost-effective and speedy approach.
8.6.1 Genotyping the -1391 single nucleotide substitution by Tag! digest.
In  order  to  accurately  genotype  the  -1391A>C  single  nucleotide  substitution  by  TaqI 
digest the main priority was to amplify by PCR a suitably sized fragment to ensure good 
size  separation  of bands  upon  agarose  gel  electrophoresis  for  reliable  allocation  of 
genotypes.  In addition, to make certain assignment of the homozygous variant genotype 
was  not  due to  failure of TaqI to  cleave the  amplicon  in  any particular sample  (TaqI 
does  not  recognise  the  DNA  sequence  produced  when  the  variant  allele,  -1391C  is 
present) it was essential that the fragment amplified included an additional  TaqI site as 
an  internal  control.  With  these  features  in  mind  a  PCR  reaction  was  optimised  using 
primers  3cPl-S:  5’  CTCTCAGCGGAGGCAGTGG  3’  and  3cP3-AS:  5’
CCGTCTAAGGAAGCTTGTGGAG  3’  originally designed  for the PCR-SSCP  screen 
of the Bm-3c promoter (details of the PCR optimisation and subsequent TaqI digest are 
described  in  method  section  3.2.16).  Primers  3cPl-S  and  3cP3-AS  generate  a  596bp 
product upon PCR within which TaqI cleaves a constant TaqI site at position 204bp and 
the wild-type but not the variant allele, -1391C at position 81bp (see Fig.  8.9b and c). 
Accordingly,  upon  agarose  gel  electrophoresis  subjects homozygous  for the wild-type 
allele, -1391A should generate three bands of 81,  123 and 392bp, subjects homozygous 
for the variant allele,  -1391C two bands of 204 and  392bp,  and subjects heterozygous 
for the -1391  single nucleotide substitution all four bands:  81,  123, 204 and 392bp (see 
Fig. 8.9b and c).
Having  devised  and  optimised  a  suitable  protocol  for  genotyping  the  -1391 
single  nucleotide  substitution  by  TaqI digest  the  -1391  single  nucleotide  substitution 
was genotyped in  142 patients characterised as having a late onset sensorineural hearing 
loss  and  145  general  population  samples  for  a  preliminary  association  study.  In  the 
absence of a banding pattern  for any sample or very faint bands, the ?CK-TaqI digest 
was repeated and the genotype assigned accordingly.  If absence of bands persisted and 
no  PCR product was visualised upon repeat  PCR this was regarded a PCR failure and 
no genotype could be assigned. An example of the banding pattern produced upon
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Figure  8.9:  TaqI  recognises  the  wild-type  allele  -1391A  but  not  the  variant  allele,  -1391C.  (a) 
Section of the Bm-3c promoter spanning the -1391 A>C sequent variant to show the wild-type allele, A 
and variant allele, C. The wild-type allele, A creates a TaqI recognition site (highlighted in red with the 
wild-type allele in red bold) and TaqI cleaves double stranded DNA within this site (shown by staggered 
black lines). The variant allele. C (shown in black bold) abolishes the TaqI recognition site preventing 
cleavage by  TaqI.  (b) and  (c)  Schematic of 596bp  PCR product produced using primers 3cPl-S and 
3cP3-AS.  Red cross denotes  TaqI recognition site formed by presence of the wild-type allele -1391 A, 
which  is  located  at  position  81 bp  within  the  596bp  fragment.  Blue  cross  denotes  a  constant  TaqI 
recognition  site within the  596bp  fragment  used as an  internal  control  in  TaqI restriction digest for 
activity of TaqI.  (b)  Shows  the  TaqI restriction  fragments produced for subjects homozygous for the 
wild-type allele,  -1391 A.  (c)  Shows the  TaqI restriction fragments produced for subjects homozygous 
for the variant allele, -1391C (for clarity only one allele is shown in b and c). Subjects heterozygous at - 
1391 will produce all four bands of 81,  123, 204 and 392bp.
agarose gel electrophoresis following TaqI digest is shown in Fig. 8.10 and the results 
obtained and subsequent association analysis performed is discussed in the next section.
303Figure 8.10  Determination of -1391 A>C genotype in  11  general population samples by PCR  -TaqI 
digest. The variant allele, -1391C abolishes a TaqI recognition site. Homozygotes for the variant allele - 
1391C produce two bands of 204 and 392bp compared to three bands of 81, 123 and 392bp for -1391A 
homozygotes.  Heterozygotes produce  all  four bands of 81,  123,  204 and 392bp.  Lane  1:  1Kb ladder, 
lanes 2-6 and 8-10:  subjects homozygous wild-type,  lane 7:  subject heterozygous and lane  11:  subject 
homozygous variant. A 2% agarose gel was use to separate bands.8.7  Association analysis to asses whether the -1391A>C single 
nucleotide  substitution  is  a  risk  factor for  late  onset  hearing 
loss.
The -1391  single nucleotide substitution was genotyped by PCR-Tag/ digest in our late 
onset hearing loss  and general population cohorts for a preliminary association study. 
The main aim being to  establish allele frequency and to  assess whether this sequence 
variant is a risk factor for late onset hearing loss as far as could be determined within 
the power of the preliminary study. One hundred percent of patient samples (142 / 142) 
and 94% (136 / 145) of general population samples were successfully genotyped for the 
-1391  sequence variant (see Table 8.10).  In a few general population samples (6%) it 
was not possible to identify genotype due to repeated PCR failure and therefore, these 
samples were excluded from subsequent frequency analysis.
Table 8.10: Genotype and allelic frequencies of the -1391A>C single nucleotide 
substitution amongst Caucasian individuals in late onset hearing 
loss and general population cohorts.
Genotype Observed Genotype frequency Allele Allele frequency
Late onset hearing loss -1391 142 A 0.78
AA 86 0.61 C 0.22
AC 49 0.34
CC 7 0.05
General population -1391 136 A 0.71
AA 73 0.54 C 0.29
AC 47 0.34
CC 16 0.12
To assess whether the genotype distribution for the -1391A>C single nucleotide 
substitution is in Hardy-Weinberg equilibrium in the late onset hearing loss and general 
population  sample  groups,  predicted  and  observed  genotypes  were  compared  by  %  
analysis  (see  method  section  3.2.17).  In  the  late  onset  hearing  loss  sample  group 
predicted values for all three genotypes assuming Hardy-Weinberg equilibrium are AA: 
AC: CC = 86.39: 48:73: 6.87 and actual observed values are AA: AC: CC = 86: 49: 7.
305Whereas,  for  the  general  population  sample  group predicted values  assuming  Hardy- 
Weinberg  equilibrium  are  AA:  AC:  CC  =  68.47:  56.06:  11:47  and  actual  observed 
values are AA: AC: CC = 73: 47:  16. These observed and predicted values do not differ 
significantly by  %2 analysis  in  either the late onset hearing loss  or general population 
sample  groups  and  hence,  show  that  both  the  late  onset  hearing  loss  and  general 
population  sample  groups  are  in  Hardy-Weinberg  equilibrium  with  regard  to  the 
distribution of the -1391A>C single nucleotide substitution.
From  in-vitro  functional  characterisation  of  the  -1391  single  nucleotide 
substitution  it is  evident that the variant allele,  C  has  a reduced  affinity for an OC-2 
derived nuclear protein and this is consistent with a subtle but,  significant decrease in 
basal  activity  of the  Bm-3c  promoter  (section  7.2  and  7.5).  Thus,  it  is  tempting  to 
speculate  that possession  of the  variant  C  allele  could  lead  to  reduced  expression  of 
Bm-3c and increase the genetic risk  for late onset hearing loss.  However,  from Table 
8.10  it  is  clear that the homozygous  genotype  for the  variant  allele,  -1391C,  is more 
prevalent in the general population sample group compared to the late onset hearing loss 
sample group; comparing a homozygous (CC) genotype frequency of 0.12 versus 0.05, 
respectively.  Hence,  suggesting  that  possession  of the  homozygous  variant  genotype 
(CC)  is  associated  with  reduced  rather than increased risk  of late  onset hearing loss, 
which is clearly not consistent with the hypothesis that possession of the variant C allele 
could lead to reduced expression of Bm-3c and increase the genetic risk for late onset 
hearing  loss.  One  explanation  for  this  anomaly  could  be  that  the  -1391A>C  single 
nucleotide  substitution  is  not  causative  for  late  onset  hearing  loss  but  in  linkage 
disequilibrium  with  a  causative  variant  for  late  onset  hearing  loss.  However,  when 
examined  by  %   analysis  the  difference  in  genotype  frequencies  between  late  onset 
hearing  loss  and  general  population  sample  groups  is  too  small  to  be  statistically 
significant.  Similarly, the difference in allele frequency between the late onset hearing 
loss and general population sample groups (in the general population sample group the 
rare -1391C allele frequency is 0.29 and this is slightly higher than a frequency of 0.22 
observed for the late onset hearing loss sample group; see Table 8.10) is not statistically 
significant  when  examined  by  %2  analysis.  Thus,  collectively  this  data  suggests  that 
there  is  no  association  between  the  -1391A>C  single  nucleotide  substitution  and 
susceptibility  to  late  onset  hearing  loss,  at  least  in  the  context  of this preliminary 
association  study.  This  result  is  discussed  further  in  the  next  section,  8.8:  General 
discussion.
3068.8  General discussion.
The  preliminary  association  analysis  performed  for  this  thesis  did  not  find  an
association  between  either  the  -3432poly-G  polymorphism  or  the  -1391A>C  single
nucleotide  substitution  and  susceptibility  to  late  onset  hearing  loss.  The  subtle
differences  in  allele  frequency observed  for both the  -3432poly-G polymorphism  and
the -1391A>C single nucleotide substitution were not significantly different in our late
2  • onset  hearing  loss  and  general  population  cohorts  when  examined  by  %   analysis. 
However, this result is not unexpected and it is important to consider the nature of late 
onset hearing loss, which is a complex disease and the design of the association study 
when interpreting these results.
The  design  of an  association  study  is  an  important  determinant  in  finding  a 
positive association and the likelihood of finding a positive association is influenced by 
many parameters. One of the most critical factors in good study design is the power of 
the  study  to  detect  an  association,  which  is  strongly  dependent  upon  the  size  of the 
sample  used;  this  is  especially important when the relative risk  carried by the  causal 
allele  is  small  and  the  frequency  of the  allele  in  the  general  population  is  low  (for 
review see Donahue and Allen, 2005). The sample size needed to detect a genetic effect 
is  related  to  the  frequency  and  relative  risk  carried  by  the  allele  under  study.  In 
principle, if a gene under study has a large effect on disease phenotype the causal allele 
will carry a high relative risk and has the potential to be detected even when the size of 
the  sample  is  small  and / or when the  frequency of the  allele  is  low  (for review  see 
Risch, 2000; Donahue and Allen, 2005). However, late onset hearing loss is a complex 
disease  many  genes  are  thought  to  contribute  to  susceptibility  and  the  relative  risk 
contributed  by  any  one  gene  is  likely  to  be  small.  Consequently,  subtle  effects  and 
genetic  heterogeneity,  coupled  with  interplay  from  the  environment  compounds  the 
likelihood  of finding  a  positive  association  in  a  small-scale  pilot  study  such  as  the 
preliminary association study presented for this thesis.
It  is  also  important to  consider that the control  sample group used to  conduct 
preliminary  association  analysis  for  this  thesis  consisted  of random  members  of the 
general  population  that  on  average  were  40  years  younger  than  the  patient  sample 
group. It was not possible to categorically exclude that these general population subjects 
have a late onset hearing loss or may go on to be affected by late onset hearing loss and 
this  anomaly increases  the  likelihood  of a  false-negative  association by reducing  the
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the  -3432poly-G  polymorphism  it  is  important  to  recognise  that  this  is  not  a simple 
dialleleic  polymorphism;  the  large  number  of alleles  identified  (nine  in  total)  further 
reduces  the  power  of the  association  study,  especially  when  only  small  numbers  of 
samples  are examined.  Therefore,  failure to  find a positive association between either 
the  -3432poly-G  polymorphism  or  the  -1391A>C  single  nucleotide  substitution  and 
susceptibility to late onset hearing loss within the context of this preliminary association 
study does not mean that these sequence variants have no affect on late onset hearing 
loss disease risk. In-vitro analysis suggests that the -3432poly-G polymorphism has an 
affect on regulation of the Bm-3c gene when SP1  levels are limiting, p<0.05 (paired t- 
test; see Fig. 5.13b, page 203) raising the possibility that this sequence variant could be 
causative  for late onset hearing loss.  Therefore,  when  all  these  factors  are taken  into 
consideration  to  categorically  exclude  that  the  -3432poly-G  polymorphism  is  not 
associated  with  susceptibility to  late  onset hearing  loss  it  is  clear that  a much  larger 
cohort of samples than was possible to recruit during the course of this PhD project is 
required.  Similarly,  there  is  some  evidence  that  the  -1391A>C  single  nucleotide 
substitution  has  an  affect  on  Bm-3c  regulation;  evidence  suggests  that  this  single 
nucleotide  substitution  has  an  effect,  albeit  subtle,  on  basal  activity  of the  Bm-3c 
promoter,  p<0.05  (t-test;  Fig.  7.8b,  page  257).  Accordingly,  it  would  be  worthwhile 
extending this functional analysis in an attempt to gain more convincing evidence of the 
affect  of  the  -1391  single  nucleotide  substitution  on  Bm-3c  regulation.  Stronger 
evidence  for a functional effect of the -1391  single nucleotide  substitution on Bm-3c 
regulation coupled with genotyping this sequence variant in a much larger cohort would 
allow  one  to  conclude  with  more  certainty  the  affect  of this  sequence  variant  on 
susceptibility to late onset hearing loss.
Certainly, use of a control sample group that has no medical history of hearing 
loss and that is more closely age-matched than the ‘control’ general population sample 
group  used  for  the  preliminary  study  would  improve  the  power  of the  association 
analysis.  With this in mind recruitment of age-matched cohorts characterised with late 
onset hearing loss and good hearing is now underway in our laboratory for use in future 
study.  Samples are being recruited from two Scottish Mental Health Survey Cohorts as 
part  of  an  on-going  collaboration  with  Professor  Lawrence  Whalley  (University  of 
Aberdeen, Scotland, U.K.) and Dr Ian Deary (University of Edinburgh, Scotland, U.K.). 
These cohorts are a valuable resource for future case-control association analysis that is 
beyond  the  capacity of this  PhD  project.  Recruitment  of subjects  into  our  late  onset
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Throat Hospital,  London, U.K.  is also continuing with the aim to collect at least  1000 
well-characterised  samples.  Both  these  London  and  Scottish  late  onset  hearing  loss 
cohorts pave the way for promising future analysis.  In addition, because these cohorts 
are  extremely well  characterised  and  diagnostic  audiogram  is  available  these  cohorts 
provide a resource by which to analyse late onset hearing loss as a quantitative trait (see 
Fransen et al, 2004; see also section 1.6.3). This approach avoids stringent ‘case’ versus 
‘control’  classification  of  subjects.  Instead,  a  continuous  parameter  for  late  onset 
hearing loss is defined and the extent by which a subject is effected by late onset hearing 
loss  is  used  in  subsequent  statistical  analysis  in  an  attempt  to  find  an  association 
between sequence variants in a candidate gene and severity of late onset hearing loss. 
This is important as by treating late onset hearing loss as a quantitative trait as opposed 
to  a  binary  trait  this  approach  holds  much  promise  as  a  power  statistical  method  to 
detect susceptibility genes of moderate effect (Fransen et al, 2004).
Genotyping  the  -3432poly-G  polymorphism  and  the  -1391A>C  single 
nucleotide  substitution  in  our  late  onset  hearing  loss  and  general  population  cohorts 
established  allele  frequency  (see  Tables  8.9  and  8.10,  respectively).  The  rare  allele 
frequency  for  the  diallelic  -139A>C  single  nucleotide  substitution  in  our  general 
population cohort is 0.29  (Table 8.10).  Based on this result it can be estimated that a 
sample size of approximately 600 would be needed to detect a small effect (relative risk: 
1.6) with at least 80% power using a stringent level of significance (see Donahue and 
Allen, 2005). To detect a smaller effect (relative risk:  1.4) whilst maintaining the same 
level  of power the sample size needed would increase to  1250.  For the multi-allelic - 
3432poly-G  polymorphism  where  the  high  allele  number  of variation  identified  (9 
alleles)  further limits the power of the association analysis it is likely that even larger 
sample sizes will be required.
Finally,  it should be remembered that the data suggest the -566(GT)n repeat in 
the  context  of  the  -3432poly-G polymorphism  and  native  5’  haplotype  is  functional 
(see  Chapter  6,  section  6.3.2).  Specifically,  the  data  suggest  functional  interplay 
between  the  -566(GT)n  repeat  and  the  -3432poly-G  polymorphism  determines  the 
response of the Bm-3c gene to  SP1  (see Fig.  6.2, page 231).  Therefore genotyping of 
the  -3432poly-G  polymorphism  in  combination  with  the  -566(GT)n repeat  would  be 
necessary to  determine whether specific haplotypes  for these sequence variants in the 
Bm-3c 5’-flanking region are associated with increased risk of late onset hearing loss. If 
specific haplotypes  for the poly-G polymorphism  at  -3432  and  the (GT)  dinucleotide
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only the  -566(GT)n repeat would be necessary  to  determine if specific 5’  haplotypes 
encompassing the -3432poly-G polymorphism and the -566(GT)n repeat are a risk factor 
for  late  onset  hearing  loss.  This  would  be  a  practical  approach  as  genotyping  the  - 
566(GT)n repeat in large sample cohorts would be technically more simple and less time 
consuming than genotyping the -3432poly-G polymorphism in such large cohorts.
3108.9  Conclusion.
In conclusion, the data presented in this thesis is one of the first studies to identify and 
undertake a functional  screen of common genetic variation in the Bm-3c gene prior to 
performing association analysis in an attempt to identify the genetic determinants that 
underlie late onset hearing loss.  In-vitro  analysis  suggests that  at least three common 
sequence  variants  in  the  Bm-3c  promoter  could  have  a  functional  effect:  a  complex 
poly-G repeat at -3432 that also exhibits single nucleotide substitutions within the poly- 
G  repeat  (poly-G  polymorphism),  a  dinucleotide  (GT)n repeat  at  -566  and  a  single 
nucleotide A to C substitution at -1391. Both the -3432poly-G polymorphism and the - 
1391A>C  single  nucleotide  substitution  were  genotyped  in  a  cohort  of  subjects 
characterised as having a late onset hearing loss alongside a similar number of general 
population samples to establish allele frequency and for a preliminary association study.
Subtle differences  in  allele frequency for both the -3432poly-G polymorphism 
and  the  -1391A>C  single  nucleotide  substitution  were  found  between  the  late  onset 
hearing loss and general population sample groups examined, but were not significantly 
different  when  examined  by  %   analysis  (see  section  8.5  and  8.7,  respectively). 
However, this result is not unexpected when one considers the multi-factorial nature of 
late  onset  hearing,  which  is  a  complex  disease  coupled  with  some  shortcomings  in 
design of this preliminary association study (see section  8.8).  Consequently,  lack of a 
positive  association between  either  the  -3432poly-G  polymorphism  or the  -1391A>C 
single  nucleotide  substitution  and  susceptibility  to  late  onset  hearing  loss  within  the 
context of this  preliminary association study can not be taken as conclusive evidence 
that these sequence variants are not a risk factor for susceptibility to late onset hearing 
loss.  This  is  especially  so  in  light  of the  evidence,  which  suggests  that  both  these 
sequence  variants  could  have  a  functional  effect  on  Bm-3c  regulation.  Therefore,  to 
conclude with certainty whether these sequence variants affect the genetic risk for late
onset  hearing  loss  further  analysis  that  is  beyond  the  scope  of this  PhD  project  is
/
required.  It  is  possible that by genotyping a much  larger cohort of samples than was 
possible to recruit during the course of this PhD project or by performing quantitative 
trait analysis in a large late onset hearing  loss cohort a positive association for either or 
both  of  these  sequence  variants  will  be  established.  Identification  of  a  positive 
association  between  the  -3432poly-G  polymorphism  and  susceptibility  to  late  onset 
hearing loss coupled with the evidence presented in this thesis which suggests that this
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functional  analysis  to  exclude  an  affect of the -3495(GT)n repeat on Bm-3c promoter 
activity  in  response  to  SP1  would  be  more  convincing  evidence  that  this  sequence 
variant  modifies  the  genetic  risk  for  late  onset  hearing  loss.  Replication  of such  an 
association  in  an  independent  cohort  and  /  or  a  meta-analysis  would  validate  this 
finding. This line of investigation would allow one to assess with more confidence the 
affect of the -3432poly-G polymorphism on susceptibility to late onset hearing loss.  It 
would also be important to take into account the affect of the -566(GT)n repeat in such 
analysis as functional analysis suggests an association between the -566(GT)n repeat and 
the  -3432poly-G  polymorphism  is  important  to  Bm-3c  regulation  (see  discussion  in 
previous section,  8.8).  Similarly, identification of a positive association between the - 
1391A>C  single  nucleotide  substitution  and  susceptibility  to  late  onset  hearing  loss, 
replication  of  this  finding  in  an  independent  cohort  coupled  with  more  extensive 
functional  analysis  than  is  presented  in  this  thesis  would  provide  more  convincing 
evidence that this sequence variant has an effect on susceptibility to late onset hearing 
loss  and  is  not just  in  linkage  disequilibrium  with  a  causative  variant  for  late  onset 
hearing  loss.  These  findings  are  summarised  in  the  next  Chapter:  9.0  General 
Discussion and Conclusion.
3129.0 General Discussion and Conclusion.
The  present  study  is  one  of the  first  to  adopt  a functional  screening  approach  of 
common genetic variation in a candidate gene prior to performing traditional candidate 
gene case-control association analysis in an attempt to identify the genetic determinants 
responsible  for  late  onset  sensorineural  hearing  loss  (see  section  1.10  for  a  detailed 
description  of the  aims  of this project).  Late onset hearing loss is  a disabling disease 
exhibited by a considerable proportion of the ageing population and the major cause of 
this disease appears to be loss of sensory hair cells from the cochlea of the inner ear (see 
discussion  in  section  1.5).  Bm-3c  the  candidate  gene  investigated  for  this  project,  a 
POU  domain transcription factor that within the inner ear is  specifically expressed in 
hair cells appears crucial for long-term hair cell survival (Erkman et al,  1996; Xiang et 
al, 1997;  1998; Vahava et al,  1998; a thorough discussion of the evidence that Bm-3c is 
a good candidate gene for susceptibility to late onset hearing loss is presented in section 
1.8.1). Thus, it was hypothesised that common inter-individual sequence variants in the 
Bm-3c gene or within the regulatory regions of this gene that have a subtle affect on 
function or expression of Bm-3c respectively, may affect the genetic risk for late onset 
hearing loss (the aims of this study are summarised in Chapter 2.0).
At  the onset of this project  genetic variation  in the Bm-3c gene had not been 
extensively studied. The data presented in this thesis constitutes the first comprehensive 
report of common genetic variation in the Bm-3c gene. Mutation scanning of the Bm-3c 
gene by PCR-SSCP analysis identified seven sequence variants at the Bm-3c locus five 
of which are novel and two that were previously reported in the NCBI SNP database but 
non-validated (see Fig. 4.16, section 4.5, page 162). Of these, two of the novel sequence 
variants  are  biallelic  single  nucleotide  substitutions:  -386C>A  within  the  5’-flanking 
region  of the  Bm-3c  gene  and  +90C>T  within  exon  one  of the  gene.  However,  the 
+90C>T single nucleotide substitution is a synonymous sequence variant and does not 
change  an  amino  acid  and  both  of these  sequence  variants  appear rare based  on  the 
results of the PCR-SSCP  screen on 45  individuals. Therefore, these sequence variants 
were  not  pursued  further within  this  project  (see  section  4.5  page  163  for  a  greater 
discussion  of the  significance of these two  sequence variants).  Of the remaining five 
sequence variants identified at the Bm-3c locus all are within the 5’-flanking region of 
the Bm-3c gene and appear common in the general population (based on the results of 
the PCR-SSCP screen on 45 individuals). Three are novel multi-allelic repeat sequence 
variants:  -3495(GT)i5-2i,24,  -3432poly-G  polymorphism  and  -566(GT)i7_23  and  two:  -
3133457(GA)i.3,  a  polymorphic  dinucleotide  repeat  and  -1391A>C,  a  single  nucleotide 
substitution  were  previously  reported  in  the  NCBI  SNP  database  but  non-validated. 
Thus,  raising  the  possibility  that  any  or  a  combination  of these  common  sequence 
variants may affect expression levels of the Bm-3c gene and hence, modify the genetic 
risk  for  late  onset  hearing  loss.  Consequently,  all  were  candidates  for  functional 
analysis.
By adopting an in-vitro functional screening approach of the common sequence 
variants  in  the  Bm-3c  5’-flanking  region  utilising  comparative  EMSA  analysis  and 
transient transfection reporter gene assay the data presented in this thesis suggest that at 
least  three  common  sequence  variants  in  the  Bm-3c  promoter:  -3432poly-G 
polymorphism,  -1391A>C  and the -566(GT)n repeat in the context of the -3432polyG 
polymorphism  could have  a functional  affect on  Bm-3c regulation.  It is  important to 
appreciate  that  the  physiological  significance  of  these  results  is  unknown.  The 
inaccessibility  of the  human  inner  ear  and  the  lack  of human  sensory hair  cell  lines 
prevent  in-vivo  confirmation  of the  effect  of these  sequence  variants  (for  a  greater 
discussion  of the  limitations  of functional  data  generated  in-vitro  see  section  5.8.1). 
Nevertheless,  these  results  do  provide  insight  into  the  possible  functional  effect  of 
common  sequence  variation  in  the  Bm-3c  promoter  on  Bm-3c  regulation  and 
undoubtedly provide candidate functional sequence variants for subsequent association 
based  analysis  designed  to  identify  the  genetic  determinants  that  underlie  late  onset 
hearing loss. In-vitro analysis shows that both the -566(GT)n repeat in the context of the 
-3432poly-G  polymorphism  (section  6.3.1)  and  the  -1391A>C  single  nucleotide 
substitution (section 7.4) have a subtle affect on basal activity of the Bm-3c promoter. 
Thus,  it  is  possible that either alone or in combination these sequence variants could 
lead to  inter-individual variations in Bm-3c expression as  small  differences in Bm-3c 
promoter activity such those reported in this thesis may have physiological effects in- 
vivo.  Indeed it is tempting to  speculate that  subtle differences  in basal  activity of the 
Bm-3c promoter could have cumulative effects such that hair cell survival is comprised 
after a certain period of time.
By using a dominant negative approach in-vitro analysis suggests that both the - 
3432poly-G polymorphism (section 5.4.1) and the -566(GT)n repeat in the context of the 
-3432poly-G  polymorphism  (section  6.3.2)  can  modulate  Bm-3c  promoter  activity 
under  conditions  where  SP1  is  limiting.  Specifically,  the  data  suggests  a  functional 
interplay between  the  -566(GT)n repeat  and  the  SP1  binding  site  in  the  -3432poly-G 
sequence is a determinant of the response of the Bm-3c promoter to SP1. It is difficult
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extremely well  characterised transcription factor and is implicated in a wide range of 
cellular responses (for review see Kaczynski et al, 2003) nothing is known of its role in 
sensory  hair  cells.  Further  analysis  that  is  beyond  the  scope  of this  PhD  project  is 
required  to  identify  the  molecular  pathways  that  regulate  SP1  activity  in  hair  cells. 
However,  these  results  do  raise  the  possibility that  allele  specific  effects  induced  by 
common repeat  sequence variants  in the Bm-3c promoter may not have a significant 
affect on Bm-3c expression by acting in isolation, but rather the combined effect(s) of 
these repeat variants  could be more important.  Replication of these findings with the 
naturally occurring common 5’ haplotypes in the Bm-3c promoter would help confirm 
the  significance  of these  results  (Bm-3c  promoter-luciferase  reporter  gene  constructs 
that  varied  in  the  length  of  the  GT  repeat  at  -566  were  created  using  controlled 
haplotypes  at  -566  in  combination  with  the  native  haplotypes  5’  of the  -3432poly-G 
polymorhism; see section 6.2). Furthermore, the fact the -3432poly-G polymorphism is 
a  second  similar  polymorphism  consisting  of  a  poly-guanine  repeat  that  exhibits 
multiple  single base substitutions that has been shown to  affect promoter activity (the 
poly-G polymorphism at -3432 in the Bm-3c promoter is very similar to one previously 
identified in the promoter of the KLK1  gene that is  associated with hypertensive end 
stage renal  disease;  Song et  al,  1997;  Yu et al,  2002;  see  also  section  5.2)  raises the 
possibility that other poly-guanine repeats of this nature may be polymorphic and has 
implications for other genes and susceptibility to disease.
The  long-term  aim  of this  research  project  is  to  use  the  candidate  functional 
sequence variants  in  the Bm-3c gene identified  from the  in-vitro  functional  screen in 
association  based  analysis  in  an  attempt  to  identify  the  genetic  determinants  that 
underlie late onset hearing loss.  At the onset of this project well-characterised patient 
cohorts for late onset hearing loss were scarce. Consequently, a major aim of this PhD 
project was to initiate collection of a large and well-characterised patient cohort for late 
onset hearing loss that could be used for a preliminary association study within the time 
constraints  of the PhD  project  and  subsequently,  for a much  larger population based 
case-control  association  study  that  is  beyond  the  scope  of the  PhD  project.  It  was 
accepted at the outset of this project that the number of samples it would be possible to 
recruit within the time frame of the PhD project would have an impact on the power of 
the preliminary association study.
Collection of a well-characterised patient cohort for late onset hearing loss was 
successfully initiated from the adult hearing aid clinic at the Royal Free Nose, Ear and
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Cadge (see section 8.2). During the course of this project 142 patients were successfully 
recruited  for  the  preliminary  association  study  and  sample  collection  is  currently 
continuing with the aim to collect at least  1000 well-characterised samples. Both the - 
3432poly-G  polymorphism  (section  8.4)  and  the  -1391A>C  single  nucleotide 
substitution (section 8.6) were genotyped in our late onset hearing loss cohort alongside 
a  similar number of general  population  samples  to  establish  allele  frequency and  for 
preliminary  association  analysis.  Subtle  differences  in  allele  frequency for both the  - 
3432poly-G polymorphism and the -1391 A>C single nucleotide substitution were found 
between the late onset hearing loss and general population sample groups examined, but 
were not significantly different when examined by % 2 analysis (see section 8.5 and 8.7, 
respectively).  However,  as  discussed  previously (section  8.8)  this  cannot be  taken  as 
conclusive evidence that these sequence variants do not modify the genetic risk for late 
onset hearing  loss.  Several  shortcomings  in the design of the preliminary association 
study  coupled  with  the  multi-factorial  nature  of late  onset  hearing  loss,  a  complex 
disease,  hinder  the  likelihood  of finding  a positive  association  in  a  small-scale  pilot 
study such as the preliminary association study presented in this thesis.
In conclusion, further analysis that is beyond the time-frame of this PhD project 
is required to obtain conclusive evidence whether the -3432poly-G polymorphism or the 
-1391A>C  single  nucleotide  substitution  or both  of these  sequence  variants  underlie 
susceptibility  to  late  onset  hearing  loss.  Continued  recruitment  of patients  with  late 
onset  hearing  loss  into  our  London  cohort  and  novel  sample  collection  from  two 
retrospective  Scottish  cohorts  means  our  laboratory  will  soon  be  in  a  position  to 
undertake association analysis on a large-scale (see section 8.8, page 308).  Large-scale 
case-control  association analysis would allow one to determine with certainty whether 
either  of  these  sequence  variants  are  associated  with  late  onset  hearing  loss. 
Alternatively, treating late onset hearing loss as a quantitative trait and using these large 
sample cohorts to perform quantitative trait analysis may be a more productive approach 
to  find  an  association  (see  Fransen  et  al,  2004;  see  also  section  1.6.3).  If a positive 
association were identified  further functional  analysis  in  addition to  that presented  in 
this thesis would be required to determine with more certainty whether either or both of 
these  common  sequence  variants  are  causative  for  late  onset  hearing  loss  (this  is 
discussed in section  8.9, page 312).  For example,  it would be especially important to 
establish if the SP1-mediated differential activity of Bm-3c promoter-luciferase reporter 
gene constructs that vary in the nature of the -3432poly-G  allele is  dependent on the
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polymorphism is only functional in the context of its native 5’ haplotype. Certainly, the 
importance  of 5’haplotypes  on  Bm-3c  regulation  is  illustrated by functional  analysis 
incorporating the effect of the -566(GT)n polymorphism (in-vitro evidence indicates that 
the  length of the  -566(GT)n repeat in the context of the -3432  poly-G polymorphism 
plays  an  important  role  in  SP1-mediated  regulation  of  Bm-3c;  section  6.3.2). 
Ultimately,  it is important to  consider that the effect of common sequence variants in 
the Bm-3c gene on late onset hearing loss disease risk may only manifest when present 
in combination with variation in another gene at another locus and / or upon repeated 
exposure  to  environmental  stress.  In  this  regard  the  future  genome  wide  association 
studies that are anticipated upon completion of the HapMap when the common patterns 
of linkage disequilibrium throughout the human genome are established will likely be a 
valuable  tool  to  determine  if haplotypes  spanning  multi-genes  can  be  identified  that 
underlie susceptibility to late onset hearing loss (for more information on the HapMap 
project  see  section  1.6.2.1).  However,  a  shortcoming  of the  HapMap  is  that  it  is 
focussing on linkage diseqilibrium between common single nucleotide substitutions and 
the(affect of common repetitive sequence variants on disease risk may be missed. Inter­
individual variations in gene expression due to common repetitive sequence variants in 
the  promoters  of  causative  genes  may  be  just  as  important  as  the  effect  of  single 
nucleotide  substitutions  on  complex  disease  risk.  Certainly,  with  the  advent  of high 
through-put  genotyping  platforms,  such  as  the  ABI  Prism  3100  genetic  analyser 
(Applied Biosystems) genotyping polymorphic dinucleotide repeats is relatively straight 
forward by using  fluorescently tagged primers  in  a PCR reaction  and then  exploiting 
differences in repeat length. Although, genotyping complex polymorphisms such as the 
-3432poly-G  polymorphism,  which  vary in mononucleotide repeat  length  and  exhibit 
single base substitutions within the mononucleotide repeat is currently technically more 
demanding  and  time-consuming.  Recently  it  has  been  reported  that  mononucleotide 
repeats  are  “a  neglected  polymorphism  for  generating  high  density  genetic  maps  in 
silico”  (Cohen  et  al,  2004).  Cohen  et  al,  developed  a  method  to  rapidly  genotype 
mononucleotide  repeats  based  on  sizing  of  fluorescent-labelled  primer  extension 
products.  The  method  was  tested  and  the  accuracy  confirmed  by  genotyping  16 
mononucleotide repeats,  14 A/T repeats, along human chromosome 22 and comparing 
the data to that obtained by direct sequencing;  10 mononucleotide repeats were found to 
be  polymorphic.  However,  such  a  method,  or  similar,  is  unlikely  to  be  suitable  for 
accurate genotyping of mononucleotide G or C repeats. The data presented in this thesis
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Poly-C  may  also  exhibit  single  nucleotide  substitutions  with  the  repeat;  alleles 
exhibiting single nucleotide substitutions would be missed in genotyping methods such 
as that devised by Cohen et al, which exploit differences in length of mononucleotide 
repeats.  Consequently,  the  value  of complex  polymorphic poly-G / poly-C  repeats  in 
association based  studies  is  currently hindered by  a  lack  of suitable high-throughput 
genotyping technologies. In addition, the tendency for such polymorphisms to be multi- 
allelic with a high allele number (Song et al,  1997; Yu et al, 2002; Cohen et al, 2004; 
data presented  in this thesis) means the value of including them in  association based 
studies can probably only be achieved when sufficiently large cohorts are available so 
as not to reduce the power of the association study. This is despite the fact they may 
well be functional and have an impact on gene expression.
Currently,  association based analysis as a method to dissect the genetic factors 
that  underlie  susceptibility  to  late  onset  hearing  loss  or  any  complex  disease  is 
compromised by a lack of knowledge about which sequence variants within the human 
genome  are  functional.  Synonymous  and  non-synonymous  sequence  variants  within 
protein coding regions of a candidate gene, sequence variants that disrupt putative cis- 
acting elements within the 5’- and 3’- flanking region,  and the 5’- and 3’-untranslated 
region of a candidate gene are all putative functional variants. However, in the absence 
of in-vitro  and  in-vivo  functional  analysis this  cannot be confirmed and such putative 
functional  sequence variants cannot be narrowed down to  small numbers of candidate 
variants  for  testing  in  association  based  analysis.  Consequently,  when  designing 
association-based studies all such putative functional variants should be considered as 
causative. Van Laer et al, 2006 have recently reported an association between sequence 
variants in KCNE1, KCNQ1  and KCNQ4 and susceptibility to NIHL. Moreover, based 
on  patch-clamp  experiments  they propose  p.D85N  a  non-synonymous  variant  in  the 
potassium channel subunit gene, KCNE1, as a possible causative variant for NIHL. This 
study was based on performing case-control  association analysis on each of 35  single 
nucleotide  substitutions  found  within  the  genomic  region  of  10  candidate  genes 
involved  in  cell-cell  communication  and  potassium  homeostasis  in  the  inner  ear. 
However,  only p.D85N was  selected for subsequent function analysis.  This is  despite 
finding  several  other  position  associations.  Hence,  although  this  study  supports  the 
value of association based analysis to delineate the genetic determinants that underlie 
late onset hearing loss; in the absence of thorough functional screening it is by no means 
conclusive.  Without  undertaking  a  functional  screen  for  all  variants  for  which  an
318association was identified one cannot conclude with certainty that p.D85N is causative. 
In  addition,  the  5’  and  3’  regulatory  regions  of the  candidate  genes  selected  for 
inclusion in this study was overlooked; p.D85N could be in linkage with a functionally 
significant variant in the KCNE1  promoter.  Thus, the value of the functional screening 
approach presented in this thesis  is undeniable.  By  obtaining functional  knowledge of 
all  the  common  sequence  variants  within  the  coding  and  regulatory  regions  of  a 
candidate  gene  more  informative  conclusions  from  association-based  studies  will  be 
able to be drawn.
To conclude,  by identifying the genetic determinants that underlie susceptibility 
to  late  onset  hearing  loss  the  underlying  pathophysiology  of this  highly  complex  and 
disabling disease will begin to be unravelled by delineation of the molecular pathways 
and key components involved.  This would be highly significant,  as it would provide a 
platform  for  future  therapeutic  intervention  to  ultimately  halt  loss  of  hearing  with 
increasing age and not least,  it would aid our understanding of the hearing process by 
building  upon  insight  gained  from  the  study  of rare  monogenic  congenital  forms  of 
deafness.
Scientific corrections for this thesis are on page 367.
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INFORMATION SHEET........................................................................VERSION 4 
Title: Investigating adult onset hearing loss.
You are being invited to take part in a research study to investigate the causes of hearing loss in adults. 
Participation in the study will not  involve you making additional visits to the hospital,  it will take about 
30 minutes on the day of your appointment.  Before you decide whether you would like to take part it is 
important for you to read this sheet which explains what the research is for and what it involves.  Please 
take your time and ask if you need more information or explanation. If you wish to then you can also take 
time to discuss your decision with others. Thank you for reading this.
Consumers for Ethics in Research (CERES) publish a leaflet entitled "Medical Research and You". This 
leaflet gives more information about medical research and looks at some questions you may want to ask. 
A copy may be obtained from CERES,  .
•  W hat is the purpose of the study ?
The Molecular Audiology Research Group at University College London is looking for volunteers to take 
part  in  an  on-going  study  to  investigate  the  causes  of adult  onset  hearing  loss.  Hearing  loss  is  very 
common  as  people  get  older;  a  third  of people  over  sixty  have  some  degree  of hearing  loss.  We  are 
looking  to  see  whether  people  who  lose  their hearing  do  so  because  they  have  inherited  an  increased 
susceptibility to hearing loss. This work will help researchers to identify if some people are at greater risk 
of developing adult onset hearing loss, and pinpoint the reasons as to why this happens. This line of work 
would pave  the  way for future preventative  therapies to prevent or halt the onset of adult hearing  loss.
•  W hy have I been chosen?
You have suffered some hearing loss as an adult so you fit the criteria to take part in the study. It is hoped 
that we will eventually have several hundred patients taking part in the study.
UCL
342•  Do I have to take part?
No. This project is entirely voluntary, if you do not wish to take part then please say so. You do not have 
to give any reason for deciding not to take part and your decision will not affect the standard of care your 
receive. If you do decide to take part you will be asked to sign a consent form. You will then be given a 
copy  of the  consent  form  and  this  information  sheet  to  keep.  You  can  chose  to  withdraw  at  any time 
without giving a reason.
•  W hat do we need from  you if you do take part?
If you  choose  to  volunteer for this project we will  take  a small blood sample  from you  (5mls,  about a 
teaspoonful). This will be taken as part of your outpatient's visit at the hearing aid clinic; no extra visits to 
the hospital are necessary to take part in the study.  You won't need to provide anything else or undergo 
any further tests for this project. The only other thing we need is for you to fill in a short questionnaire 
giving us  some  basic  information about you  & your hearing  loss.  One  question will  be  regarding your 
ethnic  background.  It  is  important  that  we  obtain  this  information  for  our  study.  This  is  because 
susceptibility to adult onset hearing loss could vary amongst different ethnic groups. We estimate that all 
this will take less than 30 minutes. A copy of your hearing test will also be supplied to the research study.
•  W ill this inform ation be confidential?
Yes. This information will be strictly confidential; it will only be used as part of this research project and 
will not be given to any third parties. The research project is carried out with each sample being given a 
reference number rather than a patient name. Your personal details including your name and address will 
not  be  disclosed  outside  this  hospital.  Therefore  you  will  not be  contacted  with  specific  results  of the 
project. You will not be identified in any scientific report or publication relating to this study. However, if 
you are interested in the general outcome of the project this will be available.
W hat will happen to my blood sample?
Genetic  testing  will  be  performed  on  your blood  sample  with  the  other  samples  from  people  who  are 
losing  their hearing.  At the same time we will be performing genetic testing on samples from people  in 
the general population who have not lost their hearing. If we find any differences between the two groups 
it will help us to  identify the cause of adult onset hearing  loss.  Your sample may also be used in other 
hearing related studies following approval by a research ethics committee.
•  Are there any advantages/disadvantages to taking part in the study?
Apart  from  helping  research  into  hearing  loss  you  will  not  receive  any  benefit  from  taking  part.  The 
disadvantage  of taking  part  is  having  a  sample  of blood  drawn  and  spending  some  time  filling  in  our 
form.
•  W ho is funding this research and who will be perform ing the work?
The project is being funded by a charity called Research into Ageing who are part of Help the Aged. The 
Molecular Audiology Group at University College London headed by Dr Sally Dawson will perform the 
research  study.  Lisa  Nolan  will  undertake  the  main  research  work  as  part  of her  PhD.  Lisa  herself is 
hearing impaired and has a keen interest in hearing research.
343•  Where can I get more information?
If you wish to know more information about the project in general or wish to find out the results of the 
research you can contact the research group  leader:  Dr Sally Dawson on    or by email at 
Or,  Lisa  Nolan  on    (minicom)    (via  BT  Type-talk)  or  by  email: 
This project has been reviewed and approved by The Royal Free Hospital and Medical School 
Local Research Ethics Committee.
Thank you for taking the time to read this information sheet, and thank you if you decide to take 
part in this study. Our research would not be possible without volunteers.
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QUESTIONNAIRE II:   Adult Onset Hearing Loss Patient number:
Thank you for helping with this project which will contribute to the understanding of the nature 
of hearing loss in advancing years. Please see the attached Information Sheet for more details. 
We are  looking  for people of any age who  have developed a  hearing  loss as an  adult.  Your 
contribution will involve answering the few questions below, and having a single blood sample 
taken which will be sent for genetic analysis.
1. At what age were you first aware of hearing problems?
<20 years  [Z\  20-40 years [^ ]  41-60 years  I  I
61-80 years 1   I  >81 years  \ZH
2. Does anyone else in your family have hearing problems?  Yes I  1   No[
If yes, please give details.--------------------------------------------------------------------------
3.  Do you think your hearing loss was due to exposure to excessive noise?
Y e sQ   No|  |
If yes, please give details.
Royal National Throat, Nose and Ear Hospital 
w
i»»s
TH £ Q U E E N S  A  w a r d  f o r
...  .   .   TFCH NO t O n iC A l  AC H IFVFM FN T
Website:  www.ucl.ac.uk/audiological-science
3454.  Have you had any other significant medical or ear problems? Yes 
If yes, please give details,
No[
5.  How old are you? years
6.  Please indicate which of the following ethnic group best describes you. If you are of mixed 
ethnicity please tick all those groups which are relevant to you.
White
n British or Irish
□ Jewish
□ North Europe
□ South Europe
Em Other, please specify
Asian or Asian British 
I  |  Indian
□   Pakistan
I  I  Bangladeshi
□   East African Asian
I  I  Other, please specify
Black or Black British 
I  I  Caribbean 
dH  African 
d l  Somali
EH  other, please specify
Other
□   Chinese  □   Japanese  EH  Arab/Iranian/
Other Please, specify
North African
Thank you for your time and attention. Your co-operation has been much
appreciated.
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Patient Number:
CONSENT FORM
Title of Project:  Adult Onset Hearing Loss
Name of Researcher: Dr Sally Dawson
Please initial box
1.  I confirm that I have read and understand the information sheet
dated..............version.............for the above study and have had  _____
the opportunity to ask questions.
2.  I understand that my participation is voluntary and that I am free to withdraw
at any  time, without giving any reason, without my medical care or legal  _____
rights being affected.
3.  I understand that sections of any of my medical notes may be looked at by
responsible individuals or from regulatory authorities where it is relevant to my  _____
taking part in research. I give permission for these individuals to have access
to my records.
4.  I agree to take part in the above study.
Name of Patient  Date  Signature
Name of Person taking consent  Date  Signature
(if different from researcher)
Researcher  Date  Signature
Royal National Throat, Nose and Ear Hospital 
Website:  www.ucl.ac.uk/audiological-science
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Reference sequence for exon 1 of Brn-3c (human): NCBI GenBank Accession U10060.1.
Reference sequence for exon 2 of Brn-3c (human): NCBI GenBank Accession U10061.1.
Reference sequence for intron of Brn-3c (human): NCBI GenBank Accession AF043452.1.
Reference  sequence  for  human  Brn-3c  promoter:  Ensembl  transcript  ID  ENST00000230732). 
Promoter sequence is shown on next page and genetic variation identified and confirmed as part of the 
PCR-SSCP  screen  is  highlighted:  -3495(GT)19 :  black  bold  (NCBI  SNP  Cluster  ID  rs28994882),  - 
3457(GA)1 : red bold (NCBI  SNP  Cluster ID rs28994881), -3432(G),,: black bold (NCBI  SNP Cluster 
ID rs29001168), -1391 A: black bold (NCBI SNP Cluster ID rs 1368402), -566(GT)2f. black bold (NCBI 
SNP Cluster ID rs28987086),  -386C:  black bold (NCBI SNP Cluster ID rs28994880).  The numbering 
above the sequence is with respect to the first A of the ATG translation start as +1.
348Reference sequence for human Brn-3c promoter: Ensembl transcript EDENST00000230732).
-3740  -3730  -3720  -3710  -3700  -3690
ctg g a   g g a ta tg g tg   c tttg tg c c c   tg a c ttc a c c   tta c a tg tg g   c a a a tc ta tg   tc c c t
-3680  -3670  -3660  -3650  -3640  -3630
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tg c tg   tta g ta g g ta   tttg g a a a tg   c tta tc g a a t  g g g g a a a a tt  c t t c c tt c a a   tg c c a
-3560  -3550  -3540  -3530  -3520  -3510
c ttg c   a ta a a tg c c c   a c a ta g tc c t  ta c a tg g a c c   t t c a c a t a t t   t t g tt t g g c c   c a ta a
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-3320  -3310  -3300  -3290  -3280  -3270
g a a tt  ta a g ttta c a   a a ttc tg g a a   a g c atag ag g   c tg tta c a a a   ttg c c g tc ta   ag g c t
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349-3020  -3010  -3000  -2990  -2980  -2970
tag g g   g c tg g ta a g g   tg a a g g tc a a   c a ttg g a g g c   a tg tg a g g a c   c a g t t a g t t t   tg c tc
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-2780  -2770  -2760  -2750  -2740  -2730
a a a ta   c a g a c c a g tg   ta tc c c tg tg   t t t c a t t c c c   c t t t t c c c t t   tg g g c ttc c a   g c a tt
-2720  -2710  -2700  -2690  -2680  -2670
gggaa  g aa aac aaa g   a c tg g tc tta   a a tc c ta g tg   a g tg a ta a a a   ta c tg c a ttc   a g c tc
-2660  -2650  -2640  -2630  -2620  -2610
tgggg  a g ttg a g tg t  c tc tg g a g a t  a a a ttc c tg a   c a tg c tc a a a   g t a t g t t t c a   ttc a a
-2600  -2590  -2580  -2570  -2560  -2550
a t t a a   c c a g a a tg a t  a g t c t t g t t a   aa g c tg g a a g   t c t t g t t a a a   g c tta g c a a t  c a tc t
-2540  -2530  -2520  -2510  -2500  -2490
ta ta c   a g c c c a c tc c   ttg ta g g ta a   a c tg a g g tc c   a g tc a g g g tc   a c c c a ta c tc   c g tg t
-2480  -2470  -2460  -2450  -2440  -2430
cag aa  tg c a g c c c c a   a a tc c a g c c c   tc c tg c a g c c   c a ta g ttc tg   a t g t g t a t t c   tg c a c
-2420  -2410  -2400  -2390  -2380  -2370
t t c t a   g a a tc c tg c c   a c c c tta tg c   t c t g t g t c t t   g ttc a tg a a t  c ta c c tc c c t  tc ta c
-2360  -2350  -2340  -2330  -2320  -2310
t g c t t   g g c a a g ttta   g a g tta a c tt  tc tg a a g tg a   a ta tta g a c t  g g tg a c tc c t  tg a g t
-2300  -2290  -2280  -2270  -2260  -2250
gccag  g a tg g a ttc t  g a ttc a c a tc   tg tg tc c c a g   c c tttg g c a t  g g g g tc tg g c   a c a a t
350-2240  -2230  -2220  -2210  -2200  -2190
gcaga  tg ttg g g tg a   a tg g a g a g c a   a g g a tc c a c a   g ta tg c a c g t  g cag acaaac  cg g g t
  I     I  I   ------| -------|    | --- |    | ----|    | --- |    |
-2180  -2170  -2160  -2150  -2140  -2130
tc c a g   g a g g a tg a c t  tg g c c c a c c c   c c a c tc tc a c   a t g c t t t c t c   t t t a a g t t g a   ggaag
-2120  -2110  -2100  -2090  -2080  -2070
aagag  a g g a a c a tg t  a ttc a a tg a t  a tc a a tg c g c   c a g g c a c tg t  g c c a tg tg c t  ta tc c
-2060  -2050  -2040  -2030  -2020  -2010
c a g tg   c a ttc c tc a c   a a c a a tc a a t  g g g a a a ta a a   tg a tc a c c c c   c a tt t t a c a g   atg g g
-2000  -1990  -1980  -1970  -1960  -1950
g acac  c g c a g ta c a g   a g a a g ttg a g   a a ta tc tc g t  g g tc tc a g c c   agcaagaggc  agagg
-1940  -1930  -1920  -1910  -1900  -1890
c g c a t  t t t g a a t c t g   aggccagggc  c tg a g c g c ta   tg g cac cag g   ttg tg a g g g a   g t t t a
-1880  -1870  -1860  -1850  -1840  -1830
c tg a g   c a c c a a tttc   g tg g c tc a a t  g c t t t t c t t c   tta c c c ta a c   tc tg a a c g tc   ttc a c
-1820  -1810  -1800  -1790  -1780  -1770
cag aa  tcca ag g ag g   c a g a c a g ta g   tg c a a ttc c a   ttta a g a g c c   g ccg aaaccg   ag g c t
-1760  -1750  -1740  -1730  -1720  -1710
cagag  g g c ttta g c g   a a a g g g ttg c   g c ttg g c tc t  ag g c a c c tg g   g c tg a g tc tt  t t t c c
-1700  -1690  -1680  -1670  -1660  -1650
ca cca  tcg cag g g cg   ggaaccag cg   gagg g g g ctg   g c tc g g a tg g   ggagaaaagc  a a c tg
-1640  -1630  -1620  -1610  -1600  -1590
gaggg  cgccgagggg  aagagggagc  c c g g a tc tg t  ca g g g cg tcc  tc ttg g a c ta   aggga
-1580  -1570  -1560  -1550  -1540  -1530
t g t t c   c c c ta a a c c a   c a c c a c c c c a   c c tc g ttc a g   a ttc tg g g a a   acccg g cacg   c a c a t
-1520  -1510  -1500  -1490  -1480  -1470
a c c c t  g c a c a a ta a c   ag g cag g g tg   a g g tc tc ta a   g ccccg aag a  t c g c tc tc tc   agcgg
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-1460  -1450  -1440  -1430  -1420  -1410
aggca  g tg g c c c tg a   cg ag g g g g ta  ca g c tg c a c g   c g c g g g g ttt  c tc tc c g a a c   cggag
|   '   '   -   . . .   i   . . . .   i   . . . .   |
-1400  -1390  -1380  -1370  -1360  -1350
tg c a g   c g ta g tc g a g   g tc c a g g a tt  c c c c a tc c a t  ta ttc a c g a t  g ttta c ta g a   gcggg
-1340  -1330  -1320  -1310  -1300  -1290
gcaag  ggagaggaaa  gaagagggaa  g tag ag a g aa  a a a g a g g c ta   ggggaggtgg  aggcg
-1280  -1270  -1260  -1250  -1240  -1230
ggcag  tg c ta a c c tc   g a g a g c c c tc   a a g ttc c g a a   a c tttg a g a a   g g aag accaa  gaggc
-1220  -1210  -1200  -1190  -1180  -1170
ta a g g   c g c ctg g g aa  gcagcaggcc  g tc a g ta a a t  a tttg ta a g a   tg g a tg g a ta   a c tg g
-1160  -1150  -1140  -1130  -1120  -1110
g tg ag   tg a g tg a a tg   g g c ta a tc a t  ta g c c c c tc t  g a t c c t tg t t   t t c c t c a t c t   g ta a a
-1100  -1090  -1080  -1070  -1060  -1050
acggg  a ta a c a tc a c   c ta c tc c a ta   c g g tg g g ta t  g a g a a tc c c a   tg g g c a a a c t  c ta a a
-1040  -1030  -1020  -1010  -1000  -990
t t g t c   ta g c a c a ta t  ta g g a a c tc t  ta a a c g g ta g   c tg ttg tc a c   g ag g aatg g g   c ttg c
-980  -970  -960  -950  -940  -930
a a g c t  c tg g c tg c c c   a g c a g a a a tg   c a c tg a a g g a   c tc c c a g g c c   tg g ag g g cca  tc c tg
-920  -910  -900  -890  -880  -870
aacag   t c g c t a t t c t   a a a a a a a a ta   c tc c a c a a g c   ttc c tta g a c   g g g ag g g ttg   gagga
-860  -850  -840  -830  -820  -810
ag a g t  g g g c c a a g tt  a c a tc c c tc a   a a tg a a a g a a   ag aaag g caa  g cgtggggag  gaagc
. . . .   I   | |   |   |   |   |   |   |   |   |   .   .   .   .   |
-800  -790  -780  -770  -760  -750
caccc  c g g a ctg ag a  a g g c a g tta c   tg c c c c ta c c   tc ta c c c c g g   a g c g c g g ttg   aggga
-740  -730  -720  -710  -700  -690
g g tg g   g g cag g g g tc  a c c tg g g c c t  c g ttc tg g c a   g c c c c tc a c c   c tc tc c a g g g   c c c g t
352-680  -670  -660  -650  -640  -630
c tg g g   c g c ttg g a g g   c g c c tc c tc g   ctg cg c cg cg   g g ac cg g ac t  c tg g tg g a c a   g c ttg
-620  -610  -600  -590  -580  -570
g g cg t  gaggccagga  g c g c c c tg g a   a a tg g g c a g t  ttg g c g g c a g   ccgggccgac  g g a g t
-560  -550  -540  -530  -520  -510
g t g t g   t g t g t g t g t g   t g t g t g t g t g   t g t g t g t g t g   t g t g t g g t g g   a g a g g g g a a g   t t g g a
-500  -490  -480  -470  -460  -450
g ta g g   g tc a a c ttc c   tg c c c c a g c t  cagcccaggg  c t a c c c t t t t   a tc c a g g c a g   ttc g a
-440  -430  -420  -410  -400  -390
g c tg g   gacaggacgg  a g a g g ttg g g   a c ttttg g g g   tg g c a tg g g g   g aag g g aag t  ccacg
-380  -370  -360  -350  -340  -330
aag aa  g a a a g a a tc g   g a a a g g tc tg   g c g g g ttg g a   gccagcgggg  cggggcggac  tg g g a
-320  -310  -300  -290  -280  -270
gaggc  caggccaggc  c c g g g ta ta a   a g g c tg tg g a   gggggcggcc  gccgcgggcg  cagaa
-260  -250  -240  -230  -220  -210
aggcg  c g c c g c ta g c   t g c t g t c t c t   c c tc a c c tc c   cgggccgccc  c tg c g a g tc c   ccggc
-200  -190  -180  -170  -160  -150
g c g tg   a g c a c g c c tg   cg cgcgcccg  g g c c c ttc c t  g g cag g ctg c  ttg ta a g a tg   a g tg a
-140  -130  -120  -110  -100  -90
agaag  cagg tg g g g g   agaggggagg  cagcgagcga  gagggcgagg  ggagcgcggg  c g c tg
-80  -70  -60  -50  -40  -30
agcag  c g c tc a c ttg   gagagcggca  a g c a a g c ta g   a c a a g c c tg a   ttc c a tg tc a   cccgc
-20  -10 
tg c c a   c c c tg c c a g g   agcgcgaag
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Table A:  Results of bioinformatic  analysis using  Matlnspector software  (www.genomatix.de/products/MatInspector/index.html) to identify putative 
transcription factor binding sites within the region spanning the -3432poly-G polymorphism.  Results are shown for each -3432poly-G allele sequence 
as  ‘core’  and  ‘matrix’  similarity scores using the following  settings:  core similarity set to 0.75  and matrix similarity set to optimised; Matrix family 
library version 3.1.1. For poly-G allele sequence see Table 3.2 section 3.2.18.
SNPG1 SNPG2 SNPG4 SNPG5 (G)10 (G),, <G)12
Family Matrix (version) Core Core Core Core Core Core Core
ZPBF ZBP-89 (01) 1.000 1.000 ■ ■ ■ 1.000 1.000 1.000
ZBPF ZF9 / CPBP (01) 0.923 0.884 0.820 0.820
EGRF Egr-4 / NGFI-C (01) 0.787
EGRF Egr-1 / NGFI-A (01) 1.000* 0.797
EGRF WT1 (01) 0.796 0.796 0.796 0.796 0.796
INSM INSM1 (01) 1.000 1.000 1.000 1.000 1.000 1.000
SP1F SP1 (01) 0.796 0.796 £1.000 0.796 0.796 0.796
MAZF MAZR(Ol) 1.000 1.000 1.000 1.000 1.000 1.000 .957  1.000
MAZF MAZ (01) 0.866
SPIF GC box elements (01) 0.819 0.819 0.819 1.000 0.819 0.819 0.819
RREB RREB1  (01) 1.000 1.000 1.000 1.000 1.000 1.000
SPIF TIEG (01)__________ 1.000 1.000 1.000 1.000 1.000 1.000 1.000
GLIF ZIC2 (01)* 1.000 1.000 1.000 1.000 1.000
* Results were obtained during preparation of this thesis using Matrix family library version 5.0.
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Probe  Q-  o.  o.  a.
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Figure 5.10  Effect of zinc on  binding of nuclear proteins A and  C to common -3432  poly-G  alleles.
Probes: SNPG1  (lanes  1   & 8), SNPG2 (lanes 2 & 9), SNPG4 (lanes 3 &  10), SNPG5 (lanes 4 &  11) (G)1 0  
(lanes 5 &  12), (G)n (lanes 6 &  13) or (G)i2 (lanes 7 &14) were incubated with 8pg OC-2 nuclear extract 
in the presence of 10|iM zinc (lanes  1-7) or  100pM zinc (lanes 8-14). Arrows A and C denote the location 
of shifted nuclear protein-DNA complexes A and C, respectively.
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SNPG1
Probe
1  2  3  4  5  6  7
Figure 5.15c  Effect  of -3432poly-G  polymorphism  on  binding of SP3  and  SP1.  The SNPG1  probe 
was  incubated  in  the  presence of 3.5pl  SP1  in-vitro translate  (lanes  1-3)  in the presence of increasing 
amounts of SP3  in-vitro translate:  lpl (lane 2) and 2pl (lane 3);  Ipl SP3  in-vitro translate (lanes 4-6) in 
the presence of increasing amounts of SP1  in-vitro translate: 3.5pl (lane 5) and 7pl (lane 6) or 8pl T7 in- 
vitro translate as a negative control for endogenous protein binding.
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(i)  Table  B:  Results  of  bioinformatic  analysis  using  Matlnspector  software 
(www.genomatix.de/products/MatInspector/index.html)  to  identify  putative 
transcription  factor  binding  sites  within  the  region  spanning  the  -1391A>C  single 
nucleotide  substitution.  Results  are  shown  for  each  allele  sequence  as  ‘core’  and 
‘matrix’  similarity  scores  using  the  following  settings:  core  similarity  set  to  0.75  and 
matrix  similarity  set  to  optimised;  Matrix family library version  3.1.1.  For -1391  allele 
sequence see Table 3.2 section 3.2.18.
-1391A -1391C
Family Matrix (version) Core Core Matrix
kc;r 1 EGR3 (01) 1.000 1.000
GFI1 GFI1 (01) 1.000 1.000 0.873
(ii)  Section  of  Brn-3c  promoter  spanning  -1391A>C.  The  single  nucleotide 
substitution  is  highlighted  in  black  bold.  Boxed  area  size  of oligonucleotide  used  in 
EMSA  analysis.  Sequence  used  by  Matlnspector  software  to  predict  putative 
transcription  factor  binding  sites  is  underlined  and  highlighted:  red  denotes  sequence 
used to  predict the  putative Gfi-1  binding  site (the  core  sequence  is in red  bold),  blue 
denotes sequence used to predict the putative Egr3 binding site (the core sequence is in 
blue bold).
-1400  -1390  -1380  -1370
rcatccat  tattc ag  cgtagtcgag  gtccaggatt  cc
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Sequencing  of  cloned  PCR  products  as  a  confirmatory  method  for  qenotvpinq  the  - 
3432polv-G polymorphism bv direct sequencing.
Sequencing of cloned PCR products to elucidate and / or to confirm discrete poly-G alleles identified by 
direct  sequencing  was  not  a  useful  approach.  ‘Stutter’  alleles  from  the  PCR  amplification  confounded 
discrimination of the genuine alleles and hence, confirmation of genotype.
‘Stutter’  alleles  are  contractions  and  /  or  expansions  of a  repetitive  DNA  sequence  and  are 
thought to arise due to DNA polymerase slippage when repetitive DNA sequences are amplified by PCR 
(Clarke et al,  2001;  Shinde et al,  2003).  Repetitive DNA sequences including both mononucleotide and 
dinucleotide repeats have an intrinsic propensity to DNA polymerase slippage; during normal replication 
slipped-strand  mispairing  results  in  short  deletions  and  /  or  additions  in  repeat  length  (Levinson  and 
Gutman,  1987a;  Gragg  et  al,  2002;  for review,  see  Kunkel  and  Bebenek,  2000).  It  is  thought  that  the 
ability of repetitive  DNA  sequences to  readily adopt secondary conformations results  in a tendency for 
progression  of the  ongoing  DNA  polymerase  to  stall  (Weaver  and  DePamphilis,  1982;  Bichara  et  al, 
2000;  Viguera  et  al,  2001  and  references  within).  ‘Slippage’  of the  DNA  polymerase  during  a  PCR 
reaction is thought to involve a transient dissociation of the template and the 3 ’  end of the primer strand 
followed by mis-pairing within the repeat unit upon annealing termed,  ‘slipped strand mis-pairing’ which 
results in an extrahelical loop composed of the unpaired repeat units (Viguera et al, 2001  and references 
within). If this loop forms on the ‘template strand’ and persists until the next round of DNA amplification, 
contraction of the repeat unit occurs. Conversely, if the loop forms on the ‘primer strand’ then expansion 
of the repeat unit occurs (Levisnon and Gutman,  1987a).
Both contraction and expansion of the -3432poly-G  repeat length was observed during analysis 
of cloned PCR products.  For example, presence of the stutter allele (G)9 (contraction) was observed for 
subjects identified (G)u / (G)i0  and the presence of the stutter allele GGC(G)n (expansion) was observed 
for subjects identified SNPG2 / SNPG6 [GGC(G)9/ GGC(G)i0]- In general, the usefulness of sequencing 
cloned  PCR  products  to  aid  elucidation  and  /  or  to  confirm  discrete  poly-G  alleles  was  very  much 
dependent on the nature of the poly-G alleles present proving more useful for homozygous samples than 
heterozygous.  For  subjects  homozygous  for  the  -3432poly-G  polymorphism  it  was  possible  to  confirm 
genuine  alleles  by  sequencing  of  cloned  PCR  products;  this  was  particularly  evident  in  the  case  of 
subjects homozygous  for allele  SNPG1,  [GGC(G)8], the shortest allele length identified that contained a 
single nucleotide substitution within the poly-G repeat. Sequencing of individual clones (n =  10) from the 
PCR product pool did not reveal the presence of any stutter alleles for subjects SNPG1  homozygous.  In 
contrast,  for  subjects  heterozygous  for  the  -3432poly-G  polymorphism  sequencing  of  cloned  PCR 
products  was  not  very  informative,  especially  if  the  longest  allele  combinations  were  present.  For 
example, for subjects identified (G)J2 / (G)n or 10. sequencing of cloned PCR products was confounded by 
stutter  alleles  of differing  poly-G  repeat  length.  The  abundance  of stutter  alleles  observed  for  some 
samples that contain long poly-G allele combinations and lack of stutter alleles  for subjects that contain 
short  poly-G  alleles  is  consistent  with  the  concept  that  the  frequency  of DNA  polymerase  slippage  is 
reported to  increase as the number of repeating units in a repetitive DNA sequence increases (Sia et al, 
1997; Clarke et al, 2001).  In addition, the degree of stutter alleles identified and the origin of the multi-
358allelic  -3432poly-G polymorphism may in part be explained by the  tendency of mononucleotide runs of 
poly-G/C  to  be  very  susceptible  to  DNA  polymerase  slippage  (Gragg  et  al,  2002);  probably  to  some 
extent  due  to  strong  stabilisation  of secondary  conformations  in  sequences  of poly-G/C  that  facilitate 
slippage (Sagher et al,  1999).
The  AmpliTaq  Gold  (Promega)  DNA  polymerase  used  to  amplify  the  -3432poly-G 
polymorphism by PCR prior to  either direct sequencing  or sequencing  of individual clones of the  PCR 
product  pool  does  not  have  proofreading  capability.  It  is  possible  that use  of a  DNA polymerase  with 
proofreading  capacity  may  have  generated  more  informative  results  from  sequencing  of cloned  PCR 
products  by  reducing  the  occurrence  of stutter  alleles  in  the  final  product  pool.  However,  it has  been 
reported  by  Clarke  et  al,  2001  that  Taq  and  the  proofreading  polymerase  Pfu  (high  fidelity)  generate 
similar errors at mononucleotide and dinucleotide repeats.  It should also be considered that some of the 
stutter alleles observed upon sequencing of cloned PCR products may not have originated during the PCR 
amplification but rather during propagation of the pGEM®-T easy plasmids in the E.Coli strain used for 
sub-cloning, XL 1-Blue (Stratagene).  Indeed, clones containing microsatellite sequence inserts can vary in 
size  due  to  mutations  that  arise  during  propagation  of the  plasmid  in  E.  Coli  (Levinson  and  Gutman, 
1987b;  Freund et  al,  1989;  Bichara  et  al,  2000).  However,  the E.coli  strain used,  XL-1, carry the  recA 
mutation, which is known to dramatically reduce the frequency of homologous recombination and hence, 
improve insert stability.
In summary, sequencing cloned PCR products as a secondary method to direct sequencing to elucidate 
and / or to confirm discrete poly-G alleles was not a useful approach; the presence of stutter alleles made 
discrimination of genuine poly-G alleles extremely difficult.
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Elucidation of problematic -3432poIv-G genotypes
SNPG4 homozvaotes.
Originally  a  total  of ten  subjects  were  assigned  to  chromatogram  group  8  based  on  direct  sequencing 
analysis. From observation of the sequencing chromatogram typical for this group of subjects (Fig. H.la) 
it appears clear that the genotype is homozygous; no convincing heterozygous peaks are observed across 
the poly-G repeat or downstream invariant region. Consequently, a genotype of SNPG4 homozygous was 
determined.
To confirm this genotype alleles were sized by PAGE analysis of radioactive PCR products for 
each of the ten subjects. The results of this secondary analysis revealed that only three subjects exhibited 
a single band of 182bp equivalent to a genotype of SNPG4 homozygous (for example see Fig. H.lc, lane 
1). The remaining seven subjects in addition to exhibiting the  182bp band also displayed an extra band of 
183bp,  which  due  to  having  a  strong  intensity could not be  discarded  as  a  stutter  allele  from  the  PCR 
reaction (for example see Fig.  H.lc,  lanes 2  and 3).  Repeat PAGE analysis of radioactive PCR products 
confirmed  these  observations.  Based  on  these  results  the  three  subjects  that  displayed  a  single  band  of 
182bp were verified as SNPG4  homozygous and the seven subjects that displayed the extra  183bp band 
were  assigned  a  different  genotype;  SNPG4  hereozygous  where  the  second  allele  was  not  determined 
(SNPG4 / ND).
It was  not possible  to clarify the genotype of subjects  identified  SNPG4 / ND accordingly this 
category of subjects was excluded from subsequent frequency analysis It is possible that the  183bp band 
is  a  PCR  artefact;  DNA  polymerase  slippage  or  the  tendency  of  Taq  DNA  polymerase  to  randomly 
append  the  3’  end  of DS  DNA  fragments  with an extra residue,  typically adenine,  are  two mechanisms 
that could explain the secondary band differing in length by an extra residue (Hauge et al,  1993). It is also 
feasible that this secondary band does not differ in length to that of the  182bp band but rather adopts an 
alternative  secondary conformation such  that migration  is retarded by a factor of lbp  (Litt et al,  1993). 
Alternatively, it is possible that these subjects are heterozygous for the SNPG4 allele in which case allele 
(G)i2 having a length equivalent to  183bp is a likely candidate for the second allele. The only other poly- 
G allele equivalent to  183bp is SNPG2 but, SNPG2 / SNPG4 heterozygotes exhibit very clear and distinct 
results upon direct sequencing (see Fig.  H.lb).  In addition, it cannot be ruled out that a novel allele may 
exist  in  this  group  of subjects.  In  either  case,  it  is  possible  that  the  SNPG4  allele  shows  preferential 
amplification over the  second allele type during  the PCR reaction hence,  leading to  the production of a 
direct sequencing chromatogram typical of SNPG4 homozygotes.
360(a)
100  110  120  130  140  130  160
TAAAC TA OAOAOCAC T  T   A C  C  CAC C  C  CC C  C  C A  C  C A  C  C A  C  CA TO O  C   A  T  T   A  A   A T  TACAA T  C   A C   A  CA C   A  C A
4 ----------1   Allele 1  and 2: SNPG4
(b)
100  110  120  130  140  150  160
GTAAAC TA GAOAOCACT TACCCACCCCCCCCCC CACCCCCCAQGOAT TAAAT TAC CAA CCCACACACACAC C
m iui i
cgccaccaccatggcattaaattacaatctcacacac 
accaccaccat  gflcattaaattacaatcacacacaca
Allele 2: SNPG4  < -
'  Allele 1: SNPG2
(c)
182  183  183 
Size (bp)  182  182
Figure  H.l  Determination of SNPG4  homozygotes, (a) and (b) Direct sequencing chromatograms; 
data obtained is for the anti-sense strand.  Alleles were elucidated by reading 3’  to 5’  from the 3’  G 
within the invariant region (underlined), (a) Direct sequencing chromatogram representative of subjects 
assigned  to  chromatogram  group  8  (genotype:  SNPG4  homozygous),  (b)  Direct  sequencing 
chromatogram  representative  of subjects  assigned  to  chromatogram  group  15  (genotype:  SNPG2  / 
SNPG4  heterozygous).  Clear  distinction  between  homozygous  and  heterozygous  peaks  facilitated 
identification of each allele; see written sequence added below the chromatogram (homozygous peaks 
are  indicated  by  the  small  red  arrows),  (c)  Sizing  of -3432poly-G  alleles  by  PAGE  analysis  of 
radioactive  PCR  products  using  primers  G3cP13-S  and  3cP12-AS  in  the  PCR.  Lane  1:  genotype 
SNPG4 homozygous, lanes 2 and 3: genotype SNPG4 / ND (second allele: Not Determined).
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A  total  of  fifty-two  subjects  were  originally  assigned  to  chromatogram  group  4  based  on  direct 
sequencing analysis. From observation of the sequencing chromatogram typical for this group of subjects 
(Fig.  H.2a)  it appears that the genotype is homozygous; no convincing heterozygous peaks are observed 
across  the  poly-G  repeat  or  invariant  region.  Counting  3’  to  5’  from  the  3’  G  in  the  invariant  region 
‘TGGCATTAAATTA’ a genotype of SNPG2 homozygous was determined.
In  some  cases  it  was  evident  that  the  peak corresponding  to  the  single  nucleotide  substitution 
characteristic of allele SNPG2 did not always occur as a clear homozygous peak (this is illustrated in the 
example  shown  in  Fig.  H.2a  by  the  small  black  arrow).  Allele  SNPG2  is  characterised  by  a  G  to  C 
substitution on the 3rd G of the poly-G repeat (see Table 8.5, page 288) which when identified on the anti­
sense strand by sequencing with anti-sense primer 3cP12-AS should occur as a clear C to G substitution 
for homozygous samples. However, in nine of the fifty-two samples the peak representing nucleotide G at 
this  position  (Fig.  H.2a,  small  black  arrow)  was  present  in  conjunction  with  a  secondary  peak 
corresponding  to  nucleotide  C.  This  secondary  peak  for  nucleotide  C  always  gave  a  weaker  signal 
compared to the peak for nucleotide G and was present alongside many additional peaks of weak signal 
across the invariant region ‘TGGCATTAAATTA’ (this is illustrated in Fig. H.2a). It is possible that these 
secondary peaks represent an artefact of the initial PCR reaction or are background from the sequencing 
reaction, but this cannot be clarified with certainty from the sequencing chromatogram alone.  The allele 
(G)n  could  be  present  in  addition  to  allele  SNPG2,  albeit  with  a  much  lower  signal  upon  sequencing 
compared  to  allele  SNPG2.  However,  SNPG2  heterozygotes  produce  very  convincing  chromatograms, 
for example: SNPG2 / SNPG4 heterozygotes (Fig. H.lb) and SNPG2 / (G)i0 heterozygotes (Fig. H.2b). 
However, despite these observations and the fact the majority of the chromatograms obtained from direct 
sequencing  are  convincing  for  genotype  SNPG2  homozygous  and  are  of much  better  quality  than  the 
example  shown in Fig.  H.2a caution was applied to  this data,  especially regarding the  large  number of 
subjects  assigned  this  particular  homozygous  genotype.  Consequently,  a  decision  was  undertaken  to 
perform secondary analysis on each of the fifty-two subjects to help confirm no loss of heterozygosity.
To  confirm  samples  assigned  genotype  SNPG2  homozygous  and  to  rule  out  loss  of 
heterozygosity manifesting from stochastic hypoamplification leading to allele drop-out alleles were sized 
by  PAGE  analysis  of  radioactive  PCR  products  for  each  of  the  fifty-two  subjects  assigned  to 
chromatogram group 4.  The  results of this  analysis confirmed a single band corresponding  to  183bp  in 
every  sample  analysed  except  three  (the  183bp  band  is  in  agreement  with  a  genotype  of  SNPG2 
homozygous;  for example  see  Fig.  H.2c  lanes 4  and  7).  For three  samples  an extra band  equivalent to 
184bp was observed that was too intense to be regarded as an artefact from the PCR reaction and which 
was  still  evident  upon  repeat  PAGE  analysis  of radioactive  PCR products.  Based  on  these  results,  all 
subjects  assigned  to  chromatogram  group  4  were  confirmed  as  SNPG2  homozygous  except  the  three 
displaying the extra band.  The three subjects not confirming to the  SNPG2 homozygous genotype were 
excluded from subsequent frequency analysis.
362(a)
100  110  130  130  140  150  160
T  AAAC TAOAOAOCACTTACC CAC CCCCCCCCOC CAC C A  C  C A  TOO CATTAAAT TACAA T  CT  CACACACA
Many weak secondary peaks can be 
observed across this region.
Allele 1  and 2: SNPG2
TAAAC TA GAGAGCACTTACCCACCCCCCCCCCCCACCCCCOT0GTTTTATTTTACAATC TCACACACAC
Allele 2: (G)10<4- Allele 1: SNPG2
(C)
Size (bp)
182  181  183  183  183  181  183
182  182
181  181
Figure  H.2  Determination  of SNPG2  homozygotes,  (a)  and  (b)  Direct sequencing chromatograms; 
data obtained is for the anti-sense strand. Alleles were elucidated by reading 3’ to 5’ from the 3’ G within 
the  invariant  region  (underlined),  (a)  Direct  sequencing  chromatogram  representative  of  subjects 
assigned to chromatogram group 4 (genotype:  SNPG2 homozygous). Example shown shows presence of 
many weak secondary peaks (small black arrow and region as indicated) that confounded assignment of 
SNPG2  homozygous,  (b)  Direct  sequencing  chromatogram  representative  of  subjects  assigned  to 
chromatogram group 5 (genotype: SNPG2 / (G)i0 heterozygous). Clear distinction between homozygous 
and  heterozygous peaks  facilitated identification of each allele;  see written sequence added below the 
chromatogram (homozygous peaks are  indicated by the small  red arrows),  (c)  Sizing of -3432poly-G 
alleles by PAGE analysis of radioactive PCR products using primers G3cP13-S and 3cP12-AS in the 
PCR.  Lanes  1   &  2:  182  and  181bp  size  markers,  respectively.  Size  markers  were  generated  from 
pGEM®-T easy constructs carrying either alleles (G)n or (G)i0as template in the PCR reaction. Lanes 3 
& 5: genotype (G)i2 / (G)n orio, lanes 4 & 7 genotype:  SNPG2 homozygous and lane 6: genotype (G)i0 
homozveous.
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A total of thirteen subjects were assigned to chromatogram group 3 based on direct sequencing analysis. 
From  observation  of the  sequencing  chromatogram  typical  for  this  group  of subjects  (Fig.  H.3a)  it  is 
evident that the genotype is a variation in poly-G length; no single nucleotide substitutions are observed 
within the poly-G repeat. Counting 3’  to 5’  from the 3’ G in the invariant region ‘TGGCATTAAATTA’ 
it is clear that the longest allele is (G)i2- This is confirmed by counting the length of the locus, L, which 
equals  23  bps  (Fig.  FI.3a).  Based  on  some  convincing  heterozygous  peaks  upstream  of the  invariant 
region ‘TGGCATTAAATTA’ for allele  1   (shown by the black arrows in Fig. FI.3a) it is possible that the 
second allele type is (G)io- Flowever, due to a lack of convincing heterozygous peaks across the invariant 
region (shown by the blue arrows in Fig. FI.3a) the second allele can not be clarified with certainty and it 
is possible that second allele type is (G)n.
Therefore,  to  clarify  genotype  allele  size  was  determined  for  each  subject  by  PAGE  analysis  of 
radioactive PCR products. If two clear bands of 183 and 18 lbp could be observed this would support the 
original  allele  assumption  of (G)i2  /  (G)io  made  from  direct  sequencing.  However,  PAGE  analysis  of 
radioactive PCR products revealed three clear bands for each subject of 183,  182 and 18lbp (for example 
see Fig.  H.3  lanes 3  and 5). Based on band intensity it appears evident that the  183bp band is a genuine 
allele and not an artefact of the PCR process. This is in agreement with the convincing data obtained from 
direct sequencing that suggests the presence of the (G)i2 allele.  It is not possible to discriminate between 
the  182 and  18 lbp bands for the second allele; both bands appear of a similar intensity. This difficulty in 
distinguishing stutter bands from the genuine allele is by no means unique. It can be very hard to clarify 
which bands are stutter alleles especially when the stutter bands from one heterozygous allele overlap the 
stutter bands from the other allele; this overlap results in a combination in band intensity and can obscure 
the identity of the true allele. Therefore, for this group of subjects the second allele could not be clarified 
unequivocally by  the  secondary  analysis  performed  although  it  was  clear  it  was  either  (G)n  or  (G)!0. 
Accordingly, in subsequent frequency analysis both possibilities (G)u and (G)i0 were counted in addition 
to (G)i2.
364(a) in   110  130  130  140  130  160
TAAAC TAOAOAOCACT  TACCCACCCCCCCCCCCCCCCCCCOOOOTTTTAATTTACAAT  CACACACACA
ccaccaccat ggca 1  taaat t  acaa tcacacac
accaccatgg1c a i t aaal  t   acaat cacacacac
Allele 2: (G),nor(G),,  ^
In the sequence added Allele 1: (G),2
the (G)io allele is shown.
(b)
1   2  3  4  5  6  7
0.  ^   x  182  181  183  183  183  181  183
(bp)  182  182
181  181
Figure H.3  Determination of (G)n / (G)u or 10. (a) Direct sequencing chromatogram representative of 
subjects assigned to chromatogram group 3 (genotype: (G)]2/ (G)n orio); data shown is for the anti-sense 
strand. Alleles were elucidated by reading 3’ to 5’ from the 3’ G within the invariant region (underlined). 
Allele  1   is (G)i2 as confirmed by the  length of the locus L.  Based on clear heterozygous peaks (small 
black  arrows)  it  is  possible  the  second  allele  is  (G)i0  but  due  to  the  presence  of  unconvincing 
heterozygous  peaks  as  indicated  by  the  small  blue  arrows  this  cannot  be  confirmed;  (G)n  is  also  a 
possibility,  (b)  Sizing  of -3432poly-G  alleles  by  PAGE  analysis  of radioactive  PCR  products  using 
primers G3cP13-S and 3cP12-AS in the PCR; this figure is reproduced from Fig. H.2c. Lanes 1  & 2:  182 
and  18lbp  size  markers,  respectively.  Size  markers were  generated  from  pGEM®-T  easy  constructs 
carrying either alleles (G)n or (G)i0as template in the PCR reaction. Lanes 3 & 5: genotype (G)i2 / (G)n or 
io, lanes 4 & 7 genotype: SNPG2 homozygous and lane 6: genotype (G)i0 homozygous.
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Extract
Antibody
Probe
OC-2
-   SP1  Gfi-1
O   CD  0
T -   0 .   T -   0 -   T -   0 -
0.  Z  0.  Z  0.  z
CO  CO  CO  CO  (/5  CO
1  2  3  4  5  6
Supershift analysis confirms nuclear protein A is SPI. The labelled SPl  consensus sequence (lanes 
1, 3 & 5) or SNPG1  probe (lanes 2, 4 & 6) were incubated with 8-10pg of OC-2 nuclear extract in the 
absence  of antibody  (lanes  1-2)  or  in  the  presence  of anti-SPl  antibody  (lanes  3-4)  or anti-Gfi-l-1 
antibody (lanes 5-6) as  indicated.  The  location of nuclear protein-DNA complex A  is denoted by the 
arrow, A.  In the presence of the anti-SPl  antibody two shifted complexes SSI  & SS2 can be observed 
confirming SPl  is a component of nuclear protein-DNA complex A.  Antibody was added subsequent 
to addition of probe and reactions were allowed to incubate for a further 30 minutes on ice. Antibodies 
were  purchased  from  Santa Cruz  Biotechnology,  Inc.:  rabbit  polyclonal  anti-SPl  antibody  [SPl  (FI- 
225) X] and goat polyclonal anti-Gfi-1  antibody [Gfi-1 (N-20) X].
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Chapter 3.
The  control  sample group has been described previously (see Crawley et  al,  1999).  In 
addition to the information detailed on page  101  all control samples were Anglo Saxon 
Caucasians  from the  U.K.  and were recruited from two  sources:  laboratory personnel 
from  central  and  northern  London  and  blood  donors  attending  two  general  medical 
practices in northern London.
Chapter 5.
After  submission  of this  thesis  supershift  analysis  with  a  rabbit  polyclonal  anti-SPl 
antibody [SPl (H-225) X; Santa Cruz Biotechnology, Inc.] confirmed that OC-2 derived 
nuclear  protein  A  is  SPl  (work  performed  during  the  PhD  project  used  a  mouse 
monoclonal  anti-SPl  antibody;  SPl  (1C6)  X,  Santa  Cruz  Biotechnology,  Inc.).  For 
supershift with the rabbit polyclonal anti-SPl antibody see Appendix I.
Chapter 8.
With  respect  to  the  association  study  it  is  acknowledged that  the null  hypothesis that 
there is no association between the -3432poly-G polymorphism and / or the -1391  A>C 
single  nucleotide  substitution and  susceptibility to  late  onset  hearing  loss  may actually 
be  true.  However,  as  discussed  in  section  8.8  (page  307)  without  for  example, 
undertaking  a  large-scale  population  based  association  study  it  cannot  be  reliably 
concluded  whether  either  or  both  of these  common  sequence  variants  in  the  Bm-3c 
promoter are associated with susceptibility to late onset hearing loss.  This is especially 
so  in light  of the  retrospective power calculation for the -1391  A>C  single nucleotide 
substitution.  Using  the  Genetic  Power  Calculator
(http://pngu.mgh.harvard.edU/~purcell/gpc/#tdt_ins)  it  can be estimated that the  power 
of the preliminary association study to detect a small genetic effect (relative risk:  1.4) is 
24% using unscreened controls for the control sample group.  Indeed,  even to detect a 
larger genetic effect (relative risk: 2.0) the power of the preliminary association study is 
limited  at  approximately  68%.  Sample  sizes  needed  to  detect  a  small  genetic  effect 
whilst maintaining at least 80% power is discussed further in section 8.8, page 309.
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